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Abstract 
Abstract 
Arginine deiminase (ADI), an arginine-degrading enzyme, is involved in the first 
step of arginine dihydrolase pathway. It catalyzes the hydrolysis of L-arginine to 
form citrulline and ammonia. ADI has been studied as a potential cancer 
therapeutic agent for the arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCC) and melanomas. Furthermore, studies also indicate that ADI 
is a potential anti-angiogenic agent; therefore it could become a novel anti-cancer 
drug targeting the neovascularization-related tumors. Studies show ADI is more 
potent for the treatment of leukemia than L-asparaginase. However, the anti-
tumor application of ADI for therapeutic purpose faces considerable challenges, 
such as, microbial ADI has low activity at physiological pH (7.35~7.45), short 
circulating half-life (~5 h) and high antigenicity. Pegylation of ADI improved its 
efficacy as a clinical drug, including its half-life in serum and antigenicity. The aim 
of the project is to improve ADI catalytic performance at physiological pH by 
directed evolution. 
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. Directed protein evolution has 
over the last decades become a versatile and successful approach for tailoring 
protein properties to industrial demands and for advancing our understanding of 
structure-function relationships in biocatalysts. Unlike rational design relying on 
the gathering of extensive structure-function relationships of enzymes, directed 
evolution is used to reengineer enzyme properties through iterative rounds of 
diversity generation and function selection for improved variants. 
 
In order to improve the ADI activity at physiological pH, we established a directed 
evolution protocol for this purpose. A microtiter plate (MTP) format colorimetric 
screening assay based on citrulline detection with diacetyl monoxime (DAM) was 
developed. Reaction temperature for color development and DAM concentration 
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were optimized to ensure sufficient sensitivity, appropriate linear range and 
throughput. With the optimized assay and PpADI wild type expressed in E. coli as 
a model protein, true standard deviation 12.8 % was obtained, which is 
appropriate for the library screening. 
 
With the established microtiter plate assay system, for the first time, we 
reengineered ADI for improved activity at physiological pH (pH 7.4) with higher 
potency in medical application. After one site directed mutagenesis and one 
round of epPCR library screening, variant M2 (K5T/D44E/H404R) was obtained. 
M2 shows 4-fold improved kcat value than the PpADI wild type, a shifted pH 
optimum at pH 7.0 (by 0.5 pH unit), and however an increased Km value, 3.6-fold 
under assay conditions (0.5 M sodium phosphate buffer).  
 
Low Km (S0.5) value for ADI is an important factor for efficient consume of arginine 
in plasma because of the low arginine concentration in human plasma (100-120 
µM). Therefore after our proof of concept of reengineering PpADI by directed 
evolution, we aim to decrease the Km value of PpADI towards arginine and 
improve the kcat furthermore thereby improve the efficiency of arginine depletion 
by ADI. The established citrulline colorimetric assay in 96-well microtiter plate is 
improved to reflect application conditions: PBS buffer and 1 mM arginine were 
used in screening system. After the second round of epPCR library and site 
directed mutagenesis, variant M5 (K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated: at pH 7.4 (PBS buffer), 
the S0.5 value decrease from 2.01 mM (parent M3, K5T/D44E/A128T/H404R) to 
1.48 mM (M5) and 0.81 mM (M6). Under physiological pH in PBS buffer, the S0.5 
value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat 
value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 
11.64 s-1 (M6, 64.7-fold). 
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Chapter 1 Arginine deiminase (ADI) 
Arginine deiminase (ADI) 
 
1.1 Arginine deiminase (ADI)  
Arginine deiminase (ADI, EC 3.5.3.6), an arginine-metabolizing hydrolase, 
catalyzes the hydrolysis of L-arginine to form citrulline and ammonia. This 
reaction is the first step in the L-arginine degradation pathway (ADH, scheme 1, 
(1). First, arginine is deiminated by arginine deiminase. The resulting citrulline is 
converted to carbamoyl phosphate and ornithine by ornithine transcarbamylase 
(EC 2.1.3.3), and finally the carbamoyl phosphate is used to phosphorylate ADP 
by carbamate kinase (EC 2.7.2.2), producing one ATP molecule. ADI is absent in 
humans but present in a wide range of bacterial species such as Pseudomonas 
aeruginosa (2), Pseudomonas plecoglossicida (3) and Mycoplasma arginini (4) 
and in parasitic protists such as Giardia intestinalis (5), Trichomonas Vaginalis 
(6), Trichomonas fetus (7), and Hexamita inflate (8). For pathogenic bacteria, ADI 
is required in arginine dehydrolase pathway for virulence and for energy 
production under anaerobic conditions (9, 10).     
 
 
Scheme 1. Arginine dihydrolase pathway. OTC, ornithine transcarbamylase; CK, carbamate 
kinase. 
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The establishment of a high-level production system for ADI is an essential step 
for further research and development of this enzyme. After ADI was discovered 
from Mycoplasma in 1960s (11), various ADI genes have been cloned, 
expressed in E. coli strains, and the enzyme properties were also studied (Table 
1). 
 3 
Table 1. ADI expression, enzymatic properties and medical applications. 
ADIs Origin 
Expression 
host/vector 
Multimeric 
form Km; kcat 
Optimum 
pH  
Specific 
activity 
Medical 
application References 
MhADI 
(SYN1903) 
Mycoplasma 
hominis PG21* 
E.coli BL21 
(DE3)/pET-47b 
Dimer   0.618 U/mg 
(pH 6.5) 
Human 
melanoma 
(G361), 0.036 
U/ml for 50 % 
IC50 
Japan, 
Harasawa, 
2009 (12) 
MhADI Mycoplasma 
hominis (ATCC 
23114) 
- 
 
Dimer   6.0 35.5 U/mg (pH 
6.0) ;  
3.9 U/mg (pH 
7.4)  
Mouse 
melanoma 
(MH134) in 
vitro, 100 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MhADI Mycoplasma 
hominis (ATCC 
14027) 
- Dimer  0.17 mM 
(pH6.6) 
   USA, Fenske, 
1976(14) 
MhADI Mycoplasma 
hominis  
E.coli BL21 
(DE3)/pET25b 
 0.24 mM; 
0.151 s-1 
   China, Luo, 
2007 (15) 
MhADI Mycoplasma 
hominis 
E.coli    20 U/mg ADI 
(37°C). [a] 
ADI-SS 
PEG20000,  
human 
melanoma, 
human HCC 
USA, Pheonix 
Pharmacologi
cs, Inc., Clark, 
2002 (16) 
PaADI 
(PA5171) 
Pseudomonas 
aeruginosa  
(ATCC 47085D) 
E. coli 
BL21(DE3)/pET10
0 
Tetramer 0.14±0.01 
mM (pH 5.6) 
5.6   USA, 
Dunaway-
Mariano, 2005 
(17) 
PaADI Pseudomonas 
aeruginosa  
 
E. coli 
BL21 (DE3)/ 
pET SUMO 
   CARD-like 
domain, no 
catalytic 
activity 
Human cancer 
cell line SKOV-3 
USA, 
Chakrabarty, 
2006 (18) 
PpADI Pseudomonas 
plecoglossicida 
E. coli 
BL21 Gold-(DE3)/ 
pET42b 
 0.7 mM; 5.6 
s-1 (pH 7.4, 
0.5 M sodium 
phosphate 
buffer) 
6.5 31.3 U/mg (pH 
7.4, 0.5 M 
sodium 
phosphate 
buffer) 
 Germany, 
Schwaneberg, 
 2010 (3) 
 4 
MaADI Mycoplasma 
arginini 
(ATCC 23838D) 
E. coli 
DH5α/PTTQ118 
   32.7 U/mg. [a] Human 
umbilical vein 
endothelial 
(HUVE) 
USA, Shen, 
2002 (19) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
E. coli 
JM101/pADTc1 
Dimer     33.6 U/mg 
(37°C, pH 6.5). 
[a] 
Mouse 
hepatoma, 17 
ng/ml for 50 % 
IC50; mouse 
fibrosarcoma, 
15 ng/ml for 50 
% IC50 
Japan, 
Hayashi, 1994 
(20) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
    42 U/mg 
(37°C, pH 6.5); 
29.9 U/mg 
(37°C, pH 7.4) 
Mouse 
melanoma 
(MH134) in 
vitro, 10 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
-     HUVE, 
neuroblastoma, 
retinoblastoma, 
osteosarcoma, 
5~10 ng/ml for 
50 % IC50 
Germany, 
Schweigerer, 
1999 (21) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
- Dimer  0.2 mM 6.0-7.5 50 U/mg Mouse tumor 
carcinoma, 
fibrosarcoma 
and melanoma, 
5~20 ng/ml for 
50 % IC50 
Japan, 
Takaku, 1992 
(22) 
LlADI L. lactis (ATCC 
7962) 
E. coli 
BL21Gold(DE3)/p
GEM-T Easy 
Trimer 8.67 mM 7.2 140.27 U/mg  Korea, Lee, 
2007 (23) 
[a] ADI was expressed in inclusion body and denaturation-renaturation had to be employed to get soluble protein. 
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1.2 ADI structure 
In 1970s, Kakimoto et al. (24, 25) diffracted the first ADI crystals from P. putida 
through multiple-step chromatography followed by crystallization. Almost three 
decades later, the X-ray crystal structure of ADI from P. aeruginosa (PaADI, 
Figure 1A) (26) and M. arginini (MaADI, Figure 1B) (4) were solved to assist in 
understanding structure-function relationships. PaADI and MaADI share 27 % 
sequence identity and belong to guanidino group-modifying enzyme superfamily 
(GMSF). The catalytic triad (Cys-His-Glu/Asp) is conserved in members of the 
GMSF. Both crystal structures of PaADI and MaADI show a characteristic 5-fold 
pseudosymmetrical barrel with ββαβ subunits. Table 2 summarizes the crystal 
structures of PaADI and MaADI. 
 
Figure 1. Structural of ADIs from P. aeruginosa and M. arginini. (A) PaADI (PDB ID: 1RXX) and 
stereo view of its catalytic triad (C406-H278-E224). (B) MaADI (PDB ID: 1S9R) and stereo view 
of its catalytic triad (C398-H269-E213) with substrate L-arginine (27). 
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Table 2.  Crystal structures of ADI in protein data bank (PDB). 
PDB 
code 
Ligand in crystal 
structure Description 
Resolution 
(year) 
2A9G Arginine 
Crystal structure of PaADI variant C406A in 
complex with L-arginine  
2.30 Å 
(2005) 
2AAF  
Crystal structure of PaADI variant H278A 
forming a S-alkylthiouronium reaction 
intermediate  
2.30 Å 
(2005) 
2ABR  
Crystal structure of PaADI variant D280A with L-
arginine forming a S-alkylthiouronium reaction 
intermediate  
2.9 Å 
(2005) 
2ACI  Crystal structure of D166A arginine deiminase  
2.50 Å 
(2005) 
1S9R Arginine 
Crystal structure of MaADI covalently linker with 
a reaction in intermediate  
1.60 Å 
(2004) 
1LXY Citrulline 
Crystal Structure of MaADI covalently linked with 
L-citrulline  
2.00 Å 
(2004) 
1RXX  Crystal structure of MaADI  
2.45 Å 
(2004) 
 
MaADI was crystallized as a homodimer and its catalytic triad is formed by 
Cys398-His269-Glu213. MaADI has a catalytic domain and a five-helix bundle 
domain (Figure 3). The buried and compact substrate binding pocket is located 
approximately at the center of the molecule, from which a small solvent channel 
leads to the surface of the enzyme. The opening to the channel is located 
adjacent to the dimer interface region, which is at the opposite side of the 5-fold 
pseudosymmetric moiety of ADI. The shape and size of the channel does not 
permit transport of the substrate (L-arginine and end product (L-citrulline) in and 
out of the pocket. Substantial conformational changes in ADI are required to 
permit entry of the substrate and expulsion of the end product. The occurrence of 
"closed" and "open" form was suspected to be dependent on binding of substrate. 
 
PaADI has a tetrametric structure with 1630 amino acid residues in total, which 
makes it the largest enzyme of its structural superfamily. The catalytic triad of 
PaADI is Cys406-His278-Glu224. Similar to MaADI, the active site of PaADI is 
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located in a narrow crevice formed by a network of charged residues. Ligand 
binding energy is derived from ion pair and hydrogen bonding interactions 
between active site residues and the guanidinium, carboxylate and ammonium 
groups of the substrate. The proposed substrate-binding model shows that the 
catalytic center contains abundant charged residues (e.g. Asp280, His405, Glu13 
and Arg165). The ion pairing interactions between these residues contribute to 
the integrity and activity of ADI. In addition, Asp116, Asp227, Arg185, Arg401, 
His278, Glu118, and Glu224 are part of an extended charged network. The 
proposed catalytic mechanism suggests that the active site of PaADI is blocked 
by Arg401, and therefore a conformational transition is taking place upon the 
substrate binding. Based on the proposed reaction mechanism, Cys406 is as a 
key residue responsible for the nucleophilic attack on the guanidinium carbon 
atom of arginine. PaADI contains only one hydrophobic residue, Phe-163 and a 
Cys-406 with an unknown protonation state. The known functions of important 
residues are shown in Table 3, and the interactions between important residues 
and substrate arginine are shown in Figure 2. 
 
 
Figure 2. A. stereoscopic view of PaADI key active site residues. B. stereoscopic view of a 
modeled arginine substrate (green) docked in the active site of ADI. Atomic colors are red, 
oxygen; blue, nitrogen; yellow, sulfur; and gray, carbon. Ion pair interactions are shown as 
dashed lines (26). 
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Table 3. Residues important for catalytic function of PaADI (28, 29). 
Residues Known/postulated function or comment 
Cys406 Mounts the nucleophilic attack on the carbon atom of the guanidinium 
group of arginine 
His278 Serves as a general base and activate the water molecule 
Glu224 Modulate the ionization state of His278 
Asp280 Interacts with the imidazole group of His405 F via the carboxylate 
group, which in turn interacts with Glu13. Invariant residue in all 
known ADIs 
Asp280, 
Asp166 
Fix the guanidinium group of the arginine substrate tightly by 
interactions with the carboxyl groups 
Arg401, 
Arg185 
Form ionic interaction with The carboxyl group of the arginine 
substrate 
Phe163 Interacts with the hydrophobic part of arginine substrate 
Glu13 Interacts His405 and is invariant in all known ADIs 
His405 Sometimes is replaced by an arginine, as in the case of McADI. This 
may explain the low pH optimum of PaADI (5.6) in contrast to the 
neutral pH optimum of McADI, the enzyme that contains an arginine 
residue instead of His405 
Arg165 Is fixed by electrostatic interactions with the main chain oxygen atoms 
of Thr408 and His405 and with the hydroxyl group of Thr-408 
Arg401 Blocks the ADI active site via the side chain by forming an ion pair 
with the carboxyl group of Asp166 and occupies approximately the 
same position as the guanidinium group of an arginine substrate 
 
The overall fold of MaADI and PaADI consist of five ββαβ modules in cyclical 
arrangement, generating a pseudo 5-fold symmetrical barrel and an additional 
85-residue α-helical domain inserted between the first and the second ββαβ 
modules giving the typical “Clip-on-fan” moiety. The α-helical domain of PaADI 
mediates tetramer formation and the α-helical domain of MaADI was speculated 
to play a role in activating the series of reaction in arginine dehydrolysis pathway 
(4). Structural alignments by Chakrabarty et al. (18) demonstrated the unique 85 
residue 5-α-helical bundle domain exhibiting structural similarity to the 
mammalian CARD (caspase recruitment domains)-containing proteins and this 
CARD-like domain is present only in the PaADI and MaADI but not in the other 
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GMSF members (Figure 3B). Furthermore, PaADI putative CARD-like domain 
induced apoptosis to cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structural characteristics of the PaADI. A. Ribbon drawing of PaADI (1RXX_A) 
highlighting the two domains. B. The presence of the CARD domain in PaADI and MaADI but its 
absence in other members of the GMSF (guanidino-group modifying superfamily) enzymes such 
as DDAH and AGAT, as shown from the structure-based sequence alignments. The CARD 
domain represents that of caspase-9. DDAH, dimethylarginine dimethylaminohydrolase; AGAT, 
arginine: glycine amidinotransferase. The β-strand and α-helices are shown as arrows and strips 
respectively. Roman numericals I to V are the five ββαβ subunits. The clip moiety (α-helical 
module) in Figure 3 is seen only in PaADI and MaADI which bears structural homology to the six-
α-helical modules that form the CARD domain of the caspase-9 protein molecule. N, N-terminal; 
C, C-terminal. C. A schematic diagram showing the overall fold and topology of PaADI, as 
reported (18). 
 
Comparison of substrate free and substrate bound structure of PaADI gives 
interesting insight into structure changes upon substrate binding (17). Pairwise 
superposition of the free wild-type PaADI (PDB code: 1rxx) and the mutant 
enzyme substrate complexes (PDB code: 2a9g) show that the overall fold of the 
structures remains similar, yet with some local changes. In particular, four loops 
(Figure 4) associated with the active site undergo conformational transitions not 
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related to crystal packing: loop 1 (residues 30-46), loop 2 (residues 178-185), 
loop 3 (residues 271-281, part of this loop is disordered in the apoADI structure), 
and loop 4 (residues 393-404). Residues adjacent to the substrate exhibit the 
most significant shifts. For example, the α-carbon atom of Leu41 (loop 1) shifts 
by 2.7Å and that of Arg185 (loop 2) by 1.8 Å; the α-carbon atom of His278 (loop 
3) shifts by 0.9 Å and that of Gly400 (loop 4) by 4.4 Å. These are localized but 
mechanistically important conformational transitions that tighten the surrounding 
of the substrate. Simultaneously, substrate binding is accompanied by 
displacement of the side chain of Arg401 (loop 4) by more than 8 Å to enable 
access to the active site. The superposition of ADI and PAD4 ADI active site is 
shielded from the solvent by a long loop (residues 25-48 in PaADI) and the 
following two turns of α-helix (residues 49-56). 
 
 
 
 
 
Figure 4 (A). Stereoscopic view of ADI in the unbound and bound states. Superposed molecules 
are colored gray where the trace of the polypeptide chain is similar in both structures. For regions 
exhibiting differences, loops of the apoADI structure are highlighted in blue, and loops of the ADI 
structure complexed with arginine are highlighted in red. 4(B). Structural relationship between ADI 
(yellow) and PAD4 (cyan) (17). 
1.3 Catalytic reaction mechanism of ADI 
The overall reaction catalyzed by ADI is the hydrolytic substitution of the ŋNH2 
group from the guanidinium group Cζ of L-arginine, leading to citrulline and 
ammonia (Figure 5). Herzberg (17) and Arnold (4) proposed ADI catalysis 
mechanism for PaADI (Figure 5) and MaADI, respectively.  Basically, both of the 
proposed mechanisms are composed of three main steps: 1) thiol group of 
B A 
  11 
Cys406 mount a nucleophilic attack on the guanidinium group of arginine and a 
proton is transferred first to ŋNH2 group; 2) water molecule is activated by His278 
and followed by attacking the covalent intermediate to replace and release NH3; 
3) the C-S covalent bond between enzyme and the resulting citrulline is cleaved 
and thus end product citrulline is released and free enzyme is generated for next 
catalytic cycle. 
 
 
Figure 5.  Mechanism of PaADI catalysis of arginine to citrulline and ammonia (17). 
1.4 Anti-tumor application of ADI 
Amino acids depletion is one type of targeted therapy for human cancers which 
are auxotrophic for a particular amino acid. Amino acids degrading enzymes, 
such as asparaginase (30), methioninase (31), arginase (32), arginine deiminase 
(27), phenylalanine ammonialyase (33) and tryptophanase (34) have been 
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studied for inhibition of tumor cells in vitro. The most representative anticancer 
enzyme is asparaginase, which is particularly effective in acute lymphoblastic 
leukaemia. PEG asparaginase is commercialized for acute lymphoblastic 
leukaemia treatment (Oncaspar®, pegaspargase) (35). However, asparaginase 
treatment is sometimes accompanied by serous side-effects including 
anaphylactic shock, coagulapathies as well as liver and pancreatic toxicity (36).  
 
Arginine is an important amino acid involved in the synthesis of a wide range of 
peptides and proteins, production of creatine and nitric oxide, and a myriad of 
metabolic pathways and cellular events. It is a precursor of proline, polyamines, 
glutamine, glutamate, and other neurotransmitters, such as g-aminobutyric acid 
and also serves as a substrate for two important enzymes, arginase and nitric 
oxide synthetase (37). Arginine is an indispensable amino acid to children but a 
semi-essential amino acid in adult humans since many adult somatic cells can 
synthesize it from citrulline in two steps via urea cycles (Figure 6). The enzyme 
argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline and 
aspartic acid to argininosuccinate which is then further converted to arginine and 
fumaric acid by argininosuccinate lyase (ASL). Arginine can be degraded to 
ornithine by the urea cycle enzyme arginase. Ornithine is then converted back to 
citrulline by ornithine carbamoyl transferase (OTC) and then recycles back to 
arginine from citrulline by ASS/ASL. Thus, the ability to regenerate arginine from 
citrulline depends on the amount/activity of ASS and ASL, which are tightly 
coupled. The sensitivity of cells to arginine deprivation depends on the ability of 
ASS and ASL to regenerate arginine from the alternative intermediate (ornithine, 
citrulline and argininosuccinate) in the urea cycle. 
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Firgure 6. Urea cycle. Argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline 
and aspartic acid to argininosuccinate which is then further converted to arginine and fumaric acid 
by argininosuccinate lyase (ASL). Arginine can be degraded to ornithine by the urea cycle 
enzyme arginase. Ornithine is then converted back to citrulline by ornithine carbamoyl transferase 
(OTC) and then recycles back to arginine from citrulline by ASS/ASL.  
 
Arginine begins to become limiting at ~10-4 M, whereas other amino acids can 
sustain growth at 10-5-10-6 M. Wheatley et al. showed that most tumour cell lines 
die considerably more quickly during arginine deprivation than in the absence of 
any other single (or group of) essential amino acids (38). Since 1930 for the first 
time arginine known is essential for the growth of some forms of cancer, the 
potential of arginine degrading enzymes as therapeutic agents was recognized, 
investigated and employed for arginine auxotrophic tumor treatments. Enzymes 
capable of depleting arginine in vitro include arginase existing in human liver, 
arginine decarboxylase from bacterial, plant and human, and ADI from 
microorganism. 
 
Arginine decarboxylase converts arginine to agmatine, which is toxic at high 
plasma concentration. Furthermore, arginine decarboxylase has a short half-life 
and it loses virtually all enzymatic activities upon pegylation though pegylation of 
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arginine decarboxylase is inefficient because not enough lysine residues for 
polyethylene glycol to attach (39). 
 
Arginase is limited for anti-tumor application because of its low substrate affinity 
(Km value 2-4 mM; plasma arginine 100-120 µM), short circulatory half-life (10-15 
min) and sub-optimal enzymatic activity at physiological pH (alkaline pH optimum, 
pH 9.3)(40). Despite these disadvantages of arginase, Lam et al. reported  
remission of hepatocellular carcinoma induced by systemic release of 
endogenous hepatic arginase (41) and Leung et al. proved pegylated 
recombinant human arginase (rhArg-peg 5,000mw) can inhibit ASS-positive 
HCCs while ADI can not (42). 
 
In addition, ADI, another arginine-degrading microbial enzyme, has various 
biological activities including anti-proliferation, anti-angiogenesis and inhibition of 
inducible nitric oxide synthase (iNOs). Figure 7 summarizes how ADI affect many 
arginine-related cellular functions. ADIs (Table 1) have been shown to have 
strong in vitro and in vivo inhibition for arginine auxotrophic tumors (e.g. 
hepatocellular carcinomas (HCCs), melanomas, retinoblastoma (43), prostate 
cancer(44)) and ADI from M. hominis (MhADI) is currently under clinical trial for 
HCC (phase II) (45) and melanomas (phase I/II) (46). Studies on human 
lymphatic leukemia cell lines confirmed ADI’s anti-angiogenic activity. Among all 
the ADIs, MhADI and MaADI were studied most intensively (Table 1). 
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Firgure 7. Summary of ADI effects on arginine-related cellular functions. rADI inhibits NO 
production via iNOS, but potentiates NO production via eNOS in the cultured endothelial cell 
model. rADI enhances or inhibits AS activity in different cells. rADI inhibits de novo protein 
synthesis in cells with low AS activity, but not in cells with high AS activity. Polyamine synthesis 
was not significantly affected by rADI, even in cells with low AS activity. Arrow representation: 
solid, potentiates; blocked, inhibits; dotted, no effect (47).  
 
In 1999, US Food and Drug Administration (FDA) designated ADI-PEG-20 
orphan drug status for treating HCC and invasive malignant melanomas. In 2005, 
also the European Agency for the Evaluation of Medicinal Products (EMEA) also 
granted ADI-PEG-20 orphan drug status for HCC. Phase II trials of ADI-PEG-20 
in patients with metastatic hepatocellular carcinomas have shown that the drug is 
safe, well tolerated, and may benefit patients with unresectable HCC. Izzo and 
coworker suspected that combination therapies of arginine deprivation and 
growth inhibition via kinase inhibitors might improve the survival rate further. 
Additionally, ADI enhances radio sensitivity of human mammary adenocarcinoma 
(MCF-7 cells) (48), exerts anti-proliferative as well as anti-angiogenic activities 
and inhibits the growth of viruses such as HIV-1 and hepatitis (49, 50). Current 
research efforts are focused on ADI’s in vivo inhibitory effect towards leukemia, 
melanoma, prostate cancer, renal cell carcinoma, and human umbilical vein 
endothelial cells (HUVEC) (19, 44, 51-53), clinical trials for HCC (phase II) (45) 
and melanoma (phase I/II) (46), and tumor inhibitory mechanisms of ADI (54). 
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The effectiveness of ADIs as anti-tumor agent depends on their enzymatic 
properties (such as Km, kcat, optimum pH, stability at neutral pH), selectivity on 
tumor cells, stability in blood circulation and immunogenicity. Pegylation (35) has 
been effective in reducing their immunogenicity in animal and increase their 
stability to various hydrolytic enzymes in plasma. Directed evolution as powerful 
algorithm to design proteins allows improving all properties that can be reflected 
in a screening system through iterative rounds of diversity generation and 
screening. Small libraries of a few thousand variants are often sufficient to find 
improved variants (55) even without rational understanding of the targeted 
property. The first example of directed ADI evolution by our group (3) provides a 
simple and effective screening system to improve activity of PpADI at 
physiological pH.  
 
1.5 Conclusion 
ADI-based arginine deprivation is a novel and promising targeted approach to the 
treatment arginine auxotrophic tumors, in particular, melanoma, hepatocellular 
carcinoma and leukemia. Certain mesotheliomas and renal cell cancers were 
also proved to be sensitive to ADI therapy. Due to its low incidence of major side 
effects (myelosuppression and gastrointestinal toxicity or other major organ 
toxicity) arginine deprivation treatment should be combined with other anticancer 
treatments to increase the response rate. Reengineering of ADI by protein 
engineering is a promising strayegy to tailor ADI properties for demands in 
medical applications. Solved ADI crystal structure enables to understand 
structure function relationships and to guide protein engineering. 
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Chapter 2 Directed evolution 
Directed evolution 
 
2.1 Introduction to directed evolution 
Enzymes are increasingly being used in the generation of products that are 
traditionally made using chemical synthesis and the field continues to expand its 
horizons, particularly as applied to the synthesis of the fine chemicals and 
pharmaceuticals (56, 57). Naturally occurring enzymes are often not designed for 
the applications of interest, since after all they are evolved in nature for a 
purpose other than being the catalysts of industrial processes. Directed evolution, 
rational design and biodiversity screening and combined approches are the main 
strategies to reengineer enzymes for addressing application demands. Directed 
evolution has emerged as a powerful enabling method for improving enzyme 
properties in iterative cycles of diversity generation and screening (Figure 1).  
 
A main advantage of directed evolution compared to rational design is that it 
does not require structural or mechanistic information for protein optimization. 
Directed protein evolution has been successfully used for altering and improving 
protein properties (solubility, expression, enantioselectivity, stability and activity 
in unusual environment, allosteric interactions, tolerance to pH), as well as for 
regulating other molecules and systems, including RNA, DNA regulatory 
elements, biosynthetic pathways and genetic regulatory circuits (58-60).  
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Figure 1. Procedure of a directed evolution experiment. It involves three key steps: 1) selection a 
good starting sequence and mutating the parent to create a library of variants; 2) identification 
variants with improved function and 3) isolation of gene encoding for improved variant and 
repeating the process until the desired function is achieved. 
 
A parent sequence (or sequences) is chosen based on its perceived proximity to 
the desired function and its evolvability (the ability of a protein to adapt in 
response to mutation and selective pressure). A parent protein for directed 
evolution should exhibit enough of the desired function that small improvements 
can be reliably discerned in a high-throughput screen.  
 
Variants library should be generated with high probability of finding improved 
variants given the screening capacity. With a high-throughput screening method, 
a library can be constructed to generate the large potential improvement. Arnold 
and coworkers(61) showed that very low mutation rates result in many functional 
sequences but only a small number are unique sequences, however very high 
mutation rates produce diverse sequences but few retain function. Schwaneberg 
and coworkers(62) reviewed random mutagenesis methods, focused library 
generation methods and computational tools for high-quality mutant libraries 
generation. Schwaneberg and coworkers (63) also summarized criteria for an 
ideal mutagenesis methods: unbiased mutational spectrum, controllable mutation 
frequency, consecutive nucleotide substitutions or codon-based substitutions, 
enable subset mutagenesis (e.g. introduction mainly positively or negatively 
charged amino acid), independent of gene length, technically simple and 
reproducible, and economical. 
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Screening is used to identify library members improved in the targeted property. 
Identification of improved variants though selection or screening is “analogous” to 
evolutionary pressure in natural evolution (i.e. only the fittest survive). As the 
word “directed” in directed evolution implies, laboratory evolutionary pressure is 
defined and applied by the researcher in screening system. Gradually increasing 
the selection pressure or evolving against a series of intermediate challenges 
often accumulates useful single mutations and yields desired variants (64).  
 
Traditional methods for screening employ microtiter plate formats (96-well, 384-
well, 1,536-well (65) and even 1,000,000-well (66)) or solid phase assay (agar 
plate, filter paper and nitrocellulose membrane), which typically enable the 
screening of no more than 106 variants by using robotic automation (67). 
Sometimes, fast and universal analytic methods like HPLC (68) or GC-MS (69) 
are utilized for performing an efficient screen of a non-natural substrate. However, 
the number of screened mutants is limited to 104-106. In recent years flow 
cytometry systems (67, 70, 71) have become increasingly attractive, especially 
after the development of emulsion technology offering compartmentalization and 
high throughput up to 107/h. In addition, Weitz and coworkers (72) recently 
reported a promising ultrahigh-throughput screening in drop-based microfluidics, 
by which one can screen a library of 108 in about 10 h. Dijkhuizen et al. 
compared in a review (73) six kinds of library screening strategies (Figure 2). 
Selection techniques rely on a direct link between cell growth and improved or 
acquired enzyme function and therefore it is limited to engineering detoxifying 
enzymes (e.g. b-lactamase) or enzymes that synthesize essential nutrients for 
cell growth and survival. The traditional microtiter plate screenings are medium-
throughput and the most simplistic format of screening. It involves the incubation 
of colonies with the substrate of targeted enzyme. The crucial factor with this 
screening technique is that substrate conversion creates a visual signal, such as 
fluorescence or color, to identify colonies expressing an enzyme with desirable 
properties. Microtiter plate based screenings are the most commonly applied 
method in identifying desirable enzyme variants. Microtiter plate based 
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screenings enable the use of various analytical tools and in the mean while they 
offer a great dynamic range. Their screening capacity is usually limited to less 
than 104 variants per day. Screening based on microfluidic device and sorting 
device is a new screening platform for directed evolution, which offers ultra-high-
throughput. It allows the discriminate between wild-type and a less active mutant 
and allows for the addition of substrates and quenchers at desired time thus 
extending the scope of directed evolution screening strategies. Cell as micro-
rector, cell surface display and in vitro compartmentalization technology are also 
FACS (fluorescence-activated cell sorting system) dependent methods for high-
throughput screening and allow 109-1010 screening capacity. 
 
Once improved enzymes are identified, encoding genes are isolated and 
subjected to further iterative cycles of mutation and screening in order to 
accumulate beneficial mutations until the targeted improvement is hopefully 
achieved. The number of iterations required depends on the starting point, the 
protein fold and the selected properties which determine the possible mutational 
load and achievable improvement. 
 
Four accepted requirements for successful directed evolution 
(http://www.che.caltech.edu/groups/fha/) are, 1) the desired function must be 
physically possible; 2) the function must also be biologically, or evolutionarily, 
feasible. In practice, this means that there exists a mutational pathway to get 
from here to there through ever-improving variants (see above). A good 
experiment will maximize the likelihood; 3) Suitable host (E. coli or S. cerevisiae) 
which allows functional expression of more than 106 variants per µg of DNA. 4) A 
rapid screen or selection that reflects the desired function. How rapid the screen 
must be depends on how rare mutations leading to the desired property are and 
how many must be accumulated to achieve the desired result. 
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Figure 2. Overview of screening technologies. (A) Experimental steps from obtaining the gene 
library as PCR product to the actual screen. Note that cloning and transformation efficiency are 
often limiting library size; (B) Explanation of symbols; (C) Cell growth/survival selection and agar 
plate screening; (D) Microtiter plate screening; (E) Cell as micro-reactor; (F) Cell surface display; 
(G) Cell-in-droplet; and (H) In vitro compartmentalization (73).  
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2.2 Directed enzyme evolution for pH tolerance of enzymes 
Application of enzymes in processes at a specified pH necessitates protein 
engineering to change their pH performance. Directed evolution and rational 
design method were applied to improve enzyme specific activity at certain pH or 
shift their pH profiles. Some representative success stories of directed protein 
evolution improving pH performance are summarized in Table 1. 
Table 1. Improvement obtained from directed evolution or rational design for pH performance. 
Enzymes Mutagenesis 
methods 
Screening 
methods 
Improvements References 
Human  
β-glucuronidase 
EpPCR and 
saturation 
mutagenesis 
Flow 
cytometry 
60-fold more active (kcat/Km) at pH 7.0 
and were up to an order of magnitude 
more effective at catalyzing the 
conversion of two structurally 
disparate glucuronide prodrugs to 
anticancer agents 
2008 (74) 
Bacterial xylanase DNA shuffling Agar plate 
assay 
About 5-fold improvement of specific 
activity at pH 9.0 
2008 (75) 
Human pancreatic 
lipase 
EpPCR Agar plate 
and microtiter 
plate assay 
1.5-fold of activity improvement at 
acidic pH 
2010 (76) 
Bacterial arginine 
deiminase 
EpPCR and site 
directed 
mutagenesis  
Microtiter 
plate assay 
pH optimum shifted from pH 6.5 to pH 
7; 4-fold of activity improvement at pH 
7.4 
2010 (3) 
Bacterial α-amylase EpPCR Microtiter 
plate assay 
5-fold higher activity at pH 10 than 
wild type 
2003 (77) 
Eukaryote D-
pantonohydrolase 
EpPCR and 
DNA shuffling 
Agar plate 
assay 
10.5-fold higher specific activity and 
retain 85% of its original activity after 
incubation under low pH 
2006 (78) 
Vanadium 
chloroperoxidase 
EpPCR, site 
saturation 
mutagenesis 
and site directed 
mutagenesis 
Microtiter 
plate assay 
About 100-fold improvement of 
specific activity at pH 8 
2006 (79) 
Bacterial class-A non-
specific acid 
phosphatase (PhoN)   
Site directed 
mutagenesis 
 
1.6-fold of activity improvement over 
broder pH range 
2006 (80) 
Aspergillus niger PhyA 
phytase 
Site directed 
mutagenesis 
 
pH shifted from 5.5 to 3.8 (1.7 unit); 
2.66 -fold improvement of activity at 
pH 3.5 than wild type. 
2006 (81) 
Bacillus cereus β-
amylase 
Site directed 
mutagenesis 
 
pH optimum shifted to pH 4.2-4.8 by 
2 pH units. 
2004 (82) 
Phytase Site directed 
mutagenesis 
 
pH optimum shifted by 0.5-1 pH unit; 
a slight increase in maximum specific 
activity 
2002 (83) 
Alcohol 
dehydrogenase 
Site directed 
mutagenesis 
 
pH optimum shifted from 7.8  to 9.0; 
about 2-fold improvement of 
maximum activity at pH 9.0 than that 
of wild type 
1991 (84) 
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Many examples of rational reengineering of an enzyme pH optimum exist (Table 
1). For shifting the pH optimum, a deep understanding of molecular dynamics is 
essential part of understanding enzyme flexibility. Rational design method 
successfully shifted enzyme pH profile. pH dependence of an enzyme is 
determined by the ionization of the catalytic groups, which is affected by various 
interactions involved in their microenvironments. In order to catalyze certain 
reactions, ionizable residues in active site should act as nucleophile or acid/base 
catalyst and they need to maintain proper ionization state for proper activities of 
proteins. The pKa value of the proton donor and the catalytic nucleophilic residue 
are therefore limiting the pH range at which the enzyme can function, and 
therefore pH-dependent activity can be differed by the pKa of the key residues. 
The pKa value of the residue is governed by intrinsic acidity of the functional 
group and other factors (electrostatic interaction from neighboring and the 
heterogeneous dielectric environment in the protein solution system). The 
electrostatic potential generated by the charged titratable residues affects the 
ground state of the protein, such as stability, binding to ligands and pKa values of 
ionizable groups. The electrostatic potential of proteins can be calculated by 
using computational procedures (Delphi, UHBD, CHARMM) and can be 
increased or decreased through mutations. For shifting the pH optimum of 
enzymes, many researchers have tried to substitute catalytic residue by site-
directed mutagenesis (Table 1).  
 
Yoo and coworkers (85) analyzed the relation between the shift of pH optimum 
and change in electrostatic potential due to mutation using Delphi. They identified 
key residues of xylanase responsible for electrostatic potential of catalytic 
residues but not affecting the catalysis directly. The latter hypothesis was proven 
by site directed mutagenesis in a later report. Wyss and coworkers (83) 
summarized strategies for enzyme pH profile modification, 1) replacement of 
ionizable groups that are directly  involved in substrate or product binding and/or 
catalysis by nonionizable ones or by amino acids with different charge or pKa 
values; 2) replacement of residues that are in direct contact with residues 
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mentioned in 1) by forming hydrogen bonds and/or salt bridges; 3) alteration of 
longer-range (indirect) charge-charge interactions by modification of the surface 
charge of the enzyme. 
 
When there is no structure-function relationship information available for an 
enzyme, directed evolution is the best option to tailor the pH performance of 
enzyme for application demands (Table 1). Directed evolution allows improving 
all properties that can be reflected in a screening system through iterative rounds 
of diversity generation and screening. Small libraries of a few thousand variants 
are often sufficient to find improved muteins even without rational understanding 
of the targeted property (76, 86). Using MTP assay, epPCR mutant libraries with 
a ratio of 50 % active and 50 % inactive clones have often been used 
successfully in directed evolution, improving enzyme properties by gradual 
changes (one or two amino acids changes per round of mutagenesis and 
screening). 
 
2.3 Directed enzyme evolution for medical application 
Directed evolution has been very useful for improving enzymes for industrial 
needs. In recent years, there is also growing number of enzymes applied for 
therapeutic purpose. For the development of protein therapeutics, directed 
evolution started to be used to tailor enzyme properties in medical field, for 
example drug delivery (87, 88) and has proven to be a useful tool for generating 
protein variants with enhanced therapeutic potential (88), for example, improving 
the effectiveness of therapeutic enzymes, antibodies, vaccines and viruses. Here, 
the improvements of therapeutic protein for anti-tumor application by directed 
evolution are discussed in more details. 
 
2.3.1 Prodrug enzymes for tumor chemotherapy    
Prodrug cancer chemotherapy has attracted considerable interest due to the 
possibilities it provids to overcome various barriers to drug formulation and 
delivery (such as poor aqueous solubility, chemical instability, insufficient oral 
  25 
adsorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity 
and local irritation) (89). Examples of such drugs currently in use in cancer 
treatment include 5-fluorocytosine, cyclophosphamide, capecitabine, mitomycin 
C, and AQ4N (90). However, the side effects of prodrug therapy remain a serious 
concern which arises from the fact that noncancerous cells also possess the 
capacity to degrade them. This has triggered the interest to generate more 
effective prodrug-activating enzymes so that prodrugs can kill tumor cells at 
concentrations that generate little or no side effects. Further goals are to design 
more powerful and tumor-specific drugs, and to devise more effective methods 
for delivering them specifically to tumors. 
 
By applying directed evolution through the technique of error-prone PCR, Martin 
and coworkers (90) indentified YieF variant exhibiting >5-fold increased capacity 
to kill HeLa cells. Furthermore, YieF variant was proved to be effectively 
delivered to tumor cells using a strain of Salmonella typhimurium (SL 7838). 
 
Human β-glucuronidase, due to low intrinsic immunogenicity in humans, is an 
attractive enzyme for tumor-specific prodrug activation. However its utility is 
limited by low activity at physiological pH. Roffler and coworkers (74) developed 
a high-throughput screening procedure for enzymatic activity based on the stable 
retention of fluorescent reaction product in mammalian cells expressing properly 
folded glycoproteins on their surface. This procedure was utilized to screen error-
prone PCR and saturation mutagenesis libraries to isolate β-glucuronidase 
tetramers that were up to 60-fold more active (kcat/Km) at pH 7.0 and were up to 
one order of magnitude more effective at catalyzing the conversion of two 
structurally disparate glucuronide prodrugs to anticancer agents. 
 
2.3.2 Oncolytic viruses for tumor chemotherapy  
Viral-mediated oncolysis is a novel cancer therapeutic approach with the 
potential to be more effective and less toxic than current therapies due to the 
agents’ selective growth and amplification in tumor cells. To date, these agents 
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have been regarded as highly safe in patients but have generally fallen short of 
their expected therapeutic value as monotherapies.  
 
Consequently, new approaches to generate highly potent oncolytic viruses are 
required. For the latter purpose, Hermiston and coworkers (91) developed a new 
method and termed it also ‘‘Directed Evolution’’ for creating highly potent 
oncolytic viruses. Viral serotypes representing Ad subgroups B-F were pooled 
and passaged twice on sub-confluent cultures of the target tumor cell lines at a 
particle-per-cell ratio of approximately 200 to invite recombination between 
serotypes (Figure 3). Supernatants from the second round of the high viral 
particle-per-cell infection of sub-confluent cultures were then used in a 10-fold 
dilution series to infect confluent T-75 tissue culture flasks of target tumor cell 
lines PC-3, HT-29, Panc-1 and MDA-231. Using this ‘‘Directed Evolution’’ 
methodology, the novel generated chimeric oncolytic virus ColoAd1 
demonstrated ~ 2 log increase in both potency and selectivity when compared to 
ONYX-015 on colon cancer cells. In vivo and ex vivo studies therefore validated 
the innovative general approach for deriving clinically-relevant and potent anti-
cancer virotherapies. 
 
Figure 3. Hermiston’s “Directed Evolution” process of viruses and derivative viral pools (91). 
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2.3.3 Amino acid depriving enzyme for anti-tumor applications 
Naturally available enzymes are usually not optimally suited for therapeutic 
purposes. This incompatibility often relates to the stability or activity of the 
enzymes under body conditions.  
 
Despite many successful efforts to broaden the understanding of the structural 
basis of protein stability, there is still no universal strategy to stabilize protein by a 
limited number of rationally designed mutations. Well-known and reasonably 
successful types of rational engineering work include substitutions that increase 
rigidity (e.g. substitute amino acid Xxx with Pro or substitute Gly with other amino 
acid Xxx or the introduction of disulfides). These substitutions have effects on the 
entropy of the unfolded state, improvement of molecular packing (e.g. shortening 
of loops, improvement of interactions in the hydrophobic core, for example, by 
the removal of internal cavities), modification of surface charge networks or 
reinforcement of a higher oligomerization state.  
 
Directed evolution provides a powerful approach for improving thermostability 
and does not need understanding of structure-function relationship. Most 
strategies for screening for enzyme stability rely on measuring residual enzyme 
activity before and after exposure to a denaturing challenge (e.g. high 
temperature, organic solvents, extreme pH) (92).  
 
Bacterial L-asparaginases have been used as therapeutic agents in the 
treatment of lymphoblastic leukaemia. The main restrictions to the therapeutic 
use of L-asparaginase include its premature inactivation. As a result frequent 
injections are required to maintain therapeutic levels. Repeated injections and 
high dose can cause several types of side reactions from mild allergies and the 
development of immune responses to dangerous anaphylactic shocks (93). 
Enhancing the stability of L-asparaginase by protein engineering improves its 
body-residence time, and thereby minimizes immunosuppressive effects by 
lowering the therapeutic dose. Labrou and coworkers (94) obtained a 
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reengineered L-asparaginase with enhanced thermal stability. Single mutation on 
the surface of the protein resulted in ~10 degree increased Tm value (half-
inactivation temperature). The thermostable variant has to be tested further on 
animals and ⁄ or humans in order to be advanced to a potent therapeutic drug. 
 
Another example of a reengineered amino acid-deprivating enzyme is PpADI. 
PpADI is a promising anti-tumor enzyme however with a non-physiological 
optimal pH and relative high Km value which hindering its medical application. By 
directed evolution and site saturation mutagenesis, PpADI variants with higher 
activity at physiological pH and at low arginine concentration of were obtained 
with improved properties to become a potent anti-tumor drug (see chapter 3 and 
chapter 4). In vitro and in vivo test of the improved variants are required to 
evaluate the anti-tumor effectiveness.  
 
2.3.4 Affibody molecules for cancer prognosis 
Affibody molecules represent a new class of affinity proteins that are based on 
the Z-domain scaffold derived from staphylococcal protein A (95). Among the 
scaffold proteins, Affibody molecules constitute the smallest non-cysteine-
containing protein scaffold. The small size (~ 7 kDa), robust structure, and 
straightforward production procedures (either by recombinant production in 
bacteria or by chemical synthesis) make Affibody molecules attractive targeting 
agents for in vivo radionuclide imaging (96) as well as for various 
biotechnological applications (97, 98). The small size offers a convenient affinity 
maturation principle. Gene synthesis allows randomizing the whole gene to 
generate diverse mutant library. The potential use of radiolabeled Affibody 
molecules for high-contrast radionuclide imaging of biomarkers has been 
demonstrated in preclinical studies and in pilot clinical studies. Affibody 
molecules are non-immunoglobulin-derived affinity proteins based on a three-
helical bundle protein domain.  
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Several of affinity proteins have been investigated for both in vivo diagnostics 
and therapy of tumor in radionuclide molecular imaging. Affinity proteins in tumor-
targeted therapy can affect tumor progression by altering signal transduction or 
by delivering a payload of toxin, drug or radionuclide. EGFR (epidermal growth 
factor receptor), one of the receptor in ErbB family, has been extensively studied 
as biomarkers in tumor targeting and over expressed in various malignancies, 
associated with poor patient prognosis and are therefore interesting targets for 
solid tumors. High affinity and especially slow dissociation rate are important for 
obtaining high contrast images. Affinity in the low nanomolar range is considered 
as a prerequisite for successful use of peptide-based tracers. 
 
Ståhl and coworkers (99) described the affinity maturation procedure for the 
generation of Affibody molecules binding with high affinity and specificity to 
EGFR. The library for affinity maturation was constructed using a single 
oligonucleotide for the rerandomization of desired positions. The new binders 
were selected with phage display technology and the best second-generation 
binders were characterized in vitro using real-time biospecific interaction analysis 
(BIA) for their binding to recombinant EGFR and with flow cytometry for their 
binding to native EGFR. Second-generation binders achieved an approximately 
30-fold improvement in affinity (Kd = 5-10 nM) for the soluble extracellular domain 
of EGFR in biospecific interaction analysis using Biacore. 
 
2.3.5 Interferon for anti-tumor applicaiton 
Alpha interferons (IFN-as) are members of the diverse helical-bundle superfamily 
of cytokine genes, which have potent antiviral and antiproliferative activities and 
therefore can be used as anticancer and antiviral agents. However, doselimiting 
toxicity, receptor cross-reactivity, and short serum half-lives significantly reduce 
the clinical use of many of these cytokines. 
 
Patten and coworkers (100) performed a family shuffling experiment with over 20 
human interferon-α (Hu-IFN-α) genes. Antiviral assay and proliferation assay 
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were used to indentify clones with improved activity on Hu-IFN-α receptor. One 
clone showed 285,000-fold improved activity relative to Hu-IFN-α2a and 185-fold 
relative to Hu-IFN-α1 (most active native human interferon). 
 
Selective breeding using DNA shuffling has proved to be very effective method to 
rapidly improve pharmaceutical proteins by which initially have low levels of the 
desired “activity” (101, 102). Backcrossing of evolved recommbinants with the 
wild type genes removes functionally neutral changes, which might reduce the 
immunogenicity of evolved proteins (103). 
 
2.4 Conclusion 
Proteins, especially enzymes, have gained a central role in modern chemical, 
biotechnological, and biopharmaceutical industries. Directed evolution has over 
the past proved to be a versatile and successful approach for tailoring protein 
properties to industrial, agricultural and medical demands and for advancing our 
understanding of structure-function relationships in biocatalysts. Appropriate 
library generation and screening methods should be employed concerning the 
target protein and desired property. To set up a sophisticated screening method, 
complex conditions in human body (pH, ion concentration, proteases, hormones 
etc.) should be considered. Subsequent in vivo or in vitro test of improved 
variants should be carried out to further validate the screening assay. 
Development of diversity generation and high-throughput screening method will 
enable evolution to solve problems efficiently. Especially, directed evolution 
provides a powerful strategy to rapidly advance the development of improved 
protein-based drugs (enzymes and antibodies, peptide and ligands). Directed 
evolution promises to play an increasingly important role to generate “desirable” 
drugs. 
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Chapter 3 
Chapter 3. Directed evolution of Arginine 
deiminase for increased activity at physiological 
pH 
 
3. 1 Abstract 
Arginine deiminase (ADI; EC 3.5.3.6) has been studied as a potential anti-tumor 
drug for the treatment of arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCCs) and melanomas. Studies with human lymphatic leukemia cell 
lines confirmed that ADI is a potential anti-angiogenic agent effective in the 
treatment of leukemia. ADI from Pseudomonas plecoglossicida (PpADI) was 
cloned and expressed in E.coli. A main limitation of PpADI lies in its pH-
dependent activity profile with a pH optimum at 6.5. A pH shift from 6.5 to 7.5 
results in ~80 % activity drop (pH of human plasma is 7.35 to 7.45). For shifting 
PpADI pH optimum to netrual pH, a directed evolution protocol based on an 
adapted citrulline screening protocol in microtiter plate (MTP) format was 
developed and validated. Proof of concept for ADI engineering resulted in a pH 
optimum of pH 7.0 and increased activity under physiological conditions: at pH 
7.4, variant M2 (K5T, D44E and H404R) is 4-fold more active than the wild type 
PpADI and retains ~30 % of its activity relative to its pH optimum, compared to 
~10 % in the case of the wild type PpADI. 
 
3.2 Introduction 
Arginine deiminase (ADI) is a potential cancer therapy agent for the treatment of 
arginine-auxotrophic tumors (e.g. hepatocellular carcinomas and melanomas). 
The hepatocellular carcinoma (HCC) accounts annually for approximately 1 
million new cases worldwide. In the US the incidence rate (per 100,000 persons; 
1992-2002) of HCC is 8.6 with a mortality rate of 6.5 due to low responses of 
hepatoma to chemotherapeutic treatments (27). Current research efforts are 
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focused on ADI’s in vivo inhibitory effect towards HCCs, leukemia, melanomas 
and human umbilical vein endothelial cells (HUVEC) (104-106), clinical trials for 
HCC (phase III) and melanoma (phase I/II) (105, 107), and PEG formulation of 
ADI to improve its efficacy as a clinical drug, including serum half-life and 
antigenicity (16, 108). ADI inhibited the growth of cultured leukemia cells at 
concentrations of 5-10 ng/ml, which were about 20-100 times lower than those of 
the L-asparaginase standard resulting in fewer side effects (106, 109). Arginine 
deprivation is speculated to be the molecular reason for ADI’s inhibitory effect on 
human lymphatic leukemia (106). ADIs catalyze the first step of the arginine 
deiminase (ADI) pathway by hydrolyzing arginine to citrulline and ammonium. 
Several ADI genes have been identified, purified, and characterized from 
bacteria, archaea and some eukaryotes excluding mammalian cells and 
summarized in a recent review (27). None of these ADIs is from a kinetic point of 
view ideally suited for in vivo applications in humans under physiological 
conditions.  
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. For the proof of concept, an 
ADI isolated from Pseudomonas plecoglossicida CGMCC2039 (accession 
number: ABS70718) which can be functionally expressed in E. coli has been 
employed. Directed evolution approaches employ mainly E. coli as host due to its 
fast growth and high transformation efficiency which is a prerequisite for 
generating complex mutant libraries. Over the last decades, directed protein 
evolution has become a versatile and successful approach for tailoring protein 
properties for industrial demands (mainly in chemical synthesis) and for 
advancing our understanding of structure-function relationships in enzymes. A 
directed evolution experiment comprises iterative cycles of diversity generation 
and functional selection for improved variants. Only a few manuscripts for 
phytases (83), xylanases (110), amylases (77, 82, 111), and an alcohol 
deyhdrogenase (112) reported a shift of pH optima using directed evolution 
algorithms. None of these directed evolution campaigns targeted a medical 
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application and arginine deiminase has to our best knowledge not been altered in 
its pH activity/resistance by directed evolution.  
 
Comparison of PaADI (Pseudomonas aeruginosa, pH optimum 5.6; His405) and 
MaADI (Mycoplasma arginini ADI, pH optimum 6.5, Arg397) led to the 
speculation that substitution of His by Arg might contribute to MaADI’s increased 
pH optimum (17). A sequence alignment of four ADIs (MaADI, MyADI 
(Mycoplasma arthritidis ADI), PaADI and PpADI) shows that for both 
Pseudomonas ADIs the synonymous amino acid positions (404 & 405), contain a 
His whereas both Mycoplasma ADIs contain at corresponding positions an Arg. 
Interestingly, both Mycoplasma ADIs have an pH optimum approximately one pH 
unit higher than both Pseudomonas ADIs. 
 
In this study we report the first directed ADI evolution protocol in which the pH 
profile of PpADI was shifted to higher pH values representing a conceptional 
proof that ADI properties can be tailored for demands in vivo treatment of 
arginine-auxotrophic tumors. An emphasis is given on detailed description of 
directed evolution conditions (mutagenic and screening).   
 
3.3 Materials and methods 
3.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
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plasmid (MEGAWHOP, 20 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
Pseudomonas plecoglossicida CGMCC2039 was provided by Professor Zhihao 
Sun (Jiangnan University, Wuxi, China). 
 
3.3.2 Methods 
3.3.2.1 Reagents used in assays 
Acid-ferric solution 
To dH2O (600 ml), concentrated H3PO4 (70 ml, 85 %) and concentrated H2SO4 
(160 ml, 90-91 %) were added slowly. After cooling to room temperature, 
FeCl3·6H2O (10 ml, 10 g/L) was added in the above solution, finally the total 
volume was adjusted to 1 liter with dH2O. 
 
Diacetyl monoxime -thiosemicarbazide (DAM-TSC) solution 
DAM solution (10 g/L) and TSC solution (0.3 g/L) were prepared separately. The 
two solutions were mixed (volume ratio = 1:1) just prior to use. 
 
3.3.2.2 Cloning of ADI into pET42b(+) 
The arginine deiminase (ADI) gene was amplified from Pseudomonas 
plecoglossicida CGMCC2039 by colony PCR (94°C for 10 min, 1 cycle; 94°C, 30 
s/ 54°C, 30 s/ 72°C, 165 s, 29 cycles; 72°C for 5 min, 1 cycle) using primer (5’-
CCGCATTCCGCTGAAAAACAGAAGTACGG-3’ and 5’-
CTTCTCGAGTTAGTAGTTGATCGGGTCGCGCACG-3’), 1.5 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix and a colony of Pseudomonas 
plecoglossicida CGMCC2039. Amplification product was purified by gel 
extraction, digested using NdeI (20 U) and XhoI (20 U) and purified using 
QIAquick PCR purification kit (QIAGEN, Hilden, Germany). Cloning vector 
pET42b(+) was digested with NdeI (20 U) and XhoI (20 U), and purified by gel 
extraction kit (QIAGEN, Hilden, Germany). Digested ADI gene and pET42b(+) 
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were ligated using T4 DNA ligase (1 U) to give pET42b(+)-ADI and transformed 
into E. coli BL21-Gold (DE3).  
 
3.3.2.3 Site directed mutagenesis of PpADI gene at position H404 
Site directed mutagenesis of ADI gene was performed according to the published 
method (113) on plasmid pET42b(+)-ADI. The following oligonucleotides were 
used for mutagenesis of H404R: 5’-
GGCCGTGGCGGCGGCCGTTGCATGACCTGCCCG-3’ and 5’-
CGGGCAGGTCATGCAACGGCCGCCGCCACGGCC-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 
cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 
s, 1 cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 
cycle), 2 U of PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, 
Finland), 0.20 mM of dNTP mix, 25 pmol of each primer together with 100 ng of 
template (pET42b(+) harboring ADI gene) were used. Following the PCR, DpnI 
(40 U; New England Biolabs) was added, and incubated overnight at 37°C. The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
3.3.2.4 Site sturation mutagenesis of PpADI gene at nine amino acid 
position  
Site saturation mutagenesis of ADI gene was performed according to the 
published method (113) on plasmid pET42b(+)-ADI. The oligonucleotides were 
used for mutagenesis were listed in table 1 (underlining indicated the substituted 
nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 cycle; 95°C, 30 
s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 s, 1 cycle; 95°C, 
30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 cycle), 2 U of 
PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, Finland), 0.20 mM 
of dNTP mix, 25 pmol of each primer together with 100 ng of template (pET42b(+) 
harboring ADI gene) were used. Following the PCR, DpnI (40 U; New England 
Biolabs) was added, and incubated overnight at 37°C. The PCR products were 
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purified by using a QIAquick PCR Purification Kit (Qiagen) and transformed into 
E. coli BL21-Gold (DE3) for expression. 
 
Table 1. Primer sequences for site saturation mutagenesis. 
Primer name Sequences 
Leu 41 FP AACTGCGACGAGCTGNNNTTCGACGATGTGATC   
Leu 41 RP GATCACATCG TCGAANNNCA GCTCGTCGCAGTT 
Asn 360 FP TGGGATGACGGCAACAACNNNGTGGCGCTGGAG 
Asn 360 RP CTCCAGCGCC ACCACNNNGT TGCCGTCATCCCA 
Arg401 FP GAACTGGGCCGGGGCNNNGGCGGCGGCCACTGC   
Arg401 RP GCAGTGGCCGCCGCCNNNGCCCCGGCCCAGTTC 
Phe163 FP CTGCCCAACACCCAGNNNACCCGCGACACCACC    
Phe163 RP GGTGGTGTCGCGGGTNNNCTGGGTGTTGGGCAG 
Asn160 FP CTGCCGCCGCTGCCCNNNACCCAGTTCACCCGC 
Asn160 RP GCGGGTGAACTGGGTNNNGGGCAGCGGCGGCAG 
Arg185 FP ATGTACTGGCCGGCNNNCGCCAGGAAACCCTG 
Arg185 RP CAGGGTTTCCTGGCGNNNGCCGGCCAGTACAT 
Arg243 FP ATCGGCATGGGTGAGNNNACCTCGCGCCAGGCC 
Arg243 RP GGCCTGGCGCGAGGTNNNCTCACCCATGCCGAT 
His405 FP GGCCGTGGCGGCGGCNNNTGCATGACCTGCCCG 
His405 RP CGGGCAGGTCATGCANNNGCCGCCGCCACGGCC 
Gly403 FP GCCGGGGCCGTGGCNNNGGCCACTGCATGACC 
Gly403 RP GGTCATGCAGTGGCCNNNGCCACGGCCCCGGCC 
 
 
3.3.2.5 Construction of PpADI error-prone library 
The library was generated by the standard error-prone PCR (epPCR) using 
improved variant H404R as template. For the mutagenic PCR (95°C for 2 min, 1 
cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C for 3 min, 1 cycle), 2.5 
U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of template (pET42b(+) 
harboring ADI gene H404R), 0.01-0.1 mM of MnCl2 and 10 pmol of each primer 
(5’-TACATATGTCCGCTGAAAAACAGAAG-3’ and 5’- GTGCTCGAGTTAGTAGT 
TGATCGG-3’) were used. The PCR products were purified by using a QIAquick 
PCR Purification Kit. The purified epPCR products were cloned into expression 
  37 
plasmid pET42b(+) by MEGAWHOP(114). For MEGAWHOP (68°C for 5 min, 1 
cycle; 95°C for 5 min, 1 cycle; 95°C, 1 min/ 55°C, 1 min/ 68°C, 13 min 30 s, 24 
cycles; 68°C for 30 min, 1 cycle), 1 U of Taq DNA polymerase, 0.1 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix together with 200 ng of template (pET42b(+) 
harboring ADI gene H404R) were used. Following the PCR, DpnI (40 U; New 
England Biolabs) was added, and incubated (4 h; 37°C). The MEGAWHOP 
products were transformed into E. coli BL21-Gold (DE3) for expression and 
screening. 
 
3.3.2.6 Expression of PpADI in LB media with IPTG induction 
The strain E. coli BL21-Gold (DE3)/ pET42b-PpADI was cultured at 37°C in 20 ml 
of LB media that contained 50 µg/ml kanamycine to an absorbance of 0.6 at 
578nm. Then, isopropyl β-D-thio-galactopyranoside (IPTG) was added to a final 
concentration 0.2 mM. The cells were harvested after 9 h induction with IPTG at 
37°C. The expressed rADI was analyzed by SDS-PAGE.  
 
3.3.2.7 Expression of PpADI in auto-induction media 
A chemically defined auto-induction medium (115) containing salts and trace 
metals, vitamins including vitamin B12, and glucose, glycerol, and lactose were 
test for PpADI expression. Five kinds of auto-induction media LS-5052, P-5052, 
MD-5052, TYM-5052 and TYP-5052 were tested for the ADI expression, under 
the following conditions: 20 ml LB media in 100 ml flask, 37°C, 250 rpm, 20 h. 
The expressed rADI was analyzed by SDS-PAGE. 
 
3.3.2.8 Cultivation and expression of PpADI in 96-well plates 
Colonies grown on LBkan agar plates were transferred, by using toothpicks, into 
96-well microtiter plates (flat bottom, polystyrene plates; Greiner Bio-One GmbH, 
Frickenhausen, Germany), containing non-inducing medium LSG (150 µL) (115) 
supplemented with kanamycin (50 µg/ml). After 16 h of cultivation in a microtiter 
plate shaker (Multitron II, Infors GmbH, Einsbach, Germany; 37°C, 900 rpm, 70 
% humidity), each well was replicated using a replicator (EnzyScreen BV, Leiden, 
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Netherlands) into a second series of 96-well microtiter plates containing 150 µL 
of auto-induction media LS-5052 (115) supplemented with kanamycin (50 µg/ml). 
The first set of plates was stored at -80°C after addition of glycerol. The clones in 
the second set of plates were cultivated for 12 h (Multitron II, Infors GmbH, 37°C, 
900 rpm) and used for screening.  
 
3.3.2.9 Screening Procedure 
96-well plate format citrulline colorimetric screening assay 
A modified protocol of citrulline detection based on carbamido-diacetyl reaction 
(116) (see Figure 1A for assay mechanism) was used for ADI activity 
measurement. Screening for increased activity was carried out by measuring the 
activity at pH 7.4 and 6.4. 20 µl of cell culture was transferred to 96-well 
microtiter plate. Enzyme reaction was initiated by addition of arginine solution 
(100 µl, 100 mM) supplemented with cetyltrimethylammoniumbromide (CTAB, 4 
mM), and incubated (20 min, 37°C). Subsequently, acid-ferric solution (60 µl) and 
diacetyl monoxime (DAM, 20 µl, 0.5 M) were added. The reaction mixture was 
further incubated (15 min, 55°C). Absorbance was measured at 492 nm using a 
microtiter plate reader (Tecan Sunrise, Tecan Group AG, Zurich, Switzerland).  
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking ADI and in a separate experiment 
containing ADI. Apparent standard deviation was based on the absolute 
absorbance values obtained from the ADI wild type plate. The true standard 
deviation was calculated by subtracting the background absorbance value of the 
microtiter plate lacking ADI from the apparent values. 
 
Cuvette format citrulline colorimetric assay 
ADI activity was routinely measured using a modified protocol of the citrulline 
detection with DAM and TSC (117) (see Figure 1A for assay mechanism) in 
Eppendorf tubes. Enzyme reaction was initiated by addition of arginine solution 
(200 µl, 100 mM) to a 2-ml eppendorf tube containing crude cell lysate (50 µl), 
and incubated (20 min, 37°C). Subsequently, acid-ferric solution (250 µl) was 
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added to stop the enzyme reaction. After appropriate dilution with deionized 
water to ensure the concentration of produced citrulline is within linear detection 
range, the reaction mixture (400 µl) was mixed with acid-ferric solution (600 µl) 
and DAM-TSC solution (100 µl). The reaction mixture was further incubated (30 
min, 70°C), followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a Specord 200 (Analytik Jena AG, 
Jena, Germany). 
 
Normalization of protein expression for wild type ADI and variants  
Agilent Protein 230 Kit (Agilent Protein 230 Kit, Agilent Technologies 
Deutschland GmbH, Böblingen, Germany) and Agilent 2100 Bioanalyzer (Agilent 
2100 Bioanalyzer, Agilent Technologies Deutschland GmbH, Böblingen, 
Germany) were used for normalization of protein expression in crude cell extract. 
The protocol used was according to Agilent protein 230 Kit Guide except BSA 
was used as an internal standard. 
 
3.3.2.10 Expression of ADI in shaking flask and purification 
Shaking flasks (1 liter) containing auto induction media LS-5052 (200 ml) 
supplemented with kanamycin (50 µg/ml) were inoculated with a 1:200 dilution of 
overnight culture (E. coli BL21-Gold(DE3) harboring pET42b-ADI) grown in non-
inducing media LSG. After 12 h of expression, E. coli cells were harvested by 
centrifugation (Eppendorf 5810R 4°C, 3220 g, 30 min) and resuspended in 
phosphate buffer (20 ml, NaxPO4, 20 mM, pH 7.0). E. coli cells were 
subsequently lysed by using a high-pressure homogenizer (1500 bar, 2 cycles; 
Avestin Emulsiflex, Mannheim, Germany). The disrupted cells were centrifuged 
(Eppendorf 5417R, 4°C, 13000 g, 20 min) and the supernatant was further 
cleared by filtration through a low protein-binding filter (0.45 µm; Minisart RC 25 
single use syringe filter; Sartorius, Hamburg, Germany). ADI wild type and 
mutants (H404R and K5T D44E H404R) were subsequently purified by a column 
chromatography procedure: (i) The filtered cell lysates were subjected to a 
Super-Q anion exchange column, which had been pre-equilibrated with 50 mM 
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phosphate buffer (NaxPO4, pH 7.0). 20 ml of cell lysate was loaded. ADI were 
eluted by a NaCl step elution in phosphate buffer (NaxPO4, 50 mM,  pH 7.0) at a 
rate of 3 ml/min. (ii) The obtained ADI protein from ion exchange chromatography 
was subjected to a gel filtration column (Matrix: Toyoperl HW-55S, Bed volume: 
33 ml, Bed height: 40 cm, Column: Omnifit). 
 
Purified ADI was subsequently concentrated using a Amicon ultra-4 centrifugal 
filter device (Millipore Corporation, Billerica, U.S.A.) with a 30-kDa cut-off 
membrane. Total protein concentration was determined by BCATM assay kit 
(Pierce, Born, Germany) and homogeneity of the purified sample was controlled 
by SDS-page electrophoresis using standard molecular biology techniques. 
 
3.3.2.11 Characterization of ADI wild type and mutants 
Determination of kcat and Km of ADI wild type and the mutants 
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath. After 10 min preincubation at 37°C, the enzyme reaction was initiated 
by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the substrate solution (200 
µl, 0.2 mM to 10 mM of arginine, 0.5 M phosphate buffer, pH 7.4) in deep well 
plates. The reaction mixture was incubated (37°C) and every two minutes 
reaction mixture (30 µl) of each well was transferred to acid-ferric solution (30 µl) 
to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. Ferric-acid solution (90 µl) and DAM-TSC 
solution (15 µl) were added to each well. The 96-well PCR plate was then 
incubated (70°C, 30 min) in thermal cycler (Eppendorf Mastercyler gradient) for 
color development, followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a microtiter plate reader 
(SPECTROstar Omega, BMG LABTECH, Offenburg, Germany). The initial 
velocity data obtained were fitted to the equation v = Vmax[S]/([S] + Km) (where v 
is the initial velocity, Vmax the maximum velocity, [S] the substrate concentration, 
and Km the Michaelis constant) using GraphPad Prism software (GraphPad 
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software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax 
and enzyme concentration. 
 
Determination of pH profile 
Enzyme reaction was carried out at 37°C in a water bath using the following 
substrate solution: arginine 0.1 M, pH 5-8 phosphate/acetate buffer (0.5 M 
phosphate, 50 mM acetate). After 10 min preincubation at 37°C, the enzyme 
reaction was initiated by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the 
substrate solution (200 µl) in deep well plates. The reaction mixture was 
incubated (37°C, 10 min) and acid-ferric solution (250 µl) was transferred to each 
well to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. The reaction mixture (60 µl), ferric-acid solution 
(90 µl) and DAM-TSC solution (15 µl) were transferred to a 96-well PCR plate. 
The 96-well PCR plate was then incubated (70°C, 30 min) in thermal cycler 
(Eppendorf Mastercyler gradient) for color development, followed by incubation in 
ice water to stop color development. Absorbance was measured at 530 nm using 
a microtiter plate reader (SPECTROstar Omega, Germany). 
 
3.3.2.12 Molecular Modeling 
Two crystal structures of PaADI (PDB codes: 1RXX, 2A9G) were used to model 
the mutations H405R and D44E. Only one monomeric unit of the tetrameric 
PaADI was used for the modeling study employing Swiss-PDB viewer (118) 
(www.expasy.org/spdbv). PaADI variants (H405R; D44E) were generated using 
the mutate command of Swiss-PDB viewer. The side chain rotamer with the best 
score was used for subsequent energy optimized with parameter of GROMOS96 
force field for in vacuum minimization (119).  
 
3.3.2.13 Stability of PpADI in presence of serum  
Purified PpADI (wild type, M1, M2; 20 µl) was incubated (37°C, 60 min) with AB--
human serum (80 ul, Invitrogen, Karlsruhe, Germany) and PBS buffer (pH7.4, 80 
ul), respectively. Subsequently, the incubated ADI-serum/PBS mix (20 µl) was 
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added to microtiter plate containing arginine solution (100 µl, 10 mM arginine in 
PBS buffer, pH 7.4) and incubated (37°C, 30 min). Acid-ferric solution (120 µl) 
was added to stop the enzyme reaction. The produced citrulline was detected 
using the assay procedure employed in “Determination of kcat and Km of ADI 
wild type and the mutants”. Before measuring absorbance at 530 nm, 
centrifugation (Eppendorf, 5810R 4°C, 3000 g, 10 min) was performed to remove 
the precipitation in the assay solution (likely proteins in serum were precipitated 
in acidic condition during assay procedure). Meanwhile, a serum control was test 
for the original citrulline concentration of serum using the same procedure 
mentioned above except that instead of PpADI, elution buffer of gel filtration 
(NaxPO4, 50 mM, pH 7.4) was used. All the absorbance values at 530 nm of 
ADI-serum sample were subtracted the value of serum control to get the citrulline 
concentration produced by PpADI. The residual activities of PpADI after 
incubation in serum compared to that in PBS buffer were calculated to show the 
stability of PpADI after incubated in human serum. 
 
3.3.2.14 Activity of PpADI (wild type, M1, M2) towards arginine derivative 
dimethylarginine 
Purified PpADI (wild type, M1, M2; 15 µl, ~0.2 mg/ml final concentration; >20-fold 
concentration used for kinetic constant determination) was incubated (37°C, 4 h) 
with (NG, NG)-dimethylarginine solution (20 mM, 100 µl). Acid-ferric solution (120 
µl) was added to stop the enzyme reaction. Activity was recorded by citrulline 
detection using citrulline colorimetric assay (see 3.3.2.11 Characterization of ADI 
wild type and mutants). 
 
3.4 Results 
3.4.1 PpADI cloning 
PpADI was cloned into pET42b(+) and expressed in E.coli BL21-Gold(DE3) 
using auto-induction media LS-5052 (see figure 2). The nucleotide sequence of 
PpADI comprises 1,254 bp nucleotide (figure 1) encoding 417 amino acids which 
have 85% identity to ADI from P. aeruginosa (PaADI). The PpADI cloned into 
  43 
pET42b(+) was confirmed by nucleotide sequencing. As indicated in Figure 1, 
sequence analysis of ADI gene showed that there was one synonymous 
mutation at amino acid position D78 (GAT to GAC) compared to ADI-sequence 
of P. plecoglossicida CGMCC2039 deposited in NCBI (accession number: 
EU030267). The deduced ADI protein sequence has a calculated molecular 
weight of 46.5 kDa and shows 85% identity to ADI from P. aeruginosa. This clone 
was used for subsequent directed evolution experiments.  
 
 
Figure 1. DNA electrophoresis of PpADI. 
 
 
Figure 2. PpADI sequencing results. 
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3.4.2 PpADI expression in LB media with IPTG as inducer 
PpADI was successfully expressed in LB media with IPTG as inducer. Figure 3 
(lane 4) shows the expression band of PpADI observed at ~45 kDa, which is 
similar to the calculated molecular weight of 46 kDa (based on 
http://expasy.org/tools/pi_tool.html). 
 
Figure 3. SDS-PAGE of PpADI expression. Lane 1: P. plecoglossicida; Lane 2: E. coli BL21-Gold 
(DE3)/ pET42b; Lane 3: E. coli BL21-Gold (DE3)/ pET42b-PpADI WT, without IPTG; Lane 4: E. 
coli BL21-Gold (DE3)/ pET42b- PpADI WT. 
 
3.4.3 PpADI expression in auto-induction media 
Expressing recombinant protein in auto-induction media is based upon the 
preferences of bacteria to selectively use different carbon sources during diauxic 
growth and upon the often-observed negative regulation of gene expression by 
catabolite repression. Auto-induction is more convenient than IPTG induction 
because the expression strain is simply inoculated into auto-inducing medium 
and grown to saturation without the need to follow culture growth and add 
inducer at the proper time. For high-throughput applications, the auto-induction 
approach has many advantages over traditional induction methods including 
avoidance of the strong induction and apparent toxicity associated with chemical 
inducers such as IPTG.  
Five kinds of auto-induction media LS-5052, P-5052, MD-5052, TYM-5052 and 
TYP-5052 were tested for the ADI expression. Figure 4(A) and 4(B) show ADI 
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activity and corresponding SDS-PAGE band of the PpADI expression in different 
auto-induction media. The expression in auto-induction media LS-5052 is shows 
the highest activity and therefore LS-5052 was used for the following directed 
evolution experiments. 
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Figure 4(A). Activity of PpADI expressed in auto-induction media. 
 
 
 
Figure 4(B). SDS-PAGE of ADI expressed in auto-induction media 1, LS-5052; 2, P-5052; 3, MD-
5052; 4 TYM-5052; 5, TYP-5052. 
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3.4.4 PpADI assay based on citrulline detection 
 
 
Figure 5. Arginine conversion by ADI and detection of citrulline using DAM/TSC assay. 
 
ADI activity was measured by detecting the production of citrulline from arginine, 
according to carbamido diacetyl reaction (colorimetric reaction). The conditions of 
the carbamido diacetyl reaction is as follows： strong acid solution (H3PO4, 
H2SO4), oxidizing agent (Fe3+), diacetyl monoxime (DAM), thiosemicarbazide 
(TSC), and boiling water bath. Figure 5 shows one postulated reaction 
mechanism for the assay which depicts the reaction between citrulline and DAM. 
By the addition of TSC to the reaction system, Coulombe and Favreau(120) 
obtained linearity of response with a more stable pink color which Amax was 
shifted from 490nm to 530nm. 
 
Figure 6 describes the assay procedure for measuring ADI activity in 2 ml 
eppendorf tube. A calibration curve was prepared using citrulline standard 
solution (Figure 7) for determining the citrulline production during the assay. 
 
Figure 6. Citrulline colorimetric assay in cuvette format using DAM/TSC assay. 
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Figure 7. Calibration curve of cuvette format citrulline colorimetric assay. 
 
3.4.5 PpADI screening system for citrulline production in microtiter plates 
Two key performance parameters for identifying improved variants in microtiter 
plate based screening systems are the true standard variation and the linear 
detection range of the employed assay. Standard deviations have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). A modified version of the DAM-TSC assay for citrulline 
detection (Scheme 1) was selected for directed evolution of PpADI. The 
microtiter plate screening format was optimized for simplified handling by 
lowering the color development temperature (55°C instead of 100°C), increasing 
the diacetylmonoxime concentration (~22-fold) and avoiding the use of the 
sensitizer thiosemicarbazide. Figure 8 shows the procedure of screening assay 
of citrulline detection. 
 
Figure 8. Citrulline colorimetric assay in MTP format using DAM assay. 
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Standard deviations of the modified citrulline detection assay have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). The preferred combination (150 µl LS5052 auto-
induction media and 20 µl cell culture, 20 min conversion time and 15 min color 
develop time) resulted in a true standard deviation of 12.8 % after subtracting the 
background (Figure 10). Screening systems with standard deviations around 10 
% have successfully been used in directed evolution experiments (121, 122). A 
wide linear detection window is important for identifying beneficial mutants in 
directed evolution experiments and screening systems for evolved mutants have 
to be constantly adapted for hitting the linear detection window. A linear detection 
range up to 6 mM citrulline could be detected (Figure 9).  
 
 
 
 
 
 
Figure 9. Calibration curve of 96-well microtiter plate format citrulline colorimetric screening assay.  
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Figure 10. Activity values in descending order of the ADI wild-type conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
 
Figure 11. PpADI model derived from PaADI crystal structure (PDB code 2a9gD) by SWISS 
MODEL WORKSPACE.  
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3.4.6 Focused libraries generated by saturation mutagenesis 
PpADI gene shares 83 % sequence identity  with PaADI of which the crystal 
structure was solved (123). After submitting the ADI sequence to SWISS MODEL 
WORKSPACE, a proposed ADI model based on the PaADI crystal structure 
(PDB code 2a9gD) was obtained (Figure 11). According to this model and 
published literatures, 9 amino acid residues: Leu41, Asn160, Phe163, Arg185, 
Arg243, Asn360, Arg401, His404, Gly 403 (Figure 11) close to the active center 
(catalytic triad: Cys406-His278-Glu224) or known to interact with substrate 
arginine were selected for saturation mutagenesis. 
 
Site saturation mutagenesis at position Leu41, Asn160, Phe163, Arg185, Arg243, 
Asn360, Arg401, His404 and Gly 403 were performed. 300 clones were 
screened for each position. However, no improved variant was identified. 
 
3.4.7 Validation of variant M1 (H404R) citrulline colorimetric assay in 
cuvette format 
Position H404 which was suspected to influence ADI pH profile by substitution to 
R404 (15). Compared to wild type PpADI, variant M1 (H404R) shows higher 
activity (1.8-fold) and improved activity ratio of pH 7.4 to 6.4 (4.7-fold). Therefore, 
M1 (H404R) was selected for directed evolution. 
 
3.4.8 epPCR library generation and screening with citrulline detection 
assay by screening error-prone mutant libraries 
Various concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Figure 12 (A) and 12 (B) 
show the epPCR products and the corresponding MEGAWHOP products. 
Concentration of 0.01 mM MnCl2 which generated 53 % inactive mutant was 
selected for library generation. EpPCR mutant libraries with a ratio of 50 % active 
and 50 % inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). A total of 7 variants (listed in 
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Table 2) were identified from an epPCR library of 2400 mutants and used for 
further characterization. The most active variant was sequenced and two 
additional amino acid substitutions (K5T D44E) were identified. 
 
 
Figure 12 (A). Electrophoresis of epPCR products. Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM 
of MnCl2; Lane 3, 0.05 mM of MnCl2.  
 
 
 
Figure 12 (B). Electrophoresis of MEGAWHOP product with epPCR products as megaprimer. 
Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM of MnCl2; Lane 3, 0.05 mM of MnCl2.  
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Figure 13. Relative activity of ADI variants towards arginine. The relative activity is the ratio of the 
activity at the pH of each variant relative to the activity at pH 7.4 of wild type ADI. White: ADI wild 
type, grey: M1 (H404R), black: M2 (K5T D44E H404R). 
 
Table 2. Activity of ADI variants towards arginine determined using citrulline colorimetric 
assay in cuvette format. Samples were diluted to ensure that detected citrulline 
concentrations are within the linear detection range of the citrulline colorimetric assay. 
Wild type, mutant M1 and the “best variant” M2 are in bold and prominent expression 
mutants (9-B3-1; 21-D5-1) are italized. 
Normalized [ADI][a] 
Citrulline production 
(mM/mg) 
Relative to activity at pH 7.4 
of WT 
ADI variants pH 7.4 pH 6.4 pH 7.4 pH 6.4 
Activity at pH 
7.4/ activity at 
pH 6.4 
WT 
9.83 
(0.74)[b] 
124.92 
(1.98) 1.00 (0.15) 12.69 (0.01) 0.08 (0.01) 
M1 
(H404R) 
17.80 
(0.49) 
45.95 
(0.87) 1.81 (0.06) 4.67 (0.02) 0.39 (0.02) 
M2 
(K5T D44E 
H404R) 
38.99 
(0.79) 39.20 (0.31) 3.96 (0.02) 3.98 (0.02) 0.99 (0.03) 
9-B3-1 
24.89 
(0.45) 54.50 (1.80) 2.53 (0.03) 5.54 (0.03) 0.46 (0.02) 
21-D5-1 
25.68 
(2.68) 50.95 (2.36) 2.61 (0.07) 5.18 (0.02) 0.50 (0.01) 
15-G10-2 
13.11 
(0.53) 47.02 (0.47) 1.33 (0.09) 4.78 (0.02) 0.28 (0.01) 
2-H4-2 
12.50 
(0.07) 21.58 (0.09) 1.27 (0.06) 2.19 (0.04) 0.58 (0.01) 
1-G11-1 
24.91 
(0.20) 29.12 (0.33) 2.53 (0.03) 2.96 (0.03) 0.85 (0.02) 
24-E10-1 
14.62 
(0.62) 32.82 (0.52) 1.49 (0.08) 3.34 (0.03) 0.45 (0.02) 
[a] (Based on quantification employing Agilent 2100 Bioanalyzer (Agilent Protein 230 Kit)) 
[b] (Standard error of triplicate measurements are given in brackets below each absolute 
and normalized value.) 
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Figure 14. Elution profile of wild type PpADI and improved variants from epPCR library, 
generated with Protein 230 Kit using a mircofluidic device (Agilent Bioanalyzer). BSA was added 
as an internal standard. 
 
3.4.9 Characterization of PpADI variants 
3.4.9.1 Determination of kcat and Km of ADI wild type and the mutants 
Variants selected from epPCR were first characterized using the crude cell 
extract to identify the most promising variants (Table 2). Using an activity ratio of 
pH 7.4 to 6.4 proved to be an effective method to eliminate expression mutants. 
Additionally ADI concentration in crude cell extract was determined using the 
Agilent Protein 230 Kit. Microfluidic elution profiles (Figure 14) semi-quantify 
differences in expression between the wild type PpADI and variants. 
Normalization of activities against the corresponding ADI concentrations reveals 
improvements in specific activities of ADI mutants (Table 2). M1, the starting 
variant for the directed evolution campaign, and M2 were selected for detailed 
characterization studies. M2 has as “best identified variants” (Figure 13) a more 
than 2.5-fold higher activity ratio at pH 7.4 to pH 6.4 than M1 and a 12-fold higher 
activity ratio than wild type in crude cell lysates. 
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For kinetic characterization of ADI variants the citrulline production was 
maintained between 0.2-0.8 mM. Calibration curve in Figure 4 shows the linear 
detection range in the employed 96-well PCR plate format citrulline colorimetric 
assay system. Figure 15 summarizes the kcat and Km values of wild type PpADI, 
identified variants M1 (H404) and M2 (K5T D44E H404R) which were expressed 
in shaking flasks cultures and purified using a two step procedure (anion 
exchange followed by gel filtration). Both variants M1 and M2 show an increase 
in kcat and Km for citrulline production at pH 7.4. Variant M2 shows a 4-fold higher 
kcat as also obtained for specific activity in Table 2 using the crude cell extract, 
validating the characterization procedure with crude cell lysate. Furthermore, an 
increased Km from 0.7 mM (wild type PpADI) to 1.2 mM (M1) and 2.5 mM (M2) 
was found. 
 
 
Figure 15. Kinetic parameters of ADI and mutants for conversion of arginine to citrulline. White: 
ADI wild type, grey: M1 (H404R), black: M2 (K5T D44E H404R). Values reported are the average 
of three measurements, and average deviations from the mean values are shown. Embedded 
calibration curve shows linearity of citrulline colorimetric assay in 96-well PCR plate format which 
was used to determine arginine conversions and kinetic constants.  
 
3.4.9.2 Relative pH profile of wild type and mutant 
The relative pH profile (Figure 16) of wild type PpADI and M1 (H404R) shows an 
identical pH optimum at pH 6.5. Compared to wild type PpADI, variant M2 (K5T 
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D44E H404R) shows a pH optimum at pH 7.0 which is shifted remarkably (0.5 
pH units). Both M1 and M2 show decreased specific activities at pH 6.5, and 
increased specific activity at pH 7.5. At pH 7.0, the specific activity of M2 
exceeds that of wild type PaADI (data not shown). 
 
Figure 16. pH profile of wild type ADI, M1(H404R), M2(K5T/D44E/H404R). The relative activity is 
the ratio of the catalytic activity at the pH relative to the maximum activity of each enzyme. (■) WT, 
(▲) M1 (H404R), (●) M2 (K5T/D44E/H404R). 
 
 
3.4.10 Stability of PpADI in the presence of human serum  
Table 3 summarizes the stability of PpADI variants in serum (37°C, 60 min; 
standard deviation of three measurements in brackets). The mutants M1 and M2 
have a similar stability in serum when compared to the wild-type PpADI wild type.  
The substitution D44E and H404R do not destabilize further the PpADI in serum.  
 
Table 3. Stability of PpADI variants in the presence of human serum. 
 PpADI WT M1 M2 
No incubation (A530) 0.08 0.27 0.98 
Incubation with serum (37°C, 
60 min) (A530) 0.05 0.15 0.69 
Residual activity 60 % 55 % 70 % 
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3.4.11 Activity of PpADI (wild type, M1, M2) towards arginine derivative (NG, 
NG)-dimethylarginine  
No detectable conversion of (NG, NG)-dimethylarginine could be detected with 
PpADI variants.  
 
3.5 Discussion 
ADI properties have to date not been engineered through directed evolution 
algorithms despite their often poor performances under physiological conditions 
and their medical importance as potential anti-tumor drug. Chemically modified of 
ADI (e.g. through PEGylation) (27) and fusion protein (e. g. Human serum 
albumin fusion, HSA) (124) have been used for addressing activity and stability 
demands in vivo. Directed evolution offers opportunities to directly improve ADI 
properties for in vivo applications and small libraries of a few thousand variants 
have often been sufficient to find improved muteins in directed evolution 
experiments (55, 125).  
 
Our main intention in this report is to provide a validated protocol for directed ADI 
evolution and improving the activity at the physiological pH 7.4. Pseudomonas 
plecoglossicida CGMCC2039 (PpADI, 7.8 U/mg; pH optimum 6.5) was selected 
for the directed evolution studies due to its functional expression in E. coli, 
coverage of sequence space in patents and “potential” for activity improvement. 
PpADI is a relatively slow ADI when compared to Mycoplasma ADIs like MhADI 
(Mycoplasma hominus ADI, 35 U/mg) which would have been good alternatives 
for directed evolution studies (105). Reported ADI activities range from 0.115 to 
140.3 IU/mg. One unit is commonly defined as the ADI amount that converts 1 
µmol of L-arginine into 1 µmol of L-citrulline per minute (27).  
 
Screening of PpADI variants yielded three amino acid positions 5, 44 and 404. 
Positions 44 and 404 resulted in a 4-fold higher kcat at pH 7.4 and a significant 
shift in the pH optimum (0.5 units) when compared to wild type PpADI (Figure 17 
& 8). Position 5 did not show any effect on PpADI activity.   
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Figure 17. Structural alignment of mutant M1 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The crystal structure of PaADI which was diffracted in 
absence of the substrate arginine (1RXX) was used to investigate the substitution of His405 to 
Arg405. The Arg405 variant shows with respect the Asp280 a different orientation of the 
guanidinium group when compared to side chain of His405 (in orange).  
 
Galkin and coworkers postulated that the histidine in position 404 (corresponding 
position in “their” PaADI is 405) is a key residue in controlling activity at acidic 
and neutral pH. In protonated state of the imidazolium ring a hydrogen bonding 
interaction can be formed with the oxygen of Asp280 (carboxyl group). This 
hydrogen bond favors stabilizing interactions between Asp280 and the substrate 
arginine. His405 in PaADI was reported (17) to share protons with Asp280 and 
Glu13 and to be important for modulating electrostatic environments of closely 
located catalytic groups. The same report postulated that H405 is likely to be 
protonated when the substrate arginine binds to catalytic triad (His278, Glu224, 
Cys406) (2). Based on these reports the His404 in PpADI was subjected to a site 
directed mutagenesis to Arg404 and named M1. The M1 variant (H404R) shows 
40 % residual activity compared to wild type PpADI at pH 6.4 and a 1.8-fold 
increase in activity at pH 7.4 (see Table 1). In the M1 (H404R) mutant (see the 
model in Figure 17; based PaADI 1RXX; residue His404 in PpADI corresponds to 
His405 in PaADI), the conformational effect due to the extended side chain of 
Arg likely weakens the hydrogen bond to Asp280 and thus reduces the stabilizing 
effect on arginine binding. As a result the activity of M1 is reduced, especially at 
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lower pH values at which His405 is protonated. However at elevated pHs, His405 
becomes increasingly deprotonated whereas Arg405 remains protonated and 
can therefore still stabilize Asp280 for arginine binding. The electrostatic effect 
suggested by theoretical and experimental studies have evidenced the 
importance of positively charged residues to modulate the reaction rate of PaADI 
(126). At pH 6.4, histidine in wild type PpADI and arginine in M1 are both 
positively charged. At pH 7.4, histidine is only partially positive charged and 
PpADI’s activity is reduced (>90 %) while arginine in M1 remains positively 
charged preserving M1’s activity (Figure 17).   
 
 
Figure 18. Structural alignment of mutant M2 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The PaADI crystal structure in presence of substrate arginine 
was used (2A9G) to investigate the role of the substitution Asp44 to Glu44. The latter was solved 
for an inactive variant in which Cys406 was replaced by Ala406. The extended side chain of 
Glu44 might improve the hydrogen bond interaction with the Arg399 inducing a conformational 
shift of loop 1. 
 
The PpADI H404R was used as starting variant for directed evolution. The amino 
acid position 44 was identified from a epPCR library (2400 variants screened) 
resulting in a triple mutant M2 (K5T D44E H404R). For investigating the role of 
each position the double mutants (K5T H404R) and (D44E H404R) were 
generated. Only the double mutant (D44E H404R) revealed improvements in kcat 
(4-fold, pH 7.4; Figure 18). The rationale behind the effects of the mutation D44E 
on the PpADI activity is more complex to extrapolate from the available ADI 
crystal structures. Comparative crystallographic studies have shown that the 
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entrance of the active site is decorated by 4 loops that undergo conformational 
transitions upon arginine binding (17). The loops exhibit significant shifts that limit 
the access of water molecules to the active site. The Asp44 is located in loop 1 
(residues 30-46) and upon binding of the substrate, Asp44 comes closer to the 
positively charged Arg399 located on loop 4 (residues 392 to 403). In the D44E 
mutant, the longer side chain reduces the distance with Arg399 favoring the 
formation of hydrogen bond (see model in Figure 18). The reinforced interaction 
between Glu44 and Arg399 might expedite conformational changes in loops, 
probably confining the arginine substrate in the active site and hence promote 
arginine conversion. In the future, we plan to further investigate the influence of 
H404R and D44E using molecular dynamics simulations, further boost the kcat at 
pH 7.4 and reduce the Km value of PpADI.  
 
Overall site directed mutagenesis of position H404R and one round of directed 
evolution (2400 variants screened) resulted in a triple mutant M2 (K5T D44E 
H404R) with 4-fold higher kcat at pH 7.4 (compared to wild type; Figure 4). The 
best mutant isolated, M2, has specific activity of 31.3 U/mg at pH 7.4 which is 
already after one round of evolution close to the specific activity of MhADI (35 
U/mg) (127) at its pH optimum. The stability and specificity of improved PpADI 
variants are furthermore important for cancer treatment in vivo. First experiments 
in AB-human serum (Invitrogen) showed an unaltered stability of M2 compared to 
the wild type PpADI and (NG, NG)-dimethylarginine conversion could not detect 
with the citrulline colorimetic assay.   
 
3.6 Conclusion 
In summary, a directed evolution protocol has been developed for PpADI and 
validated by increasing the kcat of PpADI at physiological pH (7.4). The reported 
screening system is the first one employed in directed ADI evolution and can 
likely be used for other ADIs and other properties such as temperature stability, 
salt/detergent stability or protease resistance. 
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Chapter 4 
Chapter 4. PpADI reengineered for efficient 
operation under physiological conditions 
 
4.1 Abstract 
The proof of concept for ADI engineering by directed evolution resulted in variant 
M2 (K5T/D44E/H404R). M2 has a pH optimum of pH 7.0 and 4-fold higher kcat 
value than the wild type PpADI (pH 7.4, 0.5 M phosphate buffer) and an 
increased Km value for substrate arginine. In this chapter, in order to improve the 
catalytic efficiency of PpADI at low concentration of arginine, variant M5 
(K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated from an epPCR library: 
at pH 7.4 (PBS buffer), the S0.5 value decreased from 2.01 mM (parent M3, 
K5T/D44E/A128T/H404R) to 1.48 mM (M5) and 0.81 mM (M6). The S0.5 value of 
M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat value 
improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 11.64 
s-1 (M6, 64.7-fold). 
 
4.2 Introduction 
ADI-based arginine depletion is a target specific therapy for arginine-auxotrophic 
tumors (e.g. hepatocellular carcinomas and melanomas) and pegylated ADI is 
currently under clinical trials for HCC with promising results (45). HCC is the third 
leading cause of cancer mortality world wide with a less than 10 % 5-year 
survival rate (EU and USA) (128) due to low responses of hepatoma to 
chemotherapeutic treatments. In 1999, US Food and Drug Administration (FDA) 
designated ADI-PEG-20 orphan drug status for the treatment of HCC and 
invasive malignant melanomas, and in 2005 European Agency for the Evaluation 
of Medicinal Products (EMEA) also granted ADI-PEG-20 orphan drug status for 
the treatment of HCC. Phase II trials of ADI-PEG-20 in patients with metastatic 
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hepatocellular carcinomas have shown that the drug is safe, well tolerated, and 
may benefit patients with unresectable HCC. Izzo and coworker suspected that 
combination therapies of arginine deprivation and growth inhibition via kinase 
inhibitors might improve the survival rate further more. Additionally, ADI can 
enhance radio sensitivity of human mammary adenocarcinoma (MCF-7 cells) 
(48), exerts anti-proliferative and anti-angiogenic activities and inhibits the growth 
of viruses such as HIV-1 and hepatitis (49, 50). Current research efforts are 
focused on ADI’s in vivo inhibitory effect towards leukemia, melanoma, prostate 
cancer, renal cell carcinoma, and human umbilical vein endothelial cells (HUVEC) 
(19, 44, 51-53), clinical trials for HCC (phase II) (45) and melanoma (phase I/II) 
(46), and inhibitory mechanisms of ADI to tumors (54).  
 
Arginine deprivation is believed to be a main molecular reason for ADI’s inhibitory 
effects on arginine auxotrophic tumors which do not express argininosuccinate 
synthetase (ASS). ADIs catalyze the first step of the arginine dehydrolase 
pathway by hydrolyzing arginine to citrulline and ammonium. ADI genes have 
been identified, purified, and characterized from bacteria, archaea and some 
eukaryotes excluding mammalian cells (see review (27)). Enzymatic properties of 
several recombinant ADIs have been examined, such as specific activity, 
functional expression level, temperature optimum, pH optimum, substrate affinity 
for arginine, and half-life in human plasma. Only the ADI from Mycoplasma 
hominis has so far been developed as orphan drug by Pheonix Pharmacologics 
Inc. for HCC and melanoma (129). From enzyme kinetic point of view, none of 
the ADIs is ideally suited for in vivo applications under physiological conditions. 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. PpADI (ADI from 
Pseudomonas plecoglossicida) was functionally expressed in E. coli with a 
simple protocol and has been engineered for the first time by directed evolution 
for improved activity at physiological pH (3). The variant M2 (K5T/D44E/H404R), 
by our group reported, showed a 4-fold higher specific activity than the wild type 
PpADI (0.5 M phosphate buffer, pH 7.4), but a increased Km value (3.5-fold). 
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High activity at low arginine concentration is an important prerequisite for ADI’s 
medical application, allowing low ADI dose required per treatment. 
In the present work, we improved the directed evolution protocol and identified a 
PpADI variant with further improved activity and slightly decreased “Km value” 
and PpADI variant with lowered Km value maintaining its high catalytic activity. 
Those variants were characterized in respect to their kinetic constants. 
 
4.3 Materials and methods 
4.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
plasmid (MEGAWHOP, 25 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
4.3.2 Methods 
4.3.2.1 Site saturation mutagenesis of PpADI M2 at position A128 
Site directed mutagenesis of PpADI M2 (K5T/D44E/H404R) at position A128 was 
performed according to the published method (130). The following 
oligonucleotides were used for mutagenesis of A128: 5’-
CTGATCGGCGGCGTGNNNGGCCAGGACCTGCCG-3’ and 5’- 
CGGCAGGTCCTGGCCNNNCACGCCGCCGATCAG-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 98°C for 30 s, 1 
cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 3 cycles. Second stage: 98°C for 30 
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s, 1 cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 15 cycles; 72°C for 3 min, 1 
cycle), 2 U of PhuS DNA polymerase, 0.20 mM of dNTP mix, 25 pmol of each 
primer together with 100 ng of template (pET42b(+) harboring PpADI M2 gene) 
were used. Following the PCR, DpnI (40 U; New England Biolabs) was added, 
and incubated overnight at 37°C. The PCR products were purified by using a 
QIAquick PCR Purification Kit (Qiagen) and transformed into E. coli BL21-Gold 
(DE3) for expression. 
 
4.3.2.2 Construction of PpADI error-prone library 
EpPCR library was generated by the standard error-prone PCR (epPCR) using 
improved variant M3 (K5T/D44E/A128T/H404R) as template. For the mutagenic 
PCR (95°C for 2 min, 1 cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C 
for 3 min, 1 cycle), 2.5 U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of 
template (pET42b(+) harboring PpADI M3 gene), 0.01-0.1 mM of MnCl2 and 10 
pmol of each primer (5’-TACATATGTCCGCTGAAACACAGAAG-3’ and 5’-
GTGCTCGAGTTAGTAGTTGATCGG-3’) were used. The PCR products were 
purified by using a QIAquick PCR Purification Kit. The purified epPCR products 
were cloned into expression plasmid pET42b(+) by MEGAWHOP (114). For 
MEGAWHOP (72°C for 5 min, 1 cycle; 98°C for 1 min 30 s, 1 cycle; 98°C, 45 s/ 
55°C, 45 s/72°C, 4 min, 24 cycles; 72°C for 10 min, 1 cycle), 1.2 U of PfuS DNA 
polymerase, 0.20 mM of dNTP mix, 500 ng of epPCR products together with 50 
ng of template (pET42b(+) harboring PpADI gene of variant M3) were used. 
Following the PCR, DpnI (40 U; New England Biolabs) was added, and incubated 
(overnight; 37°C). The MEGAWHOP products were transformed into E. coli BL21-
Gold (DE3) for expression and screening. 
 
4.3.2.3 Site directed mutagenesis at position D38 of PpADI M4 
Site directed mutagenesis of PpADI variant M4 at position D38 was performed 
according to the published method on plasmid pET42b(+)-ADI-M4 
(K5T/D44E/A128T/E296K/H404R). The following oligonucleotides were used for 
mutagenesis of D38H: 5’-ACCCCGAGCAACTGCCACGAGCTGCTGTTCGAC-3’ 
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and 5’-GTCGAACAGCAGCTCGTGGCAGTTGCTCGGGGT-3’ (underlining 
indicated the substituted nucleotide). Conditions for mutagenic PCR are as 
described in “Site saturation mutagenesis of PpADI M2 at position A128”.The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.4 Site saturation mutagenesis at position D38 and E296 of PpADI M3 
Site saturation mutagenesis library at position D38 and E296 of PpADI variant M3 
(K5T/D44E/A128T/H404R) were generated according to the published method on 
plasmid pET42b(+)-ADI-M3 using the  following oligonucleotides: D38FP (5’-
ACCCCGAGCAACTGCNNNGAGCTGCTGTTCGAC-3’), D38RP (5’-
GTCGAACAGCAGCTCNNNGCAGTTGCTCGGGGT-3’) and E296FP (5’-
GTCACGGTTTTCCCGNNNGTGGTGCGCGAGATC-3’), E296RP (5’-
GATCTCGCGCACCACNNNCGGGAAAACCGTGAC-3’) (underlining indicated 
the substituted nucleotide). Conditions for mutagenic PCR are as described in 
“Site saturation mutagenesis of PpADI M3 gene at position A128”.The PCR 
products were purified by using a QIAquick PCR Purification Kit (Qiagen) and 
transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.5 Cultivation and expression of PpADI in 96-well plates 
Cultivation and expression in 96-well plates (flat bottom, polystyrene plates; 
Greiner Bio-One GmbH, Frickenhausen, Germany) were performed as previously 
described in 3.3.2.8. 
 
4.3.2.6 Improved screening system in 96-well plate to identify PpADI 
variants with high activities at low arginine concentration 
As describe previously, the modified protocol of citrulline detection based on 
carbamido-diacetyl reaction was used for screening for improved ADI affinity to 
arginine at pH 7.4. 15 µl of cell culture was transferred to 96-well microtiter plate. 
Enzyme reaction was initiated by addition of arginine solution (105 µl, 1mM 
arginine in PBS buffer, pH 7.4) supplemented with 
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cetyltrimethylammoniumbromide (CTAB, 4 mM), and incubated (10 min, 37°C). 
The following color development procedure was carried out as described 
previously (3). 
 
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking PpADI and in a separate experiment 
containing PpADI variant M3. Apparent standard deviation was based on the 
absolute absorbance values obtained from the PpADI variant M3 plate. The true 
standard deviation was calculated by subtracting the background absorbance 
value of the microtiter plate lacking ADI from the apparent values. 
 
4.3.2.7 Expression of PpADI in shaking flask and purification  
Expression of PpADI in shaking flasks and purification (by anion exchange 
chromatography and gel filtration) was performed as previously described in 
3.3.2.10.  
 
4.3.2.8 Characterization of PpADI variants 
Preliminary determination of kinetic constants for site saturation mutagenesis 
variants of position 38 and 296  
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in 
incubator (Heraeus Holding GmbH, Hanau, Germany) using cell crude extract.  2 
ml of expression culture was harvested by centrifugation (Eppendorf 5415R 4°C, 
13,000 g, 10 min) and then freezed (-20°C, overnight). Cell lysate was prepared 
by resuspending the cell pellet in lysozyme (91000 U, 50 mM phosphate buffer, 
pH 7.4, 1.3 ml) followed by incubation (37°C, 40 min) and centrifugation (4°C, 
13,000 g, 10 min). 15 µl of diluted (4 times diluted with 50 mM phosphate buffer, 
pH 7.4) cell lysate was transferred to 96-well microtiter plates. Enzyme reaction 
was initiated by addition of arginine solution (105 µl, 0.25-10 mM arginine in PBS 
buffer, pH 7.4) and incubated (7 min, 37°C). Subsequently, ferric-acid solution 
(120 µl) was added to each well to stop enzyme reaction. 60 µl of terminated 
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enzyme reaction mixture was transferred to 96-well PCR plate for color 
development. Ferric-acid solution (90 µl) and DAM-TSC solution (15 µl) were 
added to each well. The 96-well PCR plate was then incubated (70°C, 30 min) in 
thermal cycler (Eppendorf Mastercyler gradient) for color development, followed 
by incubation in ice water to stop color development. Absorbance was measured 
at 530 nm using a microtiter plate reader (Tecan Sunrise TC reader, Tecan Group 
AG, Zurich, Switzerland). The initial velocity data obtained were fitted to the 
equation v = Vmax[S]/([S] + Km) (where v is the initial velocity, Vmax the maximum 
velocity, [S] the substrate concentration, and Km the Michaelis constant) using 
GraphPad Prism software (GraphPad software, San Diego, CA, USA). The kcat 
was calculated from the ratio of Vmax and enzyme concentration. 
 
Determination of kinetic constants of PpADI wild type and variants M3, M4, M5, 
M6 
The kcat and S0.5 values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath as described previously using purified enzyme (50 µl, 0.1-1.8 µM) to 
and substrate solution (200 µl, 0.5 mM to 10 mM of arginine, PBS buffer, pH 7.4) 
in deep well plates.  
 
The initial velocity data obtained were fitted to the sigmoidal model of kinetics 
equation v = Vmaxn/(S0.5n + Kn) (where v is the initial velocity, Vmax is the maximum 
velocity, K is the substrate concentration, and S0.5 is the ligand concentration 
producing half occupation (131)) using GraphPad Prism software (GraphPad 
software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax and 
enzyme concentration. 
 
4.3.2.9 Native polyacrylamide gel electrophoresis of PpADI variants 
10% of polyacrylamide native gels were used for protein electrophoresis to 
analyze the native form of PpADI variants. Purified protein of PpADI variants (7 µl 
of protein and 3 µl of loading dye) were loaded into each lane of native gel. The 
  67 
molecular marker used in the gel is NativeMarkTM Unstained Protein Standard 
(Invitrogen, Darmstadt, Germany). The electrophoresis was performed with 
tris/glycine buffer (pH 8.3) and electrophoresis chamber was incubated in ice-
water bath. Protein bands were stained with Coomassie brilliant blue solution.  
 
4.3.2.10 Homology modeling 
Homology modeling approach was used for the structure prediction of PpADI. 
The model was built by using the automated structure prediction tool, Protein 
homology/analogy recognition engine (Phyre: http://www.sbg.bio.ic.ac.uk/~phyre/) 
(132). The crystal structure of PaADI (PDB ID: 2A9G) was used as template by 
the server and It has 84.9% sequence identity (http://blast.ncbi.nlm.nih.gov/Blast) 
with PpADI. Procheck program suit (http://www.ebi.ac.uk/thornton-
srv/software/PROCHECK/) (133) was used to assess the stereochemical quality 
of the model. Ramachandran plot which represented that 84.7% residues were 
present in the most favoured region and 14.7% in additional allowed region 
(Figure 3).  Dfire was used to access non bonded atomic interaction in the model 
(http://sparks.informatics.iupui.edu/hzhou/dfire.html/) (134), and Qmean 
(http://swissmodel.expasy.org/qmean/cgi/index.cgi) (135) for the estimation of 
global protein quality. Swiss-PdbViewer (118) was used to create the tetramer 
structure by fitting the monomer model on the 4 units of the 2A9G template. The 
variant M6 (D38H, D44E, A128T, E296K, H404R) were created by using the 
“mutate” tool of the Swiss-PdbViewer and by selecting rotamers with the best 
fitness score. All tetramers were energy minimized in vacuum using GROMOS 
43B1 force field (119).  
 
4.4 Results 
4.4.1 Improved screening system in microtiter plates to identify PpADI 
variants with high activities at low arginine concentration 
Screening assay was based on the validated citrulline colorimetric screening 
protocol in microtiter plate, as reported previously (3). In order to screen for 
variants with high activity at low arginine concentration under physiological 
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condition concerning pH and ion concentrations, 1 mM arginine in PBS buffer 
(pH 7.4) as substrate solution was employed in screening assay and enzyme 
reaction time was controlled accordingly (10 min). The coefficient of variation is 
an important performance criterion of a screening system to determine its 
accuracy. Optimized assay condition with 1 mM arginine (PBS buffer, pH 7.4) as 
substrate resulted in true coefficient of variation of 14.9 % (Figure 1). The 
resulting low absolute absorbance value is a main reason for the high true 
coefficient of variation (14.9 %). In the previous screening system, 100 mM 
arginine in 0.5 M sodium phosphate buffer was used and yielded higher activity 
variants but with higher Km value. 
 
 
 
Figure 1. Activity values in descending order of the PpADI variant M3 conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
4.4.2 Genealogic tree of directed PpADI evolution  
Figure 2 shows the two rounds of PpADI evolution, generation of saturation 
mutagenesis libraries and recombination of beneficial positions to finally obtain 
the PpADI variant M6 with 64.7-fold higher kcat and reduced S0.5 (1.3 mM (WT) to 
0.81 mM (M6). Based on structure-function analysis of PaADI[16], M1 was 
generated by substitute His at position 404 with Arg. Position 404 is through 
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interactions with position Asp280 involved in substrate stabilization during 
catalysis. M1 was subject to the first round of epPCR library, from which M2 was 
identified showing a 4-fold improved kcat value and increased Km value (2.5 mM 
in 0.5 mM sodium phosphate buffer, pH 7.4)[15]. M3 was generated by a site 
saturation mutagenesis library at position 128 which increased in another clone 
the expression level (data not shown). In order to improve PpADI towards 
medical application demands (high activity at low arginine concentration), a 
second epPCR mutant library was constructed using M3 as parent. M4 with 
decreased S0.5 value (0.81 mM) and M5 with increased Kcat value (17.56 s-1) 
were identified after screening of ~1400 clones. In M4 the position E296 was 
identified to be important for lowering S0.5 and in M5 position D38 was identified 
to be important for activity increase. M6 was finally constructed by combining the 
substations at position D38 and E296. Saturation mutagenesis of these two 
positions did not yield any further improved S0.5 or activity variant.  
 
 
Figure 2. Genealogic tree of PpADI variants (M1 to M6) with generated amino acid substitutions. 
Novel substitutions are indicated by an asterisk. 
 
4.4.3 EpPCR library construction and screening for variants with high 
activities at low arginine concentration 
Variant M2 was used as a starting template. As described previously, M2 shifts 
the pH optimum from pH 6.5 to pH 7.0 and has a 4-fold faster kcat than PpADI 
wild type. In one sequenced mutant, position A128 was identified to be 
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responsible for higher expression (data not shown). Site saturation mutagenesis 
on M2 therefore was carried out at position A128. The resulting variant M3 
(K5T/D44E/A128T/H404R) showed a ~2-fold improved expression and was 
subsequently used as parent template for epPCR library. 
 
Three concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Instead of 0.02 mM 
MnCl2, 0.05 mM MnCl2 which generated 46 % of inactive mutant was selected for 
library generation. EpPCR mutant libraries with a ratio of ~50 % active and ~50 
% inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). Two variants M4 and M5 
were identified from this epPCR library (~1400 clones) and further characterized. 
Variant M4 and M5 were sequenced and one additional amino acid substitution 
was identified for each variant, E296K and D38H, respectively. 
 
4.4.4 Site saturation mutagenesis of PpADI at position D38 and E296 
To investigate their role in improving of catalytic performance for arginine, site 
saturation mutagenesis library at position D38 and E296 were generated using 
PpADI M3 as template. For each position, ~300 clones were screened at low 
concentration of arginine (1 mM, PBS buffer, pH 7.4), using 96-well plate format 
citrulline colorimetric screening assay.  
 
After the screening of site saturation mutagenesis libraries of position 38 and 296, 
variants with higher activity were chosen for preliminary kinetic investigation using 
crude cell extract. Beneficial mutants were identified and sequenced from both 
sites (Table 1). At position 38, the following beneficial substitutions were found: 
D38R (three times, AGA, CGG, CGT) and D38K (twice, AAG, AAA). In all cases, 
the negatively charged acidic amino Asp had been replaced by positively charged 
amino acids, Arg or His. Substitution by negatively charged Glu resulted in a 
clone showing a parent M3-like kinetic behavior. Hydrophobic amino acid 
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substitution by Pro resulted inactive clone under assay conditions. At position 296, 
the following substitutions were found to be beneficial: E296K (twice, AAA, AAG), 
E296N (once, AAC), E296T (once, ACC), E296G (once, GGA). Among these 
substitutions, variants with substitution to positively charged residue Lys show 
lowest S0.5 value for arginine while substitution by uncharged amino acids (Asn, 
Thr, Gly) shows relatively marginal improvement compared to E296K. 
Hydrophobic amino acid substitution by Pro and Trp resulted in very low activity 
clones. 
Table 1. Nucleotide and amino acid substitutions at position 38 in PpADI M3. 
 PpADI 
variants Substitution at position 38 km (mM) 
M3 (parent) Asp (GAC) 3.74 ± 0.35 
SSM-D38R Arg (AGA, CGG, CGT) 1.16 ± 0.21 
SSM-D38K Lys (AAG, AAA) 1.01 ± 0.28 
SSM-D38E Glu (GAG) 2.95 ± 0.77 
SSM-D38P Pro (CCA) n. d. 
SSM-D38T Thr (ACC) n. d. 
M5 His (CAC) 1.26 ± 0.12 
Kinetic experiments were performed with crude cell extracts. 
 
 
Table 2. Nucleotide and amino acid substitutions at position 296 in PpADI M3. 
 PpADI 
variants Substitution at position 296 km (mM) 
M3 (parent) Glu (GAA) 3.74 ± 0.35 
SSM-E296K Lys (AAA, AAG) 0.20 ± 0.01 
SSM-E296N Asn (AAC) 0.53 ± 0.04 
SSM-E296T Thr (ACC) 0.61 ± 0.04 
SSM-E296Q Gln (CAA) 0.79 ± 0.06 
SSM-E296G Gly (GGA) 1.29 ± 0.12 
SSM-E296W Trp (TGG) n. d. 
SSM-E296P Pro (CCT) n. d. 
M4 Lys (AAA) 0.27 ± 0.02 
Kinetic experiments were performed with crude cell extracts.  
* n. d. activity not detectable under assay conditions. 
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4.4.5 Determination of kinetic constants (kcat and S0.5) of PpADI wild type 
and variants M3, M4, M5 and M6 
 
Table 3. Kinetic constants of wild type PpADI and variants. 
 Wild type M3 (parent) M4 M5 M6 
kcat (s-1) 0.18 ± 0.05 10.13 ± 0.36 5.88 ± 0.09 17.56 ± 1.15 11.64 ± 0.50 
S0.5 (mM) 1.30 ± 0.25 2.01 ± 0.19 0.81 ± 0.03 1.48 ± 0.17 0.81 ± 0.09 
* Kinetic contants of PpADI wild type is different from our previous report because in stead of 
0.5 M phosphate buffer, PBS buffer was used for kinetic measurements. Kcat value of PpADI 
wild type dropped from 5.6 s-1 to 0.18 s-1 and kcat value of M2 is reduced ~2-fold. 
 
M3, the parent of the second round of PpADI epPCR library, M4 with decreased 
S0.5, M5 with increased kcat and best variant M6 with best combination of kcat 
value and S0.5 were selected for detailed characterization studies.  
 
Kinetic characterization of PpADI variants was performed using PBS buffer (pH 
7.4), which is commonly used in biological research. PBS buffer helps to 
maintain a constant pH and its osmolarity and ion concentrations usually match 
those of the human body. Citrulline production of PpADI variants was maintained 
between 0.2-0.8 mM. Table 3 summarizes the kcat and S0.5 values of parent M3 
(K5T/D44E/A128T/H404R), variants M4 (K5T/D44E/A128T/E296K/H404R), M5 
(K5T/D44E/A128T/D38H/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R), which were expressed in shaking 
flasks cultures and purified using a two step procedure (anion exchange follows 
by gel filtration). Compared to parent M3 (S0.5 = 2.01 mM), both variants M4 and 
M5 have a lower S0.5 for arginine conversion at pH 7.4, 0.81 mM and 1.48 mM, 
respectively. Variant M4 shows a decreased kcat value, 58% of parent M3 while 
M5 shows a 1.7-fold higher kcat compared to parent M3. Variant M6 with 
combined mutations (K5T/D38H/D44E/A128T/E296K/H404R) shows decreased 
S0.5 value, 40 % of parent M3 (K5T/D44E/A128T/H404R), 62 % of PpADI wild 
type, and a 64.7-fold faster kcat value than PpADI wild type. M6 is 42.3-fold faster 
than PpADI wild type with 0.4 mM arginine (PBS buffer, pH 7.4) as substrate. 
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After two rounds of epPCR libraries coupled with site directed mutagenesis, a 
variant M6 with 64.7-fold higher kcat and lower S0.5 value (0.81 mM) than PpADI 
wild type (0.31 mM). At low concentration of arginine, activity of M6 enhanced 
dramatically than M3 and wild type. For example, M6 is 42.3-fold faster than 
PpADI wild type in 0.4 mM arginine (PBS buffer, pH 7.4). 
 
4.4.6 Native polyacrylamide gel electrophoresis of PpADI variants 
Multimeric form of PpADI variants were investigated by native polyacrylamide gel 
electrophoresis. As shown in Figure 3, two distinct protein bands representing 
two multimeric forms tetramer and dimer (molecular weight of a subunit is ~ 46 
kDa) were observed, but with different concentration percentage. The major 
multimeric form of M3 is dimer. Compared to M3, M4 with an additional mutation 
E296K shows a very different pattern: tetramer is the main form; while M5 with 
an additional mutation D38H contains more or less equal amount of dimer and 
tetramer. M6, with both mutations E296K and D38H, contains more tetramer than 
dimer. 
 
 
 
Figure 3. Native polyacrylamide gel electrophoresis of PpADI variants (M3 to M6) with different 
dimer/tetramer distribution. Single subunit has a molecular weight of ~46 kDa. 
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4.5 Discussion 
 
Directed evolution allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
Small libraries of a few thousand variants are often sufficient to find improved 
variants [18] even without rational understanding of the targeted property. After 
establishing a first directed ADI evolution protocol yielding mutant M2, we 
adjusted the screening system to better reflect ADI’s application conditions. 
Prerequisite for ADI to become an effective anti-tumor agent is that low 
concentrations of arginine in human plasma can effectively be converted. 
 
Figure 2 shows the genealogic tree of PpADI evolution and before discussing the 
influence of each substitution individually the effect on kinetics are briefly 
summarized. Amino acid substitution D44E (M2) increases kcat and S0.5, 
substitution A128T (M3) increases the expression level, and substitution E296K 
(M4) decreases kcat and S0.5 and is responsible for tetramer formation. 
Substitution D38H (M5) increase largely kcat and reduces slightly S0.5. The 
combination of all mentioned residues in M6 result in a finally 64.7-fold improved 
PpADI activity and reduced S0.5 (1.30 to 0.81 mM).    
 
PpADI M3 was obtained from site saturation mutagenesis library at position A128 
using M2 as template (Figure 2). M3 shows improved functional expression level 
of ADI (data not shown) and was used as parent for generating an epPCR library. 
Screening of epPCR library yielded two improved variants M4 and M5, carrying 
an additional mutation, E296K (M4) and D38H (M5). M4 has a decreased S0.5 
(0.81 mM) and a decreased kcat value (5.88 s-1; see Table 3). M5 has a 
decreased S0.5 (1.48 mM) and an increased kcat value (17.56 s-1) when compared 
to parent M3 (S0.5, 2.01 mM; kcat, 10.03 s-1; see Table 3). M6 which harbors both 
substitutions (E296K and D38H) has a decreased S0.5 value (0.81 mM) 
compared to the parent M3 (1.30 mM) and the wild type (2.01 mM), and a 64.7-
fold higher kcat value than the PpADI wild type.   
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Despite further enhancing the activity of PpADI, it is crucial for an efficient 
conversion of the substrate arginine in human plasma (100-120 µM arginine) to 
reduce PpADI’s “Km” (S0.5) value. Figure 4 shows the kinetics of PpADI WT, 
parent M3, and the variants M4, M5 and M6. M3 has a significantly higher kcat 
value compared to WT, but its activity at low concentration of arginine (<1.0 mM) 
is very low (S0.5 value 2.01 mM). In contrast, the most efficient variant M6 with a 
decreased S0.5 value (0.81 mM) shows a remarkable activity improvement at low 
concentrations of arginine (<0.5 mM; see Figure 4). M6 has additional two amino 
acid substitutions (D38H and E296K) compared to M3 which increases kcat and 
reduces the S0.5 value. The combination of D38H and E296K improves especially 
the activity of M6 at low arginine concentrations (< 0.5 mM; see Figure 4). 
 
Figure 4. Kinetic curve of PpADI wild type, M3, M5 and M6. (▲) PpADI wild type, (▼) M3, (●) M4, 
(♦) M5 and (■) M6. 
 
 
Figure 5 shows the tetrameric model (based on PaADI, PDB code 2A9G) of 
PpADI WT (Figure 5A) and variant M6 (Figure 5B). Monomeric units are 
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indicated with the letters a, b, c and d. The access channel to the active sites of 
each monomer is highlighted in square and faces an internal cavity generated by 
the assembly of four PpADI monomers. The substitutions D38H (in blue) and 
D44E (in green) are localized at the interface of monomer pair a-b and c-d. The 
substitution of Glu by Asp at position 44 provides a longer side chain in close 
proximity of the also negatively charged residue Asp43 (Figure 6A). The 
substitution E296K is localized at the border of the entrance to the internal cavity 
of the PpADI tetramer. E296K promotes the tetramer formation likely by 
introducing stabilizing interactions with other residues, for example with Thr33 
(hydrogen bond). E296K inverts the charge at this position and its increased 
length of the side chain might promote further interactions to a neighboring 
monomer (Figure 6A). The combination of D44E and E296K results in a 
population consisting of mainly tetramers (see Figure 3; mutein M4). Interestingly 
with the formation of a tetramer (M4) the S0.5 value is reduced which indicates 
that the tetramer complex formation promotes interactions with the substrate 
arginine at low concentrations. The substitution D38H together with the E296K in 
the mutein M6 reestablishes an almost equal population of PpADI dimers and 
tetramers. A hypothesis is that Lys of the E296K has an electrostatic stabilizing 
interaction with the Glu38 in the M4 but not to the neutral His38. 
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Figure 5. A). The model of WT tetramer after energy minimization in vacuum (GROMOS 43B1). 
B). The model of M6 tetramer after energy minimization in vacuum (GROMOS 43B1). Active site 
residues are represented in CRK format in a square (Blue). Mutated residues are shown in 
licorice format in different colors like D38H (blue), D44E (green), A128T (magenta), E296K (red) 
and H404R (violet). Substrate arginine is represented in orange color by licorice format.  
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Figure 6. A). Structure model of variant M6. E296K is involved in intermonomer interaction 
(between chain a (orange) and b (green)) with Thr33. D44E is involved in intermonomer 
interaction, between chain A (orange) and B (green), with Asp43 (violet). B). Structure alignment 
of PpADI WT model and M6 model with four loops (loop 1:30-46, loop 2:178-175, loop 3:271-281 
and loop 4: 393-404) surrounding the entrance of the active site. The substitutions in these loops 
and the residues involved in the interaction with those substitutions are representing: D38H 
(orange), D44E (yellow) and H404R (cyan, in M6; gray, in WT), Ser35 (green), Arg 400 (pink), 
substrate arginine (ochre), catalytic triad His278, Asp280 and Cys406 (violet, highlighted in an 
oval) 
 
Figure 6B shows that the active site of the PaADI is surrounded by four loops 
(loop 1: 30-46, loop 2: 178-185, loop 3: 271-281, and loop 4: 393-404). These 
four loops undergo a conformational transition upon arginine binding and tighten 
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the surrounding of the arginine substrate[16]. D38 is located in loop 1 and faces 
towards the substrate access channel. In PpADI model (Figure 6B), the D38H 
mutation promotes the formation of a hydrogen bond interaction with the 
neighboring residues Ser35, contributing to the stability of the entropically 
unfavorable folded conformation of loop1. The rigidified loop 1 might be 
beneficial for arginine conversion. According to PaADI structure analysis, the 
side chain of gating residue Arg401 (Arg400 in PpADI) is located at the active 
site entrance and fills the substrate-binding site. The structure analysis of the 
C406A PaADI-L-arginine complex[16] shows that the Arg401 side chain (Arg400 
in PpADI) is displaced by the substrate arginine to a position near the active site 
entrance that allows its hydrocarbon chain to assist shielding the catalytic site 
from solvent. D38 is involved in an ionic interaction and hydrogen bonding with 
Arg400. The substitution of Asp to His at position 38 results in a loss of ionic 
interactions to Arg400 due to the different lengths of the side chains. His38 can 
form only a hydrogen bond with active site gating residue Arg400. A weakened 
interaction between position 38 and Arg400 might increase the flexibility of the 
side chain of Arg400 which then might block less efficiently the access of 
arginine to the active site. As a result the variant M5 shows an improved kcat 
value (1.7-fold compared to parent M3) due to the substitution D38H.  
 
For elucidating further the individual role of the five identified amino acid 
substitutions and their influence on the active site geometry and tetramer 
formation crystal structures of variant M4 and M6 have to be solved.  
 
4.6 Conclusion 
In summary, with the modified screening protocol, PpADI variants with improved 
kcat and S0.5 were identified. The increased kcat value and decreased S0.5 value 
result in significant activity improvement of PpADI at low arginine concentrations. 
Especially the kinetic constants of PpADI variant M6 demonstrate that PpADI 
properties can be tailored by directed evolution. The generated PpADI variants 
match from their kinetic behavior therapeutic application demands much better 
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than the wild type PpADI. We therefore hope that by directed evolution improved 
PpADIs will further be investigated in vivo for tumor therapy. 
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Summary and outlook 
Arginine depletion based on ADI is an emerging strategy for anti-tumor treatment. 
ADIs have been studied for the therapy of HCCs and melanomas and were 
approved as an orphan drug for both kinds of tumors. ADI is proved to be 
effective in the treatment of leukemia. The effectiveness of ADIs as anti-tumor 
agent depends on their enzymatic properties (such as Km, kcat, optimum pH, 
stability at neutral pH). Directed evolution, without rational understanding of the 
targeted property, allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
 
In order to improve PpADI activity at physiological pH by directed evolution, a 
colorimetric screening assay based on citrulline detection has been developed in 
96-well microtiter plate format. Single mutation H404R was identified according 
to PpADI homology model (based on PaADI crystal structure), introduced to 
PpADI wild type and eventually resulted in 1.4-fold of increase in kcat. M1 (H404R) 
was used as template for the first round of epPCR library generation. M2 
(K5T/D44E/H404R) obtained from the first round of epPCR library showed 4-fold 
improved kcat value when compared to the PpADI wild type. Furthermore, a shift 
of pH optimum from pH 6.5 to pH 7.0 was observed, combined with an increased 
Km value (2.5 mM) under assay conditions (0.5 M sodium phosphate buffer, pH 
7.4), compared to PpADI wild type (0.7 mM). 
 
Arginine concentration in human plasma is however relatively low (100-120 µM). 
Therefore the second round of epPCR library was performed to decrease Km 
value and further improve kcat value. The validated screening assay was modified 
to reflect more close physiological condition (1 mM arginine in PBS buffer, pH 
7.4). Two important variants with one additional mutation, M4 
(K5T/D44E/A128T/E296K/H404R) with decreased S0.5 vaule, and M5 
(K5T/D38H/D44E/A128T/H404R) with improved kcat were obtained. Their two 
mutations were combined and resulted in variants M6 
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(K5T/D38H/D44E/A128T/E296K/H404R). Under physiological pH in PBS buffer, 
the S0.5 value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); 
the kcat value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-
folds) and 11.64 s-1 (M6, 64.7-fold). 
 
A reamaining challenge facing PpADI’s anti-tumor application is to decrease the 
Km (S0.5) value further close to arginine concentration level in human plasma. A 
more sensitive assay for screening has to be developed with the addition of 
sensitizer like thiosemicarbazide (TSC), optimized temperature and incubation 
time. Improved variants should be tested tested in human plasma or with human 
plasma composition. In vitro testing of ADI variants with arginine auxotrophic 
tumor cell lines is the first step towards in vivo in human. 
 
In summary, directed evolution has been very useful algorithim for improving 
ADI’s kcat and Km at physiological pH (pH 7.4) for its medical application. Hope 
that directed evolution will be become a standard method for therapeutic protein 
like its use in industry.                                
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Abstract 
Abstract 
Arginine deiminase (ADI), an arginine-degrading enzyme, is involved in the first 
step of arginine dihydrolase pathway. It catalyzes the hydrolysis of L-arginine to 
form citrulline and ammonia. ADI has been studied as a potential cancer 
therapeutic agent for the arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCC) and melanomas. Furthermore, studies also indicate that ADI 
is a potential anti-angiogenic agent; therefore it could become a novel anti-cancer 
drug targeting the neovascularization-related tumors. Studies show ADI is more 
potent for the treatment of leukemia than L-asparaginase. However, the anti-
tumor application of ADI for therapeutic purpose faces considerable challenges, 
such as, microbial ADI has low activity at physiological pH (7.35~7.45), short 
circulating half-life (~5 h) and high antigenicity. Pegylation of ADI improved its 
efficacy as a clinical drug, including its half-life in serum and antigenicity. The aim 
of the project is to improve ADI catalytic performance at physiological pH by 
directed evolution. 
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. Directed protein evolution has 
over the last decades become a versatile and successful approach for tailoring 
protein properties to industrial demands and for advancing our understanding of 
structure-function relationships in biocatalysts. Unlike rational design relying on 
the gathering of extensive structure-function relationships of enzymes, directed 
evolution is used to reengineer enzyme properties through iterative rounds of 
diversity generation and function selection for improved variants. 
 
In order to improve the ADI activity at physiological pH, we established a directed 
evolution protocol for this purpose. A microtiter plate (MTP) format colorimetric 
screening assay based on citrulline detection with diacetyl monoxime (DAM) was 
developed. Reaction temperature for color development and DAM concentration 
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were optimized to ensure sufficient sensitivity, appropriate linear range and 
throughput. With the optimized assay and PpADI wild type expressed in E. coli as 
a model protein, true standard deviation 12.8 % was obtained, which is 
appropriate for the library screening. 
 
With the established microtiter plate assay system, for the first time, we 
reengineered ADI for improved activity at physiological pH (pH 7.4) with higher 
potency in medical application. After one site directed mutagenesis and one 
round of epPCR library screening, variant M2 (K5T/D44E/H404R) was obtained. 
M2 shows 4-fold improved kcat value than the PpADI wild type, a shifted pH 
optimum at pH 7.0 (by 0.5 pH unit), and however an increased Km value, 3.6-fold 
under assay conditions (0.5 M sodium phosphate buffer).  
 
Low Km (S0.5) value for ADI is an important factor for efficient consume of arginine 
in plasma because of the low arginine concentration in human plasma (100-120 
µM). Therefore after our proof of concept of reengineering PpADI by directed 
evolution, we aim to decrease the Km value of PpADI towards arginine and 
improve the kcat furthermore thereby improve the efficiency of arginine depletion 
by ADI. The established citrulline colorimetric assay in 96-well microtiter plate is 
improved to reflect application conditions: PBS buffer and 1 mM arginine were 
used in screening system. After the second round of epPCR library and site 
directed mutagenesis, variant M5 (K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated: at pH 7.4 (PBS buffer), 
the S0.5 value decrease from 2.01 mM (parent M3, K5T/D44E/A128T/H404R) to 
1.48 mM (M5) and 0.81 mM (M6). Under physiological pH in PBS buffer, the S0.5 
value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat 
value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 
11.64 s-1 (M6, 64.7-fold). 
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Chapter 1 Arginine deiminase (ADI) 
Arginine deiminase (ADI) 
 
1.1 Arginine deiminase (ADI)  
Arginine deiminase (ADI, EC 3.5.3.6), an arginine-metabolizing hydrolase, 
catalyzes the hydrolysis of L-arginine to form citrulline and ammonia. This 
reaction is the first step in the L-arginine degradation pathway (ADH, scheme 1, 
(1). First, arginine is deiminated by arginine deiminase. The resulting citrulline is 
converted to carbamoyl phosphate and ornithine by ornithine transcarbamylase 
(EC 2.1.3.3), and finally the carbamoyl phosphate is used to phosphorylate ADP 
by carbamate kinase (EC 2.7.2.2), producing one ATP molecule. ADI is absent in 
humans but present in a wide range of bacterial species such as Pseudomonas 
aeruginosa (2), Pseudomonas plecoglossicida (3) and Mycoplasma arginini (4) 
and in parasitic protists such as Giardia intestinalis (5), Trichomonas Vaginalis 
(6), Trichomonas fetus (7), and Hexamita inflate (8). For pathogenic bacteria, ADI 
is required in arginine dehydrolase pathway for virulence and for energy 
production under anaerobic conditions (9, 10).     
 
 
Scheme 1. Arginine dihydrolase pathway. OTC, ornithine transcarbamylase; CK, carbamate 
kinase. 
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The establishment of a high-level production system for ADI is an essential step 
for further research and development of this enzyme. After ADI was discovered 
from Mycoplasma in 1960s (11), various ADI genes have been cloned, 
expressed in E. coli strains, and the enzyme properties were also studied (Table 
1). 
 3 
Table 1. ADI expression, enzymatic properties and medical applications. 
ADIs Origin 
Expression 
host/vector 
Multimeric 
form Km; kcat 
Optimum 
pH  
Specific 
activity 
Medical 
application References 
MhADI 
(SYN1903) 
Mycoplasma 
hominis PG21* 
E.coli BL21 
(DE3)/pET-47b 
Dimer   0.618 U/mg 
(pH 6.5) 
Human 
melanoma 
(G361), 0.036 
U/ml for 50 % 
IC50 
Japan, 
Harasawa, 
2009 (12) 
MhADI Mycoplasma 
hominis (ATCC 
23114) 
- 
 
Dimer   6.0 35.5 U/mg (pH 
6.0) ;  
3.9 U/mg (pH 
7.4)  
Mouse 
melanoma 
(MH134) in 
vitro, 100 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MhADI Mycoplasma 
hominis (ATCC 
14027) 
- Dimer  0.17 mM 
(pH6.6) 
   USA, Fenske, 
1976(14) 
MhADI Mycoplasma 
hominis  
E.coli BL21 
(DE3)/pET25b 
 0.24 mM; 
0.151 s-1 
   China, Luo, 
2007 (15) 
MhADI Mycoplasma 
hominis 
E.coli    20 U/mg ADI 
(37°C). [a] 
ADI-SS 
PEG20000,  
human 
melanoma, 
human HCC 
USA, Pheonix 
Pharmacologi
cs, Inc., Clark, 
2002 (16) 
PaADI 
(PA5171) 
Pseudomonas 
aeruginosa  
(ATCC 47085D) 
E. coli 
BL21(DE3)/pET10
0 
Tetramer 0.14±0.01 
mM (pH 5.6) 
5.6   USA, 
Dunaway-
Mariano, 2005 
(17) 
PaADI Pseudomonas 
aeruginosa  
 
E. coli 
BL21 (DE3)/ 
pET SUMO 
   CARD-like 
domain, no 
catalytic 
activity 
Human cancer 
cell line SKOV-3 
USA, 
Chakrabarty, 
2006 (18) 
PpADI Pseudomonas 
plecoglossicida 
E. coli 
BL21 Gold-(DE3)/ 
pET42b 
 0.7 mM; 5.6 
s-1 (pH 7.4, 
0.5 M sodium 
phosphate 
buffer) 
6.5 31.3 U/mg (pH 
7.4, 0.5 M 
sodium 
phosphate 
buffer) 
 Germany, 
Schwaneberg, 
 2010 (3) 
 4 
MaADI Mycoplasma 
arginini 
(ATCC 23838D) 
E. coli 
DH5α/PTTQ118 
   32.7 U/mg. [a] Human 
umbilical vein 
endothelial 
(HUVE) 
USA, Shen, 
2002 (19) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
E. coli 
JM101/pADTc1 
Dimer     33.6 U/mg 
(37°C, pH 6.5). 
[a] 
Mouse 
hepatoma, 17 
ng/ml for 50 % 
IC50; mouse 
fibrosarcoma, 
15 ng/ml for 50 
% IC50 
Japan, 
Hayashi, 1994 
(20) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
    42 U/mg 
(37°C, pH 6.5); 
29.9 U/mg 
(37°C, pH 7.4) 
Mouse 
melanoma 
(MH134) in 
vitro, 10 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
-     HUVE, 
neuroblastoma, 
retinoblastoma, 
osteosarcoma, 
5~10 ng/ml for 
50 % IC50 
Germany, 
Schweigerer, 
1999 (21) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
- Dimer  0.2 mM 6.0-7.5 50 U/mg Mouse tumor 
carcinoma, 
fibrosarcoma 
and melanoma, 
5~20 ng/ml for 
50 % IC50 
Japan, 
Takaku, 1992 
(22) 
LlADI L. lactis (ATCC 
7962) 
E. coli 
BL21Gold(DE3)/p
GEM-T Easy 
Trimer 8.67 mM 7.2 140.27 U/mg  Korea, Lee, 
2007 (23) 
[a] ADI was expressed in inclusion body and denaturation-renaturation had to be employed to get soluble protein. 
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1.2 ADI structure 
In 1970s, Kakimoto et al. (24, 25) diffracted the first ADI crystals from P. putida 
through multiple-step chromatography followed by crystallization. Almost three 
decades later, the X-ray crystal structure of ADI from P. aeruginosa (PaADI, 
Figure 1A) (26) and M. arginini (MaADI, Figure 1B) (4) were solved to assist in 
understanding structure-function relationships. PaADI and MaADI share 27 % 
sequence identity and belong to guanidino group-modifying enzyme superfamily 
(GMSF). The catalytic triad (Cys-His-Glu/Asp) is conserved in members of the 
GMSF. Both crystal structures of PaADI and MaADI show a characteristic 5-fold 
pseudosymmetrical barrel with ββαβ subunits. Table 2 summarizes the crystal 
structures of PaADI and MaADI. 
 
Figure 1. Structural of ADIs from P. aeruginosa and M. arginini. (A) PaADI (PDB ID: 1RXX) and 
stereo view of its catalytic triad (C406-H278-E224). (B) MaADI (PDB ID: 1S9R) and stereo view 
of its catalytic triad (C398-H269-E213) with substrate L-arginine (27). 
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Table 2.  Crystal structures of ADI in protein data bank (PDB). 
PDB 
code 
Ligand in crystal 
structure Description 
Resolution 
(year) 
2A9G Arginine 
Crystal structure of PaADI variant C406A in 
complex with L-arginine  
2.30 Å 
(2005) 
2AAF  
Crystal structure of PaADI variant H278A 
forming a S-alkylthiouronium reaction 
intermediate  
2.30 Å 
(2005) 
2ABR  
Crystal structure of PaADI variant D280A with L-
arginine forming a S-alkylthiouronium reaction 
intermediate  
2.9 Å 
(2005) 
2ACI  Crystal structure of D166A arginine deiminase  
2.50 Å 
(2005) 
1S9R Arginine 
Crystal structure of MaADI covalently linker with 
a reaction in intermediate  
1.60 Å 
(2004) 
1LXY Citrulline 
Crystal Structure of MaADI covalently linked with 
L-citrulline  
2.00 Å 
(2004) 
1RXX  Crystal structure of MaADI  
2.45 Å 
(2004) 
 
MaADI was crystallized as a homodimer and its catalytic triad is formed by 
Cys398-His269-Glu213. MaADI has a catalytic domain and a five-helix bundle 
domain (Figure 3). The buried and compact substrate binding pocket is located 
approximately at the center of the molecule, from which a small solvent channel 
leads to the surface of the enzyme. The opening to the channel is located 
adjacent to the dimer interface region, which is at the opposite side of the 5-fold 
pseudosymmetric moiety of ADI. The shape and size of the channel does not 
permit transport of the substrate (L-arginine and end product (L-citrulline) in and 
out of the pocket. Substantial conformational changes in ADI are required to 
permit entry of the substrate and expulsion of the end product. The occurrence of 
"closed" and "open" form was suspected to be dependent on binding of substrate. 
 
PaADI has a tetrametric structure with 1630 amino acid residues in total, which 
makes it the largest enzyme of its structural superfamily. The catalytic triad of 
PaADI is Cys406-His278-Glu224. Similar to MaADI, the active site of PaADI is 
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located in a narrow crevice formed by a network of charged residues. Ligand 
binding energy is derived from ion pair and hydrogen bonding interactions 
between active site residues and the guanidinium, carboxylate and ammonium 
groups of the substrate. The proposed substrate-binding model shows that the 
catalytic center contains abundant charged residues (e.g. Asp280, His405, Glu13 
and Arg165). The ion pairing interactions between these residues contribute to 
the integrity and activity of ADI. In addition, Asp116, Asp227, Arg185, Arg401, 
His278, Glu118, and Glu224 are part of an extended charged network. The 
proposed catalytic mechanism suggests that the active site of PaADI is blocked 
by Arg401, and therefore a conformational transition is taking place upon the 
substrate binding. Based on the proposed reaction mechanism, Cys406 is as a 
key residue responsible for the nucleophilic attack on the guanidinium carbon 
atom of arginine. PaADI contains only one hydrophobic residue, Phe-163 and a 
Cys-406 with an unknown protonation state. The known functions of important 
residues are shown in Table 3, and the interactions between important residues 
and substrate arginine are shown in Figure 2. 
 
 
Figure 2. A. stereoscopic view of PaADI key active site residues. B. stereoscopic view of a 
modeled arginine substrate (green) docked in the active site of ADI. Atomic colors are red, 
oxygen; blue, nitrogen; yellow, sulfur; and gray, carbon. Ion pair interactions are shown as 
dashed lines (26). 
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Table 3. Residues important for catalytic function of PaADI (28, 29). 
Residues Known/postulated function or comment 
Cys406 Mounts the nucleophilic attack on the carbon atom of the guanidinium 
group of arginine 
His278 Serves as a general base and activate the water molecule 
Glu224 Modulate the ionization state of His278 
Asp280 Interacts with the imidazole group of His405 F via the carboxylate 
group, which in turn interacts with Glu13. Invariant residue in all 
known ADIs 
Asp280, 
Asp166 
Fix the guanidinium group of the arginine substrate tightly by 
interactions with the carboxyl groups 
Arg401, 
Arg185 
Form ionic interaction with The carboxyl group of the arginine 
substrate 
Phe163 Interacts with the hydrophobic part of arginine substrate 
Glu13 Interacts His405 and is invariant in all known ADIs 
His405 Sometimes is replaced by an arginine, as in the case of McADI. This 
may explain the low pH optimum of PaADI (5.6) in contrast to the 
neutral pH optimum of McADI, the enzyme that contains an arginine 
residue instead of His405 
Arg165 Is fixed by electrostatic interactions with the main chain oxygen atoms 
of Thr408 and His405 and with the hydroxyl group of Thr-408 
Arg401 Blocks the ADI active site via the side chain by forming an ion pair 
with the carboxyl group of Asp166 and occupies approximately the 
same position as the guanidinium group of an arginine substrate 
 
The overall fold of MaADI and PaADI consist of five ββαβ modules in cyclical 
arrangement, generating a pseudo 5-fold symmetrical barrel and an additional 
85-residue α-helical domain inserted between the first and the second ββαβ 
modules giving the typical “Clip-on-fan” moiety. The α-helical domain of PaADI 
mediates tetramer formation and the α-helical domain of MaADI was speculated 
to play a role in activating the series of reaction in arginine dehydrolysis pathway 
(4). Structural alignments by Chakrabarty et al. (18) demonstrated the unique 85 
residue 5-α-helical bundle domain exhibiting structural similarity to the 
mammalian CARD (caspase recruitment domains)-containing proteins and this 
CARD-like domain is present only in the PaADI and MaADI but not in the other 
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GMSF members (Figure 3B). Furthermore, PaADI putative CARD-like domain 
induced apoptosis to cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structural characteristics of the PaADI. A. Ribbon drawing of PaADI (1RXX_A) 
highlighting the two domains. B. The presence of the CARD domain in PaADI and MaADI but its 
absence in other members of the GMSF (guanidino-group modifying superfamily) enzymes such 
as DDAH and AGAT, as shown from the structure-based sequence alignments. The CARD 
domain represents that of caspase-9. DDAH, dimethylarginine dimethylaminohydrolase; AGAT, 
arginine: glycine amidinotransferase. The β-strand and α-helices are shown as arrows and strips 
respectively. Roman numericals I to V are the five ββαβ subunits. The clip moiety (α-helical 
module) in Figure 3 is seen only in PaADI and MaADI which bears structural homology to the six-
α-helical modules that form the CARD domain of the caspase-9 protein molecule. N, N-terminal; 
C, C-terminal. C. A schematic diagram showing the overall fold and topology of PaADI, as 
reported (18). 
 
Comparison of substrate free and substrate bound structure of PaADI gives 
interesting insight into structure changes upon substrate binding (17). Pairwise 
superposition of the free wild-type PaADI (PDB code: 1rxx) and the mutant 
enzyme substrate complexes (PDB code: 2a9g) show that the overall fold of the 
structures remains similar, yet with some local changes. In particular, four loops 
(Figure 4) associated with the active site undergo conformational transitions not 
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related to crystal packing: loop 1 (residues 30-46), loop 2 (residues 178-185), 
loop 3 (residues 271-281, part of this loop is disordered in the apoADI structure), 
and loop 4 (residues 393-404). Residues adjacent to the substrate exhibit the 
most significant shifts. For example, the α-carbon atom of Leu41 (loop 1) shifts 
by 2.7Å and that of Arg185 (loop 2) by 1.8 Å; the α-carbon atom of His278 (loop 
3) shifts by 0.9 Å and that of Gly400 (loop 4) by 4.4 Å. These are localized but 
mechanistically important conformational transitions that tighten the surrounding 
of the substrate. Simultaneously, substrate binding is accompanied by 
displacement of the side chain of Arg401 (loop 4) by more than 8 Å to enable 
access to the active site. The superposition of ADI and PAD4 ADI active site is 
shielded from the solvent by a long loop (residues 25-48 in PaADI) and the 
following two turns of α-helix (residues 49-56). 
 
 
 
 
 
Figure 4 (A). Stereoscopic view of ADI in the unbound and bound states. Superposed molecules 
are colored gray where the trace of the polypeptide chain is similar in both structures. For regions 
exhibiting differences, loops of the apoADI structure are highlighted in blue, and loops of the ADI 
structure complexed with arginine are highlighted in red. 4(B). Structural relationship between ADI 
(yellow) and PAD4 (cyan) (17). 
1.3 Catalytic reaction mechanism of ADI 
The overall reaction catalyzed by ADI is the hydrolytic substitution of the ŋNH2 
group from the guanidinium group Cζ of L-arginine, leading to citrulline and 
ammonia (Figure 5). Herzberg (17) and Arnold (4) proposed ADI catalysis 
mechanism for PaADI (Figure 5) and MaADI, respectively.  Basically, both of the 
proposed mechanisms are composed of three main steps: 1) thiol group of 
B A 
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Cys406 mount a nucleophilic attack on the guanidinium group of arginine and a 
proton is transferred first to ŋNH2 group; 2) water molecule is activated by His278 
and followed by attacking the covalent intermediate to replace and release NH3; 
3) the C-S covalent bond between enzyme and the resulting citrulline is cleaved 
and thus end product citrulline is released and free enzyme is generated for next 
catalytic cycle. 
 
 
Figure 5.  Mechanism of PaADI catalysis of arginine to citrulline and ammonia (17). 
1.4 Anti-tumor application of ADI 
Amino acids depletion is one type of targeted therapy for human cancers which 
are auxotrophic for a particular amino acid. Amino acids degrading enzymes, 
such as asparaginase (30), methioninase (31), arginase (32), arginine deiminase 
(27), phenylalanine ammonialyase (33) and tryptophanase (34) have been 
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studied for inhibition of tumor cells in vitro. The most representative anticancer 
enzyme is asparaginase, which is particularly effective in acute lymphoblastic 
leukaemia. PEG asparaginase is commercialized for acute lymphoblastic 
leukaemia treatment (Oncaspar®, pegaspargase) (35). However, asparaginase 
treatment is sometimes accompanied by serous side-effects including 
anaphylactic shock, coagulapathies as well as liver and pancreatic toxicity (36).  
 
Arginine is an important amino acid involved in the synthesis of a wide range of 
peptides and proteins, production of creatine and nitric oxide, and a myriad of 
metabolic pathways and cellular events. It is a precursor of proline, polyamines, 
glutamine, glutamate, and other neurotransmitters, such as g-aminobutyric acid 
and also serves as a substrate for two important enzymes, arginase and nitric 
oxide synthetase (37). Arginine is an indispensable amino acid to children but a 
semi-essential amino acid in adult humans since many adult somatic cells can 
synthesize it from citrulline in two steps via urea cycles (Figure 6). The enzyme 
argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline and 
aspartic acid to argininosuccinate which is then further converted to arginine and 
fumaric acid by argininosuccinate lyase (ASL). Arginine can be degraded to 
ornithine by the urea cycle enzyme arginase. Ornithine is then converted back to 
citrulline by ornithine carbamoyl transferase (OTC) and then recycles back to 
arginine from citrulline by ASS/ASL. Thus, the ability to regenerate arginine from 
citrulline depends on the amount/activity of ASS and ASL, which are tightly 
coupled. The sensitivity of cells to arginine deprivation depends on the ability of 
ASS and ASL to regenerate arginine from the alternative intermediate (ornithine, 
citrulline and argininosuccinate) in the urea cycle. 
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Firgure 6. Urea cycle. Argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline 
and aspartic acid to argininosuccinate which is then further converted to arginine and fumaric acid 
by argininosuccinate lyase (ASL). Arginine can be degraded to ornithine by the urea cycle 
enzyme arginase. Ornithine is then converted back to citrulline by ornithine carbamoyl transferase 
(OTC) and then recycles back to arginine from citrulline by ASS/ASL.  
 
Arginine begins to become limiting at ~10-4 M, whereas other amino acids can 
sustain growth at 10-5-10-6 M. Wheatley et al. showed that most tumour cell lines 
die considerably more quickly during arginine deprivation than in the absence of 
any other single (or group of) essential amino acids (38). Since 1930 for the first 
time arginine known is essential for the growth of some forms of cancer, the 
potential of arginine degrading enzymes as therapeutic agents was recognized, 
investigated and employed for arginine auxotrophic tumor treatments. Enzymes 
capable of depleting arginine in vitro include arginase existing in human liver, 
arginine decarboxylase from bacterial, plant and human, and ADI from 
microorganism. 
 
Arginine decarboxylase converts arginine to agmatine, which is toxic at high 
plasma concentration. Furthermore, arginine decarboxylase has a short half-life 
and it loses virtually all enzymatic activities upon pegylation though pegylation of 
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arginine decarboxylase is inefficient because not enough lysine residues for 
polyethylene glycol to attach (39). 
 
Arginase is limited for anti-tumor application because of its low substrate affinity 
(Km value 2-4 mM; plasma arginine 100-120 µM), short circulatory half-life (10-15 
min) and sub-optimal enzymatic activity at physiological pH (alkaline pH optimum, 
pH 9.3)(40). Despite these disadvantages of arginase, Lam et al. reported  
remission of hepatocellular carcinoma induced by systemic release of 
endogenous hepatic arginase (41) and Leung et al. proved pegylated 
recombinant human arginase (rhArg-peg 5,000mw) can inhibit ASS-positive 
HCCs while ADI can not (42). 
 
In addition, ADI, another arginine-degrading microbial enzyme, has various 
biological activities including anti-proliferation, anti-angiogenesis and inhibition of 
inducible nitric oxide synthase (iNOs). Figure 7 summarizes how ADI affect many 
arginine-related cellular functions. ADIs (Table 1) have been shown to have 
strong in vitro and in vivo inhibition for arginine auxotrophic tumors (e.g. 
hepatocellular carcinomas (HCCs), melanomas, retinoblastoma (43), prostate 
cancer(44)) and ADI from M. hominis (MhADI) is currently under clinical trial for 
HCC (phase II) (45) and melanomas (phase I/II) (46). Studies on human 
lymphatic leukemia cell lines confirmed ADI’s anti-angiogenic activity. Among all 
the ADIs, MhADI and MaADI were studied most intensively (Table 1). 
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Firgure 7. Summary of ADI effects on arginine-related cellular functions. rADI inhibits NO 
production via iNOS, but potentiates NO production via eNOS in the cultured endothelial cell 
model. rADI enhances or inhibits AS activity in different cells. rADI inhibits de novo protein 
synthesis in cells with low AS activity, but not in cells with high AS activity. Polyamine synthesis 
was not significantly affected by rADI, even in cells with low AS activity. Arrow representation: 
solid, potentiates; blocked, inhibits; dotted, no effect (47).  
 
In 1999, US Food and Drug Administration (FDA) designated ADI-PEG-20 
orphan drug status for treating HCC and invasive malignant melanomas. In 2005, 
also the European Agency for the Evaluation of Medicinal Products (EMEA) also 
granted ADI-PEG-20 orphan drug status for HCC. Phase II trials of ADI-PEG-20 
in patients with metastatic hepatocellular carcinomas have shown that the drug is 
safe, well tolerated, and may benefit patients with unresectable HCC. Izzo and 
coworker suspected that combination therapies of arginine deprivation and 
growth inhibition via kinase inhibitors might improve the survival rate further. 
Additionally, ADI enhances radio sensitivity of human mammary adenocarcinoma 
(MCF-7 cells) (48), exerts anti-proliferative as well as anti-angiogenic activities 
and inhibits the growth of viruses such as HIV-1 and hepatitis (49, 50). Current 
research efforts are focused on ADI’s in vivo inhibitory effect towards leukemia, 
melanoma, prostate cancer, renal cell carcinoma, and human umbilical vein 
endothelial cells (HUVEC) (19, 44, 51-53), clinical trials for HCC (phase II) (45) 
and melanoma (phase I/II) (46), and tumor inhibitory mechanisms of ADI (54). 
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The effectiveness of ADIs as anti-tumor agent depends on their enzymatic 
properties (such as Km, kcat, optimum pH, stability at neutral pH), selectivity on 
tumor cells, stability in blood circulation and immunogenicity. Pegylation (35) has 
been effective in reducing their immunogenicity in animal and increase their 
stability to various hydrolytic enzymes in plasma. Directed evolution as powerful 
algorithm to design proteins allows improving all properties that can be reflected 
in a screening system through iterative rounds of diversity generation and 
screening. Small libraries of a few thousand variants are often sufficient to find 
improved variants (55) even without rational understanding of the targeted 
property. The first example of directed ADI evolution by our group (3) provides a 
simple and effective screening system to improve activity of PpADI at 
physiological pH.  
 
1.5 Conclusion 
ADI-based arginine deprivation is a novel and promising targeted approach to the 
treatment arginine auxotrophic tumors, in particular, melanoma, hepatocellular 
carcinoma and leukemia. Certain mesotheliomas and renal cell cancers were 
also proved to be sensitive to ADI therapy. Due to its low incidence of major side 
effects (myelosuppression and gastrointestinal toxicity or other major organ 
toxicity) arginine deprivation treatment should be combined with other anticancer 
treatments to increase the response rate. Reengineering of ADI by protein 
engineering is a promising strayegy to tailor ADI properties for demands in 
medical applications. Solved ADI crystal structure enables to understand 
structure function relationships and to guide protein engineering. 
 
 
  
 
 
 
 
 
 
 
  17 
Chapter 2 Directed evolution 
Directed evolution 
 
2.1 Introduction to directed evolution 
Enzymes are increasingly being used in the generation of products that are 
traditionally made using chemical synthesis and the field continues to expand its 
horizons, particularly as applied to the synthesis of the fine chemicals and 
pharmaceuticals (56, 57). Naturally occurring enzymes are often not designed for 
the applications of interest, since after all they are evolved in nature for a 
purpose other than being the catalysts of industrial processes. Directed evolution, 
rational design and biodiversity screening and combined approches are the main 
strategies to reengineer enzymes for addressing application demands. Directed 
evolution has emerged as a powerful enabling method for improving enzyme 
properties in iterative cycles of diversity generation and screening (Figure 1).  
 
A main advantage of directed evolution compared to rational design is that it 
does not require structural or mechanistic information for protein optimization. 
Directed protein evolution has been successfully used for altering and improving 
protein properties (solubility, expression, enantioselectivity, stability and activity 
in unusual environment, allosteric interactions, tolerance to pH), as well as for 
regulating other molecules and systems, including RNA, DNA regulatory 
elements, biosynthetic pathways and genetic regulatory circuits (58-60).  
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Figure 1. Procedure of a directed evolution experiment. It involves three key steps: 1) selection a 
good starting sequence and mutating the parent to create a library of variants; 2) identification 
variants with improved function and 3) isolation of gene encoding for improved variant and 
repeating the process until the desired function is achieved. 
 
A parent sequence (or sequences) is chosen based on its perceived proximity to 
the desired function and its evolvability (the ability of a protein to adapt in 
response to mutation and selective pressure). A parent protein for directed 
evolution should exhibit enough of the desired function that small improvements 
can be reliably discerned in a high-throughput screen.  
 
Variants library should be generated with high probability of finding improved 
variants given the screening capacity. With a high-throughput screening method, 
a library can be constructed to generate the large potential improvement. Arnold 
and coworkers(61) showed that very low mutation rates result in many functional 
sequences but only a small number are unique sequences, however very high 
mutation rates produce diverse sequences but few retain function. Schwaneberg 
and coworkers(62) reviewed random mutagenesis methods, focused library 
generation methods and computational tools for high-quality mutant libraries 
generation. Schwaneberg and coworkers (63) also summarized criteria for an 
ideal mutagenesis methods: unbiased mutational spectrum, controllable mutation 
frequency, consecutive nucleotide substitutions or codon-based substitutions, 
enable subset mutagenesis (e.g. introduction mainly positively or negatively 
charged amino acid), independent of gene length, technically simple and 
reproducible, and economical. 
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Screening is used to identify library members improved in the targeted property. 
Identification of improved variants though selection or screening is “analogous” to 
evolutionary pressure in natural evolution (i.e. only the fittest survive). As the 
word “directed” in directed evolution implies, laboratory evolutionary pressure is 
defined and applied by the researcher in screening system. Gradually increasing 
the selection pressure or evolving against a series of intermediate challenges 
often accumulates useful single mutations and yields desired variants (64).  
 
Traditional methods for screening employ microtiter plate formats (96-well, 384-
well, 1,536-well (65) and even 1,000,000-well (66)) or solid phase assay (agar 
plate, filter paper and nitrocellulose membrane), which typically enable the 
screening of no more than 106 variants by using robotic automation (67). 
Sometimes, fast and universal analytic methods like HPLC (68) or GC-MS (69) 
are utilized for performing an efficient screen of a non-natural substrate. However, 
the number of screened mutants is limited to 104-106. In recent years flow 
cytometry systems (67, 70, 71) have become increasingly attractive, especially 
after the development of emulsion technology offering compartmentalization and 
high throughput up to 107/h. In addition, Weitz and coworkers (72) recently 
reported a promising ultrahigh-throughput screening in drop-based microfluidics, 
by which one can screen a library of 108 in about 10 h. Dijkhuizen et al. 
compared in a review (73) six kinds of library screening strategies (Figure 2). 
Selection techniques rely on a direct link between cell growth and improved or 
acquired enzyme function and therefore it is limited to engineering detoxifying 
enzymes (e.g. b-lactamase) or enzymes that synthesize essential nutrients for 
cell growth and survival. The traditional microtiter plate screenings are medium-
throughput and the most simplistic format of screening. It involves the incubation 
of colonies with the substrate of targeted enzyme. The crucial factor with this 
screening technique is that substrate conversion creates a visual signal, such as 
fluorescence or color, to identify colonies expressing an enzyme with desirable 
properties. Microtiter plate based screenings are the most commonly applied 
method in identifying desirable enzyme variants. Microtiter plate based 
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screenings enable the use of various analytical tools and in the mean while they 
offer a great dynamic range. Their screening capacity is usually limited to less 
than 104 variants per day. Screening based on microfluidic device and sorting 
device is a new screening platform for directed evolution, which offers ultra-high-
throughput. It allows the discriminate between wild-type and a less active mutant 
and allows for the addition of substrates and quenchers at desired time thus 
extending the scope of directed evolution screening strategies. Cell as micro-
rector, cell surface display and in vitro compartmentalization technology are also 
FACS (fluorescence-activated cell sorting system) dependent methods for high-
throughput screening and allow 109-1010 screening capacity. 
 
Once improved enzymes are identified, encoding genes are isolated and 
subjected to further iterative cycles of mutation and screening in order to 
accumulate beneficial mutations until the targeted improvement is hopefully 
achieved. The number of iterations required depends on the starting point, the 
protein fold and the selected properties which determine the possible mutational 
load and achievable improvement. 
 
Four accepted requirements for successful directed evolution 
(http://www.che.caltech.edu/groups/fha/) are, 1) the desired function must be 
physically possible; 2) the function must also be biologically, or evolutionarily, 
feasible. In practice, this means that there exists a mutational pathway to get 
from here to there through ever-improving variants (see above). A good 
experiment will maximize the likelihood; 3) Suitable host (E. coli or S. cerevisiae) 
which allows functional expression of more than 106 variants per µg of DNA. 4) A 
rapid screen or selection that reflects the desired function. How rapid the screen 
must be depends on how rare mutations leading to the desired property are and 
how many must be accumulated to achieve the desired result. 
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Figure 2. Overview of screening technologies. (A) Experimental steps from obtaining the gene 
library as PCR product to the actual screen. Note that cloning and transformation efficiency are 
often limiting library size; (B) Explanation of symbols; (C) Cell growth/survival selection and agar 
plate screening; (D) Microtiter plate screening; (E) Cell as micro-reactor; (F) Cell surface display; 
(G) Cell-in-droplet; and (H) In vitro compartmentalization (73).  
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2.2 Directed enzyme evolution for pH tolerance of enzymes 
Application of enzymes in processes at a specified pH necessitates protein 
engineering to change their pH performance. Directed evolution and rational 
design method were applied to improve enzyme specific activity at certain pH or 
shift their pH profiles. Some representative success stories of directed protein 
evolution improving pH performance are summarized in Table 1. 
Table 1. Improvement obtained from directed evolution or rational design for pH performance. 
Enzymes Mutagenesis 
methods 
Screening 
methods 
Improvements References 
Human  
β-glucuronidase 
EpPCR and 
saturation 
mutagenesis 
Flow 
cytometry 
60-fold more active (kcat/Km) at pH 7.0 
and were up to an order of magnitude 
more effective at catalyzing the 
conversion of two structurally 
disparate glucuronide prodrugs to 
anticancer agents 
2008 (74) 
Bacterial xylanase DNA shuffling Agar plate 
assay 
About 5-fold improvement of specific 
activity at pH 9.0 
2008 (75) 
Human pancreatic 
lipase 
EpPCR Agar plate 
and microtiter 
plate assay 
1.5-fold of activity improvement at 
acidic pH 
2010 (76) 
Bacterial arginine 
deiminase 
EpPCR and site 
directed 
mutagenesis  
Microtiter 
plate assay 
pH optimum shifted from pH 6.5 to pH 
7; 4-fold of activity improvement at pH 
7.4 
2010 (3) 
Bacterial α-amylase EpPCR Microtiter 
plate assay 
5-fold higher activity at pH 10 than 
wild type 
2003 (77) 
Eukaryote D-
pantonohydrolase 
EpPCR and 
DNA shuffling 
Agar plate 
assay 
10.5-fold higher specific activity and 
retain 85% of its original activity after 
incubation under low pH 
2006 (78) 
Vanadium 
chloroperoxidase 
EpPCR, site 
saturation 
mutagenesis 
and site directed 
mutagenesis 
Microtiter 
plate assay 
About 100-fold improvement of 
specific activity at pH 8 
2006 (79) 
Bacterial class-A non-
specific acid 
phosphatase (PhoN)   
Site directed 
mutagenesis 
 
1.6-fold of activity improvement over 
broder pH range 
2006 (80) 
Aspergillus niger PhyA 
phytase 
Site directed 
mutagenesis 
 
pH shifted from 5.5 to 3.8 (1.7 unit); 
2.66 -fold improvement of activity at 
pH 3.5 than wild type. 
2006 (81) 
Bacillus cereus β-
amylase 
Site directed 
mutagenesis 
 
pH optimum shifted to pH 4.2-4.8 by 
2 pH units. 
2004 (82) 
Phytase Site directed 
mutagenesis 
 
pH optimum shifted by 0.5-1 pH unit; 
a slight increase in maximum specific 
activity 
2002 (83) 
Alcohol 
dehydrogenase 
Site directed 
mutagenesis 
 
pH optimum shifted from 7.8  to 9.0; 
about 2-fold improvement of 
maximum activity at pH 9.0 than that 
of wild type 
1991 (84) 
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Many examples of rational reengineering of an enzyme pH optimum exist (Table 
1). For shifting the pH optimum, a deep understanding of molecular dynamics is 
essential part of understanding enzyme flexibility. Rational design method 
successfully shifted enzyme pH profile. pH dependence of an enzyme is 
determined by the ionization of the catalytic groups, which is affected by various 
interactions involved in their microenvironments. In order to catalyze certain 
reactions, ionizable residues in active site should act as nucleophile or acid/base 
catalyst and they need to maintain proper ionization state for proper activities of 
proteins. The pKa value of the proton donor and the catalytic nucleophilic residue 
are therefore limiting the pH range at which the enzyme can function, and 
therefore pH-dependent activity can be differed by the pKa of the key residues. 
The pKa value of the residue is governed by intrinsic acidity of the functional 
group and other factors (electrostatic interaction from neighboring and the 
heterogeneous dielectric environment in the protein solution system). The 
electrostatic potential generated by the charged titratable residues affects the 
ground state of the protein, such as stability, binding to ligands and pKa values of 
ionizable groups. The electrostatic potential of proteins can be calculated by 
using computational procedures (Delphi, UHBD, CHARMM) and can be 
increased or decreased through mutations. For shifting the pH optimum of 
enzymes, many researchers have tried to substitute catalytic residue by site-
directed mutagenesis (Table 1).  
 
Yoo and coworkers (85) analyzed the relation between the shift of pH optimum 
and change in electrostatic potential due to mutation using Delphi. They identified 
key residues of xylanase responsible for electrostatic potential of catalytic 
residues but not affecting the catalysis directly. The latter hypothesis was proven 
by site directed mutagenesis in a later report. Wyss and coworkers (83) 
summarized strategies for enzyme pH profile modification, 1) replacement of 
ionizable groups that are directly  involved in substrate or product binding and/or 
catalysis by nonionizable ones or by amino acids with different charge or pKa 
values; 2) replacement of residues that are in direct contact with residues 
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mentioned in 1) by forming hydrogen bonds and/or salt bridges; 3) alteration of 
longer-range (indirect) charge-charge interactions by modification of the surface 
charge of the enzyme. 
 
When there is no structure-function relationship information available for an 
enzyme, directed evolution is the best option to tailor the pH performance of 
enzyme for application demands (Table 1). Directed evolution allows improving 
all properties that can be reflected in a screening system through iterative rounds 
of diversity generation and screening. Small libraries of a few thousand variants 
are often sufficient to find improved muteins even without rational understanding 
of the targeted property (76, 86). Using MTP assay, epPCR mutant libraries with 
a ratio of 50 % active and 50 % inactive clones have often been used 
successfully in directed evolution, improving enzyme properties by gradual 
changes (one or two amino acids changes per round of mutagenesis and 
screening). 
 
2.3 Directed enzyme evolution for medical application 
Directed evolution has been very useful for improving enzymes for industrial 
needs. In recent years, there is also growing number of enzymes applied for 
therapeutic purpose. For the development of protein therapeutics, directed 
evolution started to be used to tailor enzyme properties in medical field, for 
example drug delivery (87, 88) and has proven to be a useful tool for generating 
protein variants with enhanced therapeutic potential (88), for example, improving 
the effectiveness of therapeutic enzymes, antibodies, vaccines and viruses. Here, 
the improvements of therapeutic protein for anti-tumor application by directed 
evolution are discussed in more details. 
 
2.3.1 Prodrug enzymes for tumor chemotherapy    
Prodrug cancer chemotherapy has attracted considerable interest due to the 
possibilities it provids to overcome various barriers to drug formulation and 
delivery (such as poor aqueous solubility, chemical instability, insufficient oral 
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adsorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity 
and local irritation) (89). Examples of such drugs currently in use in cancer 
treatment include 5-fluorocytosine, cyclophosphamide, capecitabine, mitomycin 
C, and AQ4N (90). However, the side effects of prodrug therapy remain a serious 
concern which arises from the fact that noncancerous cells also possess the 
capacity to degrade them. This has triggered the interest to generate more 
effective prodrug-activating enzymes so that prodrugs can kill tumor cells at 
concentrations that generate little or no side effects. Further goals are to design 
more powerful and tumor-specific drugs, and to devise more effective methods 
for delivering them specifically to tumors. 
 
By applying directed evolution through the technique of error-prone PCR, Martin 
and coworkers (90) indentified YieF variant exhibiting >5-fold increased capacity 
to kill HeLa cells. Furthermore, YieF variant was proved to be effectively 
delivered to tumor cells using a strain of Salmonella typhimurium (SL 7838). 
 
Human β-glucuronidase, due to low intrinsic immunogenicity in humans, is an 
attractive enzyme for tumor-specific prodrug activation. However its utility is 
limited by low activity at physiological pH. Roffler and coworkers (74) developed 
a high-throughput screening procedure for enzymatic activity based on the stable 
retention of fluorescent reaction product in mammalian cells expressing properly 
folded glycoproteins on their surface. This procedure was utilized to screen error-
prone PCR and saturation mutagenesis libraries to isolate β-glucuronidase 
tetramers that were up to 60-fold more active (kcat/Km) at pH 7.0 and were up to 
one order of magnitude more effective at catalyzing the conversion of two 
structurally disparate glucuronide prodrugs to anticancer agents. 
 
2.3.2 Oncolytic viruses for tumor chemotherapy  
Viral-mediated oncolysis is a novel cancer therapeutic approach with the 
potential to be more effective and less toxic than current therapies due to the 
agents’ selective growth and amplification in tumor cells. To date, these agents 
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have been regarded as highly safe in patients but have generally fallen short of 
their expected therapeutic value as monotherapies.  
 
Consequently, new approaches to generate highly potent oncolytic viruses are 
required. For the latter purpose, Hermiston and coworkers (91) developed a new 
method and termed it also ‘‘Directed Evolution’’ for creating highly potent 
oncolytic viruses. Viral serotypes representing Ad subgroups B-F were pooled 
and passaged twice on sub-confluent cultures of the target tumor cell lines at a 
particle-per-cell ratio of approximately 200 to invite recombination between 
serotypes (Figure 3). Supernatants from the second round of the high viral 
particle-per-cell infection of sub-confluent cultures were then used in a 10-fold 
dilution series to infect confluent T-75 tissue culture flasks of target tumor cell 
lines PC-3, HT-29, Panc-1 and MDA-231. Using this ‘‘Directed Evolution’’ 
methodology, the novel generated chimeric oncolytic virus ColoAd1 
demonstrated ~ 2 log increase in both potency and selectivity when compared to 
ONYX-015 on colon cancer cells. In vivo and ex vivo studies therefore validated 
the innovative general approach for deriving clinically-relevant and potent anti-
cancer virotherapies. 
 
Figure 3. Hermiston’s “Directed Evolution” process of viruses and derivative viral pools (91). 
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2.3.3 Amino acid depriving enzyme for anti-tumor applications 
Naturally available enzymes are usually not optimally suited for therapeutic 
purposes. This incompatibility often relates to the stability or activity of the 
enzymes under body conditions.  
 
Despite many successful efforts to broaden the understanding of the structural 
basis of protein stability, there is still no universal strategy to stabilize protein by a 
limited number of rationally designed mutations. Well-known and reasonably 
successful types of rational engineering work include substitutions that increase 
rigidity (e.g. substitute amino acid Xxx with Pro or substitute Gly with other amino 
acid Xxx or the introduction of disulfides). These substitutions have effects on the 
entropy of the unfolded state, improvement of molecular packing (e.g. shortening 
of loops, improvement of interactions in the hydrophobic core, for example, by 
the removal of internal cavities), modification of surface charge networks or 
reinforcement of a higher oligomerization state.  
 
Directed evolution provides a powerful approach for improving thermostability 
and does not need understanding of structure-function relationship. Most 
strategies for screening for enzyme stability rely on measuring residual enzyme 
activity before and after exposure to a denaturing challenge (e.g. high 
temperature, organic solvents, extreme pH) (92).  
 
Bacterial L-asparaginases have been used as therapeutic agents in the 
treatment of lymphoblastic leukaemia. The main restrictions to the therapeutic 
use of L-asparaginase include its premature inactivation. As a result frequent 
injections are required to maintain therapeutic levels. Repeated injections and 
high dose can cause several types of side reactions from mild allergies and the 
development of immune responses to dangerous anaphylactic shocks (93). 
Enhancing the stability of L-asparaginase by protein engineering improves its 
body-residence time, and thereby minimizes immunosuppressive effects by 
lowering the therapeutic dose. Labrou and coworkers (94) obtained a 
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reengineered L-asparaginase with enhanced thermal stability. Single mutation on 
the surface of the protein resulted in ~10 degree increased Tm value (half-
inactivation temperature). The thermostable variant has to be tested further on 
animals and ⁄ or humans in order to be advanced to a potent therapeutic drug. 
 
Another example of a reengineered amino acid-deprivating enzyme is PpADI. 
PpADI is a promising anti-tumor enzyme however with a non-physiological 
optimal pH and relative high Km value which hindering its medical application. By 
directed evolution and site saturation mutagenesis, PpADI variants with higher 
activity at physiological pH and at low arginine concentration of were obtained 
with improved properties to become a potent anti-tumor drug (see chapter 3 and 
chapter 4). In vitro and in vivo test of the improved variants are required to 
evaluate the anti-tumor effectiveness.  
 
2.3.4 Affibody molecules for cancer prognosis 
Affibody molecules represent a new class of affinity proteins that are based on 
the Z-domain scaffold derived from staphylococcal protein A (95). Among the 
scaffold proteins, Affibody molecules constitute the smallest non-cysteine-
containing protein scaffold. The small size (~ 7 kDa), robust structure, and 
straightforward production procedures (either by recombinant production in 
bacteria or by chemical synthesis) make Affibody molecules attractive targeting 
agents for in vivo radionuclide imaging (96) as well as for various 
biotechnological applications (97, 98). The small size offers a convenient affinity 
maturation principle. Gene synthesis allows randomizing the whole gene to 
generate diverse mutant library. The potential use of radiolabeled Affibody 
molecules for high-contrast radionuclide imaging of biomarkers has been 
demonstrated in preclinical studies and in pilot clinical studies. Affibody 
molecules are non-immunoglobulin-derived affinity proteins based on a three-
helical bundle protein domain.  
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Several of affinity proteins have been investigated for both in vivo diagnostics 
and therapy of tumor in radionuclide molecular imaging. Affinity proteins in tumor-
targeted therapy can affect tumor progression by altering signal transduction or 
by delivering a payload of toxin, drug or radionuclide. EGFR (epidermal growth 
factor receptor), one of the receptor in ErbB family, has been extensively studied 
as biomarkers in tumor targeting and over expressed in various malignancies, 
associated with poor patient prognosis and are therefore interesting targets for 
solid tumors. High affinity and especially slow dissociation rate are important for 
obtaining high contrast images. Affinity in the low nanomolar range is considered 
as a prerequisite for successful use of peptide-based tracers. 
 
Ståhl and coworkers (99) described the affinity maturation procedure for the 
generation of Affibody molecules binding with high affinity and specificity to 
EGFR. The library for affinity maturation was constructed using a single 
oligonucleotide for the rerandomization of desired positions. The new binders 
were selected with phage display technology and the best second-generation 
binders were characterized in vitro using real-time biospecific interaction analysis 
(BIA) for their binding to recombinant EGFR and with flow cytometry for their 
binding to native EGFR. Second-generation binders achieved an approximately 
30-fold improvement in affinity (Kd = 5-10 nM) for the soluble extracellular domain 
of EGFR in biospecific interaction analysis using Biacore. 
 
2.3.5 Interferon for anti-tumor applicaiton 
Alpha interferons (IFN-as) are members of the diverse helical-bundle superfamily 
of cytokine genes, which have potent antiviral and antiproliferative activities and 
therefore can be used as anticancer and antiviral agents. However, doselimiting 
toxicity, receptor cross-reactivity, and short serum half-lives significantly reduce 
the clinical use of many of these cytokines. 
 
Patten and coworkers (100) performed a family shuffling experiment with over 20 
human interferon-α (Hu-IFN-α) genes. Antiviral assay and proliferation assay 
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were used to indentify clones with improved activity on Hu-IFN-α receptor. One 
clone showed 285,000-fold improved activity relative to Hu-IFN-α2a and 185-fold 
relative to Hu-IFN-α1 (most active native human interferon). 
 
Selective breeding using DNA shuffling has proved to be very effective method to 
rapidly improve pharmaceutical proteins by which initially have low levels of the 
desired “activity” (101, 102). Backcrossing of evolved recommbinants with the 
wild type genes removes functionally neutral changes, which might reduce the 
immunogenicity of evolved proteins (103). 
 
2.4 Conclusion 
Proteins, especially enzymes, have gained a central role in modern chemical, 
biotechnological, and biopharmaceutical industries. Directed evolution has over 
the past proved to be a versatile and successful approach for tailoring protein 
properties to industrial, agricultural and medical demands and for advancing our 
understanding of structure-function relationships in biocatalysts. Appropriate 
library generation and screening methods should be employed concerning the 
target protein and desired property. To set up a sophisticated screening method, 
complex conditions in human body (pH, ion concentration, proteases, hormones 
etc.) should be considered. Subsequent in vivo or in vitro test of improved 
variants should be carried out to further validate the screening assay. 
Development of diversity generation and high-throughput screening method will 
enable evolution to solve problems efficiently. Especially, directed evolution 
provides a powerful strategy to rapidly advance the development of improved 
protein-based drugs (enzymes and antibodies, peptide and ligands). Directed 
evolution promises to play an increasingly important role to generate “desirable” 
drugs. 
 
 
 
  31 
Chapter 3 
Chapter 3. Directed evolution of Arginine 
deiminase for increased activity at physiological 
pH 
 
3. 1 Abstract 
Arginine deiminase (ADI; EC 3.5.3.6) has been studied as a potential anti-tumor 
drug for the treatment of arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCCs) and melanomas. Studies with human lymphatic leukemia cell 
lines confirmed that ADI is a potential anti-angiogenic agent effective in the 
treatment of leukemia. ADI from Pseudomonas plecoglossicida (PpADI) was 
cloned and expressed in E.coli. A main limitation of PpADI lies in its pH-
dependent activity profile with a pH optimum at 6.5. A pH shift from 6.5 to 7.5 
results in ~80 % activity drop (pH of human plasma is 7.35 to 7.45). For shifting 
PpADI pH optimum to netrual pH, a directed evolution protocol based on an 
adapted citrulline screening protocol in microtiter plate (MTP) format was 
developed and validated. Proof of concept for ADI engineering resulted in a pH 
optimum of pH 7.0 and increased activity under physiological conditions: at pH 
7.4, variant M2 (K5T, D44E and H404R) is 4-fold more active than the wild type 
PpADI and retains ~30 % of its activity relative to its pH optimum, compared to 
~10 % in the case of the wild type PpADI. 
 
3.2 Introduction 
Arginine deiminase (ADI) is a potential cancer therapy agent for the treatment of 
arginine-auxotrophic tumors (e.g. hepatocellular carcinomas and melanomas). 
The hepatocellular carcinoma (HCC) accounts annually for approximately 1 
million new cases worldwide. In the US the incidence rate (per 100,000 persons; 
1992-2002) of HCC is 8.6 with a mortality rate of 6.5 due to low responses of 
hepatoma to chemotherapeutic treatments (27). Current research efforts are 
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focused on ADI’s in vivo inhibitory effect towards HCCs, leukemia, melanomas 
and human umbilical vein endothelial cells (HUVEC) (104-106), clinical trials for 
HCC (phase III) and melanoma (phase I/II) (105, 107), and PEG formulation of 
ADI to improve its efficacy as a clinical drug, including serum half-life and 
antigenicity (16, 108). ADI inhibited the growth of cultured leukemia cells at 
concentrations of 5-10 ng/ml, which were about 20-100 times lower than those of 
the L-asparaginase standard resulting in fewer side effects (106, 109). Arginine 
deprivation is speculated to be the molecular reason for ADI’s inhibitory effect on 
human lymphatic leukemia (106). ADIs catalyze the first step of the arginine 
deiminase (ADI) pathway by hydrolyzing arginine to citrulline and ammonium. 
Several ADI genes have been identified, purified, and characterized from 
bacteria, archaea and some eukaryotes excluding mammalian cells and 
summarized in a recent review (27). None of these ADIs is from a kinetic point of 
view ideally suited for in vivo applications in humans under physiological 
conditions.  
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. For the proof of concept, an 
ADI isolated from Pseudomonas plecoglossicida CGMCC2039 (accession 
number: ABS70718) which can be functionally expressed in E. coli has been 
employed. Directed evolution approaches employ mainly E. coli as host due to its 
fast growth and high transformation efficiency which is a prerequisite for 
generating complex mutant libraries. Over the last decades, directed protein 
evolution has become a versatile and successful approach for tailoring protein 
properties for industrial demands (mainly in chemical synthesis) and for 
advancing our understanding of structure-function relationships in enzymes. A 
directed evolution experiment comprises iterative cycles of diversity generation 
and functional selection for improved variants. Only a few manuscripts for 
phytases (83), xylanases (110), amylases (77, 82, 111), and an alcohol 
deyhdrogenase (112) reported a shift of pH optima using directed evolution 
algorithms. None of these directed evolution campaigns targeted a medical 
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application and arginine deiminase has to our best knowledge not been altered in 
its pH activity/resistance by directed evolution.  
 
Comparison of PaADI (Pseudomonas aeruginosa, pH optimum 5.6; His405) and 
MaADI (Mycoplasma arginini ADI, pH optimum 6.5, Arg397) led to the 
speculation that substitution of His by Arg might contribute to MaADI’s increased 
pH optimum (17). A sequence alignment of four ADIs (MaADI, MyADI 
(Mycoplasma arthritidis ADI), PaADI and PpADI) shows that for both 
Pseudomonas ADIs the synonymous amino acid positions (404 & 405), contain a 
His whereas both Mycoplasma ADIs contain at corresponding positions an Arg. 
Interestingly, both Mycoplasma ADIs have an pH optimum approximately one pH 
unit higher than both Pseudomonas ADIs. 
 
In this study we report the first directed ADI evolution protocol in which the pH 
profile of PpADI was shifted to higher pH values representing a conceptional 
proof that ADI properties can be tailored for demands in vivo treatment of 
arginine-auxotrophic tumors. An emphasis is given on detailed description of 
directed evolution conditions (mutagenic and screening).   
 
3.3 Materials and methods 
3.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
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plasmid (MEGAWHOP, 20 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
Pseudomonas plecoglossicida CGMCC2039 was provided by Professor Zhihao 
Sun (Jiangnan University, Wuxi, China). 
 
3.3.2 Methods 
3.3.2.1 Reagents used in assays 
Acid-ferric solution 
To dH2O (600 ml), concentrated H3PO4 (70 ml, 85 %) and concentrated H2SO4 
(160 ml, 90-91 %) were added slowly. After cooling to room temperature, 
FeCl3·6H2O (10 ml, 10 g/L) was added in the above solution, finally the total 
volume was adjusted to 1 liter with dH2O. 
 
Diacetyl monoxime -thiosemicarbazide (DAM-TSC) solution 
DAM solution (10 g/L) and TSC solution (0.3 g/L) were prepared separately. The 
two solutions were mixed (volume ratio = 1:1) just prior to use. 
 
3.3.2.2 Cloning of ADI into pET42b(+) 
The arginine deiminase (ADI) gene was amplified from Pseudomonas 
plecoglossicida CGMCC2039 by colony PCR (94°C for 10 min, 1 cycle; 94°C, 30 
s/ 54°C, 30 s/ 72°C, 165 s, 29 cycles; 72°C for 5 min, 1 cycle) using primer (5’-
CCGCATTCCGCTGAAAAACAGAAGTACGG-3’ and 5’-
CTTCTCGAGTTAGTAGTTGATCGGGTCGCGCACG-3’), 1.5 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix and a colony of Pseudomonas 
plecoglossicida CGMCC2039. Amplification product was purified by gel 
extraction, digested using NdeI (20 U) and XhoI (20 U) and purified using 
QIAquick PCR purification kit (QIAGEN, Hilden, Germany). Cloning vector 
pET42b(+) was digested with NdeI (20 U) and XhoI (20 U), and purified by gel 
extraction kit (QIAGEN, Hilden, Germany). Digested ADI gene and pET42b(+) 
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were ligated using T4 DNA ligase (1 U) to give pET42b(+)-ADI and transformed 
into E. coli BL21-Gold (DE3).  
 
3.3.2.3 Site directed mutagenesis of PpADI gene at position H404 
Site directed mutagenesis of ADI gene was performed according to the published 
method (113) on plasmid pET42b(+)-ADI. The following oligonucleotides were 
used for mutagenesis of H404R: 5’-
GGCCGTGGCGGCGGCCGTTGCATGACCTGCCCG-3’ and 5’-
CGGGCAGGTCATGCAACGGCCGCCGCCACGGCC-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 
cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 
s, 1 cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 
cycle), 2 U of PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, 
Finland), 0.20 mM of dNTP mix, 25 pmol of each primer together with 100 ng of 
template (pET42b(+) harboring ADI gene) were used. Following the PCR, DpnI 
(40 U; New England Biolabs) was added, and incubated overnight at 37°C. The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
3.3.2.4 Site sturation mutagenesis of PpADI gene at nine amino acid 
position  
Site saturation mutagenesis of ADI gene was performed according to the 
published method (113) on plasmid pET42b(+)-ADI. The oligonucleotides were 
used for mutagenesis were listed in table 1 (underlining indicated the substituted 
nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 cycle; 95°C, 30 
s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 s, 1 cycle; 95°C, 
30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 cycle), 2 U of 
PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, Finland), 0.20 mM 
of dNTP mix, 25 pmol of each primer together with 100 ng of template (pET42b(+) 
harboring ADI gene) were used. Following the PCR, DpnI (40 U; New England 
Biolabs) was added, and incubated overnight at 37°C. The PCR products were 
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purified by using a QIAquick PCR Purification Kit (Qiagen) and transformed into 
E. coli BL21-Gold (DE3) for expression. 
 
Table 1. Primer sequences for site saturation mutagenesis. 
Primer name Sequences 
Leu 41 FP AACTGCGACGAGCTGNNNTTCGACGATGTGATC   
Leu 41 RP GATCACATCG TCGAANNNCA GCTCGTCGCAGTT 
Asn 360 FP TGGGATGACGGCAACAACNNNGTGGCGCTGGAG 
Asn 360 RP CTCCAGCGCC ACCACNNNGT TGCCGTCATCCCA 
Arg401 FP GAACTGGGCCGGGGCNNNGGCGGCGGCCACTGC   
Arg401 RP GCAGTGGCCGCCGCCNNNGCCCCGGCCCAGTTC 
Phe163 FP CTGCCCAACACCCAGNNNACCCGCGACACCACC    
Phe163 RP GGTGGTGTCGCGGGTNNNCTGGGTGTTGGGCAG 
Asn160 FP CTGCCGCCGCTGCCCNNNACCCAGTTCACCCGC 
Asn160 RP GCGGGTGAACTGGGTNNNGGGCAGCGGCGGCAG 
Arg185 FP ATGTACTGGCCGGCNNNCGCCAGGAAACCCTG 
Arg185 RP CAGGGTTTCCTGGCGNNNGCCGGCCAGTACAT 
Arg243 FP ATCGGCATGGGTGAGNNNACCTCGCGCCAGGCC 
Arg243 RP GGCCTGGCGCGAGGTNNNCTCACCCATGCCGAT 
His405 FP GGCCGTGGCGGCGGCNNNTGCATGACCTGCCCG 
His405 RP CGGGCAGGTCATGCANNNGCCGCCGCCACGGCC 
Gly403 FP GCCGGGGCCGTGGCNNNGGCCACTGCATGACC 
Gly403 RP GGTCATGCAGTGGCCNNNGCCACGGCCCCGGCC 
 
 
3.3.2.5 Construction of PpADI error-prone library 
The library was generated by the standard error-prone PCR (epPCR) using 
improved variant H404R as template. For the mutagenic PCR (95°C for 2 min, 1 
cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C for 3 min, 1 cycle), 2.5 
U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of template (pET42b(+) 
harboring ADI gene H404R), 0.01-0.1 mM of MnCl2 and 10 pmol of each primer 
(5’-TACATATGTCCGCTGAAAAACAGAAG-3’ and 5’- GTGCTCGAGTTAGTAGT 
TGATCGG-3’) were used. The PCR products were purified by using a QIAquick 
PCR Purification Kit. The purified epPCR products were cloned into expression 
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plasmid pET42b(+) by MEGAWHOP(114). For MEGAWHOP (68°C for 5 min, 1 
cycle; 95°C for 5 min, 1 cycle; 95°C, 1 min/ 55°C, 1 min/ 68°C, 13 min 30 s, 24 
cycles; 68°C for 30 min, 1 cycle), 1 U of Taq DNA polymerase, 0.1 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix together with 200 ng of template (pET42b(+) 
harboring ADI gene H404R) were used. Following the PCR, DpnI (40 U; New 
England Biolabs) was added, and incubated (4 h; 37°C). The MEGAWHOP 
products were transformed into E. coli BL21-Gold (DE3) for expression and 
screening. 
 
3.3.2.6 Expression of PpADI in LB media with IPTG induction 
The strain E. coli BL21-Gold (DE3)/ pET42b-PpADI was cultured at 37°C in 20 ml 
of LB media that contained 50 µg/ml kanamycine to an absorbance of 0.6 at 
578nm. Then, isopropyl β-D-thio-galactopyranoside (IPTG) was added to a final 
concentration 0.2 mM. The cells were harvested after 9 h induction with IPTG at 
37°C. The expressed rADI was analyzed by SDS-PAGE.  
 
3.3.2.7 Expression of PpADI in auto-induction media 
A chemically defined auto-induction medium (115) containing salts and trace 
metals, vitamins including vitamin B12, and glucose, glycerol, and lactose were 
test for PpADI expression. Five kinds of auto-induction media LS-5052, P-5052, 
MD-5052, TYM-5052 and TYP-5052 were tested for the ADI expression, under 
the following conditions: 20 ml LB media in 100 ml flask, 37°C, 250 rpm, 20 h. 
The expressed rADI was analyzed by SDS-PAGE. 
 
3.3.2.8 Cultivation and expression of PpADI in 96-well plates 
Colonies grown on LBkan agar plates were transferred, by using toothpicks, into 
96-well microtiter plates (flat bottom, polystyrene plates; Greiner Bio-One GmbH, 
Frickenhausen, Germany), containing non-inducing medium LSG (150 µL) (115) 
supplemented with kanamycin (50 µg/ml). After 16 h of cultivation in a microtiter 
plate shaker (Multitron II, Infors GmbH, Einsbach, Germany; 37°C, 900 rpm, 70 
% humidity), each well was replicated using a replicator (EnzyScreen BV, Leiden, 
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Netherlands) into a second series of 96-well microtiter plates containing 150 µL 
of auto-induction media LS-5052 (115) supplemented with kanamycin (50 µg/ml). 
The first set of plates was stored at -80°C after addition of glycerol. The clones in 
the second set of plates were cultivated for 12 h (Multitron II, Infors GmbH, 37°C, 
900 rpm) and used for screening.  
 
3.3.2.9 Screening Procedure 
96-well plate format citrulline colorimetric screening assay 
A modified protocol of citrulline detection based on carbamido-diacetyl reaction 
(116) (see Figure 1A for assay mechanism) was used for ADI activity 
measurement. Screening for increased activity was carried out by measuring the 
activity at pH 7.4 and 6.4. 20 µl of cell culture was transferred to 96-well 
microtiter plate. Enzyme reaction was initiated by addition of arginine solution 
(100 µl, 100 mM) supplemented with cetyltrimethylammoniumbromide (CTAB, 4 
mM), and incubated (20 min, 37°C). Subsequently, acid-ferric solution (60 µl) and 
diacetyl monoxime (DAM, 20 µl, 0.5 M) were added. The reaction mixture was 
further incubated (15 min, 55°C). Absorbance was measured at 492 nm using a 
microtiter plate reader (Tecan Sunrise, Tecan Group AG, Zurich, Switzerland).  
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking ADI and in a separate experiment 
containing ADI. Apparent standard deviation was based on the absolute 
absorbance values obtained from the ADI wild type plate. The true standard 
deviation was calculated by subtracting the background absorbance value of the 
microtiter plate lacking ADI from the apparent values. 
 
Cuvette format citrulline colorimetric assay 
ADI activity was routinely measured using a modified protocol of the citrulline 
detection with DAM and TSC (117) (see Figure 1A for assay mechanism) in 
Eppendorf tubes. Enzyme reaction was initiated by addition of arginine solution 
(200 µl, 100 mM) to a 2-ml eppendorf tube containing crude cell lysate (50 µl), 
and incubated (20 min, 37°C). Subsequently, acid-ferric solution (250 µl) was 
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added to stop the enzyme reaction. After appropriate dilution with deionized 
water to ensure the concentration of produced citrulline is within linear detection 
range, the reaction mixture (400 µl) was mixed with acid-ferric solution (600 µl) 
and DAM-TSC solution (100 µl). The reaction mixture was further incubated (30 
min, 70°C), followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a Specord 200 (Analytik Jena AG, 
Jena, Germany). 
 
Normalization of protein expression for wild type ADI and variants  
Agilent Protein 230 Kit (Agilent Protein 230 Kit, Agilent Technologies 
Deutschland GmbH, Böblingen, Germany) and Agilent 2100 Bioanalyzer (Agilent 
2100 Bioanalyzer, Agilent Technologies Deutschland GmbH, Böblingen, 
Germany) were used for normalization of protein expression in crude cell extract. 
The protocol used was according to Agilent protein 230 Kit Guide except BSA 
was used as an internal standard. 
 
3.3.2.10 Expression of ADI in shaking flask and purification 
Shaking flasks (1 liter) containing auto induction media LS-5052 (200 ml) 
supplemented with kanamycin (50 µg/ml) were inoculated with a 1:200 dilution of 
overnight culture (E. coli BL21-Gold(DE3) harboring pET42b-ADI) grown in non-
inducing media LSG. After 12 h of expression, E. coli cells were harvested by 
centrifugation (Eppendorf 5810R 4°C, 3220 g, 30 min) and resuspended in 
phosphate buffer (20 ml, NaxPO4, 20 mM, pH 7.0). E. coli cells were 
subsequently lysed by using a high-pressure homogenizer (1500 bar, 2 cycles; 
Avestin Emulsiflex, Mannheim, Germany). The disrupted cells were centrifuged 
(Eppendorf 5417R, 4°C, 13000 g, 20 min) and the supernatant was further 
cleared by filtration through a low protein-binding filter (0.45 µm; Minisart RC 25 
single use syringe filter; Sartorius, Hamburg, Germany). ADI wild type and 
mutants (H404R and K5T D44E H404R) were subsequently purified by a column 
chromatography procedure: (i) The filtered cell lysates were subjected to a 
Super-Q anion exchange column, which had been pre-equilibrated with 50 mM 
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phosphate buffer (NaxPO4, pH 7.0). 20 ml of cell lysate was loaded. ADI were 
eluted by a NaCl step elution in phosphate buffer (NaxPO4, 50 mM,  pH 7.0) at a 
rate of 3 ml/min. (ii) The obtained ADI protein from ion exchange chromatography 
was subjected to a gel filtration column (Matrix: Toyoperl HW-55S, Bed volume: 
33 ml, Bed height: 40 cm, Column: Omnifit). 
 
Purified ADI was subsequently concentrated using a Amicon ultra-4 centrifugal 
filter device (Millipore Corporation, Billerica, U.S.A.) with a 30-kDa cut-off 
membrane. Total protein concentration was determined by BCATM assay kit 
(Pierce, Born, Germany) and homogeneity of the purified sample was controlled 
by SDS-page electrophoresis using standard molecular biology techniques. 
 
3.3.2.11 Characterization of ADI wild type and mutants 
Determination of kcat and Km of ADI wild type and the mutants 
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath. After 10 min preincubation at 37°C, the enzyme reaction was initiated 
by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the substrate solution (200 
µl, 0.2 mM to 10 mM of arginine, 0.5 M phosphate buffer, pH 7.4) in deep well 
plates. The reaction mixture was incubated (37°C) and every two minutes 
reaction mixture (30 µl) of each well was transferred to acid-ferric solution (30 µl) 
to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. Ferric-acid solution (90 µl) and DAM-TSC 
solution (15 µl) were added to each well. The 96-well PCR plate was then 
incubated (70°C, 30 min) in thermal cycler (Eppendorf Mastercyler gradient) for 
color development, followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a microtiter plate reader 
(SPECTROstar Omega, BMG LABTECH, Offenburg, Germany). The initial 
velocity data obtained were fitted to the equation v = Vmax[S]/([S] + Km) (where v 
is the initial velocity, Vmax the maximum velocity, [S] the substrate concentration, 
and Km the Michaelis constant) using GraphPad Prism software (GraphPad 
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software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax 
and enzyme concentration. 
 
Determination of pH profile 
Enzyme reaction was carried out at 37°C in a water bath using the following 
substrate solution: arginine 0.1 M, pH 5-8 phosphate/acetate buffer (0.5 M 
phosphate, 50 mM acetate). After 10 min preincubation at 37°C, the enzyme 
reaction was initiated by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the 
substrate solution (200 µl) in deep well plates. The reaction mixture was 
incubated (37°C, 10 min) and acid-ferric solution (250 µl) was transferred to each 
well to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. The reaction mixture (60 µl), ferric-acid solution 
(90 µl) and DAM-TSC solution (15 µl) were transferred to a 96-well PCR plate. 
The 96-well PCR plate was then incubated (70°C, 30 min) in thermal cycler 
(Eppendorf Mastercyler gradient) for color development, followed by incubation in 
ice water to stop color development. Absorbance was measured at 530 nm using 
a microtiter plate reader (SPECTROstar Omega, Germany). 
 
3.3.2.12 Molecular Modeling 
Two crystal structures of PaADI (PDB codes: 1RXX, 2A9G) were used to model 
the mutations H405R and D44E. Only one monomeric unit of the tetrameric 
PaADI was used for the modeling study employing Swiss-PDB viewer (118) 
(www.expasy.org/spdbv). PaADI variants (H405R; D44E) were generated using 
the mutate command of Swiss-PDB viewer. The side chain rotamer with the best 
score was used for subsequent energy optimized with parameter of GROMOS96 
force field for in vacuum minimization (119).  
 
3.3.2.13 Stability of PpADI in presence of serum  
Purified PpADI (wild type, M1, M2; 20 µl) was incubated (37°C, 60 min) with AB--
human serum (80 ul, Invitrogen, Karlsruhe, Germany) and PBS buffer (pH7.4, 80 
ul), respectively. Subsequently, the incubated ADI-serum/PBS mix (20 µl) was 
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added to microtiter plate containing arginine solution (100 µl, 10 mM arginine in 
PBS buffer, pH 7.4) and incubated (37°C, 30 min). Acid-ferric solution (120 µl) 
was added to stop the enzyme reaction. The produced citrulline was detected 
using the assay procedure employed in “Determination of kcat and Km of ADI 
wild type and the mutants”. Before measuring absorbance at 530 nm, 
centrifugation (Eppendorf, 5810R 4°C, 3000 g, 10 min) was performed to remove 
the precipitation in the assay solution (likely proteins in serum were precipitated 
in acidic condition during assay procedure). Meanwhile, a serum control was test 
for the original citrulline concentration of serum using the same procedure 
mentioned above except that instead of PpADI, elution buffer of gel filtration 
(NaxPO4, 50 mM, pH 7.4) was used. All the absorbance values at 530 nm of 
ADI-serum sample were subtracted the value of serum control to get the citrulline 
concentration produced by PpADI. The residual activities of PpADI after 
incubation in serum compared to that in PBS buffer were calculated to show the 
stability of PpADI after incubated in human serum. 
 
3.3.2.14 Activity of PpADI (wild type, M1, M2) towards arginine derivative 
dimethylarginine 
Purified PpADI (wild type, M1, M2; 15 µl, ~0.2 mg/ml final concentration; >20-fold 
concentration used for kinetic constant determination) was incubated (37°C, 4 h) 
with (NG, NG)-dimethylarginine solution (20 mM, 100 µl). Acid-ferric solution (120 
µl) was added to stop the enzyme reaction. Activity was recorded by citrulline 
detection using citrulline colorimetric assay (see 3.3.2.11 Characterization of ADI 
wild type and mutants). 
 
3.4 Results 
3.4.1 PpADI cloning 
PpADI was cloned into pET42b(+) and expressed in E.coli BL21-Gold(DE3) 
using auto-induction media LS-5052 (see figure 2). The nucleotide sequence of 
PpADI comprises 1,254 bp nucleotide (figure 1) encoding 417 amino acids which 
have 85% identity to ADI from P. aeruginosa (PaADI). The PpADI cloned into 
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pET42b(+) was confirmed by nucleotide sequencing. As indicated in Figure 1, 
sequence analysis of ADI gene showed that there was one synonymous 
mutation at amino acid position D78 (GAT to GAC) compared to ADI-sequence 
of P. plecoglossicida CGMCC2039 deposited in NCBI (accession number: 
EU030267). The deduced ADI protein sequence has a calculated molecular 
weight of 46.5 kDa and shows 85% identity to ADI from P. aeruginosa. This clone 
was used for subsequent directed evolution experiments.  
 
 
Figure 1. DNA electrophoresis of PpADI. 
 
 
Figure 2. PpADI sequencing results. 
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3.4.2 PpADI expression in LB media with IPTG as inducer 
PpADI was successfully expressed in LB media with IPTG as inducer. Figure 3 
(lane 4) shows the expression band of PpADI observed at ~45 kDa, which is 
similar to the calculated molecular weight of 46 kDa (based on 
http://expasy.org/tools/pi_tool.html). 
 
Figure 3. SDS-PAGE of PpADI expression. Lane 1: P. plecoglossicida; Lane 2: E. coli BL21-Gold 
(DE3)/ pET42b; Lane 3: E. coli BL21-Gold (DE3)/ pET42b-PpADI WT, without IPTG; Lane 4: E. 
coli BL21-Gold (DE3)/ pET42b- PpADI WT. 
 
3.4.3 PpADI expression in auto-induction media 
Expressing recombinant protein in auto-induction media is based upon the 
preferences of bacteria to selectively use different carbon sources during diauxic 
growth and upon the often-observed negative regulation of gene expression by 
catabolite repression. Auto-induction is more convenient than IPTG induction 
because the expression strain is simply inoculated into auto-inducing medium 
and grown to saturation without the need to follow culture growth and add 
inducer at the proper time. For high-throughput applications, the auto-induction 
approach has many advantages over traditional induction methods including 
avoidance of the strong induction and apparent toxicity associated with chemical 
inducers such as IPTG.  
Five kinds of auto-induction media LS-5052, P-5052, MD-5052, TYM-5052 and 
TYP-5052 were tested for the ADI expression. Figure 4(A) and 4(B) show ADI 
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activity and corresponding SDS-PAGE band of the PpADI expression in different 
auto-induction media. The expression in auto-induction media LS-5052 is shows 
the highest activity and therefore LS-5052 was used for the following directed 
evolution experiments. 
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Figure 4(A). Activity of PpADI expressed in auto-induction media. 
 
 
 
Figure 4(B). SDS-PAGE of ADI expressed in auto-induction media 1, LS-5052; 2, P-5052; 3, MD-
5052; 4 TYM-5052; 5, TYP-5052. 
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3.4.4 PpADI assay based on citrulline detection 
 
 
Figure 5. Arginine conversion by ADI and detection of citrulline using DAM/TSC assay. 
 
ADI activity was measured by detecting the production of citrulline from arginine, 
according to carbamido diacetyl reaction (colorimetric reaction). The conditions of 
the carbamido diacetyl reaction is as follows： strong acid solution (H3PO4, 
H2SO4), oxidizing agent (Fe3+), diacetyl monoxime (DAM), thiosemicarbazide 
(TSC), and boiling water bath. Figure 5 shows one postulated reaction 
mechanism for the assay which depicts the reaction between citrulline and DAM. 
By the addition of TSC to the reaction system, Coulombe and Favreau(120) 
obtained linearity of response with a more stable pink color which Amax was 
shifted from 490nm to 530nm. 
 
Figure 6 describes the assay procedure for measuring ADI activity in 2 ml 
eppendorf tube. A calibration curve was prepared using citrulline standard 
solution (Figure 7) for determining the citrulline production during the assay. 
 
Figure 6. Citrulline colorimetric assay in cuvette format using DAM/TSC assay. 
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Figure 7. Calibration curve of cuvette format citrulline colorimetric assay. 
 
3.4.5 PpADI screening system for citrulline production in microtiter plates 
Two key performance parameters for identifying improved variants in microtiter 
plate based screening systems are the true standard variation and the linear 
detection range of the employed assay. Standard deviations have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). A modified version of the DAM-TSC assay for citrulline 
detection (Scheme 1) was selected for directed evolution of PpADI. The 
microtiter plate screening format was optimized for simplified handling by 
lowering the color development temperature (55°C instead of 100°C), increasing 
the diacetylmonoxime concentration (~22-fold) and avoiding the use of the 
sensitizer thiosemicarbazide. Figure 8 shows the procedure of screening assay 
of citrulline detection. 
 
Figure 8. Citrulline colorimetric assay in MTP format using DAM assay. 
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Standard deviations of the modified citrulline detection assay have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). The preferred combination (150 µl LS5052 auto-
induction media and 20 µl cell culture, 20 min conversion time and 15 min color 
develop time) resulted in a true standard deviation of 12.8 % after subtracting the 
background (Figure 10). Screening systems with standard deviations around 10 
% have successfully been used in directed evolution experiments (121, 122). A 
wide linear detection window is important for identifying beneficial mutants in 
directed evolution experiments and screening systems for evolved mutants have 
to be constantly adapted for hitting the linear detection window. A linear detection 
range up to 6 mM citrulline could be detected (Figure 9).  
 
 
 
 
 
 
Figure 9. Calibration curve of 96-well microtiter plate format citrulline colorimetric screening assay.  
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Figure 10. Activity values in descending order of the ADI wild-type conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
 
Figure 11. PpADI model derived from PaADI crystal structure (PDB code 2a9gD) by SWISS 
MODEL WORKSPACE.  
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3.4.6 Focused libraries generated by saturation mutagenesis 
PpADI gene shares 83 % sequence identity  with PaADI of which the crystal 
structure was solved (123). After submitting the ADI sequence to SWISS MODEL 
WORKSPACE, a proposed ADI model based on the PaADI crystal structure 
(PDB code 2a9gD) was obtained (Figure 11). According to this model and 
published literatures, 9 amino acid residues: Leu41, Asn160, Phe163, Arg185, 
Arg243, Asn360, Arg401, His404, Gly 403 (Figure 11) close to the active center 
(catalytic triad: Cys406-His278-Glu224) or known to interact with substrate 
arginine were selected for saturation mutagenesis. 
 
Site saturation mutagenesis at position Leu41, Asn160, Phe163, Arg185, Arg243, 
Asn360, Arg401, His404 and Gly 403 were performed. 300 clones were 
screened for each position. However, no improved variant was identified. 
 
3.4.7 Validation of variant M1 (H404R) citrulline colorimetric assay in 
cuvette format 
Position H404 which was suspected to influence ADI pH profile by substitution to 
R404 (15). Compared to wild type PpADI, variant M1 (H404R) shows higher 
activity (1.8-fold) and improved activity ratio of pH 7.4 to 6.4 (4.7-fold). Therefore, 
M1 (H404R) was selected for directed evolution. 
 
3.4.8 epPCR library generation and screening with citrulline detection 
assay by screening error-prone mutant libraries 
Various concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Figure 12 (A) and 12 (B) 
show the epPCR products and the corresponding MEGAWHOP products. 
Concentration of 0.01 mM MnCl2 which generated 53 % inactive mutant was 
selected for library generation. EpPCR mutant libraries with a ratio of 50 % active 
and 50 % inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). A total of 7 variants (listed in 
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Table 2) were identified from an epPCR library of 2400 mutants and used for 
further characterization. The most active variant was sequenced and two 
additional amino acid substitutions (K5T D44E) were identified. 
 
 
Figure 12 (A). Electrophoresis of epPCR products. Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM 
of MnCl2; Lane 3, 0.05 mM of MnCl2.  
 
 
 
Figure 12 (B). Electrophoresis of MEGAWHOP product with epPCR products as megaprimer. 
Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM of MnCl2; Lane 3, 0.05 mM of MnCl2.  
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Figure 13. Relative activity of ADI variants towards arginine. The relative activity is the ratio of the 
activity at the pH of each variant relative to the activity at pH 7.4 of wild type ADI. White: ADI wild 
type, grey: M1 (H404R), black: M2 (K5T D44E H404R). 
 
Table 2. Activity of ADI variants towards arginine determined using citrulline colorimetric 
assay in cuvette format. Samples were diluted to ensure that detected citrulline 
concentrations are within the linear detection range of the citrulline colorimetric assay. 
Wild type, mutant M1 and the “best variant” M2 are in bold and prominent expression 
mutants (9-B3-1; 21-D5-1) are italized. 
Normalized [ADI][a] 
Citrulline production 
(mM/mg) 
Relative to activity at pH 7.4 
of WT 
ADI variants pH 7.4 pH 6.4 pH 7.4 pH 6.4 
Activity at pH 
7.4/ activity at 
pH 6.4 
WT 
9.83 
(0.74)[b] 
124.92 
(1.98) 1.00 (0.15) 12.69 (0.01) 0.08 (0.01) 
M1 
(H404R) 
17.80 
(0.49) 
45.95 
(0.87) 1.81 (0.06) 4.67 (0.02) 0.39 (0.02) 
M2 
(K5T D44E 
H404R) 
38.99 
(0.79) 39.20 (0.31) 3.96 (0.02) 3.98 (0.02) 0.99 (0.03) 
9-B3-1 
24.89 
(0.45) 54.50 (1.80) 2.53 (0.03) 5.54 (0.03) 0.46 (0.02) 
21-D5-1 
25.68 
(2.68) 50.95 (2.36) 2.61 (0.07) 5.18 (0.02) 0.50 (0.01) 
15-G10-2 
13.11 
(0.53) 47.02 (0.47) 1.33 (0.09) 4.78 (0.02) 0.28 (0.01) 
2-H4-2 
12.50 
(0.07) 21.58 (0.09) 1.27 (0.06) 2.19 (0.04) 0.58 (0.01) 
1-G11-1 
24.91 
(0.20) 29.12 (0.33) 2.53 (0.03) 2.96 (0.03) 0.85 (0.02) 
24-E10-1 
14.62 
(0.62) 32.82 (0.52) 1.49 (0.08) 3.34 (0.03) 0.45 (0.02) 
[a] (Based on quantification employing Agilent 2100 Bioanalyzer (Agilent Protein 230 Kit)) 
[b] (Standard error of triplicate measurements are given in brackets below each absolute 
and normalized value.) 
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Figure 14. Elution profile of wild type PpADI and improved variants from epPCR library, 
generated with Protein 230 Kit using a mircofluidic device (Agilent Bioanalyzer). BSA was added 
as an internal standard. 
 
3.4.9 Characterization of PpADI variants 
3.4.9.1 Determination of kcat and Km of ADI wild type and the mutants 
Variants selected from epPCR were first characterized using the crude cell 
extract to identify the most promising variants (Table 2). Using an activity ratio of 
pH 7.4 to 6.4 proved to be an effective method to eliminate expression mutants. 
Additionally ADI concentration in crude cell extract was determined using the 
Agilent Protein 230 Kit. Microfluidic elution profiles (Figure 14) semi-quantify 
differences in expression between the wild type PpADI and variants. 
Normalization of activities against the corresponding ADI concentrations reveals 
improvements in specific activities of ADI mutants (Table 2). M1, the starting 
variant for the directed evolution campaign, and M2 were selected for detailed 
characterization studies. M2 has as “best identified variants” (Figure 13) a more 
than 2.5-fold higher activity ratio at pH 7.4 to pH 6.4 than M1 and a 12-fold higher 
activity ratio than wild type in crude cell lysates. 
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For kinetic characterization of ADI variants the citrulline production was 
maintained between 0.2-0.8 mM. Calibration curve in Figure 4 shows the linear 
detection range in the employed 96-well PCR plate format citrulline colorimetric 
assay system. Figure 15 summarizes the kcat and Km values of wild type PpADI, 
identified variants M1 (H404) and M2 (K5T D44E H404R) which were expressed 
in shaking flasks cultures and purified using a two step procedure (anion 
exchange followed by gel filtration). Both variants M1 and M2 show an increase 
in kcat and Km for citrulline production at pH 7.4. Variant M2 shows a 4-fold higher 
kcat as also obtained for specific activity in Table 2 using the crude cell extract, 
validating the characterization procedure with crude cell lysate. Furthermore, an 
increased Km from 0.7 mM (wild type PpADI) to 1.2 mM (M1) and 2.5 mM (M2) 
was found. 
 
 
Figure 15. Kinetic parameters of ADI and mutants for conversion of arginine to citrulline. White: 
ADI wild type, grey: M1 (H404R), black: M2 (K5T D44E H404R). Values reported are the average 
of three measurements, and average deviations from the mean values are shown. Embedded 
calibration curve shows linearity of citrulline colorimetric assay in 96-well PCR plate format which 
was used to determine arginine conversions and kinetic constants.  
 
3.4.9.2 Relative pH profile of wild type and mutant 
The relative pH profile (Figure 16) of wild type PpADI and M1 (H404R) shows an 
identical pH optimum at pH 6.5. Compared to wild type PpADI, variant M2 (K5T 
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D44E H404R) shows a pH optimum at pH 7.0 which is shifted remarkably (0.5 
pH units). Both M1 and M2 show decreased specific activities at pH 6.5, and 
increased specific activity at pH 7.5. At pH 7.0, the specific activity of M2 
exceeds that of wild type PaADI (data not shown). 
 
Figure 16. pH profile of wild type ADI, M1(H404R), M2(K5T/D44E/H404R). The relative activity is 
the ratio of the catalytic activity at the pH relative to the maximum activity of each enzyme. (■) WT, 
(▲) M1 (H404R), (●) M2 (K5T/D44E/H404R). 
 
 
3.4.10 Stability of PpADI in the presence of human serum  
Table 3 summarizes the stability of PpADI variants in serum (37°C, 60 min; 
standard deviation of three measurements in brackets). The mutants M1 and M2 
have a similar stability in serum when compared to the wild-type PpADI wild type.  
The substitution D44E and H404R do not destabilize further the PpADI in serum.  
 
Table 3. Stability of PpADI variants in the presence of human serum. 
 PpADI WT M1 M2 
No incubation (A530) 0.08 0.27 0.98 
Incubation with serum (37°C, 
60 min) (A530) 0.05 0.15 0.69 
Residual activity 60 % 55 % 70 % 
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3.4.11 Activity of PpADI (wild type, M1, M2) towards arginine derivative (NG, 
NG)-dimethylarginine  
No detectable conversion of (NG, NG)-dimethylarginine could be detected with 
PpADI variants.  
 
3.5 Discussion 
ADI properties have to date not been engineered through directed evolution 
algorithms despite their often poor performances under physiological conditions 
and their medical importance as potential anti-tumor drug. Chemically modified of 
ADI (e.g. through PEGylation) (27) and fusion protein (e. g. Human serum 
albumin fusion, HSA) (124) have been used for addressing activity and stability 
demands in vivo. Directed evolution offers opportunities to directly improve ADI 
properties for in vivo applications and small libraries of a few thousand variants 
have often been sufficient to find improved muteins in directed evolution 
experiments (55, 125).  
 
Our main intention in this report is to provide a validated protocol for directed ADI 
evolution and improving the activity at the physiological pH 7.4. Pseudomonas 
plecoglossicida CGMCC2039 (PpADI, 7.8 U/mg; pH optimum 6.5) was selected 
for the directed evolution studies due to its functional expression in E. coli, 
coverage of sequence space in patents and “potential” for activity improvement. 
PpADI is a relatively slow ADI when compared to Mycoplasma ADIs like MhADI 
(Mycoplasma hominus ADI, 35 U/mg) which would have been good alternatives 
for directed evolution studies (105). Reported ADI activities range from 0.115 to 
140.3 IU/mg. One unit is commonly defined as the ADI amount that converts 1 
µmol of L-arginine into 1 µmol of L-citrulline per minute (27).  
 
Screening of PpADI variants yielded three amino acid positions 5, 44 and 404. 
Positions 44 and 404 resulted in a 4-fold higher kcat at pH 7.4 and a significant 
shift in the pH optimum (0.5 units) when compared to wild type PpADI (Figure 17 
& 8). Position 5 did not show any effect on PpADI activity.   
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Figure 17. Structural alignment of mutant M1 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The crystal structure of PaADI which was diffracted in 
absence of the substrate arginine (1RXX) was used to investigate the substitution of His405 to 
Arg405. The Arg405 variant shows with respect the Asp280 a different orientation of the 
guanidinium group when compared to side chain of His405 (in orange).  
 
Galkin and coworkers postulated that the histidine in position 404 (corresponding 
position in “their” PaADI is 405) is a key residue in controlling activity at acidic 
and neutral pH. In protonated state of the imidazolium ring a hydrogen bonding 
interaction can be formed with the oxygen of Asp280 (carboxyl group). This 
hydrogen bond favors stabilizing interactions between Asp280 and the substrate 
arginine. His405 in PaADI was reported (17) to share protons with Asp280 and 
Glu13 and to be important for modulating electrostatic environments of closely 
located catalytic groups. The same report postulated that H405 is likely to be 
protonated when the substrate arginine binds to catalytic triad (His278, Glu224, 
Cys406) (2). Based on these reports the His404 in PpADI was subjected to a site 
directed mutagenesis to Arg404 and named M1. The M1 variant (H404R) shows 
40 % residual activity compared to wild type PpADI at pH 6.4 and a 1.8-fold 
increase in activity at pH 7.4 (see Table 1). In the M1 (H404R) mutant (see the 
model in Figure 17; based PaADI 1RXX; residue His404 in PpADI corresponds to 
His405 in PaADI), the conformational effect due to the extended side chain of 
Arg likely weakens the hydrogen bond to Asp280 and thus reduces the stabilizing 
effect on arginine binding. As a result the activity of M1 is reduced, especially at 
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lower pH values at which His405 is protonated. However at elevated pHs, His405 
becomes increasingly deprotonated whereas Arg405 remains protonated and 
can therefore still stabilize Asp280 for arginine binding. The electrostatic effect 
suggested by theoretical and experimental studies have evidenced the 
importance of positively charged residues to modulate the reaction rate of PaADI 
(126). At pH 6.4, histidine in wild type PpADI and arginine in M1 are both 
positively charged. At pH 7.4, histidine is only partially positive charged and 
PpADI’s activity is reduced (>90 %) while arginine in M1 remains positively 
charged preserving M1’s activity (Figure 17).   
 
 
Figure 18. Structural alignment of mutant M2 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The PaADI crystal structure in presence of substrate arginine 
was used (2A9G) to investigate the role of the substitution Asp44 to Glu44. The latter was solved 
for an inactive variant in which Cys406 was replaced by Ala406. The extended side chain of 
Glu44 might improve the hydrogen bond interaction with the Arg399 inducing a conformational 
shift of loop 1. 
 
The PpADI H404R was used as starting variant for directed evolution. The amino 
acid position 44 was identified from a epPCR library (2400 variants screened) 
resulting in a triple mutant M2 (K5T D44E H404R). For investigating the role of 
each position the double mutants (K5T H404R) and (D44E H404R) were 
generated. Only the double mutant (D44E H404R) revealed improvements in kcat 
(4-fold, pH 7.4; Figure 18). The rationale behind the effects of the mutation D44E 
on the PpADI activity is more complex to extrapolate from the available ADI 
crystal structures. Comparative crystallographic studies have shown that the 
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entrance of the active site is decorated by 4 loops that undergo conformational 
transitions upon arginine binding (17). The loops exhibit significant shifts that limit 
the access of water molecules to the active site. The Asp44 is located in loop 1 
(residues 30-46) and upon binding of the substrate, Asp44 comes closer to the 
positively charged Arg399 located on loop 4 (residues 392 to 403). In the D44E 
mutant, the longer side chain reduces the distance with Arg399 favoring the 
formation of hydrogen bond (see model in Figure 18). The reinforced interaction 
between Glu44 and Arg399 might expedite conformational changes in loops, 
probably confining the arginine substrate in the active site and hence promote 
arginine conversion. In the future, we plan to further investigate the influence of 
H404R and D44E using molecular dynamics simulations, further boost the kcat at 
pH 7.4 and reduce the Km value of PpADI.  
 
Overall site directed mutagenesis of position H404R and one round of directed 
evolution (2400 variants screened) resulted in a triple mutant M2 (K5T D44E 
H404R) with 4-fold higher kcat at pH 7.4 (compared to wild type; Figure 4). The 
best mutant isolated, M2, has specific activity of 31.3 U/mg at pH 7.4 which is 
already after one round of evolution close to the specific activity of MhADI (35 
U/mg) (127) at its pH optimum. The stability and specificity of improved PpADI 
variants are furthermore important for cancer treatment in vivo. First experiments 
in AB-human serum (Invitrogen) showed an unaltered stability of M2 compared to 
the wild type PpADI and (NG, NG)-dimethylarginine conversion could not detect 
with the citrulline colorimetic assay.   
 
3.6 Conclusion 
In summary, a directed evolution protocol has been developed for PpADI and 
validated by increasing the kcat of PpADI at physiological pH (7.4). The reported 
screening system is the first one employed in directed ADI evolution and can 
likely be used for other ADIs and other properties such as temperature stability, 
salt/detergent stability or protease resistance. 
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Chapter 4 
Chapter 4. PpADI reengineered for efficient 
operation under physiological conditions 
 
4.1 Abstract 
The proof of concept for ADI engineering by directed evolution resulted in variant 
M2 (K5T/D44E/H404R). M2 has a pH optimum of pH 7.0 and 4-fold higher kcat 
value than the wild type PpADI (pH 7.4, 0.5 M phosphate buffer) and an 
increased Km value for substrate arginine. In this chapter, in order to improve the 
catalytic efficiency of PpADI at low concentration of arginine, variant M5 
(K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated from an epPCR library: 
at pH 7.4 (PBS buffer), the S0.5 value decreased from 2.01 mM (parent M3, 
K5T/D44E/A128T/H404R) to 1.48 mM (M5) and 0.81 mM (M6). The S0.5 value of 
M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat value 
improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 11.64 
s-1 (M6, 64.7-fold). 
 
4.2 Introduction 
ADI-based arginine depletion is a target specific therapy for arginine-auxotrophic 
tumors (e.g. hepatocellular carcinomas and melanomas) and pegylated ADI is 
currently under clinical trials for HCC with promising results (45). HCC is the third 
leading cause of cancer mortality world wide with a less than 10 % 5-year 
survival rate (EU and USA) (128) due to low responses of hepatoma to 
chemotherapeutic treatments. In 1999, US Food and Drug Administration (FDA) 
designated ADI-PEG-20 orphan drug status for the treatment of HCC and 
invasive malignant melanomas, and in 2005 European Agency for the Evaluation 
of Medicinal Products (EMEA) also granted ADI-PEG-20 orphan drug status for 
the treatment of HCC. Phase II trials of ADI-PEG-20 in patients with metastatic 
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hepatocellular carcinomas have shown that the drug is safe, well tolerated, and 
may benefit patients with unresectable HCC. Izzo and coworker suspected that 
combination therapies of arginine deprivation and growth inhibition via kinase 
inhibitors might improve the survival rate further more. Additionally, ADI can 
enhance radio sensitivity of human mammary adenocarcinoma (MCF-7 cells) 
(48), exerts anti-proliferative and anti-angiogenic activities and inhibits the growth 
of viruses such as HIV-1 and hepatitis (49, 50). Current research efforts are 
focused on ADI’s in vivo inhibitory effect towards leukemia, melanoma, prostate 
cancer, renal cell carcinoma, and human umbilical vein endothelial cells (HUVEC) 
(19, 44, 51-53), clinical trials for HCC (phase II) (45) and melanoma (phase I/II) 
(46), and inhibitory mechanisms of ADI to tumors (54).  
 
Arginine deprivation is believed to be a main molecular reason for ADI’s inhibitory 
effects on arginine auxotrophic tumors which do not express argininosuccinate 
synthetase (ASS). ADIs catalyze the first step of the arginine dehydrolase 
pathway by hydrolyzing arginine to citrulline and ammonium. ADI genes have 
been identified, purified, and characterized from bacteria, archaea and some 
eukaryotes excluding mammalian cells (see review (27)). Enzymatic properties of 
several recombinant ADIs have been examined, such as specific activity, 
functional expression level, temperature optimum, pH optimum, substrate affinity 
for arginine, and half-life in human plasma. Only the ADI from Mycoplasma 
hominis has so far been developed as orphan drug by Pheonix Pharmacologics 
Inc. for HCC and melanoma (129). From enzyme kinetic point of view, none of 
the ADIs is ideally suited for in vivo applications under physiological conditions. 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. PpADI (ADI from 
Pseudomonas plecoglossicida) was functionally expressed in E. coli with a 
simple protocol and has been engineered for the first time by directed evolution 
for improved activity at physiological pH (3). The variant M2 (K5T/D44E/H404R), 
by our group reported, showed a 4-fold higher specific activity than the wild type 
PpADI (0.5 M phosphate buffer, pH 7.4), but a increased Km value (3.5-fold). 
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High activity at low arginine concentration is an important prerequisite for ADI’s 
medical application, allowing low ADI dose required per treatment. 
In the present work, we improved the directed evolution protocol and identified a 
PpADI variant with further improved activity and slightly decreased “Km value” 
and PpADI variant with lowered Km value maintaining its high catalytic activity. 
Those variants were characterized in respect to their kinetic constants. 
 
4.3 Materials and methods 
4.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
plasmid (MEGAWHOP, 25 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
4.3.2 Methods 
4.3.2.1 Site saturation mutagenesis of PpADI M2 at position A128 
Site directed mutagenesis of PpADI M2 (K5T/D44E/H404R) at position A128 was 
performed according to the published method (130). The following 
oligonucleotides were used for mutagenesis of A128: 5’-
CTGATCGGCGGCGTGNNNGGCCAGGACCTGCCG-3’ and 5’- 
CGGCAGGTCCTGGCCNNNCACGCCGCCGATCAG-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 98°C for 30 s, 1 
cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 3 cycles. Second stage: 98°C for 30 
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s, 1 cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 15 cycles; 72°C for 3 min, 1 
cycle), 2 U of PhuS DNA polymerase, 0.20 mM of dNTP mix, 25 pmol of each 
primer together with 100 ng of template (pET42b(+) harboring PpADI M2 gene) 
were used. Following the PCR, DpnI (40 U; New England Biolabs) was added, 
and incubated overnight at 37°C. The PCR products were purified by using a 
QIAquick PCR Purification Kit (Qiagen) and transformed into E. coli BL21-Gold 
(DE3) for expression. 
 
4.3.2.2 Construction of PpADI error-prone library 
EpPCR library was generated by the standard error-prone PCR (epPCR) using 
improved variant M3 (K5T/D44E/A128T/H404R) as template. For the mutagenic 
PCR (95°C for 2 min, 1 cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C 
for 3 min, 1 cycle), 2.5 U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of 
template (pET42b(+) harboring PpADI M3 gene), 0.01-0.1 mM of MnCl2 and 10 
pmol of each primer (5’-TACATATGTCCGCTGAAACACAGAAG-3’ and 5’-
GTGCTCGAGTTAGTAGTTGATCGG-3’) were used. The PCR products were 
purified by using a QIAquick PCR Purification Kit. The purified epPCR products 
were cloned into expression plasmid pET42b(+) by MEGAWHOP (114). For 
MEGAWHOP (72°C for 5 min, 1 cycle; 98°C for 1 min 30 s, 1 cycle; 98°C, 45 s/ 
55°C, 45 s/72°C, 4 min, 24 cycles; 72°C for 10 min, 1 cycle), 1.2 U of PfuS DNA 
polymerase, 0.20 mM of dNTP mix, 500 ng of epPCR products together with 50 
ng of template (pET42b(+) harboring PpADI gene of variant M3) were used. 
Following the PCR, DpnI (40 U; New England Biolabs) was added, and incubated 
(overnight; 37°C). The MEGAWHOP products were transformed into E. coli BL21-
Gold (DE3) for expression and screening. 
 
4.3.2.3 Site directed mutagenesis at position D38 of PpADI M4 
Site directed mutagenesis of PpADI variant M4 at position D38 was performed 
according to the published method on plasmid pET42b(+)-ADI-M4 
(K5T/D44E/A128T/E296K/H404R). The following oligonucleotides were used for 
mutagenesis of D38H: 5’-ACCCCGAGCAACTGCCACGAGCTGCTGTTCGAC-3’ 
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and 5’-GTCGAACAGCAGCTCGTGGCAGTTGCTCGGGGT-3’ (underlining 
indicated the substituted nucleotide). Conditions for mutagenic PCR are as 
described in “Site saturation mutagenesis of PpADI M2 at position A128”.The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.4 Site saturation mutagenesis at position D38 and E296 of PpADI M3 
Site saturation mutagenesis library at position D38 and E296 of PpADI variant M3 
(K5T/D44E/A128T/H404R) were generated according to the published method on 
plasmid pET42b(+)-ADI-M3 using the  following oligonucleotides: D38FP (5’-
ACCCCGAGCAACTGCNNNGAGCTGCTGTTCGAC-3’), D38RP (5’-
GTCGAACAGCAGCTCNNNGCAGTTGCTCGGGGT-3’) and E296FP (5’-
GTCACGGTTTTCCCGNNNGTGGTGCGCGAGATC-3’), E296RP (5’-
GATCTCGCGCACCACNNNCGGGAAAACCGTGAC-3’) (underlining indicated 
the substituted nucleotide). Conditions for mutagenic PCR are as described in 
“Site saturation mutagenesis of PpADI M3 gene at position A128”.The PCR 
products were purified by using a QIAquick PCR Purification Kit (Qiagen) and 
transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.5 Cultivation and expression of PpADI in 96-well plates 
Cultivation and expression in 96-well plates (flat bottom, polystyrene plates; 
Greiner Bio-One GmbH, Frickenhausen, Germany) were performed as previously 
described in 3.3.2.8. 
 
4.3.2.6 Improved screening system in 96-well plate to identify PpADI 
variants with high activities at low arginine concentration 
As describe previously, the modified protocol of citrulline detection based on 
carbamido-diacetyl reaction was used for screening for improved ADI affinity to 
arginine at pH 7.4. 15 µl of cell culture was transferred to 96-well microtiter plate. 
Enzyme reaction was initiated by addition of arginine solution (105 µl, 1mM 
arginine in PBS buffer, pH 7.4) supplemented with 
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cetyltrimethylammoniumbromide (CTAB, 4 mM), and incubated (10 min, 37°C). 
The following color development procedure was carried out as described 
previously (3). 
 
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking PpADI and in a separate experiment 
containing PpADI variant M3. Apparent standard deviation was based on the 
absolute absorbance values obtained from the PpADI variant M3 plate. The true 
standard deviation was calculated by subtracting the background absorbance 
value of the microtiter plate lacking ADI from the apparent values. 
 
4.3.2.7 Expression of PpADI in shaking flask and purification  
Expression of PpADI in shaking flasks and purification (by anion exchange 
chromatography and gel filtration) was performed as previously described in 
3.3.2.10.  
 
4.3.2.8 Characterization of PpADI variants 
Preliminary determination of kinetic constants for site saturation mutagenesis 
variants of position 38 and 296  
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in 
incubator (Heraeus Holding GmbH, Hanau, Germany) using cell crude extract.  2 
ml of expression culture was harvested by centrifugation (Eppendorf 5415R 4°C, 
13,000 g, 10 min) and then freezed (-20°C, overnight). Cell lysate was prepared 
by resuspending the cell pellet in lysozyme (91000 U, 50 mM phosphate buffer, 
pH 7.4, 1.3 ml) followed by incubation (37°C, 40 min) and centrifugation (4°C, 
13,000 g, 10 min). 15 µl of diluted (4 times diluted with 50 mM phosphate buffer, 
pH 7.4) cell lysate was transferred to 96-well microtiter plates. Enzyme reaction 
was initiated by addition of arginine solution (105 µl, 0.25-10 mM arginine in PBS 
buffer, pH 7.4) and incubated (7 min, 37°C). Subsequently, ferric-acid solution 
(120 µl) was added to each well to stop enzyme reaction. 60 µl of terminated 
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enzyme reaction mixture was transferred to 96-well PCR plate for color 
development. Ferric-acid solution (90 µl) and DAM-TSC solution (15 µl) were 
added to each well. The 96-well PCR plate was then incubated (70°C, 30 min) in 
thermal cycler (Eppendorf Mastercyler gradient) for color development, followed 
by incubation in ice water to stop color development. Absorbance was measured 
at 530 nm using a microtiter plate reader (Tecan Sunrise TC reader, Tecan Group 
AG, Zurich, Switzerland). The initial velocity data obtained were fitted to the 
equation v = Vmax[S]/([S] + Km) (where v is the initial velocity, Vmax the maximum 
velocity, [S] the substrate concentration, and Km the Michaelis constant) using 
GraphPad Prism software (GraphPad software, San Diego, CA, USA). The kcat 
was calculated from the ratio of Vmax and enzyme concentration. 
 
Determination of kinetic constants of PpADI wild type and variants M3, M4, M5, 
M6 
The kcat and S0.5 values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath as described previously using purified enzyme (50 µl, 0.1-1.8 µM) to 
and substrate solution (200 µl, 0.5 mM to 10 mM of arginine, PBS buffer, pH 7.4) 
in deep well plates.  
 
The initial velocity data obtained were fitted to the sigmoidal model of kinetics 
equation v = Vmaxn/(S0.5n + Kn) (where v is the initial velocity, Vmax is the maximum 
velocity, K is the substrate concentration, and S0.5 is the ligand concentration 
producing half occupation (131)) using GraphPad Prism software (GraphPad 
software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax and 
enzyme concentration. 
 
4.3.2.9 Native polyacrylamide gel electrophoresis of PpADI variants 
10% of polyacrylamide native gels were used for protein electrophoresis to 
analyze the native form of PpADI variants. Purified protein of PpADI variants (7 µl 
of protein and 3 µl of loading dye) were loaded into each lane of native gel. The 
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molecular marker used in the gel is NativeMarkTM Unstained Protein Standard 
(Invitrogen, Darmstadt, Germany). The electrophoresis was performed with 
tris/glycine buffer (pH 8.3) and electrophoresis chamber was incubated in ice-
water bath. Protein bands were stained with Coomassie brilliant blue solution.  
 
4.3.2.10 Homology modeling 
Homology modeling approach was used for the structure prediction of PpADI. 
The model was built by using the automated structure prediction tool, Protein 
homology/analogy recognition engine (Phyre: http://www.sbg.bio.ic.ac.uk/~phyre/) 
(132). The crystal structure of PaADI (PDB ID: 2A9G) was used as template by 
the server and It has 84.9% sequence identity (http://blast.ncbi.nlm.nih.gov/Blast) 
with PpADI. Procheck program suit (http://www.ebi.ac.uk/thornton-
srv/software/PROCHECK/) (133) was used to assess the stereochemical quality 
of the model. Ramachandran plot which represented that 84.7% residues were 
present in the most favoured region and 14.7% in additional allowed region 
(Figure 3).  Dfire was used to access non bonded atomic interaction in the model 
(http://sparks.informatics.iupui.edu/hzhou/dfire.html/) (134), and Qmean 
(http://swissmodel.expasy.org/qmean/cgi/index.cgi) (135) for the estimation of 
global protein quality. Swiss-PdbViewer (118) was used to create the tetramer 
structure by fitting the monomer model on the 4 units of the 2A9G template. The 
variant M6 (D38H, D44E, A128T, E296K, H404R) were created by using the 
“mutate” tool of the Swiss-PdbViewer and by selecting rotamers with the best 
fitness score. All tetramers were energy minimized in vacuum using GROMOS 
43B1 force field (119).  
 
4.4 Results 
4.4.1 Improved screening system in microtiter plates to identify PpADI 
variants with high activities at low arginine concentration 
Screening assay was based on the validated citrulline colorimetric screening 
protocol in microtiter plate, as reported previously (3). In order to screen for 
variants with high activity at low arginine concentration under physiological 
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condition concerning pH and ion concentrations, 1 mM arginine in PBS buffer 
(pH 7.4) as substrate solution was employed in screening assay and enzyme 
reaction time was controlled accordingly (10 min). The coefficient of variation is 
an important performance criterion of a screening system to determine its 
accuracy. Optimized assay condition with 1 mM arginine (PBS buffer, pH 7.4) as 
substrate resulted in true coefficient of variation of 14.9 % (Figure 1). The 
resulting low absolute absorbance value is a main reason for the high true 
coefficient of variation (14.9 %). In the previous screening system, 100 mM 
arginine in 0.5 M sodium phosphate buffer was used and yielded higher activity 
variants but with higher Km value. 
 
 
 
Figure 1. Activity values in descending order of the PpADI variant M3 conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
4.4.2 Genealogic tree of directed PpADI evolution  
Figure 2 shows the two rounds of PpADI evolution, generation of saturation 
mutagenesis libraries and recombination of beneficial positions to finally obtain 
the PpADI variant M6 with 64.7-fold higher kcat and reduced S0.5 (1.3 mM (WT) to 
0.81 mM (M6). Based on structure-function analysis of PaADI[16], M1 was 
generated by substitute His at position 404 with Arg. Position 404 is through 
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interactions with position Asp280 involved in substrate stabilization during 
catalysis. M1 was subject to the first round of epPCR library, from which M2 was 
identified showing a 4-fold improved kcat value and increased Km value (2.5 mM 
in 0.5 mM sodium phosphate buffer, pH 7.4)[15]. M3 was generated by a site 
saturation mutagenesis library at position 128 which increased in another clone 
the expression level (data not shown). In order to improve PpADI towards 
medical application demands (high activity at low arginine concentration), a 
second epPCR mutant library was constructed using M3 as parent. M4 with 
decreased S0.5 value (0.81 mM) and M5 with increased Kcat value (17.56 s-1) 
were identified after screening of ~1400 clones. In M4 the position E296 was 
identified to be important for lowering S0.5 and in M5 position D38 was identified 
to be important for activity increase. M6 was finally constructed by combining the 
substations at position D38 and E296. Saturation mutagenesis of these two 
positions did not yield any further improved S0.5 or activity variant.  
 
 
Figure 2. Genealogic tree of PpADI variants (M1 to M6) with generated amino acid substitutions. 
Novel substitutions are indicated by an asterisk. 
 
4.4.3 EpPCR library construction and screening for variants with high 
activities at low arginine concentration 
Variant M2 was used as a starting template. As described previously, M2 shifts 
the pH optimum from pH 6.5 to pH 7.0 and has a 4-fold faster kcat than PpADI 
wild type. In one sequenced mutant, position A128 was identified to be 
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responsible for higher expression (data not shown). Site saturation mutagenesis 
on M2 therefore was carried out at position A128. The resulting variant M3 
(K5T/D44E/A128T/H404R) showed a ~2-fold improved expression and was 
subsequently used as parent template for epPCR library. 
 
Three concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Instead of 0.02 mM 
MnCl2, 0.05 mM MnCl2 which generated 46 % of inactive mutant was selected for 
library generation. EpPCR mutant libraries with a ratio of ~50 % active and ~50 
% inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). Two variants M4 and M5 
were identified from this epPCR library (~1400 clones) and further characterized. 
Variant M4 and M5 were sequenced and one additional amino acid substitution 
was identified for each variant, E296K and D38H, respectively. 
 
4.4.4 Site saturation mutagenesis of PpADI at position D38 and E296 
To investigate their role in improving of catalytic performance for arginine, site 
saturation mutagenesis library at position D38 and E296 were generated using 
PpADI M3 as template. For each position, ~300 clones were screened at low 
concentration of arginine (1 mM, PBS buffer, pH 7.4), using 96-well plate format 
citrulline colorimetric screening assay.  
 
After the screening of site saturation mutagenesis libraries of position 38 and 296, 
variants with higher activity were chosen for preliminary kinetic investigation using 
crude cell extract. Beneficial mutants were identified and sequenced from both 
sites (Table 1). At position 38, the following beneficial substitutions were found: 
D38R (three times, AGA, CGG, CGT) and D38K (twice, AAG, AAA). In all cases, 
the negatively charged acidic amino Asp had been replaced by positively charged 
amino acids, Arg or His. Substitution by negatively charged Glu resulted in a 
clone showing a parent M3-like kinetic behavior. Hydrophobic amino acid 
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substitution by Pro resulted inactive clone under assay conditions. At position 296, 
the following substitutions were found to be beneficial: E296K (twice, AAA, AAG), 
E296N (once, AAC), E296T (once, ACC), E296G (once, GGA). Among these 
substitutions, variants with substitution to positively charged residue Lys show 
lowest S0.5 value for arginine while substitution by uncharged amino acids (Asn, 
Thr, Gly) shows relatively marginal improvement compared to E296K. 
Hydrophobic amino acid substitution by Pro and Trp resulted in very low activity 
clones. 
Table 1. Nucleotide and amino acid substitutions at position 38 in PpADI M3. 
 PpADI 
variants Substitution at position 38 km (mM) 
M3 (parent) Asp (GAC) 3.74 ± 0.35 
SSM-D38R Arg (AGA, CGG, CGT) 1.16 ± 0.21 
SSM-D38K Lys (AAG, AAA) 1.01 ± 0.28 
SSM-D38E Glu (GAG) 2.95 ± 0.77 
SSM-D38P Pro (CCA) n. d. 
SSM-D38T Thr (ACC) n. d. 
M5 His (CAC) 1.26 ± 0.12 
Kinetic experiments were performed with crude cell extracts. 
 
 
Table 2. Nucleotide and amino acid substitutions at position 296 in PpADI M3. 
 PpADI 
variants Substitution at position 296 km (mM) 
M3 (parent) Glu (GAA) 3.74 ± 0.35 
SSM-E296K Lys (AAA, AAG) 0.20 ± 0.01 
SSM-E296N Asn (AAC) 0.53 ± 0.04 
SSM-E296T Thr (ACC) 0.61 ± 0.04 
SSM-E296Q Gln (CAA) 0.79 ± 0.06 
SSM-E296G Gly (GGA) 1.29 ± 0.12 
SSM-E296W Trp (TGG) n. d. 
SSM-E296P Pro (CCT) n. d. 
M4 Lys (AAA) 0.27 ± 0.02 
Kinetic experiments were performed with crude cell extracts.  
* n. d. activity not detectable under assay conditions. 
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4.4.5 Determination of kinetic constants (kcat and S0.5) of PpADI wild type 
and variants M3, M4, M5 and M6 
 
Table 3. Kinetic constants of wild type PpADI and variants. 
 Wild type M3 (parent) M4 M5 M6 
kcat (s-1) 0.18 ± 0.05 10.13 ± 0.36 5.88 ± 0.09 17.56 ± 1.15 11.64 ± 0.50 
S0.5 (mM) 1.30 ± 0.25 2.01 ± 0.19 0.81 ± 0.03 1.48 ± 0.17 0.81 ± 0.09 
* Kinetic contants of PpADI wild type is different from our previous report because in stead of 
0.5 M phosphate buffer, PBS buffer was used for kinetic measurements. Kcat value of PpADI 
wild type dropped from 5.6 s-1 to 0.18 s-1 and kcat value of M2 is reduced ~2-fold. 
 
M3, the parent of the second round of PpADI epPCR library, M4 with decreased 
S0.5, M5 with increased kcat and best variant M6 with best combination of kcat 
value and S0.5 were selected for detailed characterization studies.  
 
Kinetic characterization of PpADI variants was performed using PBS buffer (pH 
7.4), which is commonly used in biological research. PBS buffer helps to 
maintain a constant pH and its osmolarity and ion concentrations usually match 
those of the human body. Citrulline production of PpADI variants was maintained 
between 0.2-0.8 mM. Table 3 summarizes the kcat and S0.5 values of parent M3 
(K5T/D44E/A128T/H404R), variants M4 (K5T/D44E/A128T/E296K/H404R), M5 
(K5T/D44E/A128T/D38H/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R), which were expressed in shaking 
flasks cultures and purified using a two step procedure (anion exchange follows 
by gel filtration). Compared to parent M3 (S0.5 = 2.01 mM), both variants M4 and 
M5 have a lower S0.5 for arginine conversion at pH 7.4, 0.81 mM and 1.48 mM, 
respectively. Variant M4 shows a decreased kcat value, 58% of parent M3 while 
M5 shows a 1.7-fold higher kcat compared to parent M3. Variant M6 with 
combined mutations (K5T/D38H/D44E/A128T/E296K/H404R) shows decreased 
S0.5 value, 40 % of parent M3 (K5T/D44E/A128T/H404R), 62 % of PpADI wild 
type, and a 64.7-fold faster kcat value than PpADI wild type. M6 is 42.3-fold faster 
than PpADI wild type with 0.4 mM arginine (PBS buffer, pH 7.4) as substrate. 
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After two rounds of epPCR libraries coupled with site directed mutagenesis, a 
variant M6 with 64.7-fold higher kcat and lower S0.5 value (0.81 mM) than PpADI 
wild type (0.31 mM). At low concentration of arginine, activity of M6 enhanced 
dramatically than M3 and wild type. For example, M6 is 42.3-fold faster than 
PpADI wild type in 0.4 mM arginine (PBS buffer, pH 7.4). 
 
4.4.6 Native polyacrylamide gel electrophoresis of PpADI variants 
Multimeric form of PpADI variants were investigated by native polyacrylamide gel 
electrophoresis. As shown in Figure 3, two distinct protein bands representing 
two multimeric forms tetramer and dimer (molecular weight of a subunit is ~ 46 
kDa) were observed, but with different concentration percentage. The major 
multimeric form of M3 is dimer. Compared to M3, M4 with an additional mutation 
E296K shows a very different pattern: tetramer is the main form; while M5 with 
an additional mutation D38H contains more or less equal amount of dimer and 
tetramer. M6, with both mutations E296K and D38H, contains more tetramer than 
dimer. 
 
 
 
Figure 3. Native polyacrylamide gel electrophoresis of PpADI variants (M3 to M6) with different 
dimer/tetramer distribution. Single subunit has a molecular weight of ~46 kDa. 
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4.5 Discussion 
 
Directed evolution allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
Small libraries of a few thousand variants are often sufficient to find improved 
variants [18] even without rational understanding of the targeted property. After 
establishing a first directed ADI evolution protocol yielding mutant M2, we 
adjusted the screening system to better reflect ADI’s application conditions. 
Prerequisite for ADI to become an effective anti-tumor agent is that low 
concentrations of arginine in human plasma can effectively be converted. 
 
Figure 2 shows the genealogic tree of PpADI evolution and before discussing the 
influence of each substitution individually the effect on kinetics are briefly 
summarized. Amino acid substitution D44E (M2) increases kcat and S0.5, 
substitution A128T (M3) increases the expression level, and substitution E296K 
(M4) decreases kcat and S0.5 and is responsible for tetramer formation. 
Substitution D38H (M5) increase largely kcat and reduces slightly S0.5. The 
combination of all mentioned residues in M6 result in a finally 64.7-fold improved 
PpADI activity and reduced S0.5 (1.30 to 0.81 mM).    
 
PpADI M3 was obtained from site saturation mutagenesis library at position A128 
using M2 as template (Figure 2). M3 shows improved functional expression level 
of ADI (data not shown) and was used as parent for generating an epPCR library. 
Screening of epPCR library yielded two improved variants M4 and M5, carrying 
an additional mutation, E296K (M4) and D38H (M5). M4 has a decreased S0.5 
(0.81 mM) and a decreased kcat value (5.88 s-1; see Table 3). M5 has a 
decreased S0.5 (1.48 mM) and an increased kcat value (17.56 s-1) when compared 
to parent M3 (S0.5, 2.01 mM; kcat, 10.03 s-1; see Table 3). M6 which harbors both 
substitutions (E296K and D38H) has a decreased S0.5 value (0.81 mM) 
compared to the parent M3 (1.30 mM) and the wild type (2.01 mM), and a 64.7-
fold higher kcat value than the PpADI wild type.   
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Despite further enhancing the activity of PpADI, it is crucial for an efficient 
conversion of the substrate arginine in human plasma (100-120 µM arginine) to 
reduce PpADI’s “Km” (S0.5) value. Figure 4 shows the kinetics of PpADI WT, 
parent M3, and the variants M4, M5 and M6. M3 has a significantly higher kcat 
value compared to WT, but its activity at low concentration of arginine (<1.0 mM) 
is very low (S0.5 value 2.01 mM). In contrast, the most efficient variant M6 with a 
decreased S0.5 value (0.81 mM) shows a remarkable activity improvement at low 
concentrations of arginine (<0.5 mM; see Figure 4). M6 has additional two amino 
acid substitutions (D38H and E296K) compared to M3 which increases kcat and 
reduces the S0.5 value. The combination of D38H and E296K improves especially 
the activity of M6 at low arginine concentrations (< 0.5 mM; see Figure 4). 
 
Figure 4. Kinetic curve of PpADI wild type, M3, M5 and M6. (▲) PpADI wild type, (▼) M3, (●) M4, 
(♦) M5 and (■) M6. 
 
 
Figure 5 shows the tetrameric model (based on PaADI, PDB code 2A9G) of 
PpADI WT (Figure 5A) and variant M6 (Figure 5B). Monomeric units are 
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indicated with the letters a, b, c and d. The access channel to the active sites of 
each monomer is highlighted in square and faces an internal cavity generated by 
the assembly of four PpADI monomers. The substitutions D38H (in blue) and 
D44E (in green) are localized at the interface of monomer pair a-b and c-d. The 
substitution of Glu by Asp at position 44 provides a longer side chain in close 
proximity of the also negatively charged residue Asp43 (Figure 6A). The 
substitution E296K is localized at the border of the entrance to the internal cavity 
of the PpADI tetramer. E296K promotes the tetramer formation likely by 
introducing stabilizing interactions with other residues, for example with Thr33 
(hydrogen bond). E296K inverts the charge at this position and its increased 
length of the side chain might promote further interactions to a neighboring 
monomer (Figure 6A). The combination of D44E and E296K results in a 
population consisting of mainly tetramers (see Figure 3; mutein M4). Interestingly 
with the formation of a tetramer (M4) the S0.5 value is reduced which indicates 
that the tetramer complex formation promotes interactions with the substrate 
arginine at low concentrations. The substitution D38H together with the E296K in 
the mutein M6 reestablishes an almost equal population of PpADI dimers and 
tetramers. A hypothesis is that Lys of the E296K has an electrostatic stabilizing 
interaction with the Glu38 in the M4 but not to the neutral His38. 
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Figure 5. A). The model of WT tetramer after energy minimization in vacuum (GROMOS 43B1). 
B). The model of M6 tetramer after energy minimization in vacuum (GROMOS 43B1). Active site 
residues are represented in CRK format in a square (Blue). Mutated residues are shown in 
licorice format in different colors like D38H (blue), D44E (green), A128T (magenta), E296K (red) 
and H404R (violet). Substrate arginine is represented in orange color by licorice format.  
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Figure 6. A). Structure model of variant M6. E296K is involved in intermonomer interaction 
(between chain a (orange) and b (green)) with Thr33. D44E is involved in intermonomer 
interaction, between chain A (orange) and B (green), with Asp43 (violet). B). Structure alignment 
of PpADI WT model and M6 model with four loops (loop 1:30-46, loop 2:178-175, loop 3:271-281 
and loop 4: 393-404) surrounding the entrance of the active site. The substitutions in these loops 
and the residues involved in the interaction with those substitutions are representing: D38H 
(orange), D44E (yellow) and H404R (cyan, in M6; gray, in WT), Ser35 (green), Arg 400 (pink), 
substrate arginine (ochre), catalytic triad His278, Asp280 and Cys406 (violet, highlighted in an 
oval) 
 
Figure 6B shows that the active site of the PaADI is surrounded by four loops 
(loop 1: 30-46, loop 2: 178-185, loop 3: 271-281, and loop 4: 393-404). These 
four loops undergo a conformational transition upon arginine binding and tighten 
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the surrounding of the arginine substrate[16]. D38 is located in loop 1 and faces 
towards the substrate access channel. In PpADI model (Figure 6B), the D38H 
mutation promotes the formation of a hydrogen bond interaction with the 
neighboring residues Ser35, contributing to the stability of the entropically 
unfavorable folded conformation of loop1. The rigidified loop 1 might be 
beneficial for arginine conversion. According to PaADI structure analysis, the 
side chain of gating residue Arg401 (Arg400 in PpADI) is located at the active 
site entrance and fills the substrate-binding site. The structure analysis of the 
C406A PaADI-L-arginine complex[16] shows that the Arg401 side chain (Arg400 
in PpADI) is displaced by the substrate arginine to a position near the active site 
entrance that allows its hydrocarbon chain to assist shielding the catalytic site 
from solvent. D38 is involved in an ionic interaction and hydrogen bonding with 
Arg400. The substitution of Asp to His at position 38 results in a loss of ionic 
interactions to Arg400 due to the different lengths of the side chains. His38 can 
form only a hydrogen bond with active site gating residue Arg400. A weakened 
interaction between position 38 and Arg400 might increase the flexibility of the 
side chain of Arg400 which then might block less efficiently the access of 
arginine to the active site. As a result the variant M5 shows an improved kcat 
value (1.7-fold compared to parent M3) due to the substitution D38H.  
 
For elucidating further the individual role of the five identified amino acid 
substitutions and their influence on the active site geometry and tetramer 
formation crystal structures of variant M4 and M6 have to be solved.  
 
4.6 Conclusion 
In summary, with the modified screening protocol, PpADI variants with improved 
kcat and S0.5 were identified. The increased kcat value and decreased S0.5 value 
result in significant activity improvement of PpADI at low arginine concentrations. 
Especially the kinetic constants of PpADI variant M6 demonstrate that PpADI 
properties can be tailored by directed evolution. The generated PpADI variants 
match from their kinetic behavior therapeutic application demands much better 
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than the wild type PpADI. We therefore hope that by directed evolution improved 
PpADIs will further be investigated in vivo for tumor therapy. 
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Summary and outlook 
Arginine depletion based on ADI is an emerging strategy for anti-tumor treatment. 
ADIs have been studied for the therapy of HCCs and melanomas and were 
approved as an orphan drug for both kinds of tumors. ADI is proved to be 
effective in the treatment of leukemia. The effectiveness of ADIs as anti-tumor 
agent depends on their enzymatic properties (such as Km, kcat, optimum pH, 
stability at neutral pH). Directed evolution, without rational understanding of the 
targeted property, allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
 
In order to improve PpADI activity at physiological pH by directed evolution, a 
colorimetric screening assay based on citrulline detection has been developed in 
96-well microtiter plate format. Single mutation H404R was identified according 
to PpADI homology model (based on PaADI crystal structure), introduced to 
PpADI wild type and eventually resulted in 1.4-fold of increase in kcat. M1 (H404R) 
was used as template for the first round of epPCR library generation. M2 
(K5T/D44E/H404R) obtained from the first round of epPCR library showed 4-fold 
improved kcat value when compared to the PpADI wild type. Furthermore, a shift 
of pH optimum from pH 6.5 to pH 7.0 was observed, combined with an increased 
Km value (2.5 mM) under assay conditions (0.5 M sodium phosphate buffer, pH 
7.4), compared to PpADI wild type (0.7 mM). 
 
Arginine concentration in human plasma is however relatively low (100-120 µM). 
Therefore the second round of epPCR library was performed to decrease Km 
value and further improve kcat value. The validated screening assay was modified 
to reflect more close physiological condition (1 mM arginine in PBS buffer, pH 
7.4). Two important variants with one additional mutation, M4 
(K5T/D44E/A128T/E296K/H404R) with decreased S0.5 vaule, and M5 
(K5T/D38H/D44E/A128T/H404R) with improved kcat were obtained. Their two 
mutations were combined and resulted in variants M6 
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(K5T/D38H/D44E/A128T/E296K/H404R). Under physiological pH in PBS buffer, 
the S0.5 value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); 
the kcat value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-
folds) and 11.64 s-1 (M6, 64.7-fold). 
 
A reamaining challenge facing PpADI’s anti-tumor application is to decrease the 
Km (S0.5) value further close to arginine concentration level in human plasma. A 
more sensitive assay for screening has to be developed with the addition of 
sensitizer like thiosemicarbazide (TSC), optimized temperature and incubation 
time. Improved variants should be tested tested in human plasma or with human 
plasma composition. In vitro testing of ADI variants with arginine auxotrophic 
tumor cell lines is the first step towards in vivo in human. 
 
In summary, directed evolution has been very useful algorithim for improving 
ADI’s kcat and Km at physiological pH (pH 7.4) for its medical application. Hope 
that directed evolution will be become a standard method for therapeutic protein 
like its use in industry.                                
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Abstract 
Abstract 
Arginine deiminase (ADI), an arginine-degrading enzyme, is involved in the first 
step of arginine dihydrolase pathway. It catalyzes the hydrolysis of L-arginine to 
form citrulline and ammonia. ADI has been studied as a potential cancer 
therapeutic agent for the arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCC) and melanomas. Furthermore, studies also indicate that ADI 
is a potential anti-angiogenic agent; therefore it could become a novel anti-cancer 
drug targeting the neovascularization-related tumors. Studies show ADI is more 
potent for the treatment of leukemia than L-asparaginase. However, the anti-
tumor application of ADI for therapeutic purpose faces considerable challenges, 
such as, microbial ADI has low activity at physiological pH (7.35~7.45), short 
circulating half-life (~5 h) and high antigenicity. Pegylation of ADI improved its 
efficacy as a clinical drug, including its half-life in serum and antigenicity. The aim 
of the project is to improve ADI catalytic performance at physiological pH by 
directed evolution. 
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. Directed protein evolution has 
over the last decades become a versatile and successful approach for tailoring 
protein properties to industrial demands and for advancing our understanding of 
structure-function relationships in biocatalysts. Unlike rational design relying on 
the gathering of extensive structure-function relationships of enzymes, directed 
evolution is used to reengineer enzyme properties through iterative rounds of 
diversity generation and function selection for improved variants. 
 
In order to improve the ADI activity at physiological pH, we established a directed 
evolution protocol for this purpose. A microtiter plate (MTP) format colorimetric 
screening assay based on citrulline detection with diacetyl monoxime (DAM) was 
developed. Reaction temperature for color development and DAM concentration 
 IV 
were optimized to ensure sufficient sensitivity, appropriate linear range and 
throughput. With the optimized assay and PpADI wild type expressed in E. coli as 
a model protein, true standard deviation 12.8 % was obtained, which is 
appropriate for the library screening. 
 
With the established microtiter plate assay system, for the first time, we 
reengineered ADI for improved activity at physiological pH (pH 7.4) with higher 
potency in medical application. After one site directed mutagenesis and one 
round of epPCR library screening, variant M2 (K5T/D44E/H404R) was obtained. 
M2 shows 4-fold improved kcat value than the PpADI wild type, a shifted pH 
optimum at pH 7.0 (by 0.5 pH unit), and however an increased Km value, 3.6-fold 
under assay conditions (0.5 M sodium phosphate buffer).  
 
Low Km (S0.5) value for ADI is an important factor for efficient consume of arginine 
in plasma because of the low arginine concentration in human plasma (100-120 
µM). Therefore after our proof of concept of reengineering PpADI by directed 
evolution, we aim to decrease the Km value of PpADI towards arginine and 
improve the kcat furthermore thereby improve the efficiency of arginine depletion 
by ADI. The established citrulline colorimetric assay in 96-well microtiter plate is 
improved to reflect application conditions: PBS buffer and 1 mM arginine were 
used in screening system. After the second round of epPCR library and site 
directed mutagenesis, variant M5 (K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated: at pH 7.4 (PBS buffer), 
the S0.5 value decrease from 2.01 mM (parent M3, K5T/D44E/A128T/H404R) to 
1.48 mM (M5) and 0.81 mM (M6). Under physiological pH in PBS buffer, the S0.5 
value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat 
value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 
11.64 s-1 (M6, 64.7-fold). 
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Chapter 1 Arginine deiminase (ADI) 
Arginine deiminase (ADI) 
 
1.1 Arginine deiminase (ADI)  
Arginine deiminase (ADI, EC 3.5.3.6), an arginine-metabolizing hydrolase, 
catalyzes the hydrolysis of L-arginine to form citrulline and ammonia. This 
reaction is the first step in the L-arginine degradation pathway (ADH, scheme 1, 
(1). First, arginine is deiminated by arginine deiminase. The resulting citrulline is 
converted to carbamoyl phosphate and ornithine by ornithine transcarbamylase 
(EC 2.1.3.3), and finally the carbamoyl phosphate is used to phosphorylate ADP 
by carbamate kinase (EC 2.7.2.2), producing one ATP molecule. ADI is absent in 
humans but present in a wide range of bacterial species such as Pseudomonas 
aeruginosa (2), Pseudomonas plecoglossicida (3) and Mycoplasma arginini (4) 
and in parasitic protists such as Giardia intestinalis (5), Trichomonas Vaginalis 
(6), Trichomonas fetus (7), and Hexamita inflate (8). For pathogenic bacteria, ADI 
is required in arginine dehydrolase pathway for virulence and for energy 
production under anaerobic conditions (9, 10).     
 
 
Scheme 1. Arginine dihydrolase pathway. OTC, ornithine transcarbamylase; CK, carbamate 
kinase. 
 
 
 
 2 
The establishment of a high-level production system for ADI is an essential step 
for further research and development of this enzyme. After ADI was discovered 
from Mycoplasma in 1960s (11), various ADI genes have been cloned, 
expressed in E. coli strains, and the enzyme properties were also studied (Table 
1). 
 3 
Table 1. ADI expression, enzymatic properties and medical applications. 
ADIs Origin 
Expression 
host/vector 
Multimeric 
form Km; kcat 
Optimum 
pH  
Specific 
activity 
Medical 
application References 
MhADI 
(SYN1903) 
Mycoplasma 
hominis PG21* 
E.coli BL21 
(DE3)/pET-47b 
Dimer   0.618 U/mg 
(pH 6.5) 
Human 
melanoma 
(G361), 0.036 
U/ml for 50 % 
IC50 
Japan, 
Harasawa, 
2009 (12) 
MhADI Mycoplasma 
hominis (ATCC 
23114) 
- 
 
Dimer   6.0 35.5 U/mg (pH 
6.0) ;  
3.9 U/mg (pH 
7.4)  
Mouse 
melanoma 
(MH134) in 
vitro, 100 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MhADI Mycoplasma 
hominis (ATCC 
14027) 
- Dimer  0.17 mM 
(pH6.6) 
   USA, Fenske, 
1976(14) 
MhADI Mycoplasma 
hominis  
E.coli BL21 
(DE3)/pET25b 
 0.24 mM; 
0.151 s-1 
   China, Luo, 
2007 (15) 
MhADI Mycoplasma 
hominis 
E.coli    20 U/mg ADI 
(37°C). [a] 
ADI-SS 
PEG20000,  
human 
melanoma, 
human HCC 
USA, Pheonix 
Pharmacologi
cs, Inc., Clark, 
2002 (16) 
PaADI 
(PA5171) 
Pseudomonas 
aeruginosa  
(ATCC 47085D) 
E. coli 
BL21(DE3)/pET10
0 
Tetramer 0.14±0.01 
mM (pH 5.6) 
5.6   USA, 
Dunaway-
Mariano, 2005 
(17) 
PaADI Pseudomonas 
aeruginosa  
 
E. coli 
BL21 (DE3)/ 
pET SUMO 
   CARD-like 
domain, no 
catalytic 
activity 
Human cancer 
cell line SKOV-3 
USA, 
Chakrabarty, 
2006 (18) 
PpADI Pseudomonas 
plecoglossicida 
E. coli 
BL21 Gold-(DE3)/ 
pET42b 
 0.7 mM; 5.6 
s-1 (pH 7.4, 
0.5 M sodium 
phosphate 
buffer) 
6.5 31.3 U/mg (pH 
7.4, 0.5 M 
sodium 
phosphate 
buffer) 
 Germany, 
Schwaneberg, 
 2010 (3) 
 4 
MaADI Mycoplasma 
arginini 
(ATCC 23838D) 
E. coli 
DH5α/PTTQ118 
   32.7 U/mg. [a] Human 
umbilical vein 
endothelial 
(HUVE) 
USA, Shen, 
2002 (19) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
E. coli 
JM101/pADTc1 
Dimer     33.6 U/mg 
(37°C, pH 6.5). 
[a] 
Mouse 
hepatoma, 17 
ng/ml for 50 % 
IC50; mouse 
fibrosarcoma, 
15 ng/ml for 50 
% IC50 
Japan, 
Hayashi, 1994 
(20) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
    42 U/mg 
(37°C, pH 6.5); 
29.9 U/mg 
(37°C, pH 7.4) 
Mouse 
melanoma 
(MH134) in 
vitro, 10 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
-     HUVE, 
neuroblastoma, 
retinoblastoma, 
osteosarcoma, 
5~10 ng/ml for 
50 % IC50 
Germany, 
Schweigerer, 
1999 (21) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
- Dimer  0.2 mM 6.0-7.5 50 U/mg Mouse tumor 
carcinoma, 
fibrosarcoma 
and melanoma, 
5~20 ng/ml for 
50 % IC50 
Japan, 
Takaku, 1992 
(22) 
LlADI L. lactis (ATCC 
7962) 
E. coli 
BL21Gold(DE3)/p
GEM-T Easy 
Trimer 8.67 mM 7.2 140.27 U/mg  Korea, Lee, 
2007 (23) 
[a] ADI was expressed in inclusion body and denaturation-renaturation had to be employed to get soluble protein. 
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1.2 ADI structure 
In 1970s, Kakimoto et al. (24, 25) diffracted the first ADI crystals from P. putida 
through multiple-step chromatography followed by crystallization. Almost three 
decades later, the X-ray crystal structure of ADI from P. aeruginosa (PaADI, 
Figure 1A) (26) and M. arginini (MaADI, Figure 1B) (4) were solved to assist in 
understanding structure-function relationships. PaADI and MaADI share 27 % 
sequence identity and belong to guanidino group-modifying enzyme superfamily 
(GMSF). The catalytic triad (Cys-His-Glu/Asp) is conserved in members of the 
GMSF. Both crystal structures of PaADI and MaADI show a characteristic 5-fold 
pseudosymmetrical barrel with ββαβ subunits. Table 2 summarizes the crystal 
structures of PaADI and MaADI. 
 
Figure 1. Structural of ADIs from P. aeruginosa and M. arginini. (A) PaADI (PDB ID: 1RXX) and 
stereo view of its catalytic triad (C406-H278-E224). (B) MaADI (PDB ID: 1S9R) and stereo view 
of its catalytic triad (C398-H269-E213) with substrate L-arginine (27). 
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Table 2.  Crystal structures of ADI in protein data bank (PDB). 
PDB 
code 
Ligand in crystal 
structure Description 
Resolution 
(year) 
2A9G Arginine 
Crystal structure of PaADI variant C406A in 
complex with L-arginine  
2.30 Å 
(2005) 
2AAF  
Crystal structure of PaADI variant H278A 
forming a S-alkylthiouronium reaction 
intermediate  
2.30 Å 
(2005) 
2ABR  
Crystal structure of PaADI variant D280A with L-
arginine forming a S-alkylthiouronium reaction 
intermediate  
2.9 Å 
(2005) 
2ACI  Crystal structure of D166A arginine deiminase  
2.50 Å 
(2005) 
1S9R Arginine 
Crystal structure of MaADI covalently linker with 
a reaction in intermediate  
1.60 Å 
(2004) 
1LXY Citrulline 
Crystal Structure of MaADI covalently linked with 
L-citrulline  
2.00 Å 
(2004) 
1RXX  Crystal structure of MaADI  
2.45 Å 
(2004) 
 
MaADI was crystallized as a homodimer and its catalytic triad is formed by 
Cys398-His269-Glu213. MaADI has a catalytic domain and a five-helix bundle 
domain (Figure 3). The buried and compact substrate binding pocket is located 
approximately at the center of the molecule, from which a small solvent channel 
leads to the surface of the enzyme. The opening to the channel is located 
adjacent to the dimer interface region, which is at the opposite side of the 5-fold 
pseudosymmetric moiety of ADI. The shape and size of the channel does not 
permit transport of the substrate (L-arginine and end product (L-citrulline) in and 
out of the pocket. Substantial conformational changes in ADI are required to 
permit entry of the substrate and expulsion of the end product. The occurrence of 
"closed" and "open" form was suspected to be dependent on binding of substrate. 
 
PaADI has a tetrametric structure with 1630 amino acid residues in total, which 
makes it the largest enzyme of its structural superfamily. The catalytic triad of 
PaADI is Cys406-His278-Glu224. Similar to MaADI, the active site of PaADI is 
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located in a narrow crevice formed by a network of charged residues. Ligand 
binding energy is derived from ion pair and hydrogen bonding interactions 
between active site residues and the guanidinium, carboxylate and ammonium 
groups of the substrate. The proposed substrate-binding model shows that the 
catalytic center contains abundant charged residues (e.g. Asp280, His405, Glu13 
and Arg165). The ion pairing interactions between these residues contribute to 
the integrity and activity of ADI. In addition, Asp116, Asp227, Arg185, Arg401, 
His278, Glu118, and Glu224 are part of an extended charged network. The 
proposed catalytic mechanism suggests that the active site of PaADI is blocked 
by Arg401, and therefore a conformational transition is taking place upon the 
substrate binding. Based on the proposed reaction mechanism, Cys406 is as a 
key residue responsible for the nucleophilic attack on the guanidinium carbon 
atom of arginine. PaADI contains only one hydrophobic residue, Phe-163 and a 
Cys-406 with an unknown protonation state. The known functions of important 
residues are shown in Table 3, and the interactions between important residues 
and substrate arginine are shown in Figure 2. 
 
 
Figure 2. A. stereoscopic view of PaADI key active site residues. B. stereoscopic view of a 
modeled arginine substrate (green) docked in the active site of ADI. Atomic colors are red, 
oxygen; blue, nitrogen; yellow, sulfur; and gray, carbon. Ion pair interactions are shown as 
dashed lines (26). 
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Table 3. Residues important for catalytic function of PaADI (28, 29). 
Residues Known/postulated function or comment 
Cys406 Mounts the nucleophilic attack on the carbon atom of the guanidinium 
group of arginine 
His278 Serves as a general base and activate the water molecule 
Glu224 Modulate the ionization state of His278 
Asp280 Interacts with the imidazole group of His405 F via the carboxylate 
group, which in turn interacts with Glu13. Invariant residue in all 
known ADIs 
Asp280, 
Asp166 
Fix the guanidinium group of the arginine substrate tightly by 
interactions with the carboxyl groups 
Arg401, 
Arg185 
Form ionic interaction with The carboxyl group of the arginine 
substrate 
Phe163 Interacts with the hydrophobic part of arginine substrate 
Glu13 Interacts His405 and is invariant in all known ADIs 
His405 Sometimes is replaced by an arginine, as in the case of McADI. This 
may explain the low pH optimum of PaADI (5.6) in contrast to the 
neutral pH optimum of McADI, the enzyme that contains an arginine 
residue instead of His405 
Arg165 Is fixed by electrostatic interactions with the main chain oxygen atoms 
of Thr408 and His405 and with the hydroxyl group of Thr-408 
Arg401 Blocks the ADI active site via the side chain by forming an ion pair 
with the carboxyl group of Asp166 and occupies approximately the 
same position as the guanidinium group of an arginine substrate 
 
The overall fold of MaADI and PaADI consist of five ββαβ modules in cyclical 
arrangement, generating a pseudo 5-fold symmetrical barrel and an additional 
85-residue α-helical domain inserted between the first and the second ββαβ 
modules giving the typical “Clip-on-fan” moiety. The α-helical domain of PaADI 
mediates tetramer formation and the α-helical domain of MaADI was speculated 
to play a role in activating the series of reaction in arginine dehydrolysis pathway 
(4). Structural alignments by Chakrabarty et al. (18) demonstrated the unique 85 
residue 5-α-helical bundle domain exhibiting structural similarity to the 
mammalian CARD (caspase recruitment domains)-containing proteins and this 
CARD-like domain is present only in the PaADI and MaADI but not in the other 
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GMSF members (Figure 3B). Furthermore, PaADI putative CARD-like domain 
induced apoptosis to cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structural characteristics of the PaADI. A. Ribbon drawing of PaADI (1RXX_A) 
highlighting the two domains. B. The presence of the CARD domain in PaADI and MaADI but its 
absence in other members of the GMSF (guanidino-group modifying superfamily) enzymes such 
as DDAH and AGAT, as shown from the structure-based sequence alignments. The CARD 
domain represents that of caspase-9. DDAH, dimethylarginine dimethylaminohydrolase; AGAT, 
arginine: glycine amidinotransferase. The β-strand and α-helices are shown as arrows and strips 
respectively. Roman numericals I to V are the five ββαβ subunits. The clip moiety (α-helical 
module) in Figure 3 is seen only in PaADI and MaADI which bears structural homology to the six-
α-helical modules that form the CARD domain of the caspase-9 protein molecule. N, N-terminal; 
C, C-terminal. C. A schematic diagram showing the overall fold and topology of PaADI, as 
reported (18). 
 
Comparison of substrate free and substrate bound structure of PaADI gives 
interesting insight into structure changes upon substrate binding (17). Pairwise 
superposition of the free wild-type PaADI (PDB code: 1rxx) and the mutant 
enzyme substrate complexes (PDB code: 2a9g) show that the overall fold of the 
structures remains similar, yet with some local changes. In particular, four loops 
(Figure 4) associated with the active site undergo conformational transitions not 
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related to crystal packing: loop 1 (residues 30-46), loop 2 (residues 178-185), 
loop 3 (residues 271-281, part of this loop is disordered in the apoADI structure), 
and loop 4 (residues 393-404). Residues adjacent to the substrate exhibit the 
most significant shifts. For example, the α-carbon atom of Leu41 (loop 1) shifts 
by 2.7Å and that of Arg185 (loop 2) by 1.8 Å; the α-carbon atom of His278 (loop 
3) shifts by 0.9 Å and that of Gly400 (loop 4) by 4.4 Å. These are localized but 
mechanistically important conformational transitions that tighten the surrounding 
of the substrate. Simultaneously, substrate binding is accompanied by 
displacement of the side chain of Arg401 (loop 4) by more than 8 Å to enable 
access to the active site. The superposition of ADI and PAD4 ADI active site is 
shielded from the solvent by a long loop (residues 25-48 in PaADI) and the 
following two turns of α-helix (residues 49-56). 
 
 
 
 
 
Figure 4 (A). Stereoscopic view of ADI in the unbound and bound states. Superposed molecules 
are colored gray where the trace of the polypeptide chain is similar in both structures. For regions 
exhibiting differences, loops of the apoADI structure are highlighted in blue, and loops of the ADI 
structure complexed with arginine are highlighted in red. 4(B). Structural relationship between ADI 
(yellow) and PAD4 (cyan) (17). 
1.3 Catalytic reaction mechanism of ADI 
The overall reaction catalyzed by ADI is the hydrolytic substitution of the ŋNH2 
group from the guanidinium group Cζ of L-arginine, leading to citrulline and 
ammonia (Figure 5). Herzberg (17) and Arnold (4) proposed ADI catalysis 
mechanism for PaADI (Figure 5) and MaADI, respectively.  Basically, both of the 
proposed mechanisms are composed of three main steps: 1) thiol group of 
B A 
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Cys406 mount a nucleophilic attack on the guanidinium group of arginine and a 
proton is transferred first to ŋNH2 group; 2) water molecule is activated by His278 
and followed by attacking the covalent intermediate to replace and release NH3; 
3) the C-S covalent bond between enzyme and the resulting citrulline is cleaved 
and thus end product citrulline is released and free enzyme is generated for next 
catalytic cycle. 
 
 
Figure 5.  Mechanism of PaADI catalysis of arginine to citrulline and ammonia (17). 
1.4 Anti-tumor application of ADI 
Amino acids depletion is one type of targeted therapy for human cancers which 
are auxotrophic for a particular amino acid. Amino acids degrading enzymes, 
such as asparaginase (30), methioninase (31), arginase (32), arginine deiminase 
(27), phenylalanine ammonialyase (33) and tryptophanase (34) have been 
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studied for inhibition of tumor cells in vitro. The most representative anticancer 
enzyme is asparaginase, which is particularly effective in acute lymphoblastic 
leukaemia. PEG asparaginase is commercialized for acute lymphoblastic 
leukaemia treatment (Oncaspar®, pegaspargase) (35). However, asparaginase 
treatment is sometimes accompanied by serous side-effects including 
anaphylactic shock, coagulapathies as well as liver and pancreatic toxicity (36).  
 
Arginine is an important amino acid involved in the synthesis of a wide range of 
peptides and proteins, production of creatine and nitric oxide, and a myriad of 
metabolic pathways and cellular events. It is a precursor of proline, polyamines, 
glutamine, glutamate, and other neurotransmitters, such as g-aminobutyric acid 
and also serves as a substrate for two important enzymes, arginase and nitric 
oxide synthetase (37). Arginine is an indispensable amino acid to children but a 
semi-essential amino acid in adult humans since many adult somatic cells can 
synthesize it from citrulline in two steps via urea cycles (Figure 6). The enzyme 
argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline and 
aspartic acid to argininosuccinate which is then further converted to arginine and 
fumaric acid by argininosuccinate lyase (ASL). Arginine can be degraded to 
ornithine by the urea cycle enzyme arginase. Ornithine is then converted back to 
citrulline by ornithine carbamoyl transferase (OTC) and then recycles back to 
arginine from citrulline by ASS/ASL. Thus, the ability to regenerate arginine from 
citrulline depends on the amount/activity of ASS and ASL, which are tightly 
coupled. The sensitivity of cells to arginine deprivation depends on the ability of 
ASS and ASL to regenerate arginine from the alternative intermediate (ornithine, 
citrulline and argininosuccinate) in the urea cycle. 
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Firgure 6. Urea cycle. Argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline 
and aspartic acid to argininosuccinate which is then further converted to arginine and fumaric acid 
by argininosuccinate lyase (ASL). Arginine can be degraded to ornithine by the urea cycle 
enzyme arginase. Ornithine is then converted back to citrulline by ornithine carbamoyl transferase 
(OTC) and then recycles back to arginine from citrulline by ASS/ASL.  
 
Arginine begins to become limiting at ~10-4 M, whereas other amino acids can 
sustain growth at 10-5-10-6 M. Wheatley et al. showed that most tumour cell lines 
die considerably more quickly during arginine deprivation than in the absence of 
any other single (or group of) essential amino acids (38). Since 1930 for the first 
time arginine known is essential for the growth of some forms of cancer, the 
potential of arginine degrading enzymes as therapeutic agents was recognized, 
investigated and employed for arginine auxotrophic tumor treatments. Enzymes 
capable of depleting arginine in vitro include arginase existing in human liver, 
arginine decarboxylase from bacterial, plant and human, and ADI from 
microorganism. 
 
Arginine decarboxylase converts arginine to agmatine, which is toxic at high 
plasma concentration. Furthermore, arginine decarboxylase has a short half-life 
and it loses virtually all enzymatic activities upon pegylation though pegylation of 
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arginine decarboxylase is inefficient because not enough lysine residues for 
polyethylene glycol to attach (39). 
 
Arginase is limited for anti-tumor application because of its low substrate affinity 
(Km value 2-4 mM; plasma arginine 100-120 µM), short circulatory half-life (10-15 
min) and sub-optimal enzymatic activity at physiological pH (alkaline pH optimum, 
pH 9.3)(40). Despite these disadvantages of arginase, Lam et al. reported  
remission of hepatocellular carcinoma induced by systemic release of 
endogenous hepatic arginase (41) and Leung et al. proved pegylated 
recombinant human arginase (rhArg-peg 5,000mw) can inhibit ASS-positive 
HCCs while ADI can not (42). 
 
In addition, ADI, another arginine-degrading microbial enzyme, has various 
biological activities including anti-proliferation, anti-angiogenesis and inhibition of 
inducible nitric oxide synthase (iNOs). Figure 7 summarizes how ADI affect many 
arginine-related cellular functions. ADIs (Table 1) have been shown to have 
strong in vitro and in vivo inhibition for arginine auxotrophic tumors (e.g. 
hepatocellular carcinomas (HCCs), melanomas, retinoblastoma (43), prostate 
cancer(44)) and ADI from M. hominis (MhADI) is currently under clinical trial for 
HCC (phase II) (45) and melanomas (phase I/II) (46). Studies on human 
lymphatic leukemia cell lines confirmed ADI’s anti-angiogenic activity. Among all 
the ADIs, MhADI and MaADI were studied most intensively (Table 1). 
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Firgure 7. Summary of ADI effects on arginine-related cellular functions. rADI inhibits NO 
production via iNOS, but potentiates NO production via eNOS in the cultured endothelial cell 
model. rADI enhances or inhibits AS activity in different cells. rADI inhibits de novo protein 
synthesis in cells with low AS activity, but not in cells with high AS activity. Polyamine synthesis 
was not significantly affected by rADI, even in cells with low AS activity. Arrow representation: 
solid, potentiates; blocked, inhibits; dotted, no effect (47).  
 
In 1999, US Food and Drug Administration (FDA) designated ADI-PEG-20 
orphan drug status for treating HCC and invasive malignant melanomas. In 2005, 
also the European Agency for the Evaluation of Medicinal Products (EMEA) also 
granted ADI-PEG-20 orphan drug status for HCC. Phase II trials of ADI-PEG-20 
in patients with metastatic hepatocellular carcinomas have shown that the drug is 
safe, well tolerated, and may benefit patients with unresectable HCC. Izzo and 
coworker suspected that combination therapies of arginine deprivation and 
growth inhibition via kinase inhibitors might improve the survival rate further. 
Additionally, ADI enhances radio sensitivity of human mammary adenocarcinoma 
(MCF-7 cells) (48), exerts anti-proliferative as well as anti-angiogenic activities 
and inhibits the growth of viruses such as HIV-1 and hepatitis (49, 50). Current 
research efforts are focused on ADI’s in vivo inhibitory effect towards leukemia, 
melanoma, prostate cancer, renal cell carcinoma, and human umbilical vein 
endothelial cells (HUVEC) (19, 44, 51-53), clinical trials for HCC (phase II) (45) 
and melanoma (phase I/II) (46), and tumor inhibitory mechanisms of ADI (54). 
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The effectiveness of ADIs as anti-tumor agent depends on their enzymatic 
properties (such as Km, kcat, optimum pH, stability at neutral pH), selectivity on 
tumor cells, stability in blood circulation and immunogenicity. Pegylation (35) has 
been effective in reducing their immunogenicity in animal and increase their 
stability to various hydrolytic enzymes in plasma. Directed evolution as powerful 
algorithm to design proteins allows improving all properties that can be reflected 
in a screening system through iterative rounds of diversity generation and 
screening. Small libraries of a few thousand variants are often sufficient to find 
improved variants (55) even without rational understanding of the targeted 
property. The first example of directed ADI evolution by our group (3) provides a 
simple and effective screening system to improve activity of PpADI at 
physiological pH.  
 
1.5 Conclusion 
ADI-based arginine deprivation is a novel and promising targeted approach to the 
treatment arginine auxotrophic tumors, in particular, melanoma, hepatocellular 
carcinoma and leukemia. Certain mesotheliomas and renal cell cancers were 
also proved to be sensitive to ADI therapy. Due to its low incidence of major side 
effects (myelosuppression and gastrointestinal toxicity or other major organ 
toxicity) arginine deprivation treatment should be combined with other anticancer 
treatments to increase the response rate. Reengineering of ADI by protein 
engineering is a promising strayegy to tailor ADI properties for demands in 
medical applications. Solved ADI crystal structure enables to understand 
structure function relationships and to guide protein engineering. 
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Chapter 2 Directed evolution 
Directed evolution 
 
2.1 Introduction to directed evolution 
Enzymes are increasingly being used in the generation of products that are 
traditionally made using chemical synthesis and the field continues to expand its 
horizons, particularly as applied to the synthesis of the fine chemicals and 
pharmaceuticals (56, 57). Naturally occurring enzymes are often not designed for 
the applications of interest, since after all they are evolved in nature for a 
purpose other than being the catalysts of industrial processes. Directed evolution, 
rational design and biodiversity screening and combined approches are the main 
strategies to reengineer enzymes for addressing application demands. Directed 
evolution has emerged as a powerful enabling method for improving enzyme 
properties in iterative cycles of diversity generation and screening (Figure 1).  
 
A main advantage of directed evolution compared to rational design is that it 
does not require structural or mechanistic information for protein optimization. 
Directed protein evolution has been successfully used for altering and improving 
protein properties (solubility, expression, enantioselectivity, stability and activity 
in unusual environment, allosteric interactions, tolerance to pH), as well as for 
regulating other molecules and systems, including RNA, DNA regulatory 
elements, biosynthetic pathways and genetic regulatory circuits (58-60).  
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Figure 1. Procedure of a directed evolution experiment. It involves three key steps: 1) selection a 
good starting sequence and mutating the parent to create a library of variants; 2) identification 
variants with improved function and 3) isolation of gene encoding for improved variant and 
repeating the process until the desired function is achieved. 
 
A parent sequence (or sequences) is chosen based on its perceived proximity to 
the desired function and its evolvability (the ability of a protein to adapt in 
response to mutation and selective pressure). A parent protein for directed 
evolution should exhibit enough of the desired function that small improvements 
can be reliably discerned in a high-throughput screen.  
 
Variants library should be generated with high probability of finding improved 
variants given the screening capacity. With a high-throughput screening method, 
a library can be constructed to generate the large potential improvement. Arnold 
and coworkers(61) showed that very low mutation rates result in many functional 
sequences but only a small number are unique sequences, however very high 
mutation rates produce diverse sequences but few retain function. Schwaneberg 
and coworkers(62) reviewed random mutagenesis methods, focused library 
generation methods and computational tools for high-quality mutant libraries 
generation. Schwaneberg and coworkers (63) also summarized criteria for an 
ideal mutagenesis methods: unbiased mutational spectrum, controllable mutation 
frequency, consecutive nucleotide substitutions or codon-based substitutions, 
enable subset mutagenesis (e.g. introduction mainly positively or negatively 
charged amino acid), independent of gene length, technically simple and 
reproducible, and economical. 
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Screening is used to identify library members improved in the targeted property. 
Identification of improved variants though selection or screening is “analogous” to 
evolutionary pressure in natural evolution (i.e. only the fittest survive). As the 
word “directed” in directed evolution implies, laboratory evolutionary pressure is 
defined and applied by the researcher in screening system. Gradually increasing 
the selection pressure or evolving against a series of intermediate challenges 
often accumulates useful single mutations and yields desired variants (64).  
 
Traditional methods for screening employ microtiter plate formats (96-well, 384-
well, 1,536-well (65) and even 1,000,000-well (66)) or solid phase assay (agar 
plate, filter paper and nitrocellulose membrane), which typically enable the 
screening of no more than 106 variants by using robotic automation (67). 
Sometimes, fast and universal analytic methods like HPLC (68) or GC-MS (69) 
are utilized for performing an efficient screen of a non-natural substrate. However, 
the number of screened mutants is limited to 104-106. In recent years flow 
cytometry systems (67, 70, 71) have become increasingly attractive, especially 
after the development of emulsion technology offering compartmentalization and 
high throughput up to 107/h. In addition, Weitz and coworkers (72) recently 
reported a promising ultrahigh-throughput screening in drop-based microfluidics, 
by which one can screen a library of 108 in about 10 h. Dijkhuizen et al. 
compared in a review (73) six kinds of library screening strategies (Figure 2). 
Selection techniques rely on a direct link between cell growth and improved or 
acquired enzyme function and therefore it is limited to engineering detoxifying 
enzymes (e.g. b-lactamase) or enzymes that synthesize essential nutrients for 
cell growth and survival. The traditional microtiter plate screenings are medium-
throughput and the most simplistic format of screening. It involves the incubation 
of colonies with the substrate of targeted enzyme. The crucial factor with this 
screening technique is that substrate conversion creates a visual signal, such as 
fluorescence or color, to identify colonies expressing an enzyme with desirable 
properties. Microtiter plate based screenings are the most commonly applied 
method in identifying desirable enzyme variants. Microtiter plate based 
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screenings enable the use of various analytical tools and in the mean while they 
offer a great dynamic range. Their screening capacity is usually limited to less 
than 104 variants per day. Screening based on microfluidic device and sorting 
device is a new screening platform for directed evolution, which offers ultra-high-
throughput. It allows the discriminate between wild-type and a less active mutant 
and allows for the addition of substrates and quenchers at desired time thus 
extending the scope of directed evolution screening strategies. Cell as micro-
rector, cell surface display and in vitro compartmentalization technology are also 
FACS (fluorescence-activated cell sorting system) dependent methods for high-
throughput screening and allow 109-1010 screening capacity. 
 
Once improved enzymes are identified, encoding genes are isolated and 
subjected to further iterative cycles of mutation and screening in order to 
accumulate beneficial mutations until the targeted improvement is hopefully 
achieved. The number of iterations required depends on the starting point, the 
protein fold and the selected properties which determine the possible mutational 
load and achievable improvement. 
 
Four accepted requirements for successful directed evolution 
(http://www.che.caltech.edu/groups/fha/) are, 1) the desired function must be 
physically possible; 2) the function must also be biologically, or evolutionarily, 
feasible. In practice, this means that there exists a mutational pathway to get 
from here to there through ever-improving variants (see above). A good 
experiment will maximize the likelihood; 3) Suitable host (E. coli or S. cerevisiae) 
which allows functional expression of more than 106 variants per µg of DNA. 4) A 
rapid screen or selection that reflects the desired function. How rapid the screen 
must be depends on how rare mutations leading to the desired property are and 
how many must be accumulated to achieve the desired result. 
  21 
 
Figure 2. Overview of screening technologies. (A) Experimental steps from obtaining the gene 
library as PCR product to the actual screen. Note that cloning and transformation efficiency are 
often limiting library size; (B) Explanation of symbols; (C) Cell growth/survival selection and agar 
plate screening; (D) Microtiter plate screening; (E) Cell as micro-reactor; (F) Cell surface display; 
(G) Cell-in-droplet; and (H) In vitro compartmentalization (73).  
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2.2 Directed enzyme evolution for pH tolerance of enzymes 
Application of enzymes in processes at a specified pH necessitates protein 
engineering to change their pH performance. Directed evolution and rational 
design method were applied to improve enzyme specific activity at certain pH or 
shift their pH profiles. Some representative success stories of directed protein 
evolution improving pH performance are summarized in Table 1. 
Table 1. Improvement obtained from directed evolution or rational design for pH performance. 
Enzymes Mutagenesis 
methods 
Screening 
methods 
Improvements References 
Human  
β-glucuronidase 
EpPCR and 
saturation 
mutagenesis 
Flow 
cytometry 
60-fold more active (kcat/Km) at pH 7.0 
and were up to an order of magnitude 
more effective at catalyzing the 
conversion of two structurally 
disparate glucuronide prodrugs to 
anticancer agents 
2008 (74) 
Bacterial xylanase DNA shuffling Agar plate 
assay 
About 5-fold improvement of specific 
activity at pH 9.0 
2008 (75) 
Human pancreatic 
lipase 
EpPCR Agar plate 
and microtiter 
plate assay 
1.5-fold of activity improvement at 
acidic pH 
2010 (76) 
Bacterial arginine 
deiminase 
EpPCR and site 
directed 
mutagenesis  
Microtiter 
plate assay 
pH optimum shifted from pH 6.5 to pH 
7; 4-fold of activity improvement at pH 
7.4 
2010 (3) 
Bacterial α-amylase EpPCR Microtiter 
plate assay 
5-fold higher activity at pH 10 than 
wild type 
2003 (77) 
Eukaryote D-
pantonohydrolase 
EpPCR and 
DNA shuffling 
Agar plate 
assay 
10.5-fold higher specific activity and 
retain 85% of its original activity after 
incubation under low pH 
2006 (78) 
Vanadium 
chloroperoxidase 
EpPCR, site 
saturation 
mutagenesis 
and site directed 
mutagenesis 
Microtiter 
plate assay 
About 100-fold improvement of 
specific activity at pH 8 
2006 (79) 
Bacterial class-A non-
specific acid 
phosphatase (PhoN)   
Site directed 
mutagenesis 
 
1.6-fold of activity improvement over 
broder pH range 
2006 (80) 
Aspergillus niger PhyA 
phytase 
Site directed 
mutagenesis 
 
pH shifted from 5.5 to 3.8 (1.7 unit); 
2.66 -fold improvement of activity at 
pH 3.5 than wild type. 
2006 (81) 
Bacillus cereus β-
amylase 
Site directed 
mutagenesis 
 
pH optimum shifted to pH 4.2-4.8 by 
2 pH units. 
2004 (82) 
Phytase Site directed 
mutagenesis 
 
pH optimum shifted by 0.5-1 pH unit; 
a slight increase in maximum specific 
activity 
2002 (83) 
Alcohol 
dehydrogenase 
Site directed 
mutagenesis 
 
pH optimum shifted from 7.8  to 9.0; 
about 2-fold improvement of 
maximum activity at pH 9.0 than that 
of wild type 
1991 (84) 
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Many examples of rational reengineering of an enzyme pH optimum exist (Table 
1). For shifting the pH optimum, a deep understanding of molecular dynamics is 
essential part of understanding enzyme flexibility. Rational design method 
successfully shifted enzyme pH profile. pH dependence of an enzyme is 
determined by the ionization of the catalytic groups, which is affected by various 
interactions involved in their microenvironments. In order to catalyze certain 
reactions, ionizable residues in active site should act as nucleophile or acid/base 
catalyst and they need to maintain proper ionization state for proper activities of 
proteins. The pKa value of the proton donor and the catalytic nucleophilic residue 
are therefore limiting the pH range at which the enzyme can function, and 
therefore pH-dependent activity can be differed by the pKa of the key residues. 
The pKa value of the residue is governed by intrinsic acidity of the functional 
group and other factors (electrostatic interaction from neighboring and the 
heterogeneous dielectric environment in the protein solution system). The 
electrostatic potential generated by the charged titratable residues affects the 
ground state of the protein, such as stability, binding to ligands and pKa values of 
ionizable groups. The electrostatic potential of proteins can be calculated by 
using computational procedures (Delphi, UHBD, CHARMM) and can be 
increased or decreased through mutations. For shifting the pH optimum of 
enzymes, many researchers have tried to substitute catalytic residue by site-
directed mutagenesis (Table 1).  
 
Yoo and coworkers (85) analyzed the relation between the shift of pH optimum 
and change in electrostatic potential due to mutation using Delphi. They identified 
key residues of xylanase responsible for electrostatic potential of catalytic 
residues but not affecting the catalysis directly. The latter hypothesis was proven 
by site directed mutagenesis in a later report. Wyss and coworkers (83) 
summarized strategies for enzyme pH profile modification, 1) replacement of 
ionizable groups that are directly  involved in substrate or product binding and/or 
catalysis by nonionizable ones or by amino acids with different charge or pKa 
values; 2) replacement of residues that are in direct contact with residues 
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mentioned in 1) by forming hydrogen bonds and/or salt bridges; 3) alteration of 
longer-range (indirect) charge-charge interactions by modification of the surface 
charge of the enzyme. 
 
When there is no structure-function relationship information available for an 
enzyme, directed evolution is the best option to tailor the pH performance of 
enzyme for application demands (Table 1). Directed evolution allows improving 
all properties that can be reflected in a screening system through iterative rounds 
of diversity generation and screening. Small libraries of a few thousand variants 
are often sufficient to find improved muteins even without rational understanding 
of the targeted property (76, 86). Using MTP assay, epPCR mutant libraries with 
a ratio of 50 % active and 50 % inactive clones have often been used 
successfully in directed evolution, improving enzyme properties by gradual 
changes (one or two amino acids changes per round of mutagenesis and 
screening). 
 
2.3 Directed enzyme evolution for medical application 
Directed evolution has been very useful for improving enzymes for industrial 
needs. In recent years, there is also growing number of enzymes applied for 
therapeutic purpose. For the development of protein therapeutics, directed 
evolution started to be used to tailor enzyme properties in medical field, for 
example drug delivery (87, 88) and has proven to be a useful tool for generating 
protein variants with enhanced therapeutic potential (88), for example, improving 
the effectiveness of therapeutic enzymes, antibodies, vaccines and viruses. Here, 
the improvements of therapeutic protein for anti-tumor application by directed 
evolution are discussed in more details. 
 
2.3.1 Prodrug enzymes for tumor chemotherapy    
Prodrug cancer chemotherapy has attracted considerable interest due to the 
possibilities it provids to overcome various barriers to drug formulation and 
delivery (such as poor aqueous solubility, chemical instability, insufficient oral 
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adsorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity 
and local irritation) (89). Examples of such drugs currently in use in cancer 
treatment include 5-fluorocytosine, cyclophosphamide, capecitabine, mitomycin 
C, and AQ4N (90). However, the side effects of prodrug therapy remain a serious 
concern which arises from the fact that noncancerous cells also possess the 
capacity to degrade them. This has triggered the interest to generate more 
effective prodrug-activating enzymes so that prodrugs can kill tumor cells at 
concentrations that generate little or no side effects. Further goals are to design 
more powerful and tumor-specific drugs, and to devise more effective methods 
for delivering them specifically to tumors. 
 
By applying directed evolution through the technique of error-prone PCR, Martin 
and coworkers (90) indentified YieF variant exhibiting >5-fold increased capacity 
to kill HeLa cells. Furthermore, YieF variant was proved to be effectively 
delivered to tumor cells using a strain of Salmonella typhimurium (SL 7838). 
 
Human β-glucuronidase, due to low intrinsic immunogenicity in humans, is an 
attractive enzyme for tumor-specific prodrug activation. However its utility is 
limited by low activity at physiological pH. Roffler and coworkers (74) developed 
a high-throughput screening procedure for enzymatic activity based on the stable 
retention of fluorescent reaction product in mammalian cells expressing properly 
folded glycoproteins on their surface. This procedure was utilized to screen error-
prone PCR and saturation mutagenesis libraries to isolate β-glucuronidase 
tetramers that were up to 60-fold more active (kcat/Km) at pH 7.0 and were up to 
one order of magnitude more effective at catalyzing the conversion of two 
structurally disparate glucuronide prodrugs to anticancer agents. 
 
2.3.2 Oncolytic viruses for tumor chemotherapy  
Viral-mediated oncolysis is a novel cancer therapeutic approach with the 
potential to be more effective and less toxic than current therapies due to the 
agents’ selective growth and amplification in tumor cells. To date, these agents 
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have been regarded as highly safe in patients but have generally fallen short of 
their expected therapeutic value as monotherapies.  
 
Consequently, new approaches to generate highly potent oncolytic viruses are 
required. For the latter purpose, Hermiston and coworkers (91) developed a new 
method and termed it also ‘‘Directed Evolution’’ for creating highly potent 
oncolytic viruses. Viral serotypes representing Ad subgroups B-F were pooled 
and passaged twice on sub-confluent cultures of the target tumor cell lines at a 
particle-per-cell ratio of approximately 200 to invite recombination between 
serotypes (Figure 3). Supernatants from the second round of the high viral 
particle-per-cell infection of sub-confluent cultures were then used in a 10-fold 
dilution series to infect confluent T-75 tissue culture flasks of target tumor cell 
lines PC-3, HT-29, Panc-1 and MDA-231. Using this ‘‘Directed Evolution’’ 
methodology, the novel generated chimeric oncolytic virus ColoAd1 
demonstrated ~ 2 log increase in both potency and selectivity when compared to 
ONYX-015 on colon cancer cells. In vivo and ex vivo studies therefore validated 
the innovative general approach for deriving clinically-relevant and potent anti-
cancer virotherapies. 
 
Figure 3. Hermiston’s “Directed Evolution” process of viruses and derivative viral pools (91). 
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2.3.3 Amino acid depriving enzyme for anti-tumor applications 
Naturally available enzymes are usually not optimally suited for therapeutic 
purposes. This incompatibility often relates to the stability or activity of the 
enzymes under body conditions.  
 
Despite many successful efforts to broaden the understanding of the structural 
basis of protein stability, there is still no universal strategy to stabilize protein by a 
limited number of rationally designed mutations. Well-known and reasonably 
successful types of rational engineering work include substitutions that increase 
rigidity (e.g. substitute amino acid Xxx with Pro or substitute Gly with other amino 
acid Xxx or the introduction of disulfides). These substitutions have effects on the 
entropy of the unfolded state, improvement of molecular packing (e.g. shortening 
of loops, improvement of interactions in the hydrophobic core, for example, by 
the removal of internal cavities), modification of surface charge networks or 
reinforcement of a higher oligomerization state.  
 
Directed evolution provides a powerful approach for improving thermostability 
and does not need understanding of structure-function relationship. Most 
strategies for screening for enzyme stability rely on measuring residual enzyme 
activity before and after exposure to a denaturing challenge (e.g. high 
temperature, organic solvents, extreme pH) (92).  
 
Bacterial L-asparaginases have been used as therapeutic agents in the 
treatment of lymphoblastic leukaemia. The main restrictions to the therapeutic 
use of L-asparaginase include its premature inactivation. As a result frequent 
injections are required to maintain therapeutic levels. Repeated injections and 
high dose can cause several types of side reactions from mild allergies and the 
development of immune responses to dangerous anaphylactic shocks (93). 
Enhancing the stability of L-asparaginase by protein engineering improves its 
body-residence time, and thereby minimizes immunosuppressive effects by 
lowering the therapeutic dose. Labrou and coworkers (94) obtained a 
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reengineered L-asparaginase with enhanced thermal stability. Single mutation on 
the surface of the protein resulted in ~10 degree increased Tm value (half-
inactivation temperature). The thermostable variant has to be tested further on 
animals and ⁄ or humans in order to be advanced to a potent therapeutic drug. 
 
Another example of a reengineered amino acid-deprivating enzyme is PpADI. 
PpADI is a promising anti-tumor enzyme however with a non-physiological 
optimal pH and relative high Km value which hindering its medical application. By 
directed evolution and site saturation mutagenesis, PpADI variants with higher 
activity at physiological pH and at low arginine concentration of were obtained 
with improved properties to become a potent anti-tumor drug (see chapter 3 and 
chapter 4). In vitro and in vivo test of the improved variants are required to 
evaluate the anti-tumor effectiveness.  
 
2.3.4 Affibody molecules for cancer prognosis 
Affibody molecules represent a new class of affinity proteins that are based on 
the Z-domain scaffold derived from staphylococcal protein A (95). Among the 
scaffold proteins, Affibody molecules constitute the smallest non-cysteine-
containing protein scaffold. The small size (~ 7 kDa), robust structure, and 
straightforward production procedures (either by recombinant production in 
bacteria or by chemical synthesis) make Affibody molecules attractive targeting 
agents for in vivo radionuclide imaging (96) as well as for various 
biotechnological applications (97, 98). The small size offers a convenient affinity 
maturation principle. Gene synthesis allows randomizing the whole gene to 
generate diverse mutant library. The potential use of radiolabeled Affibody 
molecules for high-contrast radionuclide imaging of biomarkers has been 
demonstrated in preclinical studies and in pilot clinical studies. Affibody 
molecules are non-immunoglobulin-derived affinity proteins based on a three-
helical bundle protein domain.  
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Several of affinity proteins have been investigated for both in vivo diagnostics 
and therapy of tumor in radionuclide molecular imaging. Affinity proteins in tumor-
targeted therapy can affect tumor progression by altering signal transduction or 
by delivering a payload of toxin, drug or radionuclide. EGFR (epidermal growth 
factor receptor), one of the receptor in ErbB family, has been extensively studied 
as biomarkers in tumor targeting and over expressed in various malignancies, 
associated with poor patient prognosis and are therefore interesting targets for 
solid tumors. High affinity and especially slow dissociation rate are important for 
obtaining high contrast images. Affinity in the low nanomolar range is considered 
as a prerequisite for successful use of peptide-based tracers. 
 
Ståhl and coworkers (99) described the affinity maturation procedure for the 
generation of Affibody molecules binding with high affinity and specificity to 
EGFR. The library for affinity maturation was constructed using a single 
oligonucleotide for the rerandomization of desired positions. The new binders 
were selected with phage display technology and the best second-generation 
binders were characterized in vitro using real-time biospecific interaction analysis 
(BIA) for their binding to recombinant EGFR and with flow cytometry for their 
binding to native EGFR. Second-generation binders achieved an approximately 
30-fold improvement in affinity (Kd = 5-10 nM) for the soluble extracellular domain 
of EGFR in biospecific interaction analysis using Biacore. 
 
2.3.5 Interferon for anti-tumor applicaiton 
Alpha interferons (IFN-as) are members of the diverse helical-bundle superfamily 
of cytokine genes, which have potent antiviral and antiproliferative activities and 
therefore can be used as anticancer and antiviral agents. However, doselimiting 
toxicity, receptor cross-reactivity, and short serum half-lives significantly reduce 
the clinical use of many of these cytokines. 
 
Patten and coworkers (100) performed a family shuffling experiment with over 20 
human interferon-α (Hu-IFN-α) genes. Antiviral assay and proliferation assay 
  30 
were used to indentify clones with improved activity on Hu-IFN-α receptor. One 
clone showed 285,000-fold improved activity relative to Hu-IFN-α2a and 185-fold 
relative to Hu-IFN-α1 (most active native human interferon). 
 
Selective breeding using DNA shuffling has proved to be very effective method to 
rapidly improve pharmaceutical proteins by which initially have low levels of the 
desired “activity” (101, 102). Backcrossing of evolved recommbinants with the 
wild type genes removes functionally neutral changes, which might reduce the 
immunogenicity of evolved proteins (103). 
 
2.4 Conclusion 
Proteins, especially enzymes, have gained a central role in modern chemical, 
biotechnological, and biopharmaceutical industries. Directed evolution has over 
the past proved to be a versatile and successful approach for tailoring protein 
properties to industrial, agricultural and medical demands and for advancing our 
understanding of structure-function relationships in biocatalysts. Appropriate 
library generation and screening methods should be employed concerning the 
target protein and desired property. To set up a sophisticated screening method, 
complex conditions in human body (pH, ion concentration, proteases, hormones 
etc.) should be considered. Subsequent in vivo or in vitro test of improved 
variants should be carried out to further validate the screening assay. 
Development of diversity generation and high-throughput screening method will 
enable evolution to solve problems efficiently. Especially, directed evolution 
provides a powerful strategy to rapidly advance the development of improved 
protein-based drugs (enzymes and antibodies, peptide and ligands). Directed 
evolution promises to play an increasingly important role to generate “desirable” 
drugs. 
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Chapter 3 
Chapter 3. Directed evolution of Arginine 
deiminase for increased activity at physiological 
pH 
 
3. 1 Abstract 
Arginine deiminase (ADI; EC 3.5.3.6) has been studied as a potential anti-tumor 
drug for the treatment of arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCCs) and melanomas. Studies with human lymphatic leukemia cell 
lines confirmed that ADI is a potential anti-angiogenic agent effective in the 
treatment of leukemia. ADI from Pseudomonas plecoglossicida (PpADI) was 
cloned and expressed in E.coli. A main limitation of PpADI lies in its pH-
dependent activity profile with a pH optimum at 6.5. A pH shift from 6.5 to 7.5 
results in ~80 % activity drop (pH of human plasma is 7.35 to 7.45). For shifting 
PpADI pH optimum to netrual pH, a directed evolution protocol based on an 
adapted citrulline screening protocol in microtiter plate (MTP) format was 
developed and validated. Proof of concept for ADI engineering resulted in a pH 
optimum of pH 7.0 and increased activity under physiological conditions: at pH 
7.4, variant M2 (K5T, D44E and H404R) is 4-fold more active than the wild type 
PpADI and retains ~30 % of its activity relative to its pH optimum, compared to 
~10 % in the case of the wild type PpADI. 
 
3.2 Introduction 
Arginine deiminase (ADI) is a potential cancer therapy agent for the treatment of 
arginine-auxotrophic tumors (e.g. hepatocellular carcinomas and melanomas). 
The hepatocellular carcinoma (HCC) accounts annually for approximately 1 
million new cases worldwide. In the US the incidence rate (per 100,000 persons; 
1992-2002) of HCC is 8.6 with a mortality rate of 6.5 due to low responses of 
hepatoma to chemotherapeutic treatments (27). Current research efforts are 
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focused on ADI’s in vivo inhibitory effect towards HCCs, leukemia, melanomas 
and human umbilical vein endothelial cells (HUVEC) (104-106), clinical trials for 
HCC (phase III) and melanoma (phase I/II) (105, 107), and PEG formulation of 
ADI to improve its efficacy as a clinical drug, including serum half-life and 
antigenicity (16, 108). ADI inhibited the growth of cultured leukemia cells at 
concentrations of 5-10 ng/ml, which were about 20-100 times lower than those of 
the L-asparaginase standard resulting in fewer side effects (106, 109). Arginine 
deprivation is speculated to be the molecular reason for ADI’s inhibitory effect on 
human lymphatic leukemia (106). ADIs catalyze the first step of the arginine 
deiminase (ADI) pathway by hydrolyzing arginine to citrulline and ammonium. 
Several ADI genes have been identified, purified, and characterized from 
bacteria, archaea and some eukaryotes excluding mammalian cells and 
summarized in a recent review (27). None of these ADIs is from a kinetic point of 
view ideally suited for in vivo applications in humans under physiological 
conditions.  
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. For the proof of concept, an 
ADI isolated from Pseudomonas plecoglossicida CGMCC2039 (accession 
number: ABS70718) which can be functionally expressed in E. coli has been 
employed. Directed evolution approaches employ mainly E. coli as host due to its 
fast growth and high transformation efficiency which is a prerequisite for 
generating complex mutant libraries. Over the last decades, directed protein 
evolution has become a versatile and successful approach for tailoring protein 
properties for industrial demands (mainly in chemical synthesis) and for 
advancing our understanding of structure-function relationships in enzymes. A 
directed evolution experiment comprises iterative cycles of diversity generation 
and functional selection for improved variants. Only a few manuscripts for 
phytases (83), xylanases (110), amylases (77, 82, 111), and an alcohol 
deyhdrogenase (112) reported a shift of pH optima using directed evolution 
algorithms. None of these directed evolution campaigns targeted a medical 
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application and arginine deiminase has to our best knowledge not been altered in 
its pH activity/resistance by directed evolution.  
 
Comparison of PaADI (Pseudomonas aeruginosa, pH optimum 5.6; His405) and 
MaADI (Mycoplasma arginini ADI, pH optimum 6.5, Arg397) led to the 
speculation that substitution of His by Arg might contribute to MaADI’s increased 
pH optimum (17). A sequence alignment of four ADIs (MaADI, MyADI 
(Mycoplasma arthritidis ADI), PaADI and PpADI) shows that for both 
Pseudomonas ADIs the synonymous amino acid positions (404 & 405), contain a 
His whereas both Mycoplasma ADIs contain at corresponding positions an Arg. 
Interestingly, both Mycoplasma ADIs have an pH optimum approximately one pH 
unit higher than both Pseudomonas ADIs. 
 
In this study we report the first directed ADI evolution protocol in which the pH 
profile of PpADI was shifted to higher pH values representing a conceptional 
proof that ADI properties can be tailored for demands in vivo treatment of 
arginine-auxotrophic tumors. An emphasis is given on detailed description of 
directed evolution conditions (mutagenic and screening).   
 
3.3 Materials and methods 
3.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
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plasmid (MEGAWHOP, 20 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
Pseudomonas plecoglossicida CGMCC2039 was provided by Professor Zhihao 
Sun (Jiangnan University, Wuxi, China). 
 
3.3.2 Methods 
3.3.2.1 Reagents used in assays 
Acid-ferric solution 
To dH2O (600 ml), concentrated H3PO4 (70 ml, 85 %) and concentrated H2SO4 
(160 ml, 90-91 %) were added slowly. After cooling to room temperature, 
FeCl3·6H2O (10 ml, 10 g/L) was added in the above solution, finally the total 
volume was adjusted to 1 liter with dH2O. 
 
Diacetyl monoxime -thiosemicarbazide (DAM-TSC) solution 
DAM solution (10 g/L) and TSC solution (0.3 g/L) were prepared separately. The 
two solutions were mixed (volume ratio = 1:1) just prior to use. 
 
3.3.2.2 Cloning of ADI into pET42b(+) 
The arginine deiminase (ADI) gene was amplified from Pseudomonas 
plecoglossicida CGMCC2039 by colony PCR (94°C for 10 min, 1 cycle; 94°C, 30 
s/ 54°C, 30 s/ 72°C, 165 s, 29 cycles; 72°C for 5 min, 1 cycle) using primer (5’-
CCGCATTCCGCTGAAAAACAGAAGTACGG-3’ and 5’-
CTTCTCGAGTTAGTAGTTGATCGGGTCGCGCACG-3’), 1.5 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix and a colony of Pseudomonas 
plecoglossicida CGMCC2039. Amplification product was purified by gel 
extraction, digested using NdeI (20 U) and XhoI (20 U) and purified using 
QIAquick PCR purification kit (QIAGEN, Hilden, Germany). Cloning vector 
pET42b(+) was digested with NdeI (20 U) and XhoI (20 U), and purified by gel 
extraction kit (QIAGEN, Hilden, Germany). Digested ADI gene and pET42b(+) 
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were ligated using T4 DNA ligase (1 U) to give pET42b(+)-ADI and transformed 
into E. coli BL21-Gold (DE3).  
 
3.3.2.3 Site directed mutagenesis of PpADI gene at position H404 
Site directed mutagenesis of ADI gene was performed according to the published 
method (113) on plasmid pET42b(+)-ADI. The following oligonucleotides were 
used for mutagenesis of H404R: 5’-
GGCCGTGGCGGCGGCCGTTGCATGACCTGCCCG-3’ and 5’-
CGGGCAGGTCATGCAACGGCCGCCGCCACGGCC-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 
cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 
s, 1 cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 
cycle), 2 U of PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, 
Finland), 0.20 mM of dNTP mix, 25 pmol of each primer together with 100 ng of 
template (pET42b(+) harboring ADI gene) were used. Following the PCR, DpnI 
(40 U; New England Biolabs) was added, and incubated overnight at 37°C. The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
3.3.2.4 Site sturation mutagenesis of PpADI gene at nine amino acid 
position  
Site saturation mutagenesis of ADI gene was performed according to the 
published method (113) on plasmid pET42b(+)-ADI. The oligonucleotides were 
used for mutagenesis were listed in table 1 (underlining indicated the substituted 
nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 cycle; 95°C, 30 
s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 s, 1 cycle; 95°C, 
30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 cycle), 2 U of 
PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, Finland), 0.20 mM 
of dNTP mix, 25 pmol of each primer together with 100 ng of template (pET42b(+) 
harboring ADI gene) were used. Following the PCR, DpnI (40 U; New England 
Biolabs) was added, and incubated overnight at 37°C. The PCR products were 
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purified by using a QIAquick PCR Purification Kit (Qiagen) and transformed into 
E. coli BL21-Gold (DE3) for expression. 
 
Table 1. Primer sequences for site saturation mutagenesis. 
Primer name Sequences 
Leu 41 FP AACTGCGACGAGCTGNNNTTCGACGATGTGATC   
Leu 41 RP GATCACATCG TCGAANNNCA GCTCGTCGCAGTT 
Asn 360 FP TGGGATGACGGCAACAACNNNGTGGCGCTGGAG 
Asn 360 RP CTCCAGCGCC ACCACNNNGT TGCCGTCATCCCA 
Arg401 FP GAACTGGGCCGGGGCNNNGGCGGCGGCCACTGC   
Arg401 RP GCAGTGGCCGCCGCCNNNGCCCCGGCCCAGTTC 
Phe163 FP CTGCCCAACACCCAGNNNACCCGCGACACCACC    
Phe163 RP GGTGGTGTCGCGGGTNNNCTGGGTGTTGGGCAG 
Asn160 FP CTGCCGCCGCTGCCCNNNACCCAGTTCACCCGC 
Asn160 RP GCGGGTGAACTGGGTNNNGGGCAGCGGCGGCAG 
Arg185 FP ATGTACTGGCCGGCNNNCGCCAGGAAACCCTG 
Arg185 RP CAGGGTTTCCTGGCGNNNGCCGGCCAGTACAT 
Arg243 FP ATCGGCATGGGTGAGNNNACCTCGCGCCAGGCC 
Arg243 RP GGCCTGGCGCGAGGTNNNCTCACCCATGCCGAT 
His405 FP GGCCGTGGCGGCGGCNNNTGCATGACCTGCCCG 
His405 RP CGGGCAGGTCATGCANNNGCCGCCGCCACGGCC 
Gly403 FP GCCGGGGCCGTGGCNNNGGCCACTGCATGACC 
Gly403 RP GGTCATGCAGTGGCCNNNGCCACGGCCCCGGCC 
 
 
3.3.2.5 Construction of PpADI error-prone library 
The library was generated by the standard error-prone PCR (epPCR) using 
improved variant H404R as template. For the mutagenic PCR (95°C for 2 min, 1 
cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C for 3 min, 1 cycle), 2.5 
U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of template (pET42b(+) 
harboring ADI gene H404R), 0.01-0.1 mM of MnCl2 and 10 pmol of each primer 
(5’-TACATATGTCCGCTGAAAAACAGAAG-3’ and 5’- GTGCTCGAGTTAGTAGT 
TGATCGG-3’) were used. The PCR products were purified by using a QIAquick 
PCR Purification Kit. The purified epPCR products were cloned into expression 
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plasmid pET42b(+) by MEGAWHOP(114). For MEGAWHOP (68°C for 5 min, 1 
cycle; 95°C for 5 min, 1 cycle; 95°C, 1 min/ 55°C, 1 min/ 68°C, 13 min 30 s, 24 
cycles; 68°C for 30 min, 1 cycle), 1 U of Taq DNA polymerase, 0.1 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix together with 200 ng of template (pET42b(+) 
harboring ADI gene H404R) were used. Following the PCR, DpnI (40 U; New 
England Biolabs) was added, and incubated (4 h; 37°C). The MEGAWHOP 
products were transformed into E. coli BL21-Gold (DE3) for expression and 
screening. 
 
3.3.2.6 Expression of PpADI in LB media with IPTG induction 
The strain E. coli BL21-Gold (DE3)/ pET42b-PpADI was cultured at 37°C in 20 ml 
of LB media that contained 50 µg/ml kanamycine to an absorbance of 0.6 at 
578nm. Then, isopropyl β-D-thio-galactopyranoside (IPTG) was added to a final 
concentration 0.2 mM. The cells were harvested after 9 h induction with IPTG at 
37°C. The expressed rADI was analyzed by SDS-PAGE.  
 
3.3.2.7 Expression of PpADI in auto-induction media 
A chemically defined auto-induction medium (115) containing salts and trace 
metals, vitamins including vitamin B12, and glucose, glycerol, and lactose were 
test for PpADI expression. Five kinds of auto-induction media LS-5052, P-5052, 
MD-5052, TYM-5052 and TYP-5052 were tested for the ADI expression, under 
the following conditions: 20 ml LB media in 100 ml flask, 37°C, 250 rpm, 20 h. 
The expressed rADI was analyzed by SDS-PAGE. 
 
3.3.2.8 Cultivation and expression of PpADI in 96-well plates 
Colonies grown on LBkan agar plates were transferred, by using toothpicks, into 
96-well microtiter plates (flat bottom, polystyrene plates; Greiner Bio-One GmbH, 
Frickenhausen, Germany), containing non-inducing medium LSG (150 µL) (115) 
supplemented with kanamycin (50 µg/ml). After 16 h of cultivation in a microtiter 
plate shaker (Multitron II, Infors GmbH, Einsbach, Germany; 37°C, 900 rpm, 70 
% humidity), each well was replicated using a replicator (EnzyScreen BV, Leiden, 
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Netherlands) into a second series of 96-well microtiter plates containing 150 µL 
of auto-induction media LS-5052 (115) supplemented with kanamycin (50 µg/ml). 
The first set of plates was stored at -80°C after addition of glycerol. The clones in 
the second set of plates were cultivated for 12 h (Multitron II, Infors GmbH, 37°C, 
900 rpm) and used for screening.  
 
3.3.2.9 Screening Procedure 
96-well plate format citrulline colorimetric screening assay 
A modified protocol of citrulline detection based on carbamido-diacetyl reaction 
(116) (see Figure 1A for assay mechanism) was used for ADI activity 
measurement. Screening for increased activity was carried out by measuring the 
activity at pH 7.4 and 6.4. 20 µl of cell culture was transferred to 96-well 
microtiter plate. Enzyme reaction was initiated by addition of arginine solution 
(100 µl, 100 mM) supplemented with cetyltrimethylammoniumbromide (CTAB, 4 
mM), and incubated (20 min, 37°C). Subsequently, acid-ferric solution (60 µl) and 
diacetyl monoxime (DAM, 20 µl, 0.5 M) were added. The reaction mixture was 
further incubated (15 min, 55°C). Absorbance was measured at 492 nm using a 
microtiter plate reader (Tecan Sunrise, Tecan Group AG, Zurich, Switzerland).  
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking ADI and in a separate experiment 
containing ADI. Apparent standard deviation was based on the absolute 
absorbance values obtained from the ADI wild type plate. The true standard 
deviation was calculated by subtracting the background absorbance value of the 
microtiter plate lacking ADI from the apparent values. 
 
Cuvette format citrulline colorimetric assay 
ADI activity was routinely measured using a modified protocol of the citrulline 
detection with DAM and TSC (117) (see Figure 1A for assay mechanism) in 
Eppendorf tubes. Enzyme reaction was initiated by addition of arginine solution 
(200 µl, 100 mM) to a 2-ml eppendorf tube containing crude cell lysate (50 µl), 
and incubated (20 min, 37°C). Subsequently, acid-ferric solution (250 µl) was 
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added to stop the enzyme reaction. After appropriate dilution with deionized 
water to ensure the concentration of produced citrulline is within linear detection 
range, the reaction mixture (400 µl) was mixed with acid-ferric solution (600 µl) 
and DAM-TSC solution (100 µl). The reaction mixture was further incubated (30 
min, 70°C), followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a Specord 200 (Analytik Jena AG, 
Jena, Germany). 
 
Normalization of protein expression for wild type ADI and variants  
Agilent Protein 230 Kit (Agilent Protein 230 Kit, Agilent Technologies 
Deutschland GmbH, Böblingen, Germany) and Agilent 2100 Bioanalyzer (Agilent 
2100 Bioanalyzer, Agilent Technologies Deutschland GmbH, Böblingen, 
Germany) were used for normalization of protein expression in crude cell extract. 
The protocol used was according to Agilent protein 230 Kit Guide except BSA 
was used as an internal standard. 
 
3.3.2.10 Expression of ADI in shaking flask and purification 
Shaking flasks (1 liter) containing auto induction media LS-5052 (200 ml) 
supplemented with kanamycin (50 µg/ml) were inoculated with a 1:200 dilution of 
overnight culture (E. coli BL21-Gold(DE3) harboring pET42b-ADI) grown in non-
inducing media LSG. After 12 h of expression, E. coli cells were harvested by 
centrifugation (Eppendorf 5810R 4°C, 3220 g, 30 min) and resuspended in 
phosphate buffer (20 ml, NaxPO4, 20 mM, pH 7.0). E. coli cells were 
subsequently lysed by using a high-pressure homogenizer (1500 bar, 2 cycles; 
Avestin Emulsiflex, Mannheim, Germany). The disrupted cells were centrifuged 
(Eppendorf 5417R, 4°C, 13000 g, 20 min) and the supernatant was further 
cleared by filtration through a low protein-binding filter (0.45 µm; Minisart RC 25 
single use syringe filter; Sartorius, Hamburg, Germany). ADI wild type and 
mutants (H404R and K5T D44E H404R) were subsequently purified by a column 
chromatography procedure: (i) The filtered cell lysates were subjected to a 
Super-Q anion exchange column, which had been pre-equilibrated with 50 mM 
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phosphate buffer (NaxPO4, pH 7.0). 20 ml of cell lysate was loaded. ADI were 
eluted by a NaCl step elution in phosphate buffer (NaxPO4, 50 mM,  pH 7.0) at a 
rate of 3 ml/min. (ii) The obtained ADI protein from ion exchange chromatography 
was subjected to a gel filtration column (Matrix: Toyoperl HW-55S, Bed volume: 
33 ml, Bed height: 40 cm, Column: Omnifit). 
 
Purified ADI was subsequently concentrated using a Amicon ultra-4 centrifugal 
filter device (Millipore Corporation, Billerica, U.S.A.) with a 30-kDa cut-off 
membrane. Total protein concentration was determined by BCATM assay kit 
(Pierce, Born, Germany) and homogeneity of the purified sample was controlled 
by SDS-page electrophoresis using standard molecular biology techniques. 
 
3.3.2.11 Characterization of ADI wild type and mutants 
Determination of kcat and Km of ADI wild type and the mutants 
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath. After 10 min preincubation at 37°C, the enzyme reaction was initiated 
by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the substrate solution (200 
µl, 0.2 mM to 10 mM of arginine, 0.5 M phosphate buffer, pH 7.4) in deep well 
plates. The reaction mixture was incubated (37°C) and every two minutes 
reaction mixture (30 µl) of each well was transferred to acid-ferric solution (30 µl) 
to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. Ferric-acid solution (90 µl) and DAM-TSC 
solution (15 µl) were added to each well. The 96-well PCR plate was then 
incubated (70°C, 30 min) in thermal cycler (Eppendorf Mastercyler gradient) for 
color development, followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a microtiter plate reader 
(SPECTROstar Omega, BMG LABTECH, Offenburg, Germany). The initial 
velocity data obtained were fitted to the equation v = Vmax[S]/([S] + Km) (where v 
is the initial velocity, Vmax the maximum velocity, [S] the substrate concentration, 
and Km the Michaelis constant) using GraphPad Prism software (GraphPad 
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software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax 
and enzyme concentration. 
 
Determination of pH profile 
Enzyme reaction was carried out at 37°C in a water bath using the following 
substrate solution: arginine 0.1 M, pH 5-8 phosphate/acetate buffer (0.5 M 
phosphate, 50 mM acetate). After 10 min preincubation at 37°C, the enzyme 
reaction was initiated by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the 
substrate solution (200 µl) in deep well plates. The reaction mixture was 
incubated (37°C, 10 min) and acid-ferric solution (250 µl) was transferred to each 
well to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. The reaction mixture (60 µl), ferric-acid solution 
(90 µl) and DAM-TSC solution (15 µl) were transferred to a 96-well PCR plate. 
The 96-well PCR plate was then incubated (70°C, 30 min) in thermal cycler 
(Eppendorf Mastercyler gradient) for color development, followed by incubation in 
ice water to stop color development. Absorbance was measured at 530 nm using 
a microtiter plate reader (SPECTROstar Omega, Germany). 
 
3.3.2.12 Molecular Modeling 
Two crystal structures of PaADI (PDB codes: 1RXX, 2A9G) were used to model 
the mutations H405R and D44E. Only one monomeric unit of the tetrameric 
PaADI was used for the modeling study employing Swiss-PDB viewer (118) 
(www.expasy.org/spdbv). PaADI variants (H405R; D44E) were generated using 
the mutate command of Swiss-PDB viewer. The side chain rotamer with the best 
score was used for subsequent energy optimized with parameter of GROMOS96 
force field for in vacuum minimization (119).  
 
3.3.2.13 Stability of PpADI in presence of serum  
Purified PpADI (wild type, M1, M2; 20 µl) was incubated (37°C, 60 min) with AB--
human serum (80 ul, Invitrogen, Karlsruhe, Germany) and PBS buffer (pH7.4, 80 
ul), respectively. Subsequently, the incubated ADI-serum/PBS mix (20 µl) was 
  42 
added to microtiter plate containing arginine solution (100 µl, 10 mM arginine in 
PBS buffer, pH 7.4) and incubated (37°C, 30 min). Acid-ferric solution (120 µl) 
was added to stop the enzyme reaction. The produced citrulline was detected 
using the assay procedure employed in “Determination of kcat and Km of ADI 
wild type and the mutants”. Before measuring absorbance at 530 nm, 
centrifugation (Eppendorf, 5810R 4°C, 3000 g, 10 min) was performed to remove 
the precipitation in the assay solution (likely proteins in serum were precipitated 
in acidic condition during assay procedure). Meanwhile, a serum control was test 
for the original citrulline concentration of serum using the same procedure 
mentioned above except that instead of PpADI, elution buffer of gel filtration 
(NaxPO4, 50 mM, pH 7.4) was used. All the absorbance values at 530 nm of 
ADI-serum sample were subtracted the value of serum control to get the citrulline 
concentration produced by PpADI. The residual activities of PpADI after 
incubation in serum compared to that in PBS buffer were calculated to show the 
stability of PpADI after incubated in human serum. 
 
3.3.2.14 Activity of PpADI (wild type, M1, M2) towards arginine derivative 
dimethylarginine 
Purified PpADI (wild type, M1, M2; 15 µl, ~0.2 mg/ml final concentration; >20-fold 
concentration used for kinetic constant determination) was incubated (37°C, 4 h) 
with (NG, NG)-dimethylarginine solution (20 mM, 100 µl). Acid-ferric solution (120 
µl) was added to stop the enzyme reaction. Activity was recorded by citrulline 
detection using citrulline colorimetric assay (see 3.3.2.11 Characterization of ADI 
wild type and mutants). 
 
3.4 Results 
3.4.1 PpADI cloning 
PpADI was cloned into pET42b(+) and expressed in E.coli BL21-Gold(DE3) 
using auto-induction media LS-5052 (see figure 2). The nucleotide sequence of 
PpADI comprises 1,254 bp nucleotide (figure 1) encoding 417 amino acids which 
have 85% identity to ADI from P. aeruginosa (PaADI). The PpADI cloned into 
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pET42b(+) was confirmed by nucleotide sequencing. As indicated in Figure 1, 
sequence analysis of ADI gene showed that there was one synonymous 
mutation at amino acid position D78 (GAT to GAC) compared to ADI-sequence 
of P. plecoglossicida CGMCC2039 deposited in NCBI (accession number: 
EU030267). The deduced ADI protein sequence has a calculated molecular 
weight of 46.5 kDa and shows 85% identity to ADI from P. aeruginosa. This clone 
was used for subsequent directed evolution experiments.  
 
 
Figure 1. DNA electrophoresis of PpADI. 
 
 
Figure 2. PpADI sequencing results. 
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3.4.2 PpADI expression in LB media with IPTG as inducer 
PpADI was successfully expressed in LB media with IPTG as inducer. Figure 3 
(lane 4) shows the expression band of PpADI observed at ~45 kDa, which is 
similar to the calculated molecular weight of 46 kDa (based on 
http://expasy.org/tools/pi_tool.html). 
 
Figure 3. SDS-PAGE of PpADI expression. Lane 1: P. plecoglossicida; Lane 2: E. coli BL21-Gold 
(DE3)/ pET42b; Lane 3: E. coli BL21-Gold (DE3)/ pET42b-PpADI WT, without IPTG; Lane 4: E. 
coli BL21-Gold (DE3)/ pET42b- PpADI WT. 
 
3.4.3 PpADI expression in auto-induction media 
Expressing recombinant protein in auto-induction media is based upon the 
preferences of bacteria to selectively use different carbon sources during diauxic 
growth and upon the often-observed negative regulation of gene expression by 
catabolite repression. Auto-induction is more convenient than IPTG induction 
because the expression strain is simply inoculated into auto-inducing medium 
and grown to saturation without the need to follow culture growth and add 
inducer at the proper time. For high-throughput applications, the auto-induction 
approach has many advantages over traditional induction methods including 
avoidance of the strong induction and apparent toxicity associated with chemical 
inducers such as IPTG.  
Five kinds of auto-induction media LS-5052, P-5052, MD-5052, TYM-5052 and 
TYP-5052 were tested for the ADI expression. Figure 4(A) and 4(B) show ADI 
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activity and corresponding SDS-PAGE band of the PpADI expression in different 
auto-induction media. The expression in auto-induction media LS-5052 is shows 
the highest activity and therefore LS-5052 was used for the following directed 
evolution experiments. 
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Figure 4(A). Activity of PpADI expressed in auto-induction media. 
 
 
 
Figure 4(B). SDS-PAGE of ADI expressed in auto-induction media 1, LS-5052; 2, P-5052; 3, MD-
5052; 4 TYM-5052; 5, TYP-5052. 
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3.4.4 PpADI assay based on citrulline detection 
 
 
Figure 5. Arginine conversion by ADI and detection of citrulline using DAM/TSC assay. 
 
ADI activity was measured by detecting the production of citrulline from arginine, 
according to carbamido diacetyl reaction (colorimetric reaction). The conditions of 
the carbamido diacetyl reaction is as follows： strong acid solution (H3PO4, 
H2SO4), oxidizing agent (Fe3+), diacetyl monoxime (DAM), thiosemicarbazide 
(TSC), and boiling water bath. Figure 5 shows one postulated reaction 
mechanism for the assay which depicts the reaction between citrulline and DAM. 
By the addition of TSC to the reaction system, Coulombe and Favreau(120) 
obtained linearity of response with a more stable pink color which Amax was 
shifted from 490nm to 530nm. 
 
Figure 6 describes the assay procedure for measuring ADI activity in 2 ml 
eppendorf tube. A calibration curve was prepared using citrulline standard 
solution (Figure 7) for determining the citrulline production during the assay. 
 
Figure 6. Citrulline colorimetric assay in cuvette format using DAM/TSC assay. 
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Figure 7. Calibration curve of cuvette format citrulline colorimetric assay. 
 
3.4.5 PpADI screening system for citrulline production in microtiter plates 
Two key performance parameters for identifying improved variants in microtiter 
plate based screening systems are the true standard variation and the linear 
detection range of the employed assay. Standard deviations have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). A modified version of the DAM-TSC assay for citrulline 
detection (Scheme 1) was selected for directed evolution of PpADI. The 
microtiter plate screening format was optimized for simplified handling by 
lowering the color development temperature (55°C instead of 100°C), increasing 
the diacetylmonoxime concentration (~22-fold) and avoiding the use of the 
sensitizer thiosemicarbazide. Figure 8 shows the procedure of screening assay 
of citrulline detection. 
 
Figure 8. Citrulline colorimetric assay in MTP format using DAM assay. 
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Standard deviations of the modified citrulline detection assay have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). The preferred combination (150 µl LS5052 auto-
induction media and 20 µl cell culture, 20 min conversion time and 15 min color 
develop time) resulted in a true standard deviation of 12.8 % after subtracting the 
background (Figure 10). Screening systems with standard deviations around 10 
% have successfully been used in directed evolution experiments (121, 122). A 
wide linear detection window is important for identifying beneficial mutants in 
directed evolution experiments and screening systems for evolved mutants have 
to be constantly adapted for hitting the linear detection window. A linear detection 
range up to 6 mM citrulline could be detected (Figure 9).  
 
 
 
 
 
 
Figure 9. Calibration curve of 96-well microtiter plate format citrulline colorimetric screening assay.  
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Figure 10. Activity values in descending order of the ADI wild-type conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
 
Figure 11. PpADI model derived from PaADI crystal structure (PDB code 2a9gD) by SWISS 
MODEL WORKSPACE.  
 
 
 
 
 
  50 
3.4.6 Focused libraries generated by saturation mutagenesis 
PpADI gene shares 83 % sequence identity  with PaADI of which the crystal 
structure was solved (123). After submitting the ADI sequence to SWISS MODEL 
WORKSPACE, a proposed ADI model based on the PaADI crystal structure 
(PDB code 2a9gD) was obtained (Figure 11). According to this model and 
published literatures, 9 amino acid residues: Leu41, Asn160, Phe163, Arg185, 
Arg243, Asn360, Arg401, His404, Gly 403 (Figure 11) close to the active center 
(catalytic triad: Cys406-His278-Glu224) or known to interact with substrate 
arginine were selected for saturation mutagenesis. 
 
Site saturation mutagenesis at position Leu41, Asn160, Phe163, Arg185, Arg243, 
Asn360, Arg401, His404 and Gly 403 were performed. 300 clones were 
screened for each position. However, no improved variant was identified. 
 
3.4.7 Validation of variant M1 (H404R) citrulline colorimetric assay in 
cuvette format 
Position H404 which was suspected to influence ADI pH profile by substitution to 
R404 (15). Compared to wild type PpADI, variant M1 (H404R) shows higher 
activity (1.8-fold) and improved activity ratio of pH 7.4 to 6.4 (4.7-fold). Therefore, 
M1 (H404R) was selected for directed evolution. 
 
3.4.8 epPCR library generation and screening with citrulline detection 
assay by screening error-prone mutant libraries 
Various concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Figure 12 (A) and 12 (B) 
show the epPCR products and the corresponding MEGAWHOP products. 
Concentration of 0.01 mM MnCl2 which generated 53 % inactive mutant was 
selected for library generation. EpPCR mutant libraries with a ratio of 50 % active 
and 50 % inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). A total of 7 variants (listed in 
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Table 2) were identified from an epPCR library of 2400 mutants and used for 
further characterization. The most active variant was sequenced and two 
additional amino acid substitutions (K5T D44E) were identified. 
 
 
Figure 12 (A). Electrophoresis of epPCR products. Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM 
of MnCl2; Lane 3, 0.05 mM of MnCl2.  
 
 
 
Figure 12 (B). Electrophoresis of MEGAWHOP product with epPCR products as megaprimer. 
Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM of MnCl2; Lane 3, 0.05 mM of MnCl2.  
 
 
 
 
 
 
  52 
 
 
Figure 13. Relative activity of ADI variants towards arginine. The relative activity is the ratio of the 
activity at the pH of each variant relative to the activity at pH 7.4 of wild type ADI. White: ADI wild 
type, grey: M1 (H404R), black: M2 (K5T D44E H404R). 
 
Table 2. Activity of ADI variants towards arginine determined using citrulline colorimetric 
assay in cuvette format. Samples were diluted to ensure that detected citrulline 
concentrations are within the linear detection range of the citrulline colorimetric assay. 
Wild type, mutant M1 and the “best variant” M2 are in bold and prominent expression 
mutants (9-B3-1; 21-D5-1) are italized. 
Normalized [ADI][a] 
Citrulline production 
(mM/mg) 
Relative to activity at pH 7.4 
of WT 
ADI variants pH 7.4 pH 6.4 pH 7.4 pH 6.4 
Activity at pH 
7.4/ activity at 
pH 6.4 
WT 
9.83 
(0.74)[b] 
124.92 
(1.98) 1.00 (0.15) 12.69 (0.01) 0.08 (0.01) 
M1 
(H404R) 
17.80 
(0.49) 
45.95 
(0.87) 1.81 (0.06) 4.67 (0.02) 0.39 (0.02) 
M2 
(K5T D44E 
H404R) 
38.99 
(0.79) 39.20 (0.31) 3.96 (0.02) 3.98 (0.02) 0.99 (0.03) 
9-B3-1 
24.89 
(0.45) 54.50 (1.80) 2.53 (0.03) 5.54 (0.03) 0.46 (0.02) 
21-D5-1 
25.68 
(2.68) 50.95 (2.36) 2.61 (0.07) 5.18 (0.02) 0.50 (0.01) 
15-G10-2 
13.11 
(0.53) 47.02 (0.47) 1.33 (0.09) 4.78 (0.02) 0.28 (0.01) 
2-H4-2 
12.50 
(0.07) 21.58 (0.09) 1.27 (0.06) 2.19 (0.04) 0.58 (0.01) 
1-G11-1 
24.91 
(0.20) 29.12 (0.33) 2.53 (0.03) 2.96 (0.03) 0.85 (0.02) 
24-E10-1 
14.62 
(0.62) 32.82 (0.52) 1.49 (0.08) 3.34 (0.03) 0.45 (0.02) 
[a] (Based on quantification employing Agilent 2100 Bioanalyzer (Agilent Protein 230 Kit)) 
[b] (Standard error of triplicate measurements are given in brackets below each absolute 
and normalized value.) 
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Figure 14. Elution profile of wild type PpADI and improved variants from epPCR library, 
generated with Protein 230 Kit using a mircofluidic device (Agilent Bioanalyzer). BSA was added 
as an internal standard. 
 
3.4.9 Characterization of PpADI variants 
3.4.9.1 Determination of kcat and Km of ADI wild type and the mutants 
Variants selected from epPCR were first characterized using the crude cell 
extract to identify the most promising variants (Table 2). Using an activity ratio of 
pH 7.4 to 6.4 proved to be an effective method to eliminate expression mutants. 
Additionally ADI concentration in crude cell extract was determined using the 
Agilent Protein 230 Kit. Microfluidic elution profiles (Figure 14) semi-quantify 
differences in expression between the wild type PpADI and variants. 
Normalization of activities against the corresponding ADI concentrations reveals 
improvements in specific activities of ADI mutants (Table 2). M1, the starting 
variant for the directed evolution campaign, and M2 were selected for detailed 
characterization studies. M2 has as “best identified variants” (Figure 13) a more 
than 2.5-fold higher activity ratio at pH 7.4 to pH 6.4 than M1 and a 12-fold higher 
activity ratio than wild type in crude cell lysates. 
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For kinetic characterization of ADI variants the citrulline production was 
maintained between 0.2-0.8 mM. Calibration curve in Figure 4 shows the linear 
detection range in the employed 96-well PCR plate format citrulline colorimetric 
assay system. Figure 15 summarizes the kcat and Km values of wild type PpADI, 
identified variants M1 (H404) and M2 (K5T D44E H404R) which were expressed 
in shaking flasks cultures and purified using a two step procedure (anion 
exchange followed by gel filtration). Both variants M1 and M2 show an increase 
in kcat and Km for citrulline production at pH 7.4. Variant M2 shows a 4-fold higher 
kcat as also obtained for specific activity in Table 2 using the crude cell extract, 
validating the characterization procedure with crude cell lysate. Furthermore, an 
increased Km from 0.7 mM (wild type PpADI) to 1.2 mM (M1) and 2.5 mM (M2) 
was found. 
 
 
Figure 15. Kinetic parameters of ADI and mutants for conversion of arginine to citrulline. White: 
ADI wild type, grey: M1 (H404R), black: M2 (K5T D44E H404R). Values reported are the average 
of three measurements, and average deviations from the mean values are shown. Embedded 
calibration curve shows linearity of citrulline colorimetric assay in 96-well PCR plate format which 
was used to determine arginine conversions and kinetic constants.  
 
3.4.9.2 Relative pH profile of wild type and mutant 
The relative pH profile (Figure 16) of wild type PpADI and M1 (H404R) shows an 
identical pH optimum at pH 6.5. Compared to wild type PpADI, variant M2 (K5T 
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D44E H404R) shows a pH optimum at pH 7.0 which is shifted remarkably (0.5 
pH units). Both M1 and M2 show decreased specific activities at pH 6.5, and 
increased specific activity at pH 7.5. At pH 7.0, the specific activity of M2 
exceeds that of wild type PaADI (data not shown). 
 
Figure 16. pH profile of wild type ADI, M1(H404R), M2(K5T/D44E/H404R). The relative activity is 
the ratio of the catalytic activity at the pH relative to the maximum activity of each enzyme. (■) WT, 
(▲) M1 (H404R), (●) M2 (K5T/D44E/H404R). 
 
 
3.4.10 Stability of PpADI in the presence of human serum  
Table 3 summarizes the stability of PpADI variants in serum (37°C, 60 min; 
standard deviation of three measurements in brackets). The mutants M1 and M2 
have a similar stability in serum when compared to the wild-type PpADI wild type.  
The substitution D44E and H404R do not destabilize further the PpADI in serum.  
 
Table 3. Stability of PpADI variants in the presence of human serum. 
 PpADI WT M1 M2 
No incubation (A530) 0.08 0.27 0.98 
Incubation with serum (37°C, 
60 min) (A530) 0.05 0.15 0.69 
Residual activity 60 % 55 % 70 % 
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3.4.11 Activity of PpADI (wild type, M1, M2) towards arginine derivative (NG, 
NG)-dimethylarginine  
No detectable conversion of (NG, NG)-dimethylarginine could be detected with 
PpADI variants.  
 
3.5 Discussion 
ADI properties have to date not been engineered through directed evolution 
algorithms despite their often poor performances under physiological conditions 
and their medical importance as potential anti-tumor drug. Chemically modified of 
ADI (e.g. through PEGylation) (27) and fusion protein (e. g. Human serum 
albumin fusion, HSA) (124) have been used for addressing activity and stability 
demands in vivo. Directed evolution offers opportunities to directly improve ADI 
properties for in vivo applications and small libraries of a few thousand variants 
have often been sufficient to find improved muteins in directed evolution 
experiments (55, 125).  
 
Our main intention in this report is to provide a validated protocol for directed ADI 
evolution and improving the activity at the physiological pH 7.4. Pseudomonas 
plecoglossicida CGMCC2039 (PpADI, 7.8 U/mg; pH optimum 6.5) was selected 
for the directed evolution studies due to its functional expression in E. coli, 
coverage of sequence space in patents and “potential” for activity improvement. 
PpADI is a relatively slow ADI when compared to Mycoplasma ADIs like MhADI 
(Mycoplasma hominus ADI, 35 U/mg) which would have been good alternatives 
for directed evolution studies (105). Reported ADI activities range from 0.115 to 
140.3 IU/mg. One unit is commonly defined as the ADI amount that converts 1 
µmol of L-arginine into 1 µmol of L-citrulline per minute (27).  
 
Screening of PpADI variants yielded three amino acid positions 5, 44 and 404. 
Positions 44 and 404 resulted in a 4-fold higher kcat at pH 7.4 and a significant 
shift in the pH optimum (0.5 units) when compared to wild type PpADI (Figure 17 
& 8). Position 5 did not show any effect on PpADI activity.   
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Figure 17. Structural alignment of mutant M1 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The crystal structure of PaADI which was diffracted in 
absence of the substrate arginine (1RXX) was used to investigate the substitution of His405 to 
Arg405. The Arg405 variant shows with respect the Asp280 a different orientation of the 
guanidinium group when compared to side chain of His405 (in orange).  
 
Galkin and coworkers postulated that the histidine in position 404 (corresponding 
position in “their” PaADI is 405) is a key residue in controlling activity at acidic 
and neutral pH. In protonated state of the imidazolium ring a hydrogen bonding 
interaction can be formed with the oxygen of Asp280 (carboxyl group). This 
hydrogen bond favors stabilizing interactions between Asp280 and the substrate 
arginine. His405 in PaADI was reported (17) to share protons with Asp280 and 
Glu13 and to be important for modulating electrostatic environments of closely 
located catalytic groups. The same report postulated that H405 is likely to be 
protonated when the substrate arginine binds to catalytic triad (His278, Glu224, 
Cys406) (2). Based on these reports the His404 in PpADI was subjected to a site 
directed mutagenesis to Arg404 and named M1. The M1 variant (H404R) shows 
40 % residual activity compared to wild type PpADI at pH 6.4 and a 1.8-fold 
increase in activity at pH 7.4 (see Table 1). In the M1 (H404R) mutant (see the 
model in Figure 17; based PaADI 1RXX; residue His404 in PpADI corresponds to 
His405 in PaADI), the conformational effect due to the extended side chain of 
Arg likely weakens the hydrogen bond to Asp280 and thus reduces the stabilizing 
effect on arginine binding. As a result the activity of M1 is reduced, especially at 
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lower pH values at which His405 is protonated. However at elevated pHs, His405 
becomes increasingly deprotonated whereas Arg405 remains protonated and 
can therefore still stabilize Asp280 for arginine binding. The electrostatic effect 
suggested by theoretical and experimental studies have evidenced the 
importance of positively charged residues to modulate the reaction rate of PaADI 
(126). At pH 6.4, histidine in wild type PpADI and arginine in M1 are both 
positively charged. At pH 7.4, histidine is only partially positive charged and 
PpADI’s activity is reduced (>90 %) while arginine in M1 remains positively 
charged preserving M1’s activity (Figure 17).   
 
 
Figure 18. Structural alignment of mutant M2 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The PaADI crystal structure in presence of substrate arginine 
was used (2A9G) to investigate the role of the substitution Asp44 to Glu44. The latter was solved 
for an inactive variant in which Cys406 was replaced by Ala406. The extended side chain of 
Glu44 might improve the hydrogen bond interaction with the Arg399 inducing a conformational 
shift of loop 1. 
 
The PpADI H404R was used as starting variant for directed evolution. The amino 
acid position 44 was identified from a epPCR library (2400 variants screened) 
resulting in a triple mutant M2 (K5T D44E H404R). For investigating the role of 
each position the double mutants (K5T H404R) and (D44E H404R) were 
generated. Only the double mutant (D44E H404R) revealed improvements in kcat 
(4-fold, pH 7.4; Figure 18). The rationale behind the effects of the mutation D44E 
on the PpADI activity is more complex to extrapolate from the available ADI 
crystal structures. Comparative crystallographic studies have shown that the 
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entrance of the active site is decorated by 4 loops that undergo conformational 
transitions upon arginine binding (17). The loops exhibit significant shifts that limit 
the access of water molecules to the active site. The Asp44 is located in loop 1 
(residues 30-46) and upon binding of the substrate, Asp44 comes closer to the 
positively charged Arg399 located on loop 4 (residues 392 to 403). In the D44E 
mutant, the longer side chain reduces the distance with Arg399 favoring the 
formation of hydrogen bond (see model in Figure 18). The reinforced interaction 
between Glu44 and Arg399 might expedite conformational changes in loops, 
probably confining the arginine substrate in the active site and hence promote 
arginine conversion. In the future, we plan to further investigate the influence of 
H404R and D44E using molecular dynamics simulations, further boost the kcat at 
pH 7.4 and reduce the Km value of PpADI.  
 
Overall site directed mutagenesis of position H404R and one round of directed 
evolution (2400 variants screened) resulted in a triple mutant M2 (K5T D44E 
H404R) with 4-fold higher kcat at pH 7.4 (compared to wild type; Figure 4). The 
best mutant isolated, M2, has specific activity of 31.3 U/mg at pH 7.4 which is 
already after one round of evolution close to the specific activity of MhADI (35 
U/mg) (127) at its pH optimum. The stability and specificity of improved PpADI 
variants are furthermore important for cancer treatment in vivo. First experiments 
in AB-human serum (Invitrogen) showed an unaltered stability of M2 compared to 
the wild type PpADI and (NG, NG)-dimethylarginine conversion could not detect 
with the citrulline colorimetic assay.   
 
3.6 Conclusion 
In summary, a directed evolution protocol has been developed for PpADI and 
validated by increasing the kcat of PpADI at physiological pH (7.4). The reported 
screening system is the first one employed in directed ADI evolution and can 
likely be used for other ADIs and other properties such as temperature stability, 
salt/detergent stability or protease resistance. 
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Chapter 4 
Chapter 4. PpADI reengineered for efficient 
operation under physiological conditions 
 
4.1 Abstract 
The proof of concept for ADI engineering by directed evolution resulted in variant 
M2 (K5T/D44E/H404R). M2 has a pH optimum of pH 7.0 and 4-fold higher kcat 
value than the wild type PpADI (pH 7.4, 0.5 M phosphate buffer) and an 
increased Km value for substrate arginine. In this chapter, in order to improve the 
catalytic efficiency of PpADI at low concentration of arginine, variant M5 
(K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated from an epPCR library: 
at pH 7.4 (PBS buffer), the S0.5 value decreased from 2.01 mM (parent M3, 
K5T/D44E/A128T/H404R) to 1.48 mM (M5) and 0.81 mM (M6). The S0.5 value of 
M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat value 
improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 11.64 
s-1 (M6, 64.7-fold). 
 
4.2 Introduction 
ADI-based arginine depletion is a target specific therapy for arginine-auxotrophic 
tumors (e.g. hepatocellular carcinomas and melanomas) and pegylated ADI is 
currently under clinical trials for HCC with promising results (45). HCC is the third 
leading cause of cancer mortality world wide with a less than 10 % 5-year 
survival rate (EU and USA) (128) due to low responses of hepatoma to 
chemotherapeutic treatments. In 1999, US Food and Drug Administration (FDA) 
designated ADI-PEG-20 orphan drug status for the treatment of HCC and 
invasive malignant melanomas, and in 2005 European Agency for the Evaluation 
of Medicinal Products (EMEA) also granted ADI-PEG-20 orphan drug status for 
the treatment of HCC. Phase II trials of ADI-PEG-20 in patients with metastatic 
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hepatocellular carcinomas have shown that the drug is safe, well tolerated, and 
may benefit patients with unresectable HCC. Izzo and coworker suspected that 
combination therapies of arginine deprivation and growth inhibition via kinase 
inhibitors might improve the survival rate further more. Additionally, ADI can 
enhance radio sensitivity of human mammary adenocarcinoma (MCF-7 cells) 
(48), exerts anti-proliferative and anti-angiogenic activities and inhibits the growth 
of viruses such as HIV-1 and hepatitis (49, 50). Current research efforts are 
focused on ADI’s in vivo inhibitory effect towards leukemia, melanoma, prostate 
cancer, renal cell carcinoma, and human umbilical vein endothelial cells (HUVEC) 
(19, 44, 51-53), clinical trials for HCC (phase II) (45) and melanoma (phase I/II) 
(46), and inhibitory mechanisms of ADI to tumors (54).  
 
Arginine deprivation is believed to be a main molecular reason for ADI’s inhibitory 
effects on arginine auxotrophic tumors which do not express argininosuccinate 
synthetase (ASS). ADIs catalyze the first step of the arginine dehydrolase 
pathway by hydrolyzing arginine to citrulline and ammonium. ADI genes have 
been identified, purified, and characterized from bacteria, archaea and some 
eukaryotes excluding mammalian cells (see review (27)). Enzymatic properties of 
several recombinant ADIs have been examined, such as specific activity, 
functional expression level, temperature optimum, pH optimum, substrate affinity 
for arginine, and half-life in human plasma. Only the ADI from Mycoplasma 
hominis has so far been developed as orphan drug by Pheonix Pharmacologics 
Inc. for HCC and melanoma (129). From enzyme kinetic point of view, none of 
the ADIs is ideally suited for in vivo applications under physiological conditions. 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. PpADI (ADI from 
Pseudomonas plecoglossicida) was functionally expressed in E. coli with a 
simple protocol and has been engineered for the first time by directed evolution 
for improved activity at physiological pH (3). The variant M2 (K5T/D44E/H404R), 
by our group reported, showed a 4-fold higher specific activity than the wild type 
PpADI (0.5 M phosphate buffer, pH 7.4), but a increased Km value (3.5-fold). 
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High activity at low arginine concentration is an important prerequisite for ADI’s 
medical application, allowing low ADI dose required per treatment. 
In the present work, we improved the directed evolution protocol and identified a 
PpADI variant with further improved activity and slightly decreased “Km value” 
and PpADI variant with lowered Km value maintaining its high catalytic activity. 
Those variants were characterized in respect to their kinetic constants. 
 
4.3 Materials and methods 
4.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
plasmid (MEGAWHOP, 25 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
4.3.2 Methods 
4.3.2.1 Site saturation mutagenesis of PpADI M2 at position A128 
Site directed mutagenesis of PpADI M2 (K5T/D44E/H404R) at position A128 was 
performed according to the published method (130). The following 
oligonucleotides were used for mutagenesis of A128: 5’-
CTGATCGGCGGCGTGNNNGGCCAGGACCTGCCG-3’ and 5’- 
CGGCAGGTCCTGGCCNNNCACGCCGCCGATCAG-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 98°C for 30 s, 1 
cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 3 cycles. Second stage: 98°C for 30 
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s, 1 cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 15 cycles; 72°C for 3 min, 1 
cycle), 2 U of PhuS DNA polymerase, 0.20 mM of dNTP mix, 25 pmol of each 
primer together with 100 ng of template (pET42b(+) harboring PpADI M2 gene) 
were used. Following the PCR, DpnI (40 U; New England Biolabs) was added, 
and incubated overnight at 37°C. The PCR products were purified by using a 
QIAquick PCR Purification Kit (Qiagen) and transformed into E. coli BL21-Gold 
(DE3) for expression. 
 
4.3.2.2 Construction of PpADI error-prone library 
EpPCR library was generated by the standard error-prone PCR (epPCR) using 
improved variant M3 (K5T/D44E/A128T/H404R) as template. For the mutagenic 
PCR (95°C for 2 min, 1 cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C 
for 3 min, 1 cycle), 2.5 U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of 
template (pET42b(+) harboring PpADI M3 gene), 0.01-0.1 mM of MnCl2 and 10 
pmol of each primer (5’-TACATATGTCCGCTGAAACACAGAAG-3’ and 5’-
GTGCTCGAGTTAGTAGTTGATCGG-3’) were used. The PCR products were 
purified by using a QIAquick PCR Purification Kit. The purified epPCR products 
were cloned into expression plasmid pET42b(+) by MEGAWHOP (114). For 
MEGAWHOP (72°C for 5 min, 1 cycle; 98°C for 1 min 30 s, 1 cycle; 98°C, 45 s/ 
55°C, 45 s/72°C, 4 min, 24 cycles; 72°C for 10 min, 1 cycle), 1.2 U of PfuS DNA 
polymerase, 0.20 mM of dNTP mix, 500 ng of epPCR products together with 50 
ng of template (pET42b(+) harboring PpADI gene of variant M3) were used. 
Following the PCR, DpnI (40 U; New England Biolabs) was added, and incubated 
(overnight; 37°C). The MEGAWHOP products were transformed into E. coli BL21-
Gold (DE3) for expression and screening. 
 
4.3.2.3 Site directed mutagenesis at position D38 of PpADI M4 
Site directed mutagenesis of PpADI variant M4 at position D38 was performed 
according to the published method on plasmid pET42b(+)-ADI-M4 
(K5T/D44E/A128T/E296K/H404R). The following oligonucleotides were used for 
mutagenesis of D38H: 5’-ACCCCGAGCAACTGCCACGAGCTGCTGTTCGAC-3’ 
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and 5’-GTCGAACAGCAGCTCGTGGCAGTTGCTCGGGGT-3’ (underlining 
indicated the substituted nucleotide). Conditions for mutagenic PCR are as 
described in “Site saturation mutagenesis of PpADI M2 at position A128”.The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.4 Site saturation mutagenesis at position D38 and E296 of PpADI M3 
Site saturation mutagenesis library at position D38 and E296 of PpADI variant M3 
(K5T/D44E/A128T/H404R) were generated according to the published method on 
plasmid pET42b(+)-ADI-M3 using the  following oligonucleotides: D38FP (5’-
ACCCCGAGCAACTGCNNNGAGCTGCTGTTCGAC-3’), D38RP (5’-
GTCGAACAGCAGCTCNNNGCAGTTGCTCGGGGT-3’) and E296FP (5’-
GTCACGGTTTTCCCGNNNGTGGTGCGCGAGATC-3’), E296RP (5’-
GATCTCGCGCACCACNNNCGGGAAAACCGTGAC-3’) (underlining indicated 
the substituted nucleotide). Conditions for mutagenic PCR are as described in 
“Site saturation mutagenesis of PpADI M3 gene at position A128”.The PCR 
products were purified by using a QIAquick PCR Purification Kit (Qiagen) and 
transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.5 Cultivation and expression of PpADI in 96-well plates 
Cultivation and expression in 96-well plates (flat bottom, polystyrene plates; 
Greiner Bio-One GmbH, Frickenhausen, Germany) were performed as previously 
described in 3.3.2.8. 
 
4.3.2.6 Improved screening system in 96-well plate to identify PpADI 
variants with high activities at low arginine concentration 
As describe previously, the modified protocol of citrulline detection based on 
carbamido-diacetyl reaction was used for screening for improved ADI affinity to 
arginine at pH 7.4. 15 µl of cell culture was transferred to 96-well microtiter plate. 
Enzyme reaction was initiated by addition of arginine solution (105 µl, 1mM 
arginine in PBS buffer, pH 7.4) supplemented with 
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cetyltrimethylammoniumbromide (CTAB, 4 mM), and incubated (10 min, 37°C). 
The following color development procedure was carried out as described 
previously (3). 
 
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking PpADI and in a separate experiment 
containing PpADI variant M3. Apparent standard deviation was based on the 
absolute absorbance values obtained from the PpADI variant M3 plate. The true 
standard deviation was calculated by subtracting the background absorbance 
value of the microtiter plate lacking ADI from the apparent values. 
 
4.3.2.7 Expression of PpADI in shaking flask and purification  
Expression of PpADI in shaking flasks and purification (by anion exchange 
chromatography and gel filtration) was performed as previously described in 
3.3.2.10.  
 
4.3.2.8 Characterization of PpADI variants 
Preliminary determination of kinetic constants for site saturation mutagenesis 
variants of position 38 and 296  
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in 
incubator (Heraeus Holding GmbH, Hanau, Germany) using cell crude extract.  2 
ml of expression culture was harvested by centrifugation (Eppendorf 5415R 4°C, 
13,000 g, 10 min) and then freezed (-20°C, overnight). Cell lysate was prepared 
by resuspending the cell pellet in lysozyme (91000 U, 50 mM phosphate buffer, 
pH 7.4, 1.3 ml) followed by incubation (37°C, 40 min) and centrifugation (4°C, 
13,000 g, 10 min). 15 µl of diluted (4 times diluted with 50 mM phosphate buffer, 
pH 7.4) cell lysate was transferred to 96-well microtiter plates. Enzyme reaction 
was initiated by addition of arginine solution (105 µl, 0.25-10 mM arginine in PBS 
buffer, pH 7.4) and incubated (7 min, 37°C). Subsequently, ferric-acid solution 
(120 µl) was added to each well to stop enzyme reaction. 60 µl of terminated 
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enzyme reaction mixture was transferred to 96-well PCR plate for color 
development. Ferric-acid solution (90 µl) and DAM-TSC solution (15 µl) were 
added to each well. The 96-well PCR plate was then incubated (70°C, 30 min) in 
thermal cycler (Eppendorf Mastercyler gradient) for color development, followed 
by incubation in ice water to stop color development. Absorbance was measured 
at 530 nm using a microtiter plate reader (Tecan Sunrise TC reader, Tecan Group 
AG, Zurich, Switzerland). The initial velocity data obtained were fitted to the 
equation v = Vmax[S]/([S] + Km) (where v is the initial velocity, Vmax the maximum 
velocity, [S] the substrate concentration, and Km the Michaelis constant) using 
GraphPad Prism software (GraphPad software, San Diego, CA, USA). The kcat 
was calculated from the ratio of Vmax and enzyme concentration. 
 
Determination of kinetic constants of PpADI wild type and variants M3, M4, M5, 
M6 
The kcat and S0.5 values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath as described previously using purified enzyme (50 µl, 0.1-1.8 µM) to 
and substrate solution (200 µl, 0.5 mM to 10 mM of arginine, PBS buffer, pH 7.4) 
in deep well plates.  
 
The initial velocity data obtained were fitted to the sigmoidal model of kinetics 
equation v = Vmaxn/(S0.5n + Kn) (where v is the initial velocity, Vmax is the maximum 
velocity, K is the substrate concentration, and S0.5 is the ligand concentration 
producing half occupation (131)) using GraphPad Prism software (GraphPad 
software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax and 
enzyme concentration. 
 
4.3.2.9 Native polyacrylamide gel electrophoresis of PpADI variants 
10% of polyacrylamide native gels were used for protein electrophoresis to 
analyze the native form of PpADI variants. Purified protein of PpADI variants (7 µl 
of protein and 3 µl of loading dye) were loaded into each lane of native gel. The 
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molecular marker used in the gel is NativeMarkTM Unstained Protein Standard 
(Invitrogen, Darmstadt, Germany). The electrophoresis was performed with 
tris/glycine buffer (pH 8.3) and electrophoresis chamber was incubated in ice-
water bath. Protein bands were stained with Coomassie brilliant blue solution.  
 
4.3.2.10 Homology modeling 
Homology modeling approach was used for the structure prediction of PpADI. 
The model was built by using the automated structure prediction tool, Protein 
homology/analogy recognition engine (Phyre: http://www.sbg.bio.ic.ac.uk/~phyre/) 
(132). The crystal structure of PaADI (PDB ID: 2A9G) was used as template by 
the server and It has 84.9% sequence identity (http://blast.ncbi.nlm.nih.gov/Blast) 
with PpADI. Procheck program suit (http://www.ebi.ac.uk/thornton-
srv/software/PROCHECK/) (133) was used to assess the stereochemical quality 
of the model. Ramachandran plot which represented that 84.7% residues were 
present in the most favoured region and 14.7% in additional allowed region 
(Figure 3).  Dfire was used to access non bonded atomic interaction in the model 
(http://sparks.informatics.iupui.edu/hzhou/dfire.html/) (134), and Qmean 
(http://swissmodel.expasy.org/qmean/cgi/index.cgi) (135) for the estimation of 
global protein quality. Swiss-PdbViewer (118) was used to create the tetramer 
structure by fitting the monomer model on the 4 units of the 2A9G template. The 
variant M6 (D38H, D44E, A128T, E296K, H404R) were created by using the 
“mutate” tool of the Swiss-PdbViewer and by selecting rotamers with the best 
fitness score. All tetramers were energy minimized in vacuum using GROMOS 
43B1 force field (119).  
 
4.4 Results 
4.4.1 Improved screening system in microtiter plates to identify PpADI 
variants with high activities at low arginine concentration 
Screening assay was based on the validated citrulline colorimetric screening 
protocol in microtiter plate, as reported previously (3). In order to screen for 
variants with high activity at low arginine concentration under physiological 
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condition concerning pH and ion concentrations, 1 mM arginine in PBS buffer 
(pH 7.4) as substrate solution was employed in screening assay and enzyme 
reaction time was controlled accordingly (10 min). The coefficient of variation is 
an important performance criterion of a screening system to determine its 
accuracy. Optimized assay condition with 1 mM arginine (PBS buffer, pH 7.4) as 
substrate resulted in true coefficient of variation of 14.9 % (Figure 1). The 
resulting low absolute absorbance value is a main reason for the high true 
coefficient of variation (14.9 %). In the previous screening system, 100 mM 
arginine in 0.5 M sodium phosphate buffer was used and yielded higher activity 
variants but with higher Km value. 
 
 
 
Figure 1. Activity values in descending order of the PpADI variant M3 conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
4.4.2 Genealogic tree of directed PpADI evolution  
Figure 2 shows the two rounds of PpADI evolution, generation of saturation 
mutagenesis libraries and recombination of beneficial positions to finally obtain 
the PpADI variant M6 with 64.7-fold higher kcat and reduced S0.5 (1.3 mM (WT) to 
0.81 mM (M6). Based on structure-function analysis of PaADI[16], M1 was 
generated by substitute His at position 404 with Arg. Position 404 is through 
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interactions with position Asp280 involved in substrate stabilization during 
catalysis. M1 was subject to the first round of epPCR library, from which M2 was 
identified showing a 4-fold improved kcat value and increased Km value (2.5 mM 
in 0.5 mM sodium phosphate buffer, pH 7.4)[15]. M3 was generated by a site 
saturation mutagenesis library at position 128 which increased in another clone 
the expression level (data not shown). In order to improve PpADI towards 
medical application demands (high activity at low arginine concentration), a 
second epPCR mutant library was constructed using M3 as parent. M4 with 
decreased S0.5 value (0.81 mM) and M5 with increased Kcat value (17.56 s-1) 
were identified after screening of ~1400 clones. In M4 the position E296 was 
identified to be important for lowering S0.5 and in M5 position D38 was identified 
to be important for activity increase. M6 was finally constructed by combining the 
substations at position D38 and E296. Saturation mutagenesis of these two 
positions did not yield any further improved S0.5 or activity variant.  
 
 
Figure 2. Genealogic tree of PpADI variants (M1 to M6) with generated amino acid substitutions. 
Novel substitutions are indicated by an asterisk. 
 
4.4.3 EpPCR library construction and screening for variants with high 
activities at low arginine concentration 
Variant M2 was used as a starting template. As described previously, M2 shifts 
the pH optimum from pH 6.5 to pH 7.0 and has a 4-fold faster kcat than PpADI 
wild type. In one sequenced mutant, position A128 was identified to be 
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responsible for higher expression (data not shown). Site saturation mutagenesis 
on M2 therefore was carried out at position A128. The resulting variant M3 
(K5T/D44E/A128T/H404R) showed a ~2-fold improved expression and was 
subsequently used as parent template for epPCR library. 
 
Three concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Instead of 0.02 mM 
MnCl2, 0.05 mM MnCl2 which generated 46 % of inactive mutant was selected for 
library generation. EpPCR mutant libraries with a ratio of ~50 % active and ~50 
% inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). Two variants M4 and M5 
were identified from this epPCR library (~1400 clones) and further characterized. 
Variant M4 and M5 were sequenced and one additional amino acid substitution 
was identified for each variant, E296K and D38H, respectively. 
 
4.4.4 Site saturation mutagenesis of PpADI at position D38 and E296 
To investigate their role in improving of catalytic performance for arginine, site 
saturation mutagenesis library at position D38 and E296 were generated using 
PpADI M3 as template. For each position, ~300 clones were screened at low 
concentration of arginine (1 mM, PBS buffer, pH 7.4), using 96-well plate format 
citrulline colorimetric screening assay.  
 
After the screening of site saturation mutagenesis libraries of position 38 and 296, 
variants with higher activity were chosen for preliminary kinetic investigation using 
crude cell extract. Beneficial mutants were identified and sequenced from both 
sites (Table 1). At position 38, the following beneficial substitutions were found: 
D38R (three times, AGA, CGG, CGT) and D38K (twice, AAG, AAA). In all cases, 
the negatively charged acidic amino Asp had been replaced by positively charged 
amino acids, Arg or His. Substitution by negatively charged Glu resulted in a 
clone showing a parent M3-like kinetic behavior. Hydrophobic amino acid 
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substitution by Pro resulted inactive clone under assay conditions. At position 296, 
the following substitutions were found to be beneficial: E296K (twice, AAA, AAG), 
E296N (once, AAC), E296T (once, ACC), E296G (once, GGA). Among these 
substitutions, variants with substitution to positively charged residue Lys show 
lowest S0.5 value for arginine while substitution by uncharged amino acids (Asn, 
Thr, Gly) shows relatively marginal improvement compared to E296K. 
Hydrophobic amino acid substitution by Pro and Trp resulted in very low activity 
clones. 
Table 1. Nucleotide and amino acid substitutions at position 38 in PpADI M3. 
 PpADI 
variants Substitution at position 38 km (mM) 
M3 (parent) Asp (GAC) 3.74 ± 0.35 
SSM-D38R Arg (AGA, CGG, CGT) 1.16 ± 0.21 
SSM-D38K Lys (AAG, AAA) 1.01 ± 0.28 
SSM-D38E Glu (GAG) 2.95 ± 0.77 
SSM-D38P Pro (CCA) n. d. 
SSM-D38T Thr (ACC) n. d. 
M5 His (CAC) 1.26 ± 0.12 
Kinetic experiments were performed with crude cell extracts. 
 
 
Table 2. Nucleotide and amino acid substitutions at position 296 in PpADI M3. 
 PpADI 
variants Substitution at position 296 km (mM) 
M3 (parent) Glu (GAA) 3.74 ± 0.35 
SSM-E296K Lys (AAA, AAG) 0.20 ± 0.01 
SSM-E296N Asn (AAC) 0.53 ± 0.04 
SSM-E296T Thr (ACC) 0.61 ± 0.04 
SSM-E296Q Gln (CAA) 0.79 ± 0.06 
SSM-E296G Gly (GGA) 1.29 ± 0.12 
SSM-E296W Trp (TGG) n. d. 
SSM-E296P Pro (CCT) n. d. 
M4 Lys (AAA) 0.27 ± 0.02 
Kinetic experiments were performed with crude cell extracts.  
* n. d. activity not detectable under assay conditions. 
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4.4.5 Determination of kinetic constants (kcat and S0.5) of PpADI wild type 
and variants M3, M4, M5 and M6 
 
Table 3. Kinetic constants of wild type PpADI and variants. 
 Wild type M3 (parent) M4 M5 M6 
kcat (s-1) 0.18 ± 0.05 10.13 ± 0.36 5.88 ± 0.09 17.56 ± 1.15 11.64 ± 0.50 
S0.5 (mM) 1.30 ± 0.25 2.01 ± 0.19 0.81 ± 0.03 1.48 ± 0.17 0.81 ± 0.09 
* Kinetic contants of PpADI wild type is different from our previous report because in stead of 
0.5 M phosphate buffer, PBS buffer was used for kinetic measurements. Kcat value of PpADI 
wild type dropped from 5.6 s-1 to 0.18 s-1 and kcat value of M2 is reduced ~2-fold. 
 
M3, the parent of the second round of PpADI epPCR library, M4 with decreased 
S0.5, M5 with increased kcat and best variant M6 with best combination of kcat 
value and S0.5 were selected for detailed characterization studies.  
 
Kinetic characterization of PpADI variants was performed using PBS buffer (pH 
7.4), which is commonly used in biological research. PBS buffer helps to 
maintain a constant pH and its osmolarity and ion concentrations usually match 
those of the human body. Citrulline production of PpADI variants was maintained 
between 0.2-0.8 mM. Table 3 summarizes the kcat and S0.5 values of parent M3 
(K5T/D44E/A128T/H404R), variants M4 (K5T/D44E/A128T/E296K/H404R), M5 
(K5T/D44E/A128T/D38H/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R), which were expressed in shaking 
flasks cultures and purified using a two step procedure (anion exchange follows 
by gel filtration). Compared to parent M3 (S0.5 = 2.01 mM), both variants M4 and 
M5 have a lower S0.5 for arginine conversion at pH 7.4, 0.81 mM and 1.48 mM, 
respectively. Variant M4 shows a decreased kcat value, 58% of parent M3 while 
M5 shows a 1.7-fold higher kcat compared to parent M3. Variant M6 with 
combined mutations (K5T/D38H/D44E/A128T/E296K/H404R) shows decreased 
S0.5 value, 40 % of parent M3 (K5T/D44E/A128T/H404R), 62 % of PpADI wild 
type, and a 64.7-fold faster kcat value than PpADI wild type. M6 is 42.3-fold faster 
than PpADI wild type with 0.4 mM arginine (PBS buffer, pH 7.4) as substrate. 
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After two rounds of epPCR libraries coupled with site directed mutagenesis, a 
variant M6 with 64.7-fold higher kcat and lower S0.5 value (0.81 mM) than PpADI 
wild type (0.31 mM). At low concentration of arginine, activity of M6 enhanced 
dramatically than M3 and wild type. For example, M6 is 42.3-fold faster than 
PpADI wild type in 0.4 mM arginine (PBS buffer, pH 7.4). 
 
4.4.6 Native polyacrylamide gel electrophoresis of PpADI variants 
Multimeric form of PpADI variants were investigated by native polyacrylamide gel 
electrophoresis. As shown in Figure 3, two distinct protein bands representing 
two multimeric forms tetramer and dimer (molecular weight of a subunit is ~ 46 
kDa) were observed, but with different concentration percentage. The major 
multimeric form of M3 is dimer. Compared to M3, M4 with an additional mutation 
E296K shows a very different pattern: tetramer is the main form; while M5 with 
an additional mutation D38H contains more or less equal amount of dimer and 
tetramer. M6, with both mutations E296K and D38H, contains more tetramer than 
dimer. 
 
 
 
Figure 3. Native polyacrylamide gel electrophoresis of PpADI variants (M3 to M6) with different 
dimer/tetramer distribution. Single subunit has a molecular weight of ~46 kDa. 
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4.5 Discussion 
 
Directed evolution allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
Small libraries of a few thousand variants are often sufficient to find improved 
variants [18] even without rational understanding of the targeted property. After 
establishing a first directed ADI evolution protocol yielding mutant M2, we 
adjusted the screening system to better reflect ADI’s application conditions. 
Prerequisite for ADI to become an effective anti-tumor agent is that low 
concentrations of arginine in human plasma can effectively be converted. 
 
Figure 2 shows the genealogic tree of PpADI evolution and before discussing the 
influence of each substitution individually the effect on kinetics are briefly 
summarized. Amino acid substitution D44E (M2) increases kcat and S0.5, 
substitution A128T (M3) increases the expression level, and substitution E296K 
(M4) decreases kcat and S0.5 and is responsible for tetramer formation. 
Substitution D38H (M5) increase largely kcat and reduces slightly S0.5. The 
combination of all mentioned residues in M6 result in a finally 64.7-fold improved 
PpADI activity and reduced S0.5 (1.30 to 0.81 mM).    
 
PpADI M3 was obtained from site saturation mutagenesis library at position A128 
using M2 as template (Figure 2). M3 shows improved functional expression level 
of ADI (data not shown) and was used as parent for generating an epPCR library. 
Screening of epPCR library yielded two improved variants M4 and M5, carrying 
an additional mutation, E296K (M4) and D38H (M5). M4 has a decreased S0.5 
(0.81 mM) and a decreased kcat value (5.88 s-1; see Table 3). M5 has a 
decreased S0.5 (1.48 mM) and an increased kcat value (17.56 s-1) when compared 
to parent M3 (S0.5, 2.01 mM; kcat, 10.03 s-1; see Table 3). M6 which harbors both 
substitutions (E296K and D38H) has a decreased S0.5 value (0.81 mM) 
compared to the parent M3 (1.30 mM) and the wild type (2.01 mM), and a 64.7-
fold higher kcat value than the PpADI wild type.   
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Despite further enhancing the activity of PpADI, it is crucial for an efficient 
conversion of the substrate arginine in human plasma (100-120 µM arginine) to 
reduce PpADI’s “Km” (S0.5) value. Figure 4 shows the kinetics of PpADI WT, 
parent M3, and the variants M4, M5 and M6. M3 has a significantly higher kcat 
value compared to WT, but its activity at low concentration of arginine (<1.0 mM) 
is very low (S0.5 value 2.01 mM). In contrast, the most efficient variant M6 with a 
decreased S0.5 value (0.81 mM) shows a remarkable activity improvement at low 
concentrations of arginine (<0.5 mM; see Figure 4). M6 has additional two amino 
acid substitutions (D38H and E296K) compared to M3 which increases kcat and 
reduces the S0.5 value. The combination of D38H and E296K improves especially 
the activity of M6 at low arginine concentrations (< 0.5 mM; see Figure 4). 
 
Figure 4. Kinetic curve of PpADI wild type, M3, M5 and M6. (▲) PpADI wild type, (▼) M3, (●) M4, 
(♦) M5 and (■) M6. 
 
 
Figure 5 shows the tetrameric model (based on PaADI, PDB code 2A9G) of 
PpADI WT (Figure 5A) and variant M6 (Figure 5B). Monomeric units are 
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indicated with the letters a, b, c and d. The access channel to the active sites of 
each monomer is highlighted in square and faces an internal cavity generated by 
the assembly of four PpADI monomers. The substitutions D38H (in blue) and 
D44E (in green) are localized at the interface of monomer pair a-b and c-d. The 
substitution of Glu by Asp at position 44 provides a longer side chain in close 
proximity of the also negatively charged residue Asp43 (Figure 6A). The 
substitution E296K is localized at the border of the entrance to the internal cavity 
of the PpADI tetramer. E296K promotes the tetramer formation likely by 
introducing stabilizing interactions with other residues, for example with Thr33 
(hydrogen bond). E296K inverts the charge at this position and its increased 
length of the side chain might promote further interactions to a neighboring 
monomer (Figure 6A). The combination of D44E and E296K results in a 
population consisting of mainly tetramers (see Figure 3; mutein M4). Interestingly 
with the formation of a tetramer (M4) the S0.5 value is reduced which indicates 
that the tetramer complex formation promotes interactions with the substrate 
arginine at low concentrations. The substitution D38H together with the E296K in 
the mutein M6 reestablishes an almost equal population of PpADI dimers and 
tetramers. A hypothesis is that Lys of the E296K has an electrostatic stabilizing 
interaction with the Glu38 in the M4 but not to the neutral His38. 
 
  77 
 
 
Figure 5. A). The model of WT tetramer after energy minimization in vacuum (GROMOS 43B1). 
B). The model of M6 tetramer after energy minimization in vacuum (GROMOS 43B1). Active site 
residues are represented in CRK format in a square (Blue). Mutated residues are shown in 
licorice format in different colors like D38H (blue), D44E (green), A128T (magenta), E296K (red) 
and H404R (violet). Substrate arginine is represented in orange color by licorice format.  
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Figure 6. A). Structure model of variant M6. E296K is involved in intermonomer interaction 
(between chain a (orange) and b (green)) with Thr33. D44E is involved in intermonomer 
interaction, between chain A (orange) and B (green), with Asp43 (violet). B). Structure alignment 
of PpADI WT model and M6 model with four loops (loop 1:30-46, loop 2:178-175, loop 3:271-281 
and loop 4: 393-404) surrounding the entrance of the active site. The substitutions in these loops 
and the residues involved in the interaction with those substitutions are representing: D38H 
(orange), D44E (yellow) and H404R (cyan, in M6; gray, in WT), Ser35 (green), Arg 400 (pink), 
substrate arginine (ochre), catalytic triad His278, Asp280 and Cys406 (violet, highlighted in an 
oval) 
 
Figure 6B shows that the active site of the PaADI is surrounded by four loops 
(loop 1: 30-46, loop 2: 178-185, loop 3: 271-281, and loop 4: 393-404). These 
four loops undergo a conformational transition upon arginine binding and tighten 
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the surrounding of the arginine substrate[16]. D38 is located in loop 1 and faces 
towards the substrate access channel. In PpADI model (Figure 6B), the D38H 
mutation promotes the formation of a hydrogen bond interaction with the 
neighboring residues Ser35, contributing to the stability of the entropically 
unfavorable folded conformation of loop1. The rigidified loop 1 might be 
beneficial for arginine conversion. According to PaADI structure analysis, the 
side chain of gating residue Arg401 (Arg400 in PpADI) is located at the active 
site entrance and fills the substrate-binding site. The structure analysis of the 
C406A PaADI-L-arginine complex[16] shows that the Arg401 side chain (Arg400 
in PpADI) is displaced by the substrate arginine to a position near the active site 
entrance that allows its hydrocarbon chain to assist shielding the catalytic site 
from solvent. D38 is involved in an ionic interaction and hydrogen bonding with 
Arg400. The substitution of Asp to His at position 38 results in a loss of ionic 
interactions to Arg400 due to the different lengths of the side chains. His38 can 
form only a hydrogen bond with active site gating residue Arg400. A weakened 
interaction between position 38 and Arg400 might increase the flexibility of the 
side chain of Arg400 which then might block less efficiently the access of 
arginine to the active site. As a result the variant M5 shows an improved kcat 
value (1.7-fold compared to parent M3) due to the substitution D38H.  
 
For elucidating further the individual role of the five identified amino acid 
substitutions and their influence on the active site geometry and tetramer 
formation crystal structures of variant M4 and M6 have to be solved.  
 
4.6 Conclusion 
In summary, with the modified screening protocol, PpADI variants with improved 
kcat and S0.5 were identified. The increased kcat value and decreased S0.5 value 
result in significant activity improvement of PpADI at low arginine concentrations. 
Especially the kinetic constants of PpADI variant M6 demonstrate that PpADI 
properties can be tailored by directed evolution. The generated PpADI variants 
match from their kinetic behavior therapeutic application demands much better 
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than the wild type PpADI. We therefore hope that by directed evolution improved 
PpADIs will further be investigated in vivo for tumor therapy. 
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Summary and outlook 
Arginine depletion based on ADI is an emerging strategy for anti-tumor treatment. 
ADIs have been studied for the therapy of HCCs and melanomas and were 
approved as an orphan drug for both kinds of tumors. ADI is proved to be 
effective in the treatment of leukemia. The effectiveness of ADIs as anti-tumor 
agent depends on their enzymatic properties (such as Km, kcat, optimum pH, 
stability at neutral pH). Directed evolution, without rational understanding of the 
targeted property, allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
 
In order to improve PpADI activity at physiological pH by directed evolution, a 
colorimetric screening assay based on citrulline detection has been developed in 
96-well microtiter plate format. Single mutation H404R was identified according 
to PpADI homology model (based on PaADI crystal structure), introduced to 
PpADI wild type and eventually resulted in 1.4-fold of increase in kcat. M1 (H404R) 
was used as template for the first round of epPCR library generation. M2 
(K5T/D44E/H404R) obtained from the first round of epPCR library showed 4-fold 
improved kcat value when compared to the PpADI wild type. Furthermore, a shift 
of pH optimum from pH 6.5 to pH 7.0 was observed, combined with an increased 
Km value (2.5 mM) under assay conditions (0.5 M sodium phosphate buffer, pH 
7.4), compared to PpADI wild type (0.7 mM). 
 
Arginine concentration in human plasma is however relatively low (100-120 µM). 
Therefore the second round of epPCR library was performed to decrease Km 
value and further improve kcat value. The validated screening assay was modified 
to reflect more close physiological condition (1 mM arginine in PBS buffer, pH 
7.4). Two important variants with one additional mutation, M4 
(K5T/D44E/A128T/E296K/H404R) with decreased S0.5 vaule, and M5 
(K5T/D38H/D44E/A128T/H404R) with improved kcat were obtained. Their two 
mutations were combined and resulted in variants M6 
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(K5T/D38H/D44E/A128T/E296K/H404R). Under physiological pH in PBS buffer, 
the S0.5 value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); 
the kcat value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-
folds) and 11.64 s-1 (M6, 64.7-fold). 
 
A reamaining challenge facing PpADI’s anti-tumor application is to decrease the 
Km (S0.5) value further close to arginine concentration level in human plasma. A 
more sensitive assay for screening has to be developed with the addition of 
sensitizer like thiosemicarbazide (TSC), optimized temperature and incubation 
time. Improved variants should be tested tested in human plasma or with human 
plasma composition. In vitro testing of ADI variants with arginine auxotrophic 
tumor cell lines is the first step towards in vivo in human. 
 
In summary, directed evolution has been very useful algorithim for improving 
ADI’s kcat and Km at physiological pH (pH 7.4) for its medical application. Hope 
that directed evolution will be become a standard method for therapeutic protein 
like its use in industry.                                
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Abstract 
Abstract 
Arginine deiminase (ADI), an arginine-degrading enzyme, is involved in the first 
step of arginine dihydrolase pathway. It catalyzes the hydrolysis of L-arginine to 
form citrulline and ammonia. ADI has been studied as a potential cancer 
therapeutic agent for the arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCC) and melanomas. Furthermore, studies also indicate that ADI 
is a potential anti-angiogenic agent; therefore it could become a novel anti-cancer 
drug targeting the neovascularization-related tumors. Studies show ADI is more 
potent for the treatment of leukemia than L-asparaginase. However, the anti-
tumor application of ADI for therapeutic purpose faces considerable challenges, 
such as, microbial ADI has low activity at physiological pH (7.35~7.45), short 
circulating half-life (~5 h) and high antigenicity. Pegylation of ADI improved its 
efficacy as a clinical drug, including its half-life in serum and antigenicity. The aim 
of the project is to improve ADI catalytic performance at physiological pH by 
directed evolution. 
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. Directed protein evolution has 
over the last decades become a versatile and successful approach for tailoring 
protein properties to industrial demands and for advancing our understanding of 
structure-function relationships in biocatalysts. Unlike rational design relying on 
the gathering of extensive structure-function relationships of enzymes, directed 
evolution is used to reengineer enzyme properties through iterative rounds of 
diversity generation and function selection for improved variants. 
 
In order to improve the ADI activity at physiological pH, we established a directed 
evolution protocol for this purpose. A microtiter plate (MTP) format colorimetric 
screening assay based on citrulline detection with diacetyl monoxime (DAM) was 
developed. Reaction temperature for color development and DAM concentration 
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were optimized to ensure sufficient sensitivity, appropriate linear range and 
throughput. With the optimized assay and PpADI wild type expressed in E. coli as 
a model protein, true standard deviation 12.8 % was obtained, which is 
appropriate for the library screening. 
 
With the established microtiter plate assay system, for the first time, we 
reengineered ADI for improved activity at physiological pH (pH 7.4) with higher 
potency in medical application. After one site directed mutagenesis and one 
round of epPCR library screening, variant M2 (K5T/D44E/H404R) was obtained. 
M2 shows 4-fold improved kcat value than the PpADI wild type, a shifted pH 
optimum at pH 7.0 (by 0.5 pH unit), and however an increased Km value, 3.6-fold 
under assay conditions (0.5 M sodium phosphate buffer).  
 
Low Km (S0.5) value for ADI is an important factor for efficient consume of arginine 
in plasma because of the low arginine concentration in human plasma (100-120 
µM). Therefore after our proof of concept of reengineering PpADI by directed 
evolution, we aim to decrease the Km value of PpADI towards arginine and 
improve the kcat furthermore thereby improve the efficiency of arginine depletion 
by ADI. The established citrulline colorimetric assay in 96-well microtiter plate is 
improved to reflect application conditions: PBS buffer and 1 mM arginine were 
used in screening system. After the second round of epPCR library and site 
directed mutagenesis, variant M5 (K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated: at pH 7.4 (PBS buffer), 
the S0.5 value decrease from 2.01 mM (parent M3, K5T/D44E/A128T/H404R) to 
1.48 mM (M5) and 0.81 mM (M6). Under physiological pH in PBS buffer, the S0.5 
value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat 
value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 
11.64 s-1 (M6, 64.7-fold). 
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Chapter 1 Arginine deiminase (ADI) 
Arginine deiminase (ADI) 
 
1.1 Arginine deiminase (ADI)  
Arginine deiminase (ADI, EC 3.5.3.6), an arginine-metabolizing hydrolase, 
catalyzes the hydrolysis of L-arginine to form citrulline and ammonia. This 
reaction is the first step in the L-arginine degradation pathway (ADH, scheme 1, 
(1). First, arginine is deiminated by arginine deiminase. The resulting citrulline is 
converted to carbamoyl phosphate and ornithine by ornithine transcarbamylase 
(EC 2.1.3.3), and finally the carbamoyl phosphate is used to phosphorylate ADP 
by carbamate kinase (EC 2.7.2.2), producing one ATP molecule. ADI is absent in 
humans but present in a wide range of bacterial species such as Pseudomonas 
aeruginosa (2), Pseudomonas plecoglossicida (3) and Mycoplasma arginini (4) 
and in parasitic protists such as Giardia intestinalis (5), Trichomonas Vaginalis 
(6), Trichomonas fetus (7), and Hexamita inflate (8). For pathogenic bacteria, ADI 
is required in arginine dehydrolase pathway for virulence and for energy 
production under anaerobic conditions (9, 10).     
 
 
Scheme 1. Arginine dihydrolase pathway. OTC, ornithine transcarbamylase; CK, carbamate 
kinase. 
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The establishment of a high-level production system for ADI is an essential step 
for further research and development of this enzyme. After ADI was discovered 
from Mycoplasma in 1960s (11), various ADI genes have been cloned, 
expressed in E. coli strains, and the enzyme properties were also studied (Table 
1). 
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Table 1. ADI expression, enzymatic properties and medical applications. 
ADIs Origin 
Expression 
host/vector 
Multimeric 
form Km; kcat 
Optimum 
pH  
Specific 
activity 
Medical 
application References 
MhADI 
(SYN1903) 
Mycoplasma 
hominis PG21* 
E.coli BL21 
(DE3)/pET-47b 
Dimer   0.618 U/mg 
(pH 6.5) 
Human 
melanoma 
(G361), 0.036 
U/ml for 50 % 
IC50 
Japan, 
Harasawa, 
2009 (12) 
MhADI Mycoplasma 
hominis (ATCC 
23114) 
- 
 
Dimer   6.0 35.5 U/mg (pH 
6.0) ;  
3.9 U/mg (pH 
7.4)  
Mouse 
melanoma 
(MH134) in 
vitro, 100 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MhADI Mycoplasma 
hominis (ATCC 
14027) 
- Dimer  0.17 mM 
(pH6.6) 
   USA, Fenske, 
1976(14) 
MhADI Mycoplasma 
hominis  
E.coli BL21 
(DE3)/pET25b 
 0.24 mM; 
0.151 s-1 
   China, Luo, 
2007 (15) 
MhADI Mycoplasma 
hominis 
E.coli    20 U/mg ADI 
(37°C). [a] 
ADI-SS 
PEG20000,  
human 
melanoma, 
human HCC 
USA, Pheonix 
Pharmacologi
cs, Inc., Clark, 
2002 (16) 
PaADI 
(PA5171) 
Pseudomonas 
aeruginosa  
(ATCC 47085D) 
E. coli 
BL21(DE3)/pET10
0 
Tetramer 0.14±0.01 
mM (pH 5.6) 
5.6   USA, 
Dunaway-
Mariano, 2005 
(17) 
PaADI Pseudomonas 
aeruginosa  
 
E. coli 
BL21 (DE3)/ 
pET SUMO 
   CARD-like 
domain, no 
catalytic 
activity 
Human cancer 
cell line SKOV-3 
USA, 
Chakrabarty, 
2006 (18) 
PpADI Pseudomonas 
plecoglossicida 
E. coli 
BL21 Gold-(DE3)/ 
pET42b 
 0.7 mM; 5.6 
s-1 (pH 7.4, 
0.5 M sodium 
phosphate 
buffer) 
6.5 31.3 U/mg (pH 
7.4, 0.5 M 
sodium 
phosphate 
buffer) 
 Germany, 
Schwaneberg, 
 2010 (3) 
 4 
MaADI Mycoplasma 
arginini 
(ATCC 23838D) 
E. coli 
DH5α/PTTQ118 
   32.7 U/mg. [a] Human 
umbilical vein 
endothelial 
(HUVE) 
USA, Shen, 
2002 (19) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
E. coli 
JM101/pADTc1 
Dimer     33.6 U/mg 
(37°C, pH 6.5). 
[a] 
Mouse 
hepatoma, 17 
ng/ml for 50 % 
IC50; mouse 
fibrosarcoma, 
15 ng/ml for 50 
% IC50 
Japan, 
Hayashi, 1994 
(20) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
    42 U/mg 
(37°C, pH 6.5); 
29.9 U/mg 
(37°C, pH 7.4) 
Mouse 
melanoma 
(MH134) in 
vitro, 10 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
-     HUVE, 
neuroblastoma, 
retinoblastoma, 
osteosarcoma, 
5~10 ng/ml for 
50 % IC50 
Germany, 
Schweigerer, 
1999 (21) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
- Dimer  0.2 mM 6.0-7.5 50 U/mg Mouse tumor 
carcinoma, 
fibrosarcoma 
and melanoma, 
5~20 ng/ml for 
50 % IC50 
Japan, 
Takaku, 1992 
(22) 
LlADI L. lactis (ATCC 
7962) 
E. coli 
BL21Gold(DE3)/p
GEM-T Easy 
Trimer 8.67 mM 7.2 140.27 U/mg  Korea, Lee, 
2007 (23) 
[a] ADI was expressed in inclusion body and denaturation-renaturation had to be employed to get soluble protein. 
 
  5 
1.2 ADI structure 
In 1970s, Kakimoto et al. (24, 25) diffracted the first ADI crystals from P. putida 
through multiple-step chromatography followed by crystallization. Almost three 
decades later, the X-ray crystal structure of ADI from P. aeruginosa (PaADI, 
Figure 1A) (26) and M. arginini (MaADI, Figure 1B) (4) were solved to assist in 
understanding structure-function relationships. PaADI and MaADI share 27 % 
sequence identity and belong to guanidino group-modifying enzyme superfamily 
(GMSF). The catalytic triad (Cys-His-Glu/Asp) is conserved in members of the 
GMSF. Both crystal structures of PaADI and MaADI show a characteristic 5-fold 
pseudosymmetrical barrel with ββαβ subunits. Table 2 summarizes the crystal 
structures of PaADI and MaADI. 
 
Figure 1. Structural of ADIs from P. aeruginosa and M. arginini. (A) PaADI (PDB ID: 1RXX) and 
stereo view of its catalytic triad (C406-H278-E224). (B) MaADI (PDB ID: 1S9R) and stereo view 
of its catalytic triad (C398-H269-E213) with substrate L-arginine (27). 
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Table 2.  Crystal structures of ADI in protein data bank (PDB). 
PDB 
code 
Ligand in crystal 
structure Description 
Resolution 
(year) 
2A9G Arginine 
Crystal structure of PaADI variant C406A in 
complex with L-arginine  
2.30 Å 
(2005) 
2AAF  
Crystal structure of PaADI variant H278A 
forming a S-alkylthiouronium reaction 
intermediate  
2.30 Å 
(2005) 
2ABR  
Crystal structure of PaADI variant D280A with L-
arginine forming a S-alkylthiouronium reaction 
intermediate  
2.9 Å 
(2005) 
2ACI  Crystal structure of D166A arginine deiminase  
2.50 Å 
(2005) 
1S9R Arginine 
Crystal structure of MaADI covalently linker with 
a reaction in intermediate  
1.60 Å 
(2004) 
1LXY Citrulline 
Crystal Structure of MaADI covalently linked with 
L-citrulline  
2.00 Å 
(2004) 
1RXX  Crystal structure of MaADI  
2.45 Å 
(2004) 
 
MaADI was crystallized as a homodimer and its catalytic triad is formed by 
Cys398-His269-Glu213. MaADI has a catalytic domain and a five-helix bundle 
domain (Figure 3). The buried and compact substrate binding pocket is located 
approximately at the center of the molecule, from which a small solvent channel 
leads to the surface of the enzyme. The opening to the channel is located 
adjacent to the dimer interface region, which is at the opposite side of the 5-fold 
pseudosymmetric moiety of ADI. The shape and size of the channel does not 
permit transport of the substrate (L-arginine and end product (L-citrulline) in and 
out of the pocket. Substantial conformational changes in ADI are required to 
permit entry of the substrate and expulsion of the end product. The occurrence of 
"closed" and "open" form was suspected to be dependent on binding of substrate. 
 
PaADI has a tetrametric structure with 1630 amino acid residues in total, which 
makes it the largest enzyme of its structural superfamily. The catalytic triad of 
PaADI is Cys406-His278-Glu224. Similar to MaADI, the active site of PaADI is 
  7 
located in a narrow crevice formed by a network of charged residues. Ligand 
binding energy is derived from ion pair and hydrogen bonding interactions 
between active site residues and the guanidinium, carboxylate and ammonium 
groups of the substrate. The proposed substrate-binding model shows that the 
catalytic center contains abundant charged residues (e.g. Asp280, His405, Glu13 
and Arg165). The ion pairing interactions between these residues contribute to 
the integrity and activity of ADI. In addition, Asp116, Asp227, Arg185, Arg401, 
His278, Glu118, and Glu224 are part of an extended charged network. The 
proposed catalytic mechanism suggests that the active site of PaADI is blocked 
by Arg401, and therefore a conformational transition is taking place upon the 
substrate binding. Based on the proposed reaction mechanism, Cys406 is as a 
key residue responsible for the nucleophilic attack on the guanidinium carbon 
atom of arginine. PaADI contains only one hydrophobic residue, Phe-163 and a 
Cys-406 with an unknown protonation state. The known functions of important 
residues are shown in Table 3, and the interactions between important residues 
and substrate arginine are shown in Figure 2. 
 
 
Figure 2. A. stereoscopic view of PaADI key active site residues. B. stereoscopic view of a 
modeled arginine substrate (green) docked in the active site of ADI. Atomic colors are red, 
oxygen; blue, nitrogen; yellow, sulfur; and gray, carbon. Ion pair interactions are shown as 
dashed lines (26). 
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Table 3. Residues important for catalytic function of PaADI (28, 29). 
Residues Known/postulated function or comment 
Cys406 Mounts the nucleophilic attack on the carbon atom of the guanidinium 
group of arginine 
His278 Serves as a general base and activate the water molecule 
Glu224 Modulate the ionization state of His278 
Asp280 Interacts with the imidazole group of His405 F via the carboxylate 
group, which in turn interacts with Glu13. Invariant residue in all 
known ADIs 
Asp280, 
Asp166 
Fix the guanidinium group of the arginine substrate tightly by 
interactions with the carboxyl groups 
Arg401, 
Arg185 
Form ionic interaction with The carboxyl group of the arginine 
substrate 
Phe163 Interacts with the hydrophobic part of arginine substrate 
Glu13 Interacts His405 and is invariant in all known ADIs 
His405 Sometimes is replaced by an arginine, as in the case of McADI. This 
may explain the low pH optimum of PaADI (5.6) in contrast to the 
neutral pH optimum of McADI, the enzyme that contains an arginine 
residue instead of His405 
Arg165 Is fixed by electrostatic interactions with the main chain oxygen atoms 
of Thr408 and His405 and with the hydroxyl group of Thr-408 
Arg401 Blocks the ADI active site via the side chain by forming an ion pair 
with the carboxyl group of Asp166 and occupies approximately the 
same position as the guanidinium group of an arginine substrate 
 
The overall fold of MaADI and PaADI consist of five ββαβ modules in cyclical 
arrangement, generating a pseudo 5-fold symmetrical barrel and an additional 
85-residue α-helical domain inserted between the first and the second ββαβ 
modules giving the typical “Clip-on-fan” moiety. The α-helical domain of PaADI 
mediates tetramer formation and the α-helical domain of MaADI was speculated 
to play a role in activating the series of reaction in arginine dehydrolysis pathway 
(4). Structural alignments by Chakrabarty et al. (18) demonstrated the unique 85 
residue 5-α-helical bundle domain exhibiting structural similarity to the 
mammalian CARD (caspase recruitment domains)-containing proteins and this 
CARD-like domain is present only in the PaADI and MaADI but not in the other 
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GMSF members (Figure 3B). Furthermore, PaADI putative CARD-like domain 
induced apoptosis to cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structural characteristics of the PaADI. A. Ribbon drawing of PaADI (1RXX_A) 
highlighting the two domains. B. The presence of the CARD domain in PaADI and MaADI but its 
absence in other members of the GMSF (guanidino-group modifying superfamily) enzymes such 
as DDAH and AGAT, as shown from the structure-based sequence alignments. The CARD 
domain represents that of caspase-9. DDAH, dimethylarginine dimethylaminohydrolase; AGAT, 
arginine: glycine amidinotransferase. The β-strand and α-helices are shown as arrows and strips 
respectively. Roman numericals I to V are the five ββαβ subunits. The clip moiety (α-helical 
module) in Figure 3 is seen only in PaADI and MaADI which bears structural homology to the six-
α-helical modules that form the CARD domain of the caspase-9 protein molecule. N, N-terminal; 
C, C-terminal. C. A schematic diagram showing the overall fold and topology of PaADI, as 
reported (18). 
 
Comparison of substrate free and substrate bound structure of PaADI gives 
interesting insight into structure changes upon substrate binding (17). Pairwise 
superposition of the free wild-type PaADI (PDB code: 1rxx) and the mutant 
enzyme substrate complexes (PDB code: 2a9g) show that the overall fold of the 
structures remains similar, yet with some local changes. In particular, four loops 
(Figure 4) associated with the active site undergo conformational transitions not 
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related to crystal packing: loop 1 (residues 30-46), loop 2 (residues 178-185), 
loop 3 (residues 271-281, part of this loop is disordered in the apoADI structure), 
and loop 4 (residues 393-404). Residues adjacent to the substrate exhibit the 
most significant shifts. For example, the α-carbon atom of Leu41 (loop 1) shifts 
by 2.7Å and that of Arg185 (loop 2) by 1.8 Å; the α-carbon atom of His278 (loop 
3) shifts by 0.9 Å and that of Gly400 (loop 4) by 4.4 Å. These are localized but 
mechanistically important conformational transitions that tighten the surrounding 
of the substrate. Simultaneously, substrate binding is accompanied by 
displacement of the side chain of Arg401 (loop 4) by more than 8 Å to enable 
access to the active site. The superposition of ADI and PAD4 ADI active site is 
shielded from the solvent by a long loop (residues 25-48 in PaADI) and the 
following two turns of α-helix (residues 49-56). 
 
 
 
 
 
Figure 4 (A). Stereoscopic view of ADI in the unbound and bound states. Superposed molecules 
are colored gray where the trace of the polypeptide chain is similar in both structures. For regions 
exhibiting differences, loops of the apoADI structure are highlighted in blue, and loops of the ADI 
structure complexed with arginine are highlighted in red. 4(B). Structural relationship between ADI 
(yellow) and PAD4 (cyan) (17). 
1.3 Catalytic reaction mechanism of ADI 
The overall reaction catalyzed by ADI is the hydrolytic substitution of the ŋNH2 
group from the guanidinium group Cζ of L-arginine, leading to citrulline and 
ammonia (Figure 5). Herzberg (17) and Arnold (4) proposed ADI catalysis 
mechanism for PaADI (Figure 5) and MaADI, respectively.  Basically, both of the 
proposed mechanisms are composed of three main steps: 1) thiol group of 
B A 
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Cys406 mount a nucleophilic attack on the guanidinium group of arginine and a 
proton is transferred first to ŋNH2 group; 2) water molecule is activated by His278 
and followed by attacking the covalent intermediate to replace and release NH3; 
3) the C-S covalent bond between enzyme and the resulting citrulline is cleaved 
and thus end product citrulline is released and free enzyme is generated for next 
catalytic cycle. 
 
 
Figure 5.  Mechanism of PaADI catalysis of arginine to citrulline and ammonia (17). 
1.4 Anti-tumor application of ADI 
Amino acids depletion is one type of targeted therapy for human cancers which 
are auxotrophic for a particular amino acid. Amino acids degrading enzymes, 
such as asparaginase (30), methioninase (31), arginase (32), arginine deiminase 
(27), phenylalanine ammonialyase (33) and tryptophanase (34) have been 
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studied for inhibition of tumor cells in vitro. The most representative anticancer 
enzyme is asparaginase, which is particularly effective in acute lymphoblastic 
leukaemia. PEG asparaginase is commercialized for acute lymphoblastic 
leukaemia treatment (Oncaspar®, pegaspargase) (35). However, asparaginase 
treatment is sometimes accompanied by serous side-effects including 
anaphylactic shock, coagulapathies as well as liver and pancreatic toxicity (36).  
 
Arginine is an important amino acid involved in the synthesis of a wide range of 
peptides and proteins, production of creatine and nitric oxide, and a myriad of 
metabolic pathways and cellular events. It is a precursor of proline, polyamines, 
glutamine, glutamate, and other neurotransmitters, such as g-aminobutyric acid 
and also serves as a substrate for two important enzymes, arginase and nitric 
oxide synthetase (37). Arginine is an indispensable amino acid to children but a 
semi-essential amino acid in adult humans since many adult somatic cells can 
synthesize it from citrulline in two steps via urea cycles (Figure 6). The enzyme 
argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline and 
aspartic acid to argininosuccinate which is then further converted to arginine and 
fumaric acid by argininosuccinate lyase (ASL). Arginine can be degraded to 
ornithine by the urea cycle enzyme arginase. Ornithine is then converted back to 
citrulline by ornithine carbamoyl transferase (OTC) and then recycles back to 
arginine from citrulline by ASS/ASL. Thus, the ability to regenerate arginine from 
citrulline depends on the amount/activity of ASS and ASL, which are tightly 
coupled. The sensitivity of cells to arginine deprivation depends on the ability of 
ASS and ASL to regenerate arginine from the alternative intermediate (ornithine, 
citrulline and argininosuccinate) in the urea cycle. 
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Firgure 6. Urea cycle. Argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline 
and aspartic acid to argininosuccinate which is then further converted to arginine and fumaric acid 
by argininosuccinate lyase (ASL). Arginine can be degraded to ornithine by the urea cycle 
enzyme arginase. Ornithine is then converted back to citrulline by ornithine carbamoyl transferase 
(OTC) and then recycles back to arginine from citrulline by ASS/ASL.  
 
Arginine begins to become limiting at ~10-4 M, whereas other amino acids can 
sustain growth at 10-5-10-6 M. Wheatley et al. showed that most tumour cell lines 
die considerably more quickly during arginine deprivation than in the absence of 
any other single (or group of) essential amino acids (38). Since 1930 for the first 
time arginine known is essential for the growth of some forms of cancer, the 
potential of arginine degrading enzymes as therapeutic agents was recognized, 
investigated and employed for arginine auxotrophic tumor treatments. Enzymes 
capable of depleting arginine in vitro include arginase existing in human liver, 
arginine decarboxylase from bacterial, plant and human, and ADI from 
microorganism. 
 
Arginine decarboxylase converts arginine to agmatine, which is toxic at high 
plasma concentration. Furthermore, arginine decarboxylase has a short half-life 
and it loses virtually all enzymatic activities upon pegylation though pegylation of 
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arginine decarboxylase is inefficient because not enough lysine residues for 
polyethylene glycol to attach (39). 
 
Arginase is limited for anti-tumor application because of its low substrate affinity 
(Km value 2-4 mM; plasma arginine 100-120 µM), short circulatory half-life (10-15 
min) and sub-optimal enzymatic activity at physiological pH (alkaline pH optimum, 
pH 9.3)(40). Despite these disadvantages of arginase, Lam et al. reported  
remission of hepatocellular carcinoma induced by systemic release of 
endogenous hepatic arginase (41) and Leung et al. proved pegylated 
recombinant human arginase (rhArg-peg 5,000mw) can inhibit ASS-positive 
HCCs while ADI can not (42). 
 
In addition, ADI, another arginine-degrading microbial enzyme, has various 
biological activities including anti-proliferation, anti-angiogenesis and inhibition of 
inducible nitric oxide synthase (iNOs). Figure 7 summarizes how ADI affect many 
arginine-related cellular functions. ADIs (Table 1) have been shown to have 
strong in vitro and in vivo inhibition for arginine auxotrophic tumors (e.g. 
hepatocellular carcinomas (HCCs), melanomas, retinoblastoma (43), prostate 
cancer(44)) and ADI from M. hominis (MhADI) is currently under clinical trial for 
HCC (phase II) (45) and melanomas (phase I/II) (46). Studies on human 
lymphatic leukemia cell lines confirmed ADI’s anti-angiogenic activity. Among all 
the ADIs, MhADI and MaADI were studied most intensively (Table 1). 
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Firgure 7. Summary of ADI effects on arginine-related cellular functions. rADI inhibits NO 
production via iNOS, but potentiates NO production via eNOS in the cultured endothelial cell 
model. rADI enhances or inhibits AS activity in different cells. rADI inhibits de novo protein 
synthesis in cells with low AS activity, but not in cells with high AS activity. Polyamine synthesis 
was not significantly affected by rADI, even in cells with low AS activity. Arrow representation: 
solid, potentiates; blocked, inhibits; dotted, no effect (47).  
 
In 1999, US Food and Drug Administration (FDA) designated ADI-PEG-20 
orphan drug status for treating HCC and invasive malignant melanomas. In 2005, 
also the European Agency for the Evaluation of Medicinal Products (EMEA) also 
granted ADI-PEG-20 orphan drug status for HCC. Phase II trials of ADI-PEG-20 
in patients with metastatic hepatocellular carcinomas have shown that the drug is 
safe, well tolerated, and may benefit patients with unresectable HCC. Izzo and 
coworker suspected that combination therapies of arginine deprivation and 
growth inhibition via kinase inhibitors might improve the survival rate further. 
Additionally, ADI enhances radio sensitivity of human mammary adenocarcinoma 
(MCF-7 cells) (48), exerts anti-proliferative as well as anti-angiogenic activities 
and inhibits the growth of viruses such as HIV-1 and hepatitis (49, 50). Current 
research efforts are focused on ADI’s in vivo inhibitory effect towards leukemia, 
melanoma, prostate cancer, renal cell carcinoma, and human umbilical vein 
endothelial cells (HUVEC) (19, 44, 51-53), clinical trials for HCC (phase II) (45) 
and melanoma (phase I/II) (46), and tumor inhibitory mechanisms of ADI (54). 
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The effectiveness of ADIs as anti-tumor agent depends on their enzymatic 
properties (such as Km, kcat, optimum pH, stability at neutral pH), selectivity on 
tumor cells, stability in blood circulation and immunogenicity. Pegylation (35) has 
been effective in reducing their immunogenicity in animal and increase their 
stability to various hydrolytic enzymes in plasma. Directed evolution as powerful 
algorithm to design proteins allows improving all properties that can be reflected 
in a screening system through iterative rounds of diversity generation and 
screening. Small libraries of a few thousand variants are often sufficient to find 
improved variants (55) even without rational understanding of the targeted 
property. The first example of directed ADI evolution by our group (3) provides a 
simple and effective screening system to improve activity of PpADI at 
physiological pH.  
 
1.5 Conclusion 
ADI-based arginine deprivation is a novel and promising targeted approach to the 
treatment arginine auxotrophic tumors, in particular, melanoma, hepatocellular 
carcinoma and leukemia. Certain mesotheliomas and renal cell cancers were 
also proved to be sensitive to ADI therapy. Due to its low incidence of major side 
effects (myelosuppression and gastrointestinal toxicity or other major organ 
toxicity) arginine deprivation treatment should be combined with other anticancer 
treatments to increase the response rate. Reengineering of ADI by protein 
engineering is a promising strayegy to tailor ADI properties for demands in 
medical applications. Solved ADI crystal structure enables to understand 
structure function relationships and to guide protein engineering. 
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Chapter 2 Directed evolution 
Directed evolution 
 
2.1 Introduction to directed evolution 
Enzymes are increasingly being used in the generation of products that are 
traditionally made using chemical synthesis and the field continues to expand its 
horizons, particularly as applied to the synthesis of the fine chemicals and 
pharmaceuticals (56, 57). Naturally occurring enzymes are often not designed for 
the applications of interest, since after all they are evolved in nature for a 
purpose other than being the catalysts of industrial processes. Directed evolution, 
rational design and biodiversity screening and combined approches are the main 
strategies to reengineer enzymes for addressing application demands. Directed 
evolution has emerged as a powerful enabling method for improving enzyme 
properties in iterative cycles of diversity generation and screening (Figure 1).  
 
A main advantage of directed evolution compared to rational design is that it 
does not require structural or mechanistic information for protein optimization. 
Directed protein evolution has been successfully used for altering and improving 
protein properties (solubility, expression, enantioselectivity, stability and activity 
in unusual environment, allosteric interactions, tolerance to pH), as well as for 
regulating other molecules and systems, including RNA, DNA regulatory 
elements, biosynthetic pathways and genetic regulatory circuits (58-60).  
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Figure 1. Procedure of a directed evolution experiment. It involves three key steps: 1) selection a 
good starting sequence and mutating the parent to create a library of variants; 2) identification 
variants with improved function and 3) isolation of gene encoding for improved variant and 
repeating the process until the desired function is achieved. 
 
A parent sequence (or sequences) is chosen based on its perceived proximity to 
the desired function and its evolvability (the ability of a protein to adapt in 
response to mutation and selective pressure). A parent protein for directed 
evolution should exhibit enough of the desired function that small improvements 
can be reliably discerned in a high-throughput screen.  
 
Variants library should be generated with high probability of finding improved 
variants given the screening capacity. With a high-throughput screening method, 
a library can be constructed to generate the large potential improvement. Arnold 
and coworkers(61) showed that very low mutation rates result in many functional 
sequences but only a small number are unique sequences, however very high 
mutation rates produce diverse sequences but few retain function. Schwaneberg 
and coworkers(62) reviewed random mutagenesis methods, focused library 
generation methods and computational tools for high-quality mutant libraries 
generation. Schwaneberg and coworkers (63) also summarized criteria for an 
ideal mutagenesis methods: unbiased mutational spectrum, controllable mutation 
frequency, consecutive nucleotide substitutions or codon-based substitutions, 
enable subset mutagenesis (e.g. introduction mainly positively or negatively 
charged amino acid), independent of gene length, technically simple and 
reproducible, and economical. 
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Screening is used to identify library members improved in the targeted property. 
Identification of improved variants though selection or screening is “analogous” to 
evolutionary pressure in natural evolution (i.e. only the fittest survive). As the 
word “directed” in directed evolution implies, laboratory evolutionary pressure is 
defined and applied by the researcher in screening system. Gradually increasing 
the selection pressure or evolving against a series of intermediate challenges 
often accumulates useful single mutations and yields desired variants (64).  
 
Traditional methods for screening employ microtiter plate formats (96-well, 384-
well, 1,536-well (65) and even 1,000,000-well (66)) or solid phase assay (agar 
plate, filter paper and nitrocellulose membrane), which typically enable the 
screening of no more than 106 variants by using robotic automation (67). 
Sometimes, fast and universal analytic methods like HPLC (68) or GC-MS (69) 
are utilized for performing an efficient screen of a non-natural substrate. However, 
the number of screened mutants is limited to 104-106. In recent years flow 
cytometry systems (67, 70, 71) have become increasingly attractive, especially 
after the development of emulsion technology offering compartmentalization and 
high throughput up to 107/h. In addition, Weitz and coworkers (72) recently 
reported a promising ultrahigh-throughput screening in drop-based microfluidics, 
by which one can screen a library of 108 in about 10 h. Dijkhuizen et al. 
compared in a review (73) six kinds of library screening strategies (Figure 2). 
Selection techniques rely on a direct link between cell growth and improved or 
acquired enzyme function and therefore it is limited to engineering detoxifying 
enzymes (e.g. b-lactamase) or enzymes that synthesize essential nutrients for 
cell growth and survival. The traditional microtiter plate screenings are medium-
throughput and the most simplistic format of screening. It involves the incubation 
of colonies with the substrate of targeted enzyme. The crucial factor with this 
screening technique is that substrate conversion creates a visual signal, such as 
fluorescence or color, to identify colonies expressing an enzyme with desirable 
properties. Microtiter plate based screenings are the most commonly applied 
method in identifying desirable enzyme variants. Microtiter plate based 
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screenings enable the use of various analytical tools and in the mean while they 
offer a great dynamic range. Their screening capacity is usually limited to less 
than 104 variants per day. Screening based on microfluidic device and sorting 
device is a new screening platform for directed evolution, which offers ultra-high-
throughput. It allows the discriminate between wild-type and a less active mutant 
and allows for the addition of substrates and quenchers at desired time thus 
extending the scope of directed evolution screening strategies. Cell as micro-
rector, cell surface display and in vitro compartmentalization technology are also 
FACS (fluorescence-activated cell sorting system) dependent methods for high-
throughput screening and allow 109-1010 screening capacity. 
 
Once improved enzymes are identified, encoding genes are isolated and 
subjected to further iterative cycles of mutation and screening in order to 
accumulate beneficial mutations until the targeted improvement is hopefully 
achieved. The number of iterations required depends on the starting point, the 
protein fold and the selected properties which determine the possible mutational 
load and achievable improvement. 
 
Four accepted requirements for successful directed evolution 
(http://www.che.caltech.edu/groups/fha/) are, 1) the desired function must be 
physically possible; 2) the function must also be biologically, or evolutionarily, 
feasible. In practice, this means that there exists a mutational pathway to get 
from here to there through ever-improving variants (see above). A good 
experiment will maximize the likelihood; 3) Suitable host (E. coli or S. cerevisiae) 
which allows functional expression of more than 106 variants per µg of DNA. 4) A 
rapid screen or selection that reflects the desired function. How rapid the screen 
must be depends on how rare mutations leading to the desired property are and 
how many must be accumulated to achieve the desired result. 
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Figure 2. Overview of screening technologies. (A) Experimental steps from obtaining the gene 
library as PCR product to the actual screen. Note that cloning and transformation efficiency are 
often limiting library size; (B) Explanation of symbols; (C) Cell growth/survival selection and agar 
plate screening; (D) Microtiter plate screening; (E) Cell as micro-reactor; (F) Cell surface display; 
(G) Cell-in-droplet; and (H) In vitro compartmentalization (73).  
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2.2 Directed enzyme evolution for pH tolerance of enzymes 
Application of enzymes in processes at a specified pH necessitates protein 
engineering to change their pH performance. Directed evolution and rational 
design method were applied to improve enzyme specific activity at certain pH or 
shift their pH profiles. Some representative success stories of directed protein 
evolution improving pH performance are summarized in Table 1. 
Table 1. Improvement obtained from directed evolution or rational design for pH performance. 
Enzymes Mutagenesis 
methods 
Screening 
methods 
Improvements References 
Human  
β-glucuronidase 
EpPCR and 
saturation 
mutagenesis 
Flow 
cytometry 
60-fold more active (kcat/Km) at pH 7.0 
and were up to an order of magnitude 
more effective at catalyzing the 
conversion of two structurally 
disparate glucuronide prodrugs to 
anticancer agents 
2008 (74) 
Bacterial xylanase DNA shuffling Agar plate 
assay 
About 5-fold improvement of specific 
activity at pH 9.0 
2008 (75) 
Human pancreatic 
lipase 
EpPCR Agar plate 
and microtiter 
plate assay 
1.5-fold of activity improvement at 
acidic pH 
2010 (76) 
Bacterial arginine 
deiminase 
EpPCR and site 
directed 
mutagenesis  
Microtiter 
plate assay 
pH optimum shifted from pH 6.5 to pH 
7; 4-fold of activity improvement at pH 
7.4 
2010 (3) 
Bacterial α-amylase EpPCR Microtiter 
plate assay 
5-fold higher activity at pH 10 than 
wild type 
2003 (77) 
Eukaryote D-
pantonohydrolase 
EpPCR and 
DNA shuffling 
Agar plate 
assay 
10.5-fold higher specific activity and 
retain 85% of its original activity after 
incubation under low pH 
2006 (78) 
Vanadium 
chloroperoxidase 
EpPCR, site 
saturation 
mutagenesis 
and site directed 
mutagenesis 
Microtiter 
plate assay 
About 100-fold improvement of 
specific activity at pH 8 
2006 (79) 
Bacterial class-A non-
specific acid 
phosphatase (PhoN)   
Site directed 
mutagenesis 
 
1.6-fold of activity improvement over 
broder pH range 
2006 (80) 
Aspergillus niger PhyA 
phytase 
Site directed 
mutagenesis 
 
pH shifted from 5.5 to 3.8 (1.7 unit); 
2.66 -fold improvement of activity at 
pH 3.5 than wild type. 
2006 (81) 
Bacillus cereus β-
amylase 
Site directed 
mutagenesis 
 
pH optimum shifted to pH 4.2-4.8 by 
2 pH units. 
2004 (82) 
Phytase Site directed 
mutagenesis 
 
pH optimum shifted by 0.5-1 pH unit; 
a slight increase in maximum specific 
activity 
2002 (83) 
Alcohol 
dehydrogenase 
Site directed 
mutagenesis 
 
pH optimum shifted from 7.8  to 9.0; 
about 2-fold improvement of 
maximum activity at pH 9.0 than that 
of wild type 
1991 (84) 
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Many examples of rational reengineering of an enzyme pH optimum exist (Table 
1). For shifting the pH optimum, a deep understanding of molecular dynamics is 
essential part of understanding enzyme flexibility. Rational design method 
successfully shifted enzyme pH profile. pH dependence of an enzyme is 
determined by the ionization of the catalytic groups, which is affected by various 
interactions involved in their microenvironments. In order to catalyze certain 
reactions, ionizable residues in active site should act as nucleophile or acid/base 
catalyst and they need to maintain proper ionization state for proper activities of 
proteins. The pKa value of the proton donor and the catalytic nucleophilic residue 
are therefore limiting the pH range at which the enzyme can function, and 
therefore pH-dependent activity can be differed by the pKa of the key residues. 
The pKa value of the residue is governed by intrinsic acidity of the functional 
group and other factors (electrostatic interaction from neighboring and the 
heterogeneous dielectric environment in the protein solution system). The 
electrostatic potential generated by the charged titratable residues affects the 
ground state of the protein, such as stability, binding to ligands and pKa values of 
ionizable groups. The electrostatic potential of proteins can be calculated by 
using computational procedures (Delphi, UHBD, CHARMM) and can be 
increased or decreased through mutations. For shifting the pH optimum of 
enzymes, many researchers have tried to substitute catalytic residue by site-
directed mutagenesis (Table 1).  
 
Yoo and coworkers (85) analyzed the relation between the shift of pH optimum 
and change in electrostatic potential due to mutation using Delphi. They identified 
key residues of xylanase responsible for electrostatic potential of catalytic 
residues but not affecting the catalysis directly. The latter hypothesis was proven 
by site directed mutagenesis in a later report. Wyss and coworkers (83) 
summarized strategies for enzyme pH profile modification, 1) replacement of 
ionizable groups that are directly  involved in substrate or product binding and/or 
catalysis by nonionizable ones or by amino acids with different charge or pKa 
values; 2) replacement of residues that are in direct contact with residues 
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mentioned in 1) by forming hydrogen bonds and/or salt bridges; 3) alteration of 
longer-range (indirect) charge-charge interactions by modification of the surface 
charge of the enzyme. 
 
When there is no structure-function relationship information available for an 
enzyme, directed evolution is the best option to tailor the pH performance of 
enzyme for application demands (Table 1). Directed evolution allows improving 
all properties that can be reflected in a screening system through iterative rounds 
of diversity generation and screening. Small libraries of a few thousand variants 
are often sufficient to find improved muteins even without rational understanding 
of the targeted property (76, 86). Using MTP assay, epPCR mutant libraries with 
a ratio of 50 % active and 50 % inactive clones have often been used 
successfully in directed evolution, improving enzyme properties by gradual 
changes (one or two amino acids changes per round of mutagenesis and 
screening). 
 
2.3 Directed enzyme evolution for medical application 
Directed evolution has been very useful for improving enzymes for industrial 
needs. In recent years, there is also growing number of enzymes applied for 
therapeutic purpose. For the development of protein therapeutics, directed 
evolution started to be used to tailor enzyme properties in medical field, for 
example drug delivery (87, 88) and has proven to be a useful tool for generating 
protein variants with enhanced therapeutic potential (88), for example, improving 
the effectiveness of therapeutic enzymes, antibodies, vaccines and viruses. Here, 
the improvements of therapeutic protein for anti-tumor application by directed 
evolution are discussed in more details. 
 
2.3.1 Prodrug enzymes for tumor chemotherapy    
Prodrug cancer chemotherapy has attracted considerable interest due to the 
possibilities it provids to overcome various barriers to drug formulation and 
delivery (such as poor aqueous solubility, chemical instability, insufficient oral 
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adsorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity 
and local irritation) (89). Examples of such drugs currently in use in cancer 
treatment include 5-fluorocytosine, cyclophosphamide, capecitabine, mitomycin 
C, and AQ4N (90). However, the side effects of prodrug therapy remain a serious 
concern which arises from the fact that noncancerous cells also possess the 
capacity to degrade them. This has triggered the interest to generate more 
effective prodrug-activating enzymes so that prodrugs can kill tumor cells at 
concentrations that generate little or no side effects. Further goals are to design 
more powerful and tumor-specific drugs, and to devise more effective methods 
for delivering them specifically to tumors. 
 
By applying directed evolution through the technique of error-prone PCR, Martin 
and coworkers (90) indentified YieF variant exhibiting >5-fold increased capacity 
to kill HeLa cells. Furthermore, YieF variant was proved to be effectively 
delivered to tumor cells using a strain of Salmonella typhimurium (SL 7838). 
 
Human β-glucuronidase, due to low intrinsic immunogenicity in humans, is an 
attractive enzyme for tumor-specific prodrug activation. However its utility is 
limited by low activity at physiological pH. Roffler and coworkers (74) developed 
a high-throughput screening procedure for enzymatic activity based on the stable 
retention of fluorescent reaction product in mammalian cells expressing properly 
folded glycoproteins on their surface. This procedure was utilized to screen error-
prone PCR and saturation mutagenesis libraries to isolate β-glucuronidase 
tetramers that were up to 60-fold more active (kcat/Km) at pH 7.0 and were up to 
one order of magnitude more effective at catalyzing the conversion of two 
structurally disparate glucuronide prodrugs to anticancer agents. 
 
2.3.2 Oncolytic viruses for tumor chemotherapy  
Viral-mediated oncolysis is a novel cancer therapeutic approach with the 
potential to be more effective and less toxic than current therapies due to the 
agents’ selective growth and amplification in tumor cells. To date, these agents 
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have been regarded as highly safe in patients but have generally fallen short of 
their expected therapeutic value as monotherapies.  
 
Consequently, new approaches to generate highly potent oncolytic viruses are 
required. For the latter purpose, Hermiston and coworkers (91) developed a new 
method and termed it also ‘‘Directed Evolution’’ for creating highly potent 
oncolytic viruses. Viral serotypes representing Ad subgroups B-F were pooled 
and passaged twice on sub-confluent cultures of the target tumor cell lines at a 
particle-per-cell ratio of approximately 200 to invite recombination between 
serotypes (Figure 3). Supernatants from the second round of the high viral 
particle-per-cell infection of sub-confluent cultures were then used in a 10-fold 
dilution series to infect confluent T-75 tissue culture flasks of target tumor cell 
lines PC-3, HT-29, Panc-1 and MDA-231. Using this ‘‘Directed Evolution’’ 
methodology, the novel generated chimeric oncolytic virus ColoAd1 
demonstrated ~ 2 log increase in both potency and selectivity when compared to 
ONYX-015 on colon cancer cells. In vivo and ex vivo studies therefore validated 
the innovative general approach for deriving clinically-relevant and potent anti-
cancer virotherapies. 
 
Figure 3. Hermiston’s “Directed Evolution” process of viruses and derivative viral pools (91). 
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2.3.3 Amino acid depriving enzyme for anti-tumor applications 
Naturally available enzymes are usually not optimally suited for therapeutic 
purposes. This incompatibility often relates to the stability or activity of the 
enzymes under body conditions.  
 
Despite many successful efforts to broaden the understanding of the structural 
basis of protein stability, there is still no universal strategy to stabilize protein by a 
limited number of rationally designed mutations. Well-known and reasonably 
successful types of rational engineering work include substitutions that increase 
rigidity (e.g. substitute amino acid Xxx with Pro or substitute Gly with other amino 
acid Xxx or the introduction of disulfides). These substitutions have effects on the 
entropy of the unfolded state, improvement of molecular packing (e.g. shortening 
of loops, improvement of interactions in the hydrophobic core, for example, by 
the removal of internal cavities), modification of surface charge networks or 
reinforcement of a higher oligomerization state.  
 
Directed evolution provides a powerful approach for improving thermostability 
and does not need understanding of structure-function relationship. Most 
strategies for screening for enzyme stability rely on measuring residual enzyme 
activity before and after exposure to a denaturing challenge (e.g. high 
temperature, organic solvents, extreme pH) (92).  
 
Bacterial L-asparaginases have been used as therapeutic agents in the 
treatment of lymphoblastic leukaemia. The main restrictions to the therapeutic 
use of L-asparaginase include its premature inactivation. As a result frequent 
injections are required to maintain therapeutic levels. Repeated injections and 
high dose can cause several types of side reactions from mild allergies and the 
development of immune responses to dangerous anaphylactic shocks (93). 
Enhancing the stability of L-asparaginase by protein engineering improves its 
body-residence time, and thereby minimizes immunosuppressive effects by 
lowering the therapeutic dose. Labrou and coworkers (94) obtained a 
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reengineered L-asparaginase with enhanced thermal stability. Single mutation on 
the surface of the protein resulted in ~10 degree increased Tm value (half-
inactivation temperature). The thermostable variant has to be tested further on 
animals and ⁄ or humans in order to be advanced to a potent therapeutic drug. 
 
Another example of a reengineered amino acid-deprivating enzyme is PpADI. 
PpADI is a promising anti-tumor enzyme however with a non-physiological 
optimal pH and relative high Km value which hindering its medical application. By 
directed evolution and site saturation mutagenesis, PpADI variants with higher 
activity at physiological pH and at low arginine concentration of were obtained 
with improved properties to become a potent anti-tumor drug (see chapter 3 and 
chapter 4). In vitro and in vivo test of the improved variants are required to 
evaluate the anti-tumor effectiveness.  
 
2.3.4 Affibody molecules for cancer prognosis 
Affibody molecules represent a new class of affinity proteins that are based on 
the Z-domain scaffold derived from staphylococcal protein A (95). Among the 
scaffold proteins, Affibody molecules constitute the smallest non-cysteine-
containing protein scaffold. The small size (~ 7 kDa), robust structure, and 
straightforward production procedures (either by recombinant production in 
bacteria or by chemical synthesis) make Affibody molecules attractive targeting 
agents for in vivo radionuclide imaging (96) as well as for various 
biotechnological applications (97, 98). The small size offers a convenient affinity 
maturation principle. Gene synthesis allows randomizing the whole gene to 
generate diverse mutant library. The potential use of radiolabeled Affibody 
molecules for high-contrast radionuclide imaging of biomarkers has been 
demonstrated in preclinical studies and in pilot clinical studies. Affibody 
molecules are non-immunoglobulin-derived affinity proteins based on a three-
helical bundle protein domain.  
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Several of affinity proteins have been investigated for both in vivo diagnostics 
and therapy of tumor in radionuclide molecular imaging. Affinity proteins in tumor-
targeted therapy can affect tumor progression by altering signal transduction or 
by delivering a payload of toxin, drug or radionuclide. EGFR (epidermal growth 
factor receptor), one of the receptor in ErbB family, has been extensively studied 
as biomarkers in tumor targeting and over expressed in various malignancies, 
associated with poor patient prognosis and are therefore interesting targets for 
solid tumors. High affinity and especially slow dissociation rate are important for 
obtaining high contrast images. Affinity in the low nanomolar range is considered 
as a prerequisite for successful use of peptide-based tracers. 
 
Ståhl and coworkers (99) described the affinity maturation procedure for the 
generation of Affibody molecules binding with high affinity and specificity to 
EGFR. The library for affinity maturation was constructed using a single 
oligonucleotide for the rerandomization of desired positions. The new binders 
were selected with phage display technology and the best second-generation 
binders were characterized in vitro using real-time biospecific interaction analysis 
(BIA) for their binding to recombinant EGFR and with flow cytometry for their 
binding to native EGFR. Second-generation binders achieved an approximately 
30-fold improvement in affinity (Kd = 5-10 nM) for the soluble extracellular domain 
of EGFR in biospecific interaction analysis using Biacore. 
 
2.3.5 Interferon for anti-tumor applicaiton 
Alpha interferons (IFN-as) are members of the diverse helical-bundle superfamily 
of cytokine genes, which have potent antiviral and antiproliferative activities and 
therefore can be used as anticancer and antiviral agents. However, doselimiting 
toxicity, receptor cross-reactivity, and short serum half-lives significantly reduce 
the clinical use of many of these cytokines. 
 
Patten and coworkers (100) performed a family shuffling experiment with over 20 
human interferon-α (Hu-IFN-α) genes. Antiviral assay and proliferation assay 
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were used to indentify clones with improved activity on Hu-IFN-α receptor. One 
clone showed 285,000-fold improved activity relative to Hu-IFN-α2a and 185-fold 
relative to Hu-IFN-α1 (most active native human interferon). 
 
Selective breeding using DNA shuffling has proved to be very effective method to 
rapidly improve pharmaceutical proteins by which initially have low levels of the 
desired “activity” (101, 102). Backcrossing of evolved recommbinants with the 
wild type genes removes functionally neutral changes, which might reduce the 
immunogenicity of evolved proteins (103). 
 
2.4 Conclusion 
Proteins, especially enzymes, have gained a central role in modern chemical, 
biotechnological, and biopharmaceutical industries. Directed evolution has over 
the past proved to be a versatile and successful approach for tailoring protein 
properties to industrial, agricultural and medical demands and for advancing our 
understanding of structure-function relationships in biocatalysts. Appropriate 
library generation and screening methods should be employed concerning the 
target protein and desired property. To set up a sophisticated screening method, 
complex conditions in human body (pH, ion concentration, proteases, hormones 
etc.) should be considered. Subsequent in vivo or in vitro test of improved 
variants should be carried out to further validate the screening assay. 
Development of diversity generation and high-throughput screening method will 
enable evolution to solve problems efficiently. Especially, directed evolution 
provides a powerful strategy to rapidly advance the development of improved 
protein-based drugs (enzymes and antibodies, peptide and ligands). Directed 
evolution promises to play an increasingly important role to generate “desirable” 
drugs. 
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Chapter 3 
Chapter 3. Directed evolution of Arginine 
deiminase for increased activity at physiological 
pH 
 
3. 1 Abstract 
Arginine deiminase (ADI; EC 3.5.3.6) has been studied as a potential anti-tumor 
drug for the treatment of arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCCs) and melanomas. Studies with human lymphatic leukemia cell 
lines confirmed that ADI is a potential anti-angiogenic agent effective in the 
treatment of leukemia. ADI from Pseudomonas plecoglossicida (PpADI) was 
cloned and expressed in E.coli. A main limitation of PpADI lies in its pH-
dependent activity profile with a pH optimum at 6.5. A pH shift from 6.5 to 7.5 
results in ~80 % activity drop (pH of human plasma is 7.35 to 7.45). For shifting 
PpADI pH optimum to netrual pH, a directed evolution protocol based on an 
adapted citrulline screening protocol in microtiter plate (MTP) format was 
developed and validated. Proof of concept for ADI engineering resulted in a pH 
optimum of pH 7.0 and increased activity under physiological conditions: at pH 
7.4, variant M2 (K5T, D44E and H404R) is 4-fold more active than the wild type 
PpADI and retains ~30 % of its activity relative to its pH optimum, compared to 
~10 % in the case of the wild type PpADI. 
 
3.2 Introduction 
Arginine deiminase (ADI) is a potential cancer therapy agent for the treatment of 
arginine-auxotrophic tumors (e.g. hepatocellular carcinomas and melanomas). 
The hepatocellular carcinoma (HCC) accounts annually for approximately 1 
million new cases worldwide. In the US the incidence rate (per 100,000 persons; 
1992-2002) of HCC is 8.6 with a mortality rate of 6.5 due to low responses of 
hepatoma to chemotherapeutic treatments (27). Current research efforts are 
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focused on ADI’s in vivo inhibitory effect towards HCCs, leukemia, melanomas 
and human umbilical vein endothelial cells (HUVEC) (104-106), clinical trials for 
HCC (phase III) and melanoma (phase I/II) (105, 107), and PEG formulation of 
ADI to improve its efficacy as a clinical drug, including serum half-life and 
antigenicity (16, 108). ADI inhibited the growth of cultured leukemia cells at 
concentrations of 5-10 ng/ml, which were about 20-100 times lower than those of 
the L-asparaginase standard resulting in fewer side effects (106, 109). Arginine 
deprivation is speculated to be the molecular reason for ADI’s inhibitory effect on 
human lymphatic leukemia (106). ADIs catalyze the first step of the arginine 
deiminase (ADI) pathway by hydrolyzing arginine to citrulline and ammonium. 
Several ADI genes have been identified, purified, and characterized from 
bacteria, archaea and some eukaryotes excluding mammalian cells and 
summarized in a recent review (27). None of these ADIs is from a kinetic point of 
view ideally suited for in vivo applications in humans under physiological 
conditions.  
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. For the proof of concept, an 
ADI isolated from Pseudomonas plecoglossicida CGMCC2039 (accession 
number: ABS70718) which can be functionally expressed in E. coli has been 
employed. Directed evolution approaches employ mainly E. coli as host due to its 
fast growth and high transformation efficiency which is a prerequisite for 
generating complex mutant libraries. Over the last decades, directed protein 
evolution has become a versatile and successful approach for tailoring protein 
properties for industrial demands (mainly in chemical synthesis) and for 
advancing our understanding of structure-function relationships in enzymes. A 
directed evolution experiment comprises iterative cycles of diversity generation 
and functional selection for improved variants. Only a few manuscripts for 
phytases (83), xylanases (110), amylases (77, 82, 111), and an alcohol 
deyhdrogenase (112) reported a shift of pH optima using directed evolution 
algorithms. None of these directed evolution campaigns targeted a medical 
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application and arginine deiminase has to our best knowledge not been altered in 
its pH activity/resistance by directed evolution.  
 
Comparison of PaADI (Pseudomonas aeruginosa, pH optimum 5.6; His405) and 
MaADI (Mycoplasma arginini ADI, pH optimum 6.5, Arg397) led to the 
speculation that substitution of His by Arg might contribute to MaADI’s increased 
pH optimum (17). A sequence alignment of four ADIs (MaADI, MyADI 
(Mycoplasma arthritidis ADI), PaADI and PpADI) shows that for both 
Pseudomonas ADIs the synonymous amino acid positions (404 & 405), contain a 
His whereas both Mycoplasma ADIs contain at corresponding positions an Arg. 
Interestingly, both Mycoplasma ADIs have an pH optimum approximately one pH 
unit higher than both Pseudomonas ADIs. 
 
In this study we report the first directed ADI evolution protocol in which the pH 
profile of PpADI was shifted to higher pH values representing a conceptional 
proof that ADI properties can be tailored for demands in vivo treatment of 
arginine-auxotrophic tumors. An emphasis is given on detailed description of 
directed evolution conditions (mutagenic and screening).   
 
3.3 Materials and methods 
3.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
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plasmid (MEGAWHOP, 20 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
Pseudomonas plecoglossicida CGMCC2039 was provided by Professor Zhihao 
Sun (Jiangnan University, Wuxi, China). 
 
3.3.2 Methods 
3.3.2.1 Reagents used in assays 
Acid-ferric solution 
To dH2O (600 ml), concentrated H3PO4 (70 ml, 85 %) and concentrated H2SO4 
(160 ml, 90-91 %) were added slowly. After cooling to room temperature, 
FeCl3·6H2O (10 ml, 10 g/L) was added in the above solution, finally the total 
volume was adjusted to 1 liter with dH2O. 
 
Diacetyl monoxime -thiosemicarbazide (DAM-TSC) solution 
DAM solution (10 g/L) and TSC solution (0.3 g/L) were prepared separately. The 
two solutions were mixed (volume ratio = 1:1) just prior to use. 
 
3.3.2.2 Cloning of ADI into pET42b(+) 
The arginine deiminase (ADI) gene was amplified from Pseudomonas 
plecoglossicida CGMCC2039 by colony PCR (94°C for 10 min, 1 cycle; 94°C, 30 
s/ 54°C, 30 s/ 72°C, 165 s, 29 cycles; 72°C for 5 min, 1 cycle) using primer (5’-
CCGCATTCCGCTGAAAAACAGAAGTACGG-3’ and 5’-
CTTCTCGAGTTAGTAGTTGATCGGGTCGCGCACG-3’), 1.5 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix and a colony of Pseudomonas 
plecoglossicida CGMCC2039. Amplification product was purified by gel 
extraction, digested using NdeI (20 U) and XhoI (20 U) and purified using 
QIAquick PCR purification kit (QIAGEN, Hilden, Germany). Cloning vector 
pET42b(+) was digested with NdeI (20 U) and XhoI (20 U), and purified by gel 
extraction kit (QIAGEN, Hilden, Germany). Digested ADI gene and pET42b(+) 
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were ligated using T4 DNA ligase (1 U) to give pET42b(+)-ADI and transformed 
into E. coli BL21-Gold (DE3).  
 
3.3.2.3 Site directed mutagenesis of PpADI gene at position H404 
Site directed mutagenesis of ADI gene was performed according to the published 
method (113) on plasmid pET42b(+)-ADI. The following oligonucleotides were 
used for mutagenesis of H404R: 5’-
GGCCGTGGCGGCGGCCGTTGCATGACCTGCCCG-3’ and 5’-
CGGGCAGGTCATGCAACGGCCGCCGCCACGGCC-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 
cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 
s, 1 cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 
cycle), 2 U of PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, 
Finland), 0.20 mM of dNTP mix, 25 pmol of each primer together with 100 ng of 
template (pET42b(+) harboring ADI gene) were used. Following the PCR, DpnI 
(40 U; New England Biolabs) was added, and incubated overnight at 37°C. The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
3.3.2.4 Site sturation mutagenesis of PpADI gene at nine amino acid 
position  
Site saturation mutagenesis of ADI gene was performed according to the 
published method (113) on plasmid pET42b(+)-ADI. The oligonucleotides were 
used for mutagenesis were listed in table 1 (underlining indicated the substituted 
nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 cycle; 95°C, 30 
s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 s, 1 cycle; 95°C, 
30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 cycle), 2 U of 
PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, Finland), 0.20 mM 
of dNTP mix, 25 pmol of each primer together with 100 ng of template (pET42b(+) 
harboring ADI gene) were used. Following the PCR, DpnI (40 U; New England 
Biolabs) was added, and incubated overnight at 37°C. The PCR products were 
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purified by using a QIAquick PCR Purification Kit (Qiagen) and transformed into 
E. coli BL21-Gold (DE3) for expression. 
 
Table 1. Primer sequences for site saturation mutagenesis. 
Primer name Sequences 
Leu 41 FP AACTGCGACGAGCTGNNNTTCGACGATGTGATC   
Leu 41 RP GATCACATCG TCGAANNNCA GCTCGTCGCAGTT 
Asn 360 FP TGGGATGACGGCAACAACNNNGTGGCGCTGGAG 
Asn 360 RP CTCCAGCGCC ACCACNNNGT TGCCGTCATCCCA 
Arg401 FP GAACTGGGCCGGGGCNNNGGCGGCGGCCACTGC   
Arg401 RP GCAGTGGCCGCCGCCNNNGCCCCGGCCCAGTTC 
Phe163 FP CTGCCCAACACCCAGNNNACCCGCGACACCACC    
Phe163 RP GGTGGTGTCGCGGGTNNNCTGGGTGTTGGGCAG 
Asn160 FP CTGCCGCCGCTGCCCNNNACCCAGTTCACCCGC 
Asn160 RP GCGGGTGAACTGGGTNNNGGGCAGCGGCGGCAG 
Arg185 FP ATGTACTGGCCGGCNNNCGCCAGGAAACCCTG 
Arg185 RP CAGGGTTTCCTGGCGNNNGCCGGCCAGTACAT 
Arg243 FP ATCGGCATGGGTGAGNNNACCTCGCGCCAGGCC 
Arg243 RP GGCCTGGCGCGAGGTNNNCTCACCCATGCCGAT 
His405 FP GGCCGTGGCGGCGGCNNNTGCATGACCTGCCCG 
His405 RP CGGGCAGGTCATGCANNNGCCGCCGCCACGGCC 
Gly403 FP GCCGGGGCCGTGGCNNNGGCCACTGCATGACC 
Gly403 RP GGTCATGCAGTGGCCNNNGCCACGGCCCCGGCC 
 
 
3.3.2.5 Construction of PpADI error-prone library 
The library was generated by the standard error-prone PCR (epPCR) using 
improved variant H404R as template. For the mutagenic PCR (95°C for 2 min, 1 
cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C for 3 min, 1 cycle), 2.5 
U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of template (pET42b(+) 
harboring ADI gene H404R), 0.01-0.1 mM of MnCl2 and 10 pmol of each primer 
(5’-TACATATGTCCGCTGAAAAACAGAAG-3’ and 5’- GTGCTCGAGTTAGTAGT 
TGATCGG-3’) were used. The PCR products were purified by using a QIAquick 
PCR Purification Kit. The purified epPCR products were cloned into expression 
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plasmid pET42b(+) by MEGAWHOP(114). For MEGAWHOP (68°C for 5 min, 1 
cycle; 95°C for 5 min, 1 cycle; 95°C, 1 min/ 55°C, 1 min/ 68°C, 13 min 30 s, 24 
cycles; 68°C for 30 min, 1 cycle), 1 U of Taq DNA polymerase, 0.1 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix together with 200 ng of template (pET42b(+) 
harboring ADI gene H404R) were used. Following the PCR, DpnI (40 U; New 
England Biolabs) was added, and incubated (4 h; 37°C). The MEGAWHOP 
products were transformed into E. coli BL21-Gold (DE3) for expression and 
screening. 
 
3.3.2.6 Expression of PpADI in LB media with IPTG induction 
The strain E. coli BL21-Gold (DE3)/ pET42b-PpADI was cultured at 37°C in 20 ml 
of LB media that contained 50 µg/ml kanamycine to an absorbance of 0.6 at 
578nm. Then, isopropyl β-D-thio-galactopyranoside (IPTG) was added to a final 
concentration 0.2 mM. The cells were harvested after 9 h induction with IPTG at 
37°C. The expressed rADI was analyzed by SDS-PAGE.  
 
3.3.2.7 Expression of PpADI in auto-induction media 
A chemically defined auto-induction medium (115) containing salts and trace 
metals, vitamins including vitamin B12, and glucose, glycerol, and lactose were 
test for PpADI expression. Five kinds of auto-induction media LS-5052, P-5052, 
MD-5052, TYM-5052 and TYP-5052 were tested for the ADI expression, under 
the following conditions: 20 ml LB media in 100 ml flask, 37°C, 250 rpm, 20 h. 
The expressed rADI was analyzed by SDS-PAGE. 
 
3.3.2.8 Cultivation and expression of PpADI in 96-well plates 
Colonies grown on LBkan agar plates were transferred, by using toothpicks, into 
96-well microtiter plates (flat bottom, polystyrene plates; Greiner Bio-One GmbH, 
Frickenhausen, Germany), containing non-inducing medium LSG (150 µL) (115) 
supplemented with kanamycin (50 µg/ml). After 16 h of cultivation in a microtiter 
plate shaker (Multitron II, Infors GmbH, Einsbach, Germany; 37°C, 900 rpm, 70 
% humidity), each well was replicated using a replicator (EnzyScreen BV, Leiden, 
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Netherlands) into a second series of 96-well microtiter plates containing 150 µL 
of auto-induction media LS-5052 (115) supplemented with kanamycin (50 µg/ml). 
The first set of plates was stored at -80°C after addition of glycerol. The clones in 
the second set of plates were cultivated for 12 h (Multitron II, Infors GmbH, 37°C, 
900 rpm) and used for screening.  
 
3.3.2.9 Screening Procedure 
96-well plate format citrulline colorimetric screening assay 
A modified protocol of citrulline detection based on carbamido-diacetyl reaction 
(116) (see Figure 1A for assay mechanism) was used for ADI activity 
measurement. Screening for increased activity was carried out by measuring the 
activity at pH 7.4 and 6.4. 20 µl of cell culture was transferred to 96-well 
microtiter plate. Enzyme reaction was initiated by addition of arginine solution 
(100 µl, 100 mM) supplemented with cetyltrimethylammoniumbromide (CTAB, 4 
mM), and incubated (20 min, 37°C). Subsequently, acid-ferric solution (60 µl) and 
diacetyl monoxime (DAM, 20 µl, 0.5 M) were added. The reaction mixture was 
further incubated (15 min, 55°C). Absorbance was measured at 492 nm using a 
microtiter plate reader (Tecan Sunrise, Tecan Group AG, Zurich, Switzerland).  
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking ADI and in a separate experiment 
containing ADI. Apparent standard deviation was based on the absolute 
absorbance values obtained from the ADI wild type plate. The true standard 
deviation was calculated by subtracting the background absorbance value of the 
microtiter plate lacking ADI from the apparent values. 
 
Cuvette format citrulline colorimetric assay 
ADI activity was routinely measured using a modified protocol of the citrulline 
detection with DAM and TSC (117) (see Figure 1A for assay mechanism) in 
Eppendorf tubes. Enzyme reaction was initiated by addition of arginine solution 
(200 µl, 100 mM) to a 2-ml eppendorf tube containing crude cell lysate (50 µl), 
and incubated (20 min, 37°C). Subsequently, acid-ferric solution (250 µl) was 
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added to stop the enzyme reaction. After appropriate dilution with deionized 
water to ensure the concentration of produced citrulline is within linear detection 
range, the reaction mixture (400 µl) was mixed with acid-ferric solution (600 µl) 
and DAM-TSC solution (100 µl). The reaction mixture was further incubated (30 
min, 70°C), followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a Specord 200 (Analytik Jena AG, 
Jena, Germany). 
 
Normalization of protein expression for wild type ADI and variants  
Agilent Protein 230 Kit (Agilent Protein 230 Kit, Agilent Technologies 
Deutschland GmbH, Böblingen, Germany) and Agilent 2100 Bioanalyzer (Agilent 
2100 Bioanalyzer, Agilent Technologies Deutschland GmbH, Böblingen, 
Germany) were used for normalization of protein expression in crude cell extract. 
The protocol used was according to Agilent protein 230 Kit Guide except BSA 
was used as an internal standard. 
 
3.3.2.10 Expression of ADI in shaking flask and purification 
Shaking flasks (1 liter) containing auto induction media LS-5052 (200 ml) 
supplemented with kanamycin (50 µg/ml) were inoculated with a 1:200 dilution of 
overnight culture (E. coli BL21-Gold(DE3) harboring pET42b-ADI) grown in non-
inducing media LSG. After 12 h of expression, E. coli cells were harvested by 
centrifugation (Eppendorf 5810R 4°C, 3220 g, 30 min) and resuspended in 
phosphate buffer (20 ml, NaxPO4, 20 mM, pH 7.0). E. coli cells were 
subsequently lysed by using a high-pressure homogenizer (1500 bar, 2 cycles; 
Avestin Emulsiflex, Mannheim, Germany). The disrupted cells were centrifuged 
(Eppendorf 5417R, 4°C, 13000 g, 20 min) and the supernatant was further 
cleared by filtration through a low protein-binding filter (0.45 µm; Minisart RC 25 
single use syringe filter; Sartorius, Hamburg, Germany). ADI wild type and 
mutants (H404R and K5T D44E H404R) were subsequently purified by a column 
chromatography procedure: (i) The filtered cell lysates were subjected to a 
Super-Q anion exchange column, which had been pre-equilibrated with 50 mM 
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phosphate buffer (NaxPO4, pH 7.0). 20 ml of cell lysate was loaded. ADI were 
eluted by a NaCl step elution in phosphate buffer (NaxPO4, 50 mM,  pH 7.0) at a 
rate of 3 ml/min. (ii) The obtained ADI protein from ion exchange chromatography 
was subjected to a gel filtration column (Matrix: Toyoperl HW-55S, Bed volume: 
33 ml, Bed height: 40 cm, Column: Omnifit). 
 
Purified ADI was subsequently concentrated using a Amicon ultra-4 centrifugal 
filter device (Millipore Corporation, Billerica, U.S.A.) with a 30-kDa cut-off 
membrane. Total protein concentration was determined by BCATM assay kit 
(Pierce, Born, Germany) and homogeneity of the purified sample was controlled 
by SDS-page electrophoresis using standard molecular biology techniques. 
 
3.3.2.11 Characterization of ADI wild type and mutants 
Determination of kcat and Km of ADI wild type and the mutants 
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath. After 10 min preincubation at 37°C, the enzyme reaction was initiated 
by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the substrate solution (200 
µl, 0.2 mM to 10 mM of arginine, 0.5 M phosphate buffer, pH 7.4) in deep well 
plates. The reaction mixture was incubated (37°C) and every two minutes 
reaction mixture (30 µl) of each well was transferred to acid-ferric solution (30 µl) 
to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. Ferric-acid solution (90 µl) and DAM-TSC 
solution (15 µl) were added to each well. The 96-well PCR plate was then 
incubated (70°C, 30 min) in thermal cycler (Eppendorf Mastercyler gradient) for 
color development, followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a microtiter plate reader 
(SPECTROstar Omega, BMG LABTECH, Offenburg, Germany). The initial 
velocity data obtained were fitted to the equation v = Vmax[S]/([S] + Km) (where v 
is the initial velocity, Vmax the maximum velocity, [S] the substrate concentration, 
and Km the Michaelis constant) using GraphPad Prism software (GraphPad 
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software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax 
and enzyme concentration. 
 
Determination of pH profile 
Enzyme reaction was carried out at 37°C in a water bath using the following 
substrate solution: arginine 0.1 M, pH 5-8 phosphate/acetate buffer (0.5 M 
phosphate, 50 mM acetate). After 10 min preincubation at 37°C, the enzyme 
reaction was initiated by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the 
substrate solution (200 µl) in deep well plates. The reaction mixture was 
incubated (37°C, 10 min) and acid-ferric solution (250 µl) was transferred to each 
well to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. The reaction mixture (60 µl), ferric-acid solution 
(90 µl) and DAM-TSC solution (15 µl) were transferred to a 96-well PCR plate. 
The 96-well PCR plate was then incubated (70°C, 30 min) in thermal cycler 
(Eppendorf Mastercyler gradient) for color development, followed by incubation in 
ice water to stop color development. Absorbance was measured at 530 nm using 
a microtiter plate reader (SPECTROstar Omega, Germany). 
 
3.3.2.12 Molecular Modeling 
Two crystal structures of PaADI (PDB codes: 1RXX, 2A9G) were used to model 
the mutations H405R and D44E. Only one monomeric unit of the tetrameric 
PaADI was used for the modeling study employing Swiss-PDB viewer (118) 
(www.expasy.org/spdbv). PaADI variants (H405R; D44E) were generated using 
the mutate command of Swiss-PDB viewer. The side chain rotamer with the best 
score was used for subsequent energy optimized with parameter of GROMOS96 
force field for in vacuum minimization (119).  
 
3.3.2.13 Stability of PpADI in presence of serum  
Purified PpADI (wild type, M1, M2; 20 µl) was incubated (37°C, 60 min) with AB--
human serum (80 ul, Invitrogen, Karlsruhe, Germany) and PBS buffer (pH7.4, 80 
ul), respectively. Subsequently, the incubated ADI-serum/PBS mix (20 µl) was 
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added to microtiter plate containing arginine solution (100 µl, 10 mM arginine in 
PBS buffer, pH 7.4) and incubated (37°C, 30 min). Acid-ferric solution (120 µl) 
was added to stop the enzyme reaction. The produced citrulline was detected 
using the assay procedure employed in “Determination of kcat and Km of ADI 
wild type and the mutants”. Before measuring absorbance at 530 nm, 
centrifugation (Eppendorf, 5810R 4°C, 3000 g, 10 min) was performed to remove 
the precipitation in the assay solution (likely proteins in serum were precipitated 
in acidic condition during assay procedure). Meanwhile, a serum control was test 
for the original citrulline concentration of serum using the same procedure 
mentioned above except that instead of PpADI, elution buffer of gel filtration 
(NaxPO4, 50 mM, pH 7.4) was used. All the absorbance values at 530 nm of 
ADI-serum sample were subtracted the value of serum control to get the citrulline 
concentration produced by PpADI. The residual activities of PpADI after 
incubation in serum compared to that in PBS buffer were calculated to show the 
stability of PpADI after incubated in human serum. 
 
3.3.2.14 Activity of PpADI (wild type, M1, M2) towards arginine derivative 
dimethylarginine 
Purified PpADI (wild type, M1, M2; 15 µl, ~0.2 mg/ml final concentration; >20-fold 
concentration used for kinetic constant determination) was incubated (37°C, 4 h) 
with (NG, NG)-dimethylarginine solution (20 mM, 100 µl). Acid-ferric solution (120 
µl) was added to stop the enzyme reaction. Activity was recorded by citrulline 
detection using citrulline colorimetric assay (see 3.3.2.11 Characterization of ADI 
wild type and mutants). 
 
3.4 Results 
3.4.1 PpADI cloning 
PpADI was cloned into pET42b(+) and expressed in E.coli BL21-Gold(DE3) 
using auto-induction media LS-5052 (see figure 2). The nucleotide sequence of 
PpADI comprises 1,254 bp nucleotide (figure 1) encoding 417 amino acids which 
have 85% identity to ADI from P. aeruginosa (PaADI). The PpADI cloned into 
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pET42b(+) was confirmed by nucleotide sequencing. As indicated in Figure 1, 
sequence analysis of ADI gene showed that there was one synonymous 
mutation at amino acid position D78 (GAT to GAC) compared to ADI-sequence 
of P. plecoglossicida CGMCC2039 deposited in NCBI (accession number: 
EU030267). The deduced ADI protein sequence has a calculated molecular 
weight of 46.5 kDa and shows 85% identity to ADI from P. aeruginosa. This clone 
was used for subsequent directed evolution experiments.  
 
 
Figure 1. DNA electrophoresis of PpADI. 
 
 
Figure 2. PpADI sequencing results. 
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3.4.2 PpADI expression in LB media with IPTG as inducer 
PpADI was successfully expressed in LB media with IPTG as inducer. Figure 3 
(lane 4) shows the expression band of PpADI observed at ~45 kDa, which is 
similar to the calculated molecular weight of 46 kDa (based on 
http://expasy.org/tools/pi_tool.html). 
 
Figure 3. SDS-PAGE of PpADI expression. Lane 1: P. plecoglossicida; Lane 2: E. coli BL21-Gold 
(DE3)/ pET42b; Lane 3: E. coli BL21-Gold (DE3)/ pET42b-PpADI WT, without IPTG; Lane 4: E. 
coli BL21-Gold (DE3)/ pET42b- PpADI WT. 
 
3.4.3 PpADI expression in auto-induction media 
Expressing recombinant protein in auto-induction media is based upon the 
preferences of bacteria to selectively use different carbon sources during diauxic 
growth and upon the often-observed negative regulation of gene expression by 
catabolite repression. Auto-induction is more convenient than IPTG induction 
because the expression strain is simply inoculated into auto-inducing medium 
and grown to saturation without the need to follow culture growth and add 
inducer at the proper time. For high-throughput applications, the auto-induction 
approach has many advantages over traditional induction methods including 
avoidance of the strong induction and apparent toxicity associated with chemical 
inducers such as IPTG.  
Five kinds of auto-induction media LS-5052, P-5052, MD-5052, TYM-5052 and 
TYP-5052 were tested for the ADI expression. Figure 4(A) and 4(B) show ADI 
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activity and corresponding SDS-PAGE band of the PpADI expression in different 
auto-induction media. The expression in auto-induction media LS-5052 is shows 
the highest activity and therefore LS-5052 was used for the following directed 
evolution experiments. 
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Figure 4(A). Activity of PpADI expressed in auto-induction media. 
 
 
 
Figure 4(B). SDS-PAGE of ADI expressed in auto-induction media 1, LS-5052; 2, P-5052; 3, MD-
5052; 4 TYM-5052; 5, TYP-5052. 
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3.4.4 PpADI assay based on citrulline detection 
 
 
Figure 5. Arginine conversion by ADI and detection of citrulline using DAM/TSC assay. 
 
ADI activity was measured by detecting the production of citrulline from arginine, 
according to carbamido diacetyl reaction (colorimetric reaction). The conditions of 
the carbamido diacetyl reaction is as follows： strong acid solution (H3PO4, 
H2SO4), oxidizing agent (Fe3+), diacetyl monoxime (DAM), thiosemicarbazide 
(TSC), and boiling water bath. Figure 5 shows one postulated reaction 
mechanism for the assay which depicts the reaction between citrulline and DAM. 
By the addition of TSC to the reaction system, Coulombe and Favreau(120) 
obtained linearity of response with a more stable pink color which Amax was 
shifted from 490nm to 530nm. 
 
Figure 6 describes the assay procedure for measuring ADI activity in 2 ml 
eppendorf tube. A calibration curve was prepared using citrulline standard 
solution (Figure 7) for determining the citrulline production during the assay. 
 
Figure 6. Citrulline colorimetric assay in cuvette format using DAM/TSC assay. 
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Figure 7. Calibration curve of cuvette format citrulline colorimetric assay. 
 
3.4.5 PpADI screening system for citrulline production in microtiter plates 
Two key performance parameters for identifying improved variants in microtiter 
plate based screening systems are the true standard variation and the linear 
detection range of the employed assay. Standard deviations have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). A modified version of the DAM-TSC assay for citrulline 
detection (Scheme 1) was selected for directed evolution of PpADI. The 
microtiter plate screening format was optimized for simplified handling by 
lowering the color development temperature (55°C instead of 100°C), increasing 
the diacetylmonoxime concentration (~22-fold) and avoiding the use of the 
sensitizer thiosemicarbazide. Figure 8 shows the procedure of screening assay 
of citrulline detection. 
 
Figure 8. Citrulline colorimetric assay in MTP format using DAM assay. 
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Standard deviations of the modified citrulline detection assay have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). The preferred combination (150 µl LS5052 auto-
induction media and 20 µl cell culture, 20 min conversion time and 15 min color 
develop time) resulted in a true standard deviation of 12.8 % after subtracting the 
background (Figure 10). Screening systems with standard deviations around 10 
% have successfully been used in directed evolution experiments (121, 122). A 
wide linear detection window is important for identifying beneficial mutants in 
directed evolution experiments and screening systems for evolved mutants have 
to be constantly adapted for hitting the linear detection window. A linear detection 
range up to 6 mM citrulline could be detected (Figure 9).  
 
 
 
 
 
 
Figure 9. Calibration curve of 96-well microtiter plate format citrulline colorimetric screening assay.  
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Figure 10. Activity values in descending order of the ADI wild-type conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
 
Figure 11. PpADI model derived from PaADI crystal structure (PDB code 2a9gD) by SWISS 
MODEL WORKSPACE.  
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3.4.6 Focused libraries generated by saturation mutagenesis 
PpADI gene shares 83 % sequence identity  with PaADI of which the crystal 
structure was solved (123). After submitting the ADI sequence to SWISS MODEL 
WORKSPACE, a proposed ADI model based on the PaADI crystal structure 
(PDB code 2a9gD) was obtained (Figure 11). According to this model and 
published literatures, 9 amino acid residues: Leu41, Asn160, Phe163, Arg185, 
Arg243, Asn360, Arg401, His404, Gly 403 (Figure 11) close to the active center 
(catalytic triad: Cys406-His278-Glu224) or known to interact with substrate 
arginine were selected for saturation mutagenesis. 
 
Site saturation mutagenesis at position Leu41, Asn160, Phe163, Arg185, Arg243, 
Asn360, Arg401, His404 and Gly 403 were performed. 300 clones were 
screened for each position. However, no improved variant was identified. 
 
3.4.7 Validation of variant M1 (H404R) citrulline colorimetric assay in 
cuvette format 
Position H404 which was suspected to influence ADI pH profile by substitution to 
R404 (15). Compared to wild type PpADI, variant M1 (H404R) shows higher 
activity (1.8-fold) and improved activity ratio of pH 7.4 to 6.4 (4.7-fold). Therefore, 
M1 (H404R) was selected for directed evolution. 
 
3.4.8 epPCR library generation and screening with citrulline detection 
assay by screening error-prone mutant libraries 
Various concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Figure 12 (A) and 12 (B) 
show the epPCR products and the corresponding MEGAWHOP products. 
Concentration of 0.01 mM MnCl2 which generated 53 % inactive mutant was 
selected for library generation. EpPCR mutant libraries with a ratio of 50 % active 
and 50 % inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). A total of 7 variants (listed in 
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Table 2) were identified from an epPCR library of 2400 mutants and used for 
further characterization. The most active variant was sequenced and two 
additional amino acid substitutions (K5T D44E) were identified. 
 
 
Figure 12 (A). Electrophoresis of epPCR products. Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM 
of MnCl2; Lane 3, 0.05 mM of MnCl2.  
 
 
 
Figure 12 (B). Electrophoresis of MEGAWHOP product with epPCR products as megaprimer. 
Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM of MnCl2; Lane 3, 0.05 mM of MnCl2.  
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Figure 13. Relative activity of ADI variants towards arginine. The relative activity is the ratio of the 
activity at the pH of each variant relative to the activity at pH 7.4 of wild type ADI. White: ADI wild 
type, grey: M1 (H404R), black: M2 (K5T D44E H404R). 
 
Table 2. Activity of ADI variants towards arginine determined using citrulline colorimetric 
assay in cuvette format. Samples were diluted to ensure that detected citrulline 
concentrations are within the linear detection range of the citrulline colorimetric assay. 
Wild type, mutant M1 and the “best variant” M2 are in bold and prominent expression 
mutants (9-B3-1; 21-D5-1) are italized. 
Normalized [ADI][a] 
Citrulline production 
(mM/mg) 
Relative to activity at pH 7.4 
of WT 
ADI variants pH 7.4 pH 6.4 pH 7.4 pH 6.4 
Activity at pH 
7.4/ activity at 
pH 6.4 
WT 
9.83 
(0.74)[b] 
124.92 
(1.98) 1.00 (0.15) 12.69 (0.01) 0.08 (0.01) 
M1 
(H404R) 
17.80 
(0.49) 
45.95 
(0.87) 1.81 (0.06) 4.67 (0.02) 0.39 (0.02) 
M2 
(K5T D44E 
H404R) 
38.99 
(0.79) 39.20 (0.31) 3.96 (0.02) 3.98 (0.02) 0.99 (0.03) 
9-B3-1 
24.89 
(0.45) 54.50 (1.80) 2.53 (0.03) 5.54 (0.03) 0.46 (0.02) 
21-D5-1 
25.68 
(2.68) 50.95 (2.36) 2.61 (0.07) 5.18 (0.02) 0.50 (0.01) 
15-G10-2 
13.11 
(0.53) 47.02 (0.47) 1.33 (0.09) 4.78 (0.02) 0.28 (0.01) 
2-H4-2 
12.50 
(0.07) 21.58 (0.09) 1.27 (0.06) 2.19 (0.04) 0.58 (0.01) 
1-G11-1 
24.91 
(0.20) 29.12 (0.33) 2.53 (0.03) 2.96 (0.03) 0.85 (0.02) 
24-E10-1 
14.62 
(0.62) 32.82 (0.52) 1.49 (0.08) 3.34 (0.03) 0.45 (0.02) 
[a] (Based on quantification employing Agilent 2100 Bioanalyzer (Agilent Protein 230 Kit)) 
[b] (Standard error of triplicate measurements are given in brackets below each absolute 
and normalized value.) 
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Figure 14. Elution profile of wild type PpADI and improved variants from epPCR library, 
generated with Protein 230 Kit using a mircofluidic device (Agilent Bioanalyzer). BSA was added 
as an internal standard. 
 
3.4.9 Characterization of PpADI variants 
3.4.9.1 Determination of kcat and Km of ADI wild type and the mutants 
Variants selected from epPCR were first characterized using the crude cell 
extract to identify the most promising variants (Table 2). Using an activity ratio of 
pH 7.4 to 6.4 proved to be an effective method to eliminate expression mutants. 
Additionally ADI concentration in crude cell extract was determined using the 
Agilent Protein 230 Kit. Microfluidic elution profiles (Figure 14) semi-quantify 
differences in expression between the wild type PpADI and variants. 
Normalization of activities against the corresponding ADI concentrations reveals 
improvements in specific activities of ADI mutants (Table 2). M1, the starting 
variant for the directed evolution campaign, and M2 were selected for detailed 
characterization studies. M2 has as “best identified variants” (Figure 13) a more 
than 2.5-fold higher activity ratio at pH 7.4 to pH 6.4 than M1 and a 12-fold higher 
activity ratio than wild type in crude cell lysates. 
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For kinetic characterization of ADI variants the citrulline production was 
maintained between 0.2-0.8 mM. Calibration curve in Figure 4 shows the linear 
detection range in the employed 96-well PCR plate format citrulline colorimetric 
assay system. Figure 15 summarizes the kcat and Km values of wild type PpADI, 
identified variants M1 (H404) and M2 (K5T D44E H404R) which were expressed 
in shaking flasks cultures and purified using a two step procedure (anion 
exchange followed by gel filtration). Both variants M1 and M2 show an increase 
in kcat and Km for citrulline production at pH 7.4. Variant M2 shows a 4-fold higher 
kcat as also obtained for specific activity in Table 2 using the crude cell extract, 
validating the characterization procedure with crude cell lysate. Furthermore, an 
increased Km from 0.7 mM (wild type PpADI) to 1.2 mM (M1) and 2.5 mM (M2) 
was found. 
 
 
Figure 15. Kinetic parameters of ADI and mutants for conversion of arginine to citrulline. White: 
ADI wild type, grey: M1 (H404R), black: M2 (K5T D44E H404R). Values reported are the average 
of three measurements, and average deviations from the mean values are shown. Embedded 
calibration curve shows linearity of citrulline colorimetric assay in 96-well PCR plate format which 
was used to determine arginine conversions and kinetic constants.  
 
3.4.9.2 Relative pH profile of wild type and mutant 
The relative pH profile (Figure 16) of wild type PpADI and M1 (H404R) shows an 
identical pH optimum at pH 6.5. Compared to wild type PpADI, variant M2 (K5T 
  55 
D44E H404R) shows a pH optimum at pH 7.0 which is shifted remarkably (0.5 
pH units). Both M1 and M2 show decreased specific activities at pH 6.5, and 
increased specific activity at pH 7.5. At pH 7.0, the specific activity of M2 
exceeds that of wild type PaADI (data not shown). 
 
Figure 16. pH profile of wild type ADI, M1(H404R), M2(K5T/D44E/H404R). The relative activity is 
the ratio of the catalytic activity at the pH relative to the maximum activity of each enzyme. (■) WT, 
(▲) M1 (H404R), (●) M2 (K5T/D44E/H404R). 
 
 
3.4.10 Stability of PpADI in the presence of human serum  
Table 3 summarizes the stability of PpADI variants in serum (37°C, 60 min; 
standard deviation of three measurements in brackets). The mutants M1 and M2 
have a similar stability in serum when compared to the wild-type PpADI wild type.  
The substitution D44E and H404R do not destabilize further the PpADI in serum.  
 
Table 3. Stability of PpADI variants in the presence of human serum. 
 PpADI WT M1 M2 
No incubation (A530) 0.08 0.27 0.98 
Incubation with serum (37°C, 
60 min) (A530) 0.05 0.15 0.69 
Residual activity 60 % 55 % 70 % 
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3.4.11 Activity of PpADI (wild type, M1, M2) towards arginine derivative (NG, 
NG)-dimethylarginine  
No detectable conversion of (NG, NG)-dimethylarginine could be detected with 
PpADI variants.  
 
3.5 Discussion 
ADI properties have to date not been engineered through directed evolution 
algorithms despite their often poor performances under physiological conditions 
and their medical importance as potential anti-tumor drug. Chemically modified of 
ADI (e.g. through PEGylation) (27) and fusion protein (e. g. Human serum 
albumin fusion, HSA) (124) have been used for addressing activity and stability 
demands in vivo. Directed evolution offers opportunities to directly improve ADI 
properties for in vivo applications and small libraries of a few thousand variants 
have often been sufficient to find improved muteins in directed evolution 
experiments (55, 125).  
 
Our main intention in this report is to provide a validated protocol for directed ADI 
evolution and improving the activity at the physiological pH 7.4. Pseudomonas 
plecoglossicida CGMCC2039 (PpADI, 7.8 U/mg; pH optimum 6.5) was selected 
for the directed evolution studies due to its functional expression in E. coli, 
coverage of sequence space in patents and “potential” for activity improvement. 
PpADI is a relatively slow ADI when compared to Mycoplasma ADIs like MhADI 
(Mycoplasma hominus ADI, 35 U/mg) which would have been good alternatives 
for directed evolution studies (105). Reported ADI activities range from 0.115 to 
140.3 IU/mg. One unit is commonly defined as the ADI amount that converts 1 
µmol of L-arginine into 1 µmol of L-citrulline per minute (27).  
 
Screening of PpADI variants yielded three amino acid positions 5, 44 and 404. 
Positions 44 and 404 resulted in a 4-fold higher kcat at pH 7.4 and a significant 
shift in the pH optimum (0.5 units) when compared to wild type PpADI (Figure 17 
& 8). Position 5 did not show any effect on PpADI activity.   
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Figure 17. Structural alignment of mutant M1 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The crystal structure of PaADI which was diffracted in 
absence of the substrate arginine (1RXX) was used to investigate the substitution of His405 to 
Arg405. The Arg405 variant shows with respect the Asp280 a different orientation of the 
guanidinium group when compared to side chain of His405 (in orange).  
 
Galkin and coworkers postulated that the histidine in position 404 (corresponding 
position in “their” PaADI is 405) is a key residue in controlling activity at acidic 
and neutral pH. In protonated state of the imidazolium ring a hydrogen bonding 
interaction can be formed with the oxygen of Asp280 (carboxyl group). This 
hydrogen bond favors stabilizing interactions between Asp280 and the substrate 
arginine. His405 in PaADI was reported (17) to share protons with Asp280 and 
Glu13 and to be important for modulating electrostatic environments of closely 
located catalytic groups. The same report postulated that H405 is likely to be 
protonated when the substrate arginine binds to catalytic triad (His278, Glu224, 
Cys406) (2). Based on these reports the His404 in PpADI was subjected to a site 
directed mutagenesis to Arg404 and named M1. The M1 variant (H404R) shows 
40 % residual activity compared to wild type PpADI at pH 6.4 and a 1.8-fold 
increase in activity at pH 7.4 (see Table 1). In the M1 (H404R) mutant (see the 
model in Figure 17; based PaADI 1RXX; residue His404 in PpADI corresponds to 
His405 in PaADI), the conformational effect due to the extended side chain of 
Arg likely weakens the hydrogen bond to Asp280 and thus reduces the stabilizing 
effect on arginine binding. As a result the activity of M1 is reduced, especially at 
  58 
lower pH values at which His405 is protonated. However at elevated pHs, His405 
becomes increasingly deprotonated whereas Arg405 remains protonated and 
can therefore still stabilize Asp280 for arginine binding. The electrostatic effect 
suggested by theoretical and experimental studies have evidenced the 
importance of positively charged residues to modulate the reaction rate of PaADI 
(126). At pH 6.4, histidine in wild type PpADI and arginine in M1 are both 
positively charged. At pH 7.4, histidine is only partially positive charged and 
PpADI’s activity is reduced (>90 %) while arginine in M1 remains positively 
charged preserving M1’s activity (Figure 17).   
 
 
Figure 18. Structural alignment of mutant M2 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The PaADI crystal structure in presence of substrate arginine 
was used (2A9G) to investigate the role of the substitution Asp44 to Glu44. The latter was solved 
for an inactive variant in which Cys406 was replaced by Ala406. The extended side chain of 
Glu44 might improve the hydrogen bond interaction with the Arg399 inducing a conformational 
shift of loop 1. 
 
The PpADI H404R was used as starting variant for directed evolution. The amino 
acid position 44 was identified from a epPCR library (2400 variants screened) 
resulting in a triple mutant M2 (K5T D44E H404R). For investigating the role of 
each position the double mutants (K5T H404R) and (D44E H404R) were 
generated. Only the double mutant (D44E H404R) revealed improvements in kcat 
(4-fold, pH 7.4; Figure 18). The rationale behind the effects of the mutation D44E 
on the PpADI activity is more complex to extrapolate from the available ADI 
crystal structures. Comparative crystallographic studies have shown that the 
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entrance of the active site is decorated by 4 loops that undergo conformational 
transitions upon arginine binding (17). The loops exhibit significant shifts that limit 
the access of water molecules to the active site. The Asp44 is located in loop 1 
(residues 30-46) and upon binding of the substrate, Asp44 comes closer to the 
positively charged Arg399 located on loop 4 (residues 392 to 403). In the D44E 
mutant, the longer side chain reduces the distance with Arg399 favoring the 
formation of hydrogen bond (see model in Figure 18). The reinforced interaction 
between Glu44 and Arg399 might expedite conformational changes in loops, 
probably confining the arginine substrate in the active site and hence promote 
arginine conversion. In the future, we plan to further investigate the influence of 
H404R and D44E using molecular dynamics simulations, further boost the kcat at 
pH 7.4 and reduce the Km value of PpADI.  
 
Overall site directed mutagenesis of position H404R and one round of directed 
evolution (2400 variants screened) resulted in a triple mutant M2 (K5T D44E 
H404R) with 4-fold higher kcat at pH 7.4 (compared to wild type; Figure 4). The 
best mutant isolated, M2, has specific activity of 31.3 U/mg at pH 7.4 which is 
already after one round of evolution close to the specific activity of MhADI (35 
U/mg) (127) at its pH optimum. The stability and specificity of improved PpADI 
variants are furthermore important for cancer treatment in vivo. First experiments 
in AB-human serum (Invitrogen) showed an unaltered stability of M2 compared to 
the wild type PpADI and (NG, NG)-dimethylarginine conversion could not detect 
with the citrulline colorimetic assay.   
 
3.6 Conclusion 
In summary, a directed evolution protocol has been developed for PpADI and 
validated by increasing the kcat of PpADI at physiological pH (7.4). The reported 
screening system is the first one employed in directed ADI evolution and can 
likely be used for other ADIs and other properties such as temperature stability, 
salt/detergent stability or protease resistance. 
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Chapter 4 
Chapter 4. PpADI reengineered for efficient 
operation under physiological conditions 
 
4.1 Abstract 
The proof of concept for ADI engineering by directed evolution resulted in variant 
M2 (K5T/D44E/H404R). M2 has a pH optimum of pH 7.0 and 4-fold higher kcat 
value than the wild type PpADI (pH 7.4, 0.5 M phosphate buffer) and an 
increased Km value for substrate arginine. In this chapter, in order to improve the 
catalytic efficiency of PpADI at low concentration of arginine, variant M5 
(K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated from an epPCR library: 
at pH 7.4 (PBS buffer), the S0.5 value decreased from 2.01 mM (parent M3, 
K5T/D44E/A128T/H404R) to 1.48 mM (M5) and 0.81 mM (M6). The S0.5 value of 
M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat value 
improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 11.64 
s-1 (M6, 64.7-fold). 
 
4.2 Introduction 
ADI-based arginine depletion is a target specific therapy for arginine-auxotrophic 
tumors (e.g. hepatocellular carcinomas and melanomas) and pegylated ADI is 
currently under clinical trials for HCC with promising results (45). HCC is the third 
leading cause of cancer mortality world wide with a less than 10 % 5-year 
survival rate (EU and USA) (128) due to low responses of hepatoma to 
chemotherapeutic treatments. In 1999, US Food and Drug Administration (FDA) 
designated ADI-PEG-20 orphan drug status for the treatment of HCC and 
invasive malignant melanomas, and in 2005 European Agency for the Evaluation 
of Medicinal Products (EMEA) also granted ADI-PEG-20 orphan drug status for 
the treatment of HCC. Phase II trials of ADI-PEG-20 in patients with metastatic 
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hepatocellular carcinomas have shown that the drug is safe, well tolerated, and 
may benefit patients with unresectable HCC. Izzo and coworker suspected that 
combination therapies of arginine deprivation and growth inhibition via kinase 
inhibitors might improve the survival rate further more. Additionally, ADI can 
enhance radio sensitivity of human mammary adenocarcinoma (MCF-7 cells) 
(48), exerts anti-proliferative and anti-angiogenic activities and inhibits the growth 
of viruses such as HIV-1 and hepatitis (49, 50). Current research efforts are 
focused on ADI’s in vivo inhibitory effect towards leukemia, melanoma, prostate 
cancer, renal cell carcinoma, and human umbilical vein endothelial cells (HUVEC) 
(19, 44, 51-53), clinical trials for HCC (phase II) (45) and melanoma (phase I/II) 
(46), and inhibitory mechanisms of ADI to tumors (54).  
 
Arginine deprivation is believed to be a main molecular reason for ADI’s inhibitory 
effects on arginine auxotrophic tumors which do not express argininosuccinate 
synthetase (ASS). ADIs catalyze the first step of the arginine dehydrolase 
pathway by hydrolyzing arginine to citrulline and ammonium. ADI genes have 
been identified, purified, and characterized from bacteria, archaea and some 
eukaryotes excluding mammalian cells (see review (27)). Enzymatic properties of 
several recombinant ADIs have been examined, such as specific activity, 
functional expression level, temperature optimum, pH optimum, substrate affinity 
for arginine, and half-life in human plasma. Only the ADI from Mycoplasma 
hominis has so far been developed as orphan drug by Pheonix Pharmacologics 
Inc. for HCC and melanoma (129). From enzyme kinetic point of view, none of 
the ADIs is ideally suited for in vivo applications under physiological conditions. 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. PpADI (ADI from 
Pseudomonas plecoglossicida) was functionally expressed in E. coli with a 
simple protocol and has been engineered for the first time by directed evolution 
for improved activity at physiological pH (3). The variant M2 (K5T/D44E/H404R), 
by our group reported, showed a 4-fold higher specific activity than the wild type 
PpADI (0.5 M phosphate buffer, pH 7.4), but a increased Km value (3.5-fold). 
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High activity at low arginine concentration is an important prerequisite for ADI’s 
medical application, allowing low ADI dose required per treatment. 
In the present work, we improved the directed evolution protocol and identified a 
PpADI variant with further improved activity and slightly decreased “Km value” 
and PpADI variant with lowered Km value maintaining its high catalytic activity. 
Those variants were characterized in respect to their kinetic constants. 
 
4.3 Materials and methods 
4.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
plasmid (MEGAWHOP, 25 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
4.3.2 Methods 
4.3.2.1 Site saturation mutagenesis of PpADI M2 at position A128 
Site directed mutagenesis of PpADI M2 (K5T/D44E/H404R) at position A128 was 
performed according to the published method (130). The following 
oligonucleotides were used for mutagenesis of A128: 5’-
CTGATCGGCGGCGTGNNNGGCCAGGACCTGCCG-3’ and 5’- 
CGGCAGGTCCTGGCCNNNCACGCCGCCGATCAG-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 98°C for 30 s, 1 
cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 3 cycles. Second stage: 98°C for 30 
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s, 1 cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 15 cycles; 72°C for 3 min, 1 
cycle), 2 U of PhuS DNA polymerase, 0.20 mM of dNTP mix, 25 pmol of each 
primer together with 100 ng of template (pET42b(+) harboring PpADI M2 gene) 
were used. Following the PCR, DpnI (40 U; New England Biolabs) was added, 
and incubated overnight at 37°C. The PCR products were purified by using a 
QIAquick PCR Purification Kit (Qiagen) and transformed into E. coli BL21-Gold 
(DE3) for expression. 
 
4.3.2.2 Construction of PpADI error-prone library 
EpPCR library was generated by the standard error-prone PCR (epPCR) using 
improved variant M3 (K5T/D44E/A128T/H404R) as template. For the mutagenic 
PCR (95°C for 2 min, 1 cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C 
for 3 min, 1 cycle), 2.5 U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of 
template (pET42b(+) harboring PpADI M3 gene), 0.01-0.1 mM of MnCl2 and 10 
pmol of each primer (5’-TACATATGTCCGCTGAAACACAGAAG-3’ and 5’-
GTGCTCGAGTTAGTAGTTGATCGG-3’) were used. The PCR products were 
purified by using a QIAquick PCR Purification Kit. The purified epPCR products 
were cloned into expression plasmid pET42b(+) by MEGAWHOP (114). For 
MEGAWHOP (72°C for 5 min, 1 cycle; 98°C for 1 min 30 s, 1 cycle; 98°C, 45 s/ 
55°C, 45 s/72°C, 4 min, 24 cycles; 72°C for 10 min, 1 cycle), 1.2 U of PfuS DNA 
polymerase, 0.20 mM of dNTP mix, 500 ng of epPCR products together with 50 
ng of template (pET42b(+) harboring PpADI gene of variant M3) were used. 
Following the PCR, DpnI (40 U; New England Biolabs) was added, and incubated 
(overnight; 37°C). The MEGAWHOP products were transformed into E. coli BL21-
Gold (DE3) for expression and screening. 
 
4.3.2.3 Site directed mutagenesis at position D38 of PpADI M4 
Site directed mutagenesis of PpADI variant M4 at position D38 was performed 
according to the published method on plasmid pET42b(+)-ADI-M4 
(K5T/D44E/A128T/E296K/H404R). The following oligonucleotides were used for 
mutagenesis of D38H: 5’-ACCCCGAGCAACTGCCACGAGCTGCTGTTCGAC-3’ 
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and 5’-GTCGAACAGCAGCTCGTGGCAGTTGCTCGGGGT-3’ (underlining 
indicated the substituted nucleotide). Conditions for mutagenic PCR are as 
described in “Site saturation mutagenesis of PpADI M2 at position A128”.The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.4 Site saturation mutagenesis at position D38 and E296 of PpADI M3 
Site saturation mutagenesis library at position D38 and E296 of PpADI variant M3 
(K5T/D44E/A128T/H404R) were generated according to the published method on 
plasmid pET42b(+)-ADI-M3 using the  following oligonucleotides: D38FP (5’-
ACCCCGAGCAACTGCNNNGAGCTGCTGTTCGAC-3’), D38RP (5’-
GTCGAACAGCAGCTCNNNGCAGTTGCTCGGGGT-3’) and E296FP (5’-
GTCACGGTTTTCCCGNNNGTGGTGCGCGAGATC-3’), E296RP (5’-
GATCTCGCGCACCACNNNCGGGAAAACCGTGAC-3’) (underlining indicated 
the substituted nucleotide). Conditions for mutagenic PCR are as described in 
“Site saturation mutagenesis of PpADI M3 gene at position A128”.The PCR 
products were purified by using a QIAquick PCR Purification Kit (Qiagen) and 
transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.5 Cultivation and expression of PpADI in 96-well plates 
Cultivation and expression in 96-well plates (flat bottom, polystyrene plates; 
Greiner Bio-One GmbH, Frickenhausen, Germany) were performed as previously 
described in 3.3.2.8. 
 
4.3.2.6 Improved screening system in 96-well plate to identify PpADI 
variants with high activities at low arginine concentration 
As describe previously, the modified protocol of citrulline detection based on 
carbamido-diacetyl reaction was used for screening for improved ADI affinity to 
arginine at pH 7.4. 15 µl of cell culture was transferred to 96-well microtiter plate. 
Enzyme reaction was initiated by addition of arginine solution (105 µl, 1mM 
arginine in PBS buffer, pH 7.4) supplemented with 
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cetyltrimethylammoniumbromide (CTAB, 4 mM), and incubated (10 min, 37°C). 
The following color development procedure was carried out as described 
previously (3). 
 
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking PpADI and in a separate experiment 
containing PpADI variant M3. Apparent standard deviation was based on the 
absolute absorbance values obtained from the PpADI variant M3 plate. The true 
standard deviation was calculated by subtracting the background absorbance 
value of the microtiter plate lacking ADI from the apparent values. 
 
4.3.2.7 Expression of PpADI in shaking flask and purification  
Expression of PpADI in shaking flasks and purification (by anion exchange 
chromatography and gel filtration) was performed as previously described in 
3.3.2.10.  
 
4.3.2.8 Characterization of PpADI variants 
Preliminary determination of kinetic constants for site saturation mutagenesis 
variants of position 38 and 296  
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in 
incubator (Heraeus Holding GmbH, Hanau, Germany) using cell crude extract.  2 
ml of expression culture was harvested by centrifugation (Eppendorf 5415R 4°C, 
13,000 g, 10 min) and then freezed (-20°C, overnight). Cell lysate was prepared 
by resuspending the cell pellet in lysozyme (91000 U, 50 mM phosphate buffer, 
pH 7.4, 1.3 ml) followed by incubation (37°C, 40 min) and centrifugation (4°C, 
13,000 g, 10 min). 15 µl of diluted (4 times diluted with 50 mM phosphate buffer, 
pH 7.4) cell lysate was transferred to 96-well microtiter plates. Enzyme reaction 
was initiated by addition of arginine solution (105 µl, 0.25-10 mM arginine in PBS 
buffer, pH 7.4) and incubated (7 min, 37°C). Subsequently, ferric-acid solution 
(120 µl) was added to each well to stop enzyme reaction. 60 µl of terminated 
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enzyme reaction mixture was transferred to 96-well PCR plate for color 
development. Ferric-acid solution (90 µl) and DAM-TSC solution (15 µl) were 
added to each well. The 96-well PCR plate was then incubated (70°C, 30 min) in 
thermal cycler (Eppendorf Mastercyler gradient) for color development, followed 
by incubation in ice water to stop color development. Absorbance was measured 
at 530 nm using a microtiter plate reader (Tecan Sunrise TC reader, Tecan Group 
AG, Zurich, Switzerland). The initial velocity data obtained were fitted to the 
equation v = Vmax[S]/([S] + Km) (where v is the initial velocity, Vmax the maximum 
velocity, [S] the substrate concentration, and Km the Michaelis constant) using 
GraphPad Prism software (GraphPad software, San Diego, CA, USA). The kcat 
was calculated from the ratio of Vmax and enzyme concentration. 
 
Determination of kinetic constants of PpADI wild type and variants M3, M4, M5, 
M6 
The kcat and S0.5 values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath as described previously using purified enzyme (50 µl, 0.1-1.8 µM) to 
and substrate solution (200 µl, 0.5 mM to 10 mM of arginine, PBS buffer, pH 7.4) 
in deep well plates.  
 
The initial velocity data obtained were fitted to the sigmoidal model of kinetics 
equation v = Vmaxn/(S0.5n + Kn) (where v is the initial velocity, Vmax is the maximum 
velocity, K is the substrate concentration, and S0.5 is the ligand concentration 
producing half occupation (131)) using GraphPad Prism software (GraphPad 
software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax and 
enzyme concentration. 
 
4.3.2.9 Native polyacrylamide gel electrophoresis of PpADI variants 
10% of polyacrylamide native gels were used for protein electrophoresis to 
analyze the native form of PpADI variants. Purified protein of PpADI variants (7 µl 
of protein and 3 µl of loading dye) were loaded into each lane of native gel. The 
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molecular marker used in the gel is NativeMarkTM Unstained Protein Standard 
(Invitrogen, Darmstadt, Germany). The electrophoresis was performed with 
tris/glycine buffer (pH 8.3) and electrophoresis chamber was incubated in ice-
water bath. Protein bands were stained with Coomassie brilliant blue solution.  
 
4.3.2.10 Homology modeling 
Homology modeling approach was used for the structure prediction of PpADI. 
The model was built by using the automated structure prediction tool, Protein 
homology/analogy recognition engine (Phyre: http://www.sbg.bio.ic.ac.uk/~phyre/) 
(132). The crystal structure of PaADI (PDB ID: 2A9G) was used as template by 
the server and It has 84.9% sequence identity (http://blast.ncbi.nlm.nih.gov/Blast) 
with PpADI. Procheck program suit (http://www.ebi.ac.uk/thornton-
srv/software/PROCHECK/) (133) was used to assess the stereochemical quality 
of the model. Ramachandran plot which represented that 84.7% residues were 
present in the most favoured region and 14.7% in additional allowed region 
(Figure 3).  Dfire was used to access non bonded atomic interaction in the model 
(http://sparks.informatics.iupui.edu/hzhou/dfire.html/) (134), and Qmean 
(http://swissmodel.expasy.org/qmean/cgi/index.cgi) (135) for the estimation of 
global protein quality. Swiss-PdbViewer (118) was used to create the tetramer 
structure by fitting the monomer model on the 4 units of the 2A9G template. The 
variant M6 (D38H, D44E, A128T, E296K, H404R) were created by using the 
“mutate” tool of the Swiss-PdbViewer and by selecting rotamers with the best 
fitness score. All tetramers were energy minimized in vacuum using GROMOS 
43B1 force field (119).  
 
4.4 Results 
4.4.1 Improved screening system in microtiter plates to identify PpADI 
variants with high activities at low arginine concentration 
Screening assay was based on the validated citrulline colorimetric screening 
protocol in microtiter plate, as reported previously (3). In order to screen for 
variants with high activity at low arginine concentration under physiological 
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condition concerning pH and ion concentrations, 1 mM arginine in PBS buffer 
(pH 7.4) as substrate solution was employed in screening assay and enzyme 
reaction time was controlled accordingly (10 min). The coefficient of variation is 
an important performance criterion of a screening system to determine its 
accuracy. Optimized assay condition with 1 mM arginine (PBS buffer, pH 7.4) as 
substrate resulted in true coefficient of variation of 14.9 % (Figure 1). The 
resulting low absolute absorbance value is a main reason for the high true 
coefficient of variation (14.9 %). In the previous screening system, 100 mM 
arginine in 0.5 M sodium phosphate buffer was used and yielded higher activity 
variants but with higher Km value. 
 
 
 
Figure 1. Activity values in descending order of the PpADI variant M3 conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
4.4.2 Genealogic tree of directed PpADI evolution  
Figure 2 shows the two rounds of PpADI evolution, generation of saturation 
mutagenesis libraries and recombination of beneficial positions to finally obtain 
the PpADI variant M6 with 64.7-fold higher kcat and reduced S0.5 (1.3 mM (WT) to 
0.81 mM (M6). Based on structure-function analysis of PaADI[16], M1 was 
generated by substitute His at position 404 with Arg. Position 404 is through 
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interactions with position Asp280 involved in substrate stabilization during 
catalysis. M1 was subject to the first round of epPCR library, from which M2 was 
identified showing a 4-fold improved kcat value and increased Km value (2.5 mM 
in 0.5 mM sodium phosphate buffer, pH 7.4)[15]. M3 was generated by a site 
saturation mutagenesis library at position 128 which increased in another clone 
the expression level (data not shown). In order to improve PpADI towards 
medical application demands (high activity at low arginine concentration), a 
second epPCR mutant library was constructed using M3 as parent. M4 with 
decreased S0.5 value (0.81 mM) and M5 with increased Kcat value (17.56 s-1) 
were identified after screening of ~1400 clones. In M4 the position E296 was 
identified to be important for lowering S0.5 and in M5 position D38 was identified 
to be important for activity increase. M6 was finally constructed by combining the 
substations at position D38 and E296. Saturation mutagenesis of these two 
positions did not yield any further improved S0.5 or activity variant.  
 
 
Figure 2. Genealogic tree of PpADI variants (M1 to M6) with generated amino acid substitutions. 
Novel substitutions are indicated by an asterisk. 
 
4.4.3 EpPCR library construction and screening for variants with high 
activities at low arginine concentration 
Variant M2 was used as a starting template. As described previously, M2 shifts 
the pH optimum from pH 6.5 to pH 7.0 and has a 4-fold faster kcat than PpADI 
wild type. In one sequenced mutant, position A128 was identified to be 
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responsible for higher expression (data not shown). Site saturation mutagenesis 
on M2 therefore was carried out at position A128. The resulting variant M3 
(K5T/D44E/A128T/H404R) showed a ~2-fold improved expression and was 
subsequently used as parent template for epPCR library. 
 
Three concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Instead of 0.02 mM 
MnCl2, 0.05 mM MnCl2 which generated 46 % of inactive mutant was selected for 
library generation. EpPCR mutant libraries with a ratio of ~50 % active and ~50 
% inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). Two variants M4 and M5 
were identified from this epPCR library (~1400 clones) and further characterized. 
Variant M4 and M5 were sequenced and one additional amino acid substitution 
was identified for each variant, E296K and D38H, respectively. 
 
4.4.4 Site saturation mutagenesis of PpADI at position D38 and E296 
To investigate their role in improving of catalytic performance for arginine, site 
saturation mutagenesis library at position D38 and E296 were generated using 
PpADI M3 as template. For each position, ~300 clones were screened at low 
concentration of arginine (1 mM, PBS buffer, pH 7.4), using 96-well plate format 
citrulline colorimetric screening assay.  
 
After the screening of site saturation mutagenesis libraries of position 38 and 296, 
variants with higher activity were chosen for preliminary kinetic investigation using 
crude cell extract. Beneficial mutants were identified and sequenced from both 
sites (Table 1). At position 38, the following beneficial substitutions were found: 
D38R (three times, AGA, CGG, CGT) and D38K (twice, AAG, AAA). In all cases, 
the negatively charged acidic amino Asp had been replaced by positively charged 
amino acids, Arg or His. Substitution by negatively charged Glu resulted in a 
clone showing a parent M3-like kinetic behavior. Hydrophobic amino acid 
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substitution by Pro resulted inactive clone under assay conditions. At position 296, 
the following substitutions were found to be beneficial: E296K (twice, AAA, AAG), 
E296N (once, AAC), E296T (once, ACC), E296G (once, GGA). Among these 
substitutions, variants with substitution to positively charged residue Lys show 
lowest S0.5 value for arginine while substitution by uncharged amino acids (Asn, 
Thr, Gly) shows relatively marginal improvement compared to E296K. 
Hydrophobic amino acid substitution by Pro and Trp resulted in very low activity 
clones. 
Table 1. Nucleotide and amino acid substitutions at position 38 in PpADI M3. 
 PpADI 
variants Substitution at position 38 km (mM) 
M3 (parent) Asp (GAC) 3.74 ± 0.35 
SSM-D38R Arg (AGA, CGG, CGT) 1.16 ± 0.21 
SSM-D38K Lys (AAG, AAA) 1.01 ± 0.28 
SSM-D38E Glu (GAG) 2.95 ± 0.77 
SSM-D38P Pro (CCA) n. d. 
SSM-D38T Thr (ACC) n. d. 
M5 His (CAC) 1.26 ± 0.12 
Kinetic experiments were performed with crude cell extracts. 
 
 
Table 2. Nucleotide and amino acid substitutions at position 296 in PpADI M3. 
 PpADI 
variants Substitution at position 296 km (mM) 
M3 (parent) Glu (GAA) 3.74 ± 0.35 
SSM-E296K Lys (AAA, AAG) 0.20 ± 0.01 
SSM-E296N Asn (AAC) 0.53 ± 0.04 
SSM-E296T Thr (ACC) 0.61 ± 0.04 
SSM-E296Q Gln (CAA) 0.79 ± 0.06 
SSM-E296G Gly (GGA) 1.29 ± 0.12 
SSM-E296W Trp (TGG) n. d. 
SSM-E296P Pro (CCT) n. d. 
M4 Lys (AAA) 0.27 ± 0.02 
Kinetic experiments were performed with crude cell extracts.  
* n. d. activity not detectable under assay conditions. 
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4.4.5 Determination of kinetic constants (kcat and S0.5) of PpADI wild type 
and variants M3, M4, M5 and M6 
 
Table 3. Kinetic constants of wild type PpADI and variants. 
 Wild type M3 (parent) M4 M5 M6 
kcat (s-1) 0.18 ± 0.05 10.13 ± 0.36 5.88 ± 0.09 17.56 ± 1.15 11.64 ± 0.50 
S0.5 (mM) 1.30 ± 0.25 2.01 ± 0.19 0.81 ± 0.03 1.48 ± 0.17 0.81 ± 0.09 
* Kinetic contants of PpADI wild type is different from our previous report because in stead of 
0.5 M phosphate buffer, PBS buffer was used for kinetic measurements. Kcat value of PpADI 
wild type dropped from 5.6 s-1 to 0.18 s-1 and kcat value of M2 is reduced ~2-fold. 
 
M3, the parent of the second round of PpADI epPCR library, M4 with decreased 
S0.5, M5 with increased kcat and best variant M6 with best combination of kcat 
value and S0.5 were selected for detailed characterization studies.  
 
Kinetic characterization of PpADI variants was performed using PBS buffer (pH 
7.4), which is commonly used in biological research. PBS buffer helps to 
maintain a constant pH and its osmolarity and ion concentrations usually match 
those of the human body. Citrulline production of PpADI variants was maintained 
between 0.2-0.8 mM. Table 3 summarizes the kcat and S0.5 values of parent M3 
(K5T/D44E/A128T/H404R), variants M4 (K5T/D44E/A128T/E296K/H404R), M5 
(K5T/D44E/A128T/D38H/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R), which were expressed in shaking 
flasks cultures and purified using a two step procedure (anion exchange follows 
by gel filtration). Compared to parent M3 (S0.5 = 2.01 mM), both variants M4 and 
M5 have a lower S0.5 for arginine conversion at pH 7.4, 0.81 mM and 1.48 mM, 
respectively. Variant M4 shows a decreased kcat value, 58% of parent M3 while 
M5 shows a 1.7-fold higher kcat compared to parent M3. Variant M6 with 
combined mutations (K5T/D38H/D44E/A128T/E296K/H404R) shows decreased 
S0.5 value, 40 % of parent M3 (K5T/D44E/A128T/H404R), 62 % of PpADI wild 
type, and a 64.7-fold faster kcat value than PpADI wild type. M6 is 42.3-fold faster 
than PpADI wild type with 0.4 mM arginine (PBS buffer, pH 7.4) as substrate. 
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After two rounds of epPCR libraries coupled with site directed mutagenesis, a 
variant M6 with 64.7-fold higher kcat and lower S0.5 value (0.81 mM) than PpADI 
wild type (0.31 mM). At low concentration of arginine, activity of M6 enhanced 
dramatically than M3 and wild type. For example, M6 is 42.3-fold faster than 
PpADI wild type in 0.4 mM arginine (PBS buffer, pH 7.4). 
 
4.4.6 Native polyacrylamide gel electrophoresis of PpADI variants 
Multimeric form of PpADI variants were investigated by native polyacrylamide gel 
electrophoresis. As shown in Figure 3, two distinct protein bands representing 
two multimeric forms tetramer and dimer (molecular weight of a subunit is ~ 46 
kDa) were observed, but with different concentration percentage. The major 
multimeric form of M3 is dimer. Compared to M3, M4 with an additional mutation 
E296K shows a very different pattern: tetramer is the main form; while M5 with 
an additional mutation D38H contains more or less equal amount of dimer and 
tetramer. M6, with both mutations E296K and D38H, contains more tetramer than 
dimer. 
 
 
 
Figure 3. Native polyacrylamide gel electrophoresis of PpADI variants (M3 to M6) with different 
dimer/tetramer distribution. Single subunit has a molecular weight of ~46 kDa. 
 
 
  74 
4.5 Discussion 
 
Directed evolution allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
Small libraries of a few thousand variants are often sufficient to find improved 
variants [18] even without rational understanding of the targeted property. After 
establishing a first directed ADI evolution protocol yielding mutant M2, we 
adjusted the screening system to better reflect ADI’s application conditions. 
Prerequisite for ADI to become an effective anti-tumor agent is that low 
concentrations of arginine in human plasma can effectively be converted. 
 
Figure 2 shows the genealogic tree of PpADI evolution and before discussing the 
influence of each substitution individually the effect on kinetics are briefly 
summarized. Amino acid substitution D44E (M2) increases kcat and S0.5, 
substitution A128T (M3) increases the expression level, and substitution E296K 
(M4) decreases kcat and S0.5 and is responsible for tetramer formation. 
Substitution D38H (M5) increase largely kcat and reduces slightly S0.5. The 
combination of all mentioned residues in M6 result in a finally 64.7-fold improved 
PpADI activity and reduced S0.5 (1.30 to 0.81 mM).    
 
PpADI M3 was obtained from site saturation mutagenesis library at position A128 
using M2 as template (Figure 2). M3 shows improved functional expression level 
of ADI (data not shown) and was used as parent for generating an epPCR library. 
Screening of epPCR library yielded two improved variants M4 and M5, carrying 
an additional mutation, E296K (M4) and D38H (M5). M4 has a decreased S0.5 
(0.81 mM) and a decreased kcat value (5.88 s-1; see Table 3). M5 has a 
decreased S0.5 (1.48 mM) and an increased kcat value (17.56 s-1) when compared 
to parent M3 (S0.5, 2.01 mM; kcat, 10.03 s-1; see Table 3). M6 which harbors both 
substitutions (E296K and D38H) has a decreased S0.5 value (0.81 mM) 
compared to the parent M3 (1.30 mM) and the wild type (2.01 mM), and a 64.7-
fold higher kcat value than the PpADI wild type.   
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Despite further enhancing the activity of PpADI, it is crucial for an efficient 
conversion of the substrate arginine in human plasma (100-120 µM arginine) to 
reduce PpADI’s “Km” (S0.5) value. Figure 4 shows the kinetics of PpADI WT, 
parent M3, and the variants M4, M5 and M6. M3 has a significantly higher kcat 
value compared to WT, but its activity at low concentration of arginine (<1.0 mM) 
is very low (S0.5 value 2.01 mM). In contrast, the most efficient variant M6 with a 
decreased S0.5 value (0.81 mM) shows a remarkable activity improvement at low 
concentrations of arginine (<0.5 mM; see Figure 4). M6 has additional two amino 
acid substitutions (D38H and E296K) compared to M3 which increases kcat and 
reduces the S0.5 value. The combination of D38H and E296K improves especially 
the activity of M6 at low arginine concentrations (< 0.5 mM; see Figure 4). 
 
Figure 4. Kinetic curve of PpADI wild type, M3, M5 and M6. (▲) PpADI wild type, (▼) M3, (●) M4, 
(♦) M5 and (■) M6. 
 
 
Figure 5 shows the tetrameric model (based on PaADI, PDB code 2A9G) of 
PpADI WT (Figure 5A) and variant M6 (Figure 5B). Monomeric units are 
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indicated with the letters a, b, c and d. The access channel to the active sites of 
each monomer is highlighted in square and faces an internal cavity generated by 
the assembly of four PpADI monomers. The substitutions D38H (in blue) and 
D44E (in green) are localized at the interface of monomer pair a-b and c-d. The 
substitution of Glu by Asp at position 44 provides a longer side chain in close 
proximity of the also negatively charged residue Asp43 (Figure 6A). The 
substitution E296K is localized at the border of the entrance to the internal cavity 
of the PpADI tetramer. E296K promotes the tetramer formation likely by 
introducing stabilizing interactions with other residues, for example with Thr33 
(hydrogen bond). E296K inverts the charge at this position and its increased 
length of the side chain might promote further interactions to a neighboring 
monomer (Figure 6A). The combination of D44E and E296K results in a 
population consisting of mainly tetramers (see Figure 3; mutein M4). Interestingly 
with the formation of a tetramer (M4) the S0.5 value is reduced which indicates 
that the tetramer complex formation promotes interactions with the substrate 
arginine at low concentrations. The substitution D38H together with the E296K in 
the mutein M6 reestablishes an almost equal population of PpADI dimers and 
tetramers. A hypothesis is that Lys of the E296K has an electrostatic stabilizing 
interaction with the Glu38 in the M4 but not to the neutral His38. 
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Figure 5. A). The model of WT tetramer after energy minimization in vacuum (GROMOS 43B1). 
B). The model of M6 tetramer after energy minimization in vacuum (GROMOS 43B1). Active site 
residues are represented in CRK format in a square (Blue). Mutated residues are shown in 
licorice format in different colors like D38H (blue), D44E (green), A128T (magenta), E296K (red) 
and H404R (violet). Substrate arginine is represented in orange color by licorice format.  
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Figure 6. A). Structure model of variant M6. E296K is involved in intermonomer interaction 
(between chain a (orange) and b (green)) with Thr33. D44E is involved in intermonomer 
interaction, between chain A (orange) and B (green), with Asp43 (violet). B). Structure alignment 
of PpADI WT model and M6 model with four loops (loop 1:30-46, loop 2:178-175, loop 3:271-281 
and loop 4: 393-404) surrounding the entrance of the active site. The substitutions in these loops 
and the residues involved in the interaction with those substitutions are representing: D38H 
(orange), D44E (yellow) and H404R (cyan, in M6; gray, in WT), Ser35 (green), Arg 400 (pink), 
substrate arginine (ochre), catalytic triad His278, Asp280 and Cys406 (violet, highlighted in an 
oval) 
 
Figure 6B shows that the active site of the PaADI is surrounded by four loops 
(loop 1: 30-46, loop 2: 178-185, loop 3: 271-281, and loop 4: 393-404). These 
four loops undergo a conformational transition upon arginine binding and tighten 
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the surrounding of the arginine substrate[16]. D38 is located in loop 1 and faces 
towards the substrate access channel. In PpADI model (Figure 6B), the D38H 
mutation promotes the formation of a hydrogen bond interaction with the 
neighboring residues Ser35, contributing to the stability of the entropically 
unfavorable folded conformation of loop1. The rigidified loop 1 might be 
beneficial for arginine conversion. According to PaADI structure analysis, the 
side chain of gating residue Arg401 (Arg400 in PpADI) is located at the active 
site entrance and fills the substrate-binding site. The structure analysis of the 
C406A PaADI-L-arginine complex[16] shows that the Arg401 side chain (Arg400 
in PpADI) is displaced by the substrate arginine to a position near the active site 
entrance that allows its hydrocarbon chain to assist shielding the catalytic site 
from solvent. D38 is involved in an ionic interaction and hydrogen bonding with 
Arg400. The substitution of Asp to His at position 38 results in a loss of ionic 
interactions to Arg400 due to the different lengths of the side chains. His38 can 
form only a hydrogen bond with active site gating residue Arg400. A weakened 
interaction between position 38 and Arg400 might increase the flexibility of the 
side chain of Arg400 which then might block less efficiently the access of 
arginine to the active site. As a result the variant M5 shows an improved kcat 
value (1.7-fold compared to parent M3) due to the substitution D38H.  
 
For elucidating further the individual role of the five identified amino acid 
substitutions and their influence on the active site geometry and tetramer 
formation crystal structures of variant M4 and M6 have to be solved.  
 
4.6 Conclusion 
In summary, with the modified screening protocol, PpADI variants with improved 
kcat and S0.5 were identified. The increased kcat value and decreased S0.5 value 
result in significant activity improvement of PpADI at low arginine concentrations. 
Especially the kinetic constants of PpADI variant M6 demonstrate that PpADI 
properties can be tailored by directed evolution. The generated PpADI variants 
match from their kinetic behavior therapeutic application demands much better 
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than the wild type PpADI. We therefore hope that by directed evolution improved 
PpADIs will further be investigated in vivo for tumor therapy. 
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Summary and outlook 
Arginine depletion based on ADI is an emerging strategy for anti-tumor treatment. 
ADIs have been studied for the therapy of HCCs and melanomas and were 
approved as an orphan drug for both kinds of tumors. ADI is proved to be 
effective in the treatment of leukemia. The effectiveness of ADIs as anti-tumor 
agent depends on their enzymatic properties (such as Km, kcat, optimum pH, 
stability at neutral pH). Directed evolution, without rational understanding of the 
targeted property, allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
 
In order to improve PpADI activity at physiological pH by directed evolution, a 
colorimetric screening assay based on citrulline detection has been developed in 
96-well microtiter plate format. Single mutation H404R was identified according 
to PpADI homology model (based on PaADI crystal structure), introduced to 
PpADI wild type and eventually resulted in 1.4-fold of increase in kcat. M1 (H404R) 
was used as template for the first round of epPCR library generation. M2 
(K5T/D44E/H404R) obtained from the first round of epPCR library showed 4-fold 
improved kcat value when compared to the PpADI wild type. Furthermore, a shift 
of pH optimum from pH 6.5 to pH 7.0 was observed, combined with an increased 
Km value (2.5 mM) under assay conditions (0.5 M sodium phosphate buffer, pH 
7.4), compared to PpADI wild type (0.7 mM). 
 
Arginine concentration in human plasma is however relatively low (100-120 µM). 
Therefore the second round of epPCR library was performed to decrease Km 
value and further improve kcat value. The validated screening assay was modified 
to reflect more close physiological condition (1 mM arginine in PBS buffer, pH 
7.4). Two important variants with one additional mutation, M4 
(K5T/D44E/A128T/E296K/H404R) with decreased S0.5 vaule, and M5 
(K5T/D38H/D44E/A128T/H404R) with improved kcat were obtained. Their two 
mutations were combined and resulted in variants M6 
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(K5T/D38H/D44E/A128T/E296K/H404R). Under physiological pH in PBS buffer, 
the S0.5 value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); 
the kcat value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-
folds) and 11.64 s-1 (M6, 64.7-fold). 
 
A reamaining challenge facing PpADI’s anti-tumor application is to decrease the 
Km (S0.5) value further close to arginine concentration level in human plasma. A 
more sensitive assay for screening has to be developed with the addition of 
sensitizer like thiosemicarbazide (TSC), optimized temperature and incubation 
time. Improved variants should be tested tested in human plasma or with human 
plasma composition. In vitro testing of ADI variants with arginine auxotrophic 
tumor cell lines is the first step towards in vivo in human. 
 
In summary, directed evolution has been very useful algorithim for improving 
ADI’s kcat and Km at physiological pH (pH 7.4) for its medical application. Hope 
that directed evolution will be become a standard method for therapeutic protein 
like its use in industry.                                
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Abstract 
Abstract 
Arginine deiminase (ADI), an arginine-degrading enzyme, is involved in the first 
step of arginine dihydrolase pathway. It catalyzes the hydrolysis of L-arginine to 
form citrulline and ammonia. ADI has been studied as a potential cancer 
therapeutic agent for the arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCC) and melanomas. Furthermore, studies also indicate that ADI 
is a potential anti-angiogenic agent; therefore it could become a novel anti-cancer 
drug targeting the neovascularization-related tumors. Studies show ADI is more 
potent for the treatment of leukemia than L-asparaginase. However, the anti-
tumor application of ADI for therapeutic purpose faces considerable challenges, 
such as, microbial ADI has low activity at physiological pH (7.35~7.45), short 
circulating half-life (~5 h) and high antigenicity. Pegylation of ADI improved its 
efficacy as a clinical drug, including its half-life in serum and antigenicity. The aim 
of the project is to improve ADI catalytic performance at physiological pH by 
directed evolution. 
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. Directed protein evolution has 
over the last decades become a versatile and successful approach for tailoring 
protein properties to industrial demands and for advancing our understanding of 
structure-function relationships in biocatalysts. Unlike rational design relying on 
the gathering of extensive structure-function relationships of enzymes, directed 
evolution is used to reengineer enzyme properties through iterative rounds of 
diversity generation and function selection for improved variants. 
 
In order to improve the ADI activity at physiological pH, we established a directed 
evolution protocol for this purpose. A microtiter plate (MTP) format colorimetric 
screening assay based on citrulline detection with diacetyl monoxime (DAM) was 
developed. Reaction temperature for color development and DAM concentration 
 IV 
were optimized to ensure sufficient sensitivity, appropriate linear range and 
throughput. With the optimized assay and PpADI wild type expressed in E. coli as 
a model protein, true standard deviation 12.8 % was obtained, which is 
appropriate for the library screening. 
 
With the established microtiter plate assay system, for the first time, we 
reengineered ADI for improved activity at physiological pH (pH 7.4) with higher 
potency in medical application. After one site directed mutagenesis and one 
round of epPCR library screening, variant M2 (K5T/D44E/H404R) was obtained. 
M2 shows 4-fold improved kcat value than the PpADI wild type, a shifted pH 
optimum at pH 7.0 (by 0.5 pH unit), and however an increased Km value, 3.6-fold 
under assay conditions (0.5 M sodium phosphate buffer).  
 
Low Km (S0.5) value for ADI is an important factor for efficient consume of arginine 
in plasma because of the low arginine concentration in human plasma (100-120 
µM). Therefore after our proof of concept of reengineering PpADI by directed 
evolution, we aim to decrease the Km value of PpADI towards arginine and 
improve the kcat furthermore thereby improve the efficiency of arginine depletion 
by ADI. The established citrulline colorimetric assay in 96-well microtiter plate is 
improved to reflect application conditions: PBS buffer and 1 mM arginine were 
used in screening system. After the second round of epPCR library and site 
directed mutagenesis, variant M5 (K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated: at pH 7.4 (PBS buffer), 
the S0.5 value decrease from 2.01 mM (parent M3, K5T/D44E/A128T/H404R) to 
1.48 mM (M5) and 0.81 mM (M6). Under physiological pH in PBS buffer, the S0.5 
value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat 
value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 
11.64 s-1 (M6, 64.7-fold). 
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Chapter 1 Arginine deiminase (ADI) 
Arginine deiminase (ADI) 
 
1.1 Arginine deiminase (ADI)  
Arginine deiminase (ADI, EC 3.5.3.6), an arginine-metabolizing hydrolase, 
catalyzes the hydrolysis of L-arginine to form citrulline and ammonia. This 
reaction is the first step in the L-arginine degradation pathway (ADH, scheme 1, 
(1). First, arginine is deiminated by arginine deiminase. The resulting citrulline is 
converted to carbamoyl phosphate and ornithine by ornithine transcarbamylase 
(EC 2.1.3.3), and finally the carbamoyl phosphate is used to phosphorylate ADP 
by carbamate kinase (EC 2.7.2.2), producing one ATP molecule. ADI is absent in 
humans but present in a wide range of bacterial species such as Pseudomonas 
aeruginosa (2), Pseudomonas plecoglossicida (3) and Mycoplasma arginini (4) 
and in parasitic protists such as Giardia intestinalis (5), Trichomonas Vaginalis 
(6), Trichomonas fetus (7), and Hexamita inflate (8). For pathogenic bacteria, ADI 
is required in arginine dehydrolase pathway for virulence and for energy 
production under anaerobic conditions (9, 10).     
 
 
Scheme 1. Arginine dihydrolase pathway. OTC, ornithine transcarbamylase; CK, carbamate 
kinase. 
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The establishment of a high-level production system for ADI is an essential step 
for further research and development of this enzyme. After ADI was discovered 
from Mycoplasma in 1960s (11), various ADI genes have been cloned, 
expressed in E. coli strains, and the enzyme properties were also studied (Table 
1). 
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Table 1. ADI expression, enzymatic properties and medical applications. 
ADIs Origin 
Expression 
host/vector 
Multimeric 
form Km; kcat 
Optimum 
pH  
Specific 
activity 
Medical 
application References 
MhADI 
(SYN1903) 
Mycoplasma 
hominis PG21* 
E.coli BL21 
(DE3)/pET-47b 
Dimer   0.618 U/mg 
(pH 6.5) 
Human 
melanoma 
(G361), 0.036 
U/ml for 50 % 
IC50 
Japan, 
Harasawa, 
2009 (12) 
MhADI Mycoplasma 
hominis (ATCC 
23114) 
- 
 
Dimer   6.0 35.5 U/mg (pH 
6.0) ;  
3.9 U/mg (pH 
7.4)  
Mouse 
melanoma 
(MH134) in 
vitro, 100 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MhADI Mycoplasma 
hominis (ATCC 
14027) 
- Dimer  0.17 mM 
(pH6.6) 
   USA, Fenske, 
1976(14) 
MhADI Mycoplasma 
hominis  
E.coli BL21 
(DE3)/pET25b 
 0.24 mM; 
0.151 s-1 
   China, Luo, 
2007 (15) 
MhADI Mycoplasma 
hominis 
E.coli    20 U/mg ADI 
(37°C). [a] 
ADI-SS 
PEG20000,  
human 
melanoma, 
human HCC 
USA, Pheonix 
Pharmacologi
cs, Inc., Clark, 
2002 (16) 
PaADI 
(PA5171) 
Pseudomonas 
aeruginosa  
(ATCC 47085D) 
E. coli 
BL21(DE3)/pET10
0 
Tetramer 0.14±0.01 
mM (pH 5.6) 
5.6   USA, 
Dunaway-
Mariano, 2005 
(17) 
PaADI Pseudomonas 
aeruginosa  
 
E. coli 
BL21 (DE3)/ 
pET SUMO 
   CARD-like 
domain, no 
catalytic 
activity 
Human cancer 
cell line SKOV-3 
USA, 
Chakrabarty, 
2006 (18) 
PpADI Pseudomonas 
plecoglossicida 
E. coli 
BL21 Gold-(DE3)/ 
pET42b 
 0.7 mM; 5.6 
s-1 (pH 7.4, 
0.5 M sodium 
phosphate 
buffer) 
6.5 31.3 U/mg (pH 
7.4, 0.5 M 
sodium 
phosphate 
buffer) 
 Germany, 
Schwaneberg, 
 2010 (3) 
 4 
MaADI Mycoplasma 
arginini 
(ATCC 23838D) 
E. coli 
DH5α/PTTQ118 
   32.7 U/mg. [a] Human 
umbilical vein 
endothelial 
(HUVE) 
USA, Shen, 
2002 (19) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
E. coli 
JM101/pADTc1 
Dimer     33.6 U/mg 
(37°C, pH 6.5). 
[a] 
Mouse 
hepatoma, 17 
ng/ml for 50 % 
IC50; mouse 
fibrosarcoma, 
15 ng/ml for 50 
% IC50 
Japan, 
Hayashi, 1994 
(20) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
    42 U/mg 
(37°C, pH 6.5); 
29.9 U/mg 
(37°C, pH 7.4) 
Mouse 
melanoma 
(MH134) in 
vitro, 10 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
-     HUVE, 
neuroblastoma, 
retinoblastoma, 
osteosarcoma, 
5~10 ng/ml for 
50 % IC50 
Germany, 
Schweigerer, 
1999 (21) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
- Dimer  0.2 mM 6.0-7.5 50 U/mg Mouse tumor 
carcinoma, 
fibrosarcoma 
and melanoma, 
5~20 ng/ml for 
50 % IC50 
Japan, 
Takaku, 1992 
(22) 
LlADI L. lactis (ATCC 
7962) 
E. coli 
BL21Gold(DE3)/p
GEM-T Easy 
Trimer 8.67 mM 7.2 140.27 U/mg  Korea, Lee, 
2007 (23) 
[a] ADI was expressed in inclusion body and denaturation-renaturation had to be employed to get soluble protein. 
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1.2 ADI structure 
In 1970s, Kakimoto et al. (24, 25) diffracted the first ADI crystals from P. putida 
through multiple-step chromatography followed by crystallization. Almost three 
decades later, the X-ray crystal structure of ADI from P. aeruginosa (PaADI, 
Figure 1A) (26) and M. arginini (MaADI, Figure 1B) (4) were solved to assist in 
understanding structure-function relationships. PaADI and MaADI share 27 % 
sequence identity and belong to guanidino group-modifying enzyme superfamily 
(GMSF). The catalytic triad (Cys-His-Glu/Asp) is conserved in members of the 
GMSF. Both crystal structures of PaADI and MaADI show a characteristic 5-fold 
pseudosymmetrical barrel with ββαβ subunits. Table 2 summarizes the crystal 
structures of PaADI and MaADI. 
 
Figure 1. Structural of ADIs from P. aeruginosa and M. arginini. (A) PaADI (PDB ID: 1RXX) and 
stereo view of its catalytic triad (C406-H278-E224). (B) MaADI (PDB ID: 1S9R) and stereo view 
of its catalytic triad (C398-H269-E213) with substrate L-arginine (27). 
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Table 2.  Crystal structures of ADI in protein data bank (PDB). 
PDB 
code 
Ligand in crystal 
structure Description 
Resolution 
(year) 
2A9G Arginine 
Crystal structure of PaADI variant C406A in 
complex with L-arginine  
2.30 Å 
(2005) 
2AAF  
Crystal structure of PaADI variant H278A 
forming a S-alkylthiouronium reaction 
intermediate  
2.30 Å 
(2005) 
2ABR  
Crystal structure of PaADI variant D280A with L-
arginine forming a S-alkylthiouronium reaction 
intermediate  
2.9 Å 
(2005) 
2ACI  Crystal structure of D166A arginine deiminase  
2.50 Å 
(2005) 
1S9R Arginine 
Crystal structure of MaADI covalently linker with 
a reaction in intermediate  
1.60 Å 
(2004) 
1LXY Citrulline 
Crystal Structure of MaADI covalently linked with 
L-citrulline  
2.00 Å 
(2004) 
1RXX  Crystal structure of MaADI  
2.45 Å 
(2004) 
 
MaADI was crystallized as a homodimer and its catalytic triad is formed by 
Cys398-His269-Glu213. MaADI has a catalytic domain and a five-helix bundle 
domain (Figure 3). The buried and compact substrate binding pocket is located 
approximately at the center of the molecule, from which a small solvent channel 
leads to the surface of the enzyme. The opening to the channel is located 
adjacent to the dimer interface region, which is at the opposite side of the 5-fold 
pseudosymmetric moiety of ADI. The shape and size of the channel does not 
permit transport of the substrate (L-arginine and end product (L-citrulline) in and 
out of the pocket. Substantial conformational changes in ADI are required to 
permit entry of the substrate and expulsion of the end product. The occurrence of 
"closed" and "open" form was suspected to be dependent on binding of substrate. 
 
PaADI has a tetrametric structure with 1630 amino acid residues in total, which 
makes it the largest enzyme of its structural superfamily. The catalytic triad of 
PaADI is Cys406-His278-Glu224. Similar to MaADI, the active site of PaADI is 
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located in a narrow crevice formed by a network of charged residues. Ligand 
binding energy is derived from ion pair and hydrogen bonding interactions 
between active site residues and the guanidinium, carboxylate and ammonium 
groups of the substrate. The proposed substrate-binding model shows that the 
catalytic center contains abundant charged residues (e.g. Asp280, His405, Glu13 
and Arg165). The ion pairing interactions between these residues contribute to 
the integrity and activity of ADI. In addition, Asp116, Asp227, Arg185, Arg401, 
His278, Glu118, and Glu224 are part of an extended charged network. The 
proposed catalytic mechanism suggests that the active site of PaADI is blocked 
by Arg401, and therefore a conformational transition is taking place upon the 
substrate binding. Based on the proposed reaction mechanism, Cys406 is as a 
key residue responsible for the nucleophilic attack on the guanidinium carbon 
atom of arginine. PaADI contains only one hydrophobic residue, Phe-163 and a 
Cys-406 with an unknown protonation state. The known functions of important 
residues are shown in Table 3, and the interactions between important residues 
and substrate arginine are shown in Figure 2. 
 
 
Figure 2. A. stereoscopic view of PaADI key active site residues. B. stereoscopic view of a 
modeled arginine substrate (green) docked in the active site of ADI. Atomic colors are red, 
oxygen; blue, nitrogen; yellow, sulfur; and gray, carbon. Ion pair interactions are shown as 
dashed lines (26). 
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Table 3. Residues important for catalytic function of PaADI (28, 29). 
Residues Known/postulated function or comment 
Cys406 Mounts the nucleophilic attack on the carbon atom of the guanidinium 
group of arginine 
His278 Serves as a general base and activate the water molecule 
Glu224 Modulate the ionization state of His278 
Asp280 Interacts with the imidazole group of His405 F via the carboxylate 
group, which in turn interacts with Glu13. Invariant residue in all 
known ADIs 
Asp280, 
Asp166 
Fix the guanidinium group of the arginine substrate tightly by 
interactions with the carboxyl groups 
Arg401, 
Arg185 
Form ionic interaction with The carboxyl group of the arginine 
substrate 
Phe163 Interacts with the hydrophobic part of arginine substrate 
Glu13 Interacts His405 and is invariant in all known ADIs 
His405 Sometimes is replaced by an arginine, as in the case of McADI. This 
may explain the low pH optimum of PaADI (5.6) in contrast to the 
neutral pH optimum of McADI, the enzyme that contains an arginine 
residue instead of His405 
Arg165 Is fixed by electrostatic interactions with the main chain oxygen atoms 
of Thr408 and His405 and with the hydroxyl group of Thr-408 
Arg401 Blocks the ADI active site via the side chain by forming an ion pair 
with the carboxyl group of Asp166 and occupies approximately the 
same position as the guanidinium group of an arginine substrate 
 
The overall fold of MaADI and PaADI consist of five ββαβ modules in cyclical 
arrangement, generating a pseudo 5-fold symmetrical barrel and an additional 
85-residue α-helical domain inserted between the first and the second ββαβ 
modules giving the typical “Clip-on-fan” moiety. The α-helical domain of PaADI 
mediates tetramer formation and the α-helical domain of MaADI was speculated 
to play a role in activating the series of reaction in arginine dehydrolysis pathway 
(4). Structural alignments by Chakrabarty et al. (18) demonstrated the unique 85 
residue 5-α-helical bundle domain exhibiting structural similarity to the 
mammalian CARD (caspase recruitment domains)-containing proteins and this 
CARD-like domain is present only in the PaADI and MaADI but not in the other 
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GMSF members (Figure 3B). Furthermore, PaADI putative CARD-like domain 
induced apoptosis to cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structural characteristics of the PaADI. A. Ribbon drawing of PaADI (1RXX_A) 
highlighting the two domains. B. The presence of the CARD domain in PaADI and MaADI but its 
absence in other members of the GMSF (guanidino-group modifying superfamily) enzymes such 
as DDAH and AGAT, as shown from the structure-based sequence alignments. The CARD 
domain represents that of caspase-9. DDAH, dimethylarginine dimethylaminohydrolase; AGAT, 
arginine: glycine amidinotransferase. The β-strand and α-helices are shown as arrows and strips 
respectively. Roman numericals I to V are the five ββαβ subunits. The clip moiety (α-helical 
module) in Figure 3 is seen only in PaADI and MaADI which bears structural homology to the six-
α-helical modules that form the CARD domain of the caspase-9 protein molecule. N, N-terminal; 
C, C-terminal. C. A schematic diagram showing the overall fold and topology of PaADI, as 
reported (18). 
 
Comparison of substrate free and substrate bound structure of PaADI gives 
interesting insight into structure changes upon substrate binding (17). Pairwise 
superposition of the free wild-type PaADI (PDB code: 1rxx) and the mutant 
enzyme substrate complexes (PDB code: 2a9g) show that the overall fold of the 
structures remains similar, yet with some local changes. In particular, four loops 
(Figure 4) associated with the active site undergo conformational transitions not 
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related to crystal packing: loop 1 (residues 30-46), loop 2 (residues 178-185), 
loop 3 (residues 271-281, part of this loop is disordered in the apoADI structure), 
and loop 4 (residues 393-404). Residues adjacent to the substrate exhibit the 
most significant shifts. For example, the α-carbon atom of Leu41 (loop 1) shifts 
by 2.7Å and that of Arg185 (loop 2) by 1.8 Å; the α-carbon atom of His278 (loop 
3) shifts by 0.9 Å and that of Gly400 (loop 4) by 4.4 Å. These are localized but 
mechanistically important conformational transitions that tighten the surrounding 
of the substrate. Simultaneously, substrate binding is accompanied by 
displacement of the side chain of Arg401 (loop 4) by more than 8 Å to enable 
access to the active site. The superposition of ADI and PAD4 ADI active site is 
shielded from the solvent by a long loop (residues 25-48 in PaADI) and the 
following two turns of α-helix (residues 49-56). 
 
 
 
 
 
Figure 4 (A). Stereoscopic view of ADI in the unbound and bound states. Superposed molecules 
are colored gray where the trace of the polypeptide chain is similar in both structures. For regions 
exhibiting differences, loops of the apoADI structure are highlighted in blue, and loops of the ADI 
structure complexed with arginine are highlighted in red. 4(B). Structural relationship between ADI 
(yellow) and PAD4 (cyan) (17). 
1.3 Catalytic reaction mechanism of ADI 
The overall reaction catalyzed by ADI is the hydrolytic substitution of the ŋNH2 
group from the guanidinium group Cζ of L-arginine, leading to citrulline and 
ammonia (Figure 5). Herzberg (17) and Arnold (4) proposed ADI catalysis 
mechanism for PaADI (Figure 5) and MaADI, respectively.  Basically, both of the 
proposed mechanisms are composed of three main steps: 1) thiol group of 
B A 
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Cys406 mount a nucleophilic attack on the guanidinium group of arginine and a 
proton is transferred first to ŋNH2 group; 2) water molecule is activated by His278 
and followed by attacking the covalent intermediate to replace and release NH3; 
3) the C-S covalent bond between enzyme and the resulting citrulline is cleaved 
and thus end product citrulline is released and free enzyme is generated for next 
catalytic cycle. 
 
 
Figure 5.  Mechanism of PaADI catalysis of arginine to citrulline and ammonia (17). 
1.4 Anti-tumor application of ADI 
Amino acids depletion is one type of targeted therapy for human cancers which 
are auxotrophic for a particular amino acid. Amino acids degrading enzymes, 
such as asparaginase (30), methioninase (31), arginase (32), arginine deiminase 
(27), phenylalanine ammonialyase (33) and tryptophanase (34) have been 
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studied for inhibition of tumor cells in vitro. The most representative anticancer 
enzyme is asparaginase, which is particularly effective in acute lymphoblastic 
leukaemia. PEG asparaginase is commercialized for acute lymphoblastic 
leukaemia treatment (Oncaspar®, pegaspargase) (35). However, asparaginase 
treatment is sometimes accompanied by serous side-effects including 
anaphylactic shock, coagulapathies as well as liver and pancreatic toxicity (36).  
 
Arginine is an important amino acid involved in the synthesis of a wide range of 
peptides and proteins, production of creatine and nitric oxide, and a myriad of 
metabolic pathways and cellular events. It is a precursor of proline, polyamines, 
glutamine, glutamate, and other neurotransmitters, such as g-aminobutyric acid 
and also serves as a substrate for two important enzymes, arginase and nitric 
oxide synthetase (37). Arginine is an indispensable amino acid to children but a 
semi-essential amino acid in adult humans since many adult somatic cells can 
synthesize it from citrulline in two steps via urea cycles (Figure 6). The enzyme 
argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline and 
aspartic acid to argininosuccinate which is then further converted to arginine and 
fumaric acid by argininosuccinate lyase (ASL). Arginine can be degraded to 
ornithine by the urea cycle enzyme arginase. Ornithine is then converted back to 
citrulline by ornithine carbamoyl transferase (OTC) and then recycles back to 
arginine from citrulline by ASS/ASL. Thus, the ability to regenerate arginine from 
citrulline depends on the amount/activity of ASS and ASL, which are tightly 
coupled. The sensitivity of cells to arginine deprivation depends on the ability of 
ASS and ASL to regenerate arginine from the alternative intermediate (ornithine, 
citrulline and argininosuccinate) in the urea cycle. 
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Firgure 6. Urea cycle. Argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline 
and aspartic acid to argininosuccinate which is then further converted to arginine and fumaric acid 
by argininosuccinate lyase (ASL). Arginine can be degraded to ornithine by the urea cycle 
enzyme arginase. Ornithine is then converted back to citrulline by ornithine carbamoyl transferase 
(OTC) and then recycles back to arginine from citrulline by ASS/ASL.  
 
Arginine begins to become limiting at ~10-4 M, whereas other amino acids can 
sustain growth at 10-5-10-6 M. Wheatley et al. showed that most tumour cell lines 
die considerably more quickly during arginine deprivation than in the absence of 
any other single (or group of) essential amino acids (38). Since 1930 for the first 
time arginine known is essential for the growth of some forms of cancer, the 
potential of arginine degrading enzymes as therapeutic agents was recognized, 
investigated and employed for arginine auxotrophic tumor treatments. Enzymes 
capable of depleting arginine in vitro include arginase existing in human liver, 
arginine decarboxylase from bacterial, plant and human, and ADI from 
microorganism. 
 
Arginine decarboxylase converts arginine to agmatine, which is toxic at high 
plasma concentration. Furthermore, arginine decarboxylase has a short half-life 
and it loses virtually all enzymatic activities upon pegylation though pegylation of 
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arginine decarboxylase is inefficient because not enough lysine residues for 
polyethylene glycol to attach (39). 
 
Arginase is limited for anti-tumor application because of its low substrate affinity 
(Km value 2-4 mM; plasma arginine 100-120 µM), short circulatory half-life (10-15 
min) and sub-optimal enzymatic activity at physiological pH (alkaline pH optimum, 
pH 9.3)(40). Despite these disadvantages of arginase, Lam et al. reported  
remission of hepatocellular carcinoma induced by systemic release of 
endogenous hepatic arginase (41) and Leung et al. proved pegylated 
recombinant human arginase (rhArg-peg 5,000mw) can inhibit ASS-positive 
HCCs while ADI can not (42). 
 
In addition, ADI, another arginine-degrading microbial enzyme, has various 
biological activities including anti-proliferation, anti-angiogenesis and inhibition of 
inducible nitric oxide synthase (iNOs). Figure 7 summarizes how ADI affect many 
arginine-related cellular functions. ADIs (Table 1) have been shown to have 
strong in vitro and in vivo inhibition for arginine auxotrophic tumors (e.g. 
hepatocellular carcinomas (HCCs), melanomas, retinoblastoma (43), prostate 
cancer(44)) and ADI from M. hominis (MhADI) is currently under clinical trial for 
HCC (phase II) (45) and melanomas (phase I/II) (46). Studies on human 
lymphatic leukemia cell lines confirmed ADI’s anti-angiogenic activity. Among all 
the ADIs, MhADI and MaADI were studied most intensively (Table 1). 
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Firgure 7. Summary of ADI effects on arginine-related cellular functions. rADI inhibits NO 
production via iNOS, but potentiates NO production via eNOS in the cultured endothelial cell 
model. rADI enhances or inhibits AS activity in different cells. rADI inhibits de novo protein 
synthesis in cells with low AS activity, but not in cells with high AS activity. Polyamine synthesis 
was not significantly affected by rADI, even in cells with low AS activity. Arrow representation: 
solid, potentiates; blocked, inhibits; dotted, no effect (47).  
 
In 1999, US Food and Drug Administration (FDA) designated ADI-PEG-20 
orphan drug status for treating HCC and invasive malignant melanomas. In 2005, 
also the European Agency for the Evaluation of Medicinal Products (EMEA) also 
granted ADI-PEG-20 orphan drug status for HCC. Phase II trials of ADI-PEG-20 
in patients with metastatic hepatocellular carcinomas have shown that the drug is 
safe, well tolerated, and may benefit patients with unresectable HCC. Izzo and 
coworker suspected that combination therapies of arginine deprivation and 
growth inhibition via kinase inhibitors might improve the survival rate further. 
Additionally, ADI enhances radio sensitivity of human mammary adenocarcinoma 
(MCF-7 cells) (48), exerts anti-proliferative as well as anti-angiogenic activities 
and inhibits the growth of viruses such as HIV-1 and hepatitis (49, 50). Current 
research efforts are focused on ADI’s in vivo inhibitory effect towards leukemia, 
melanoma, prostate cancer, renal cell carcinoma, and human umbilical vein 
endothelial cells (HUVEC) (19, 44, 51-53), clinical trials for HCC (phase II) (45) 
and melanoma (phase I/II) (46), and tumor inhibitory mechanisms of ADI (54). 
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The effectiveness of ADIs as anti-tumor agent depends on their enzymatic 
properties (such as Km, kcat, optimum pH, stability at neutral pH), selectivity on 
tumor cells, stability in blood circulation and immunogenicity. Pegylation (35) has 
been effective in reducing their immunogenicity in animal and increase their 
stability to various hydrolytic enzymes in plasma. Directed evolution as powerful 
algorithm to design proteins allows improving all properties that can be reflected 
in a screening system through iterative rounds of diversity generation and 
screening. Small libraries of a few thousand variants are often sufficient to find 
improved variants (55) even without rational understanding of the targeted 
property. The first example of directed ADI evolution by our group (3) provides a 
simple and effective screening system to improve activity of PpADI at 
physiological pH.  
 
1.5 Conclusion 
ADI-based arginine deprivation is a novel and promising targeted approach to the 
treatment arginine auxotrophic tumors, in particular, melanoma, hepatocellular 
carcinoma and leukemia. Certain mesotheliomas and renal cell cancers were 
also proved to be sensitive to ADI therapy. Due to its low incidence of major side 
effects (myelosuppression and gastrointestinal toxicity or other major organ 
toxicity) arginine deprivation treatment should be combined with other anticancer 
treatments to increase the response rate. Reengineering of ADI by protein 
engineering is a promising strayegy to tailor ADI properties for demands in 
medical applications. Solved ADI crystal structure enables to understand 
structure function relationships and to guide protein engineering. 
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Chapter 2 Directed evolution 
Directed evolution 
 
2.1 Introduction to directed evolution 
Enzymes are increasingly being used in the generation of products that are 
traditionally made using chemical synthesis and the field continues to expand its 
horizons, particularly as applied to the synthesis of the fine chemicals and 
pharmaceuticals (56, 57). Naturally occurring enzymes are often not designed for 
the applications of interest, since after all they are evolved in nature for a 
purpose other than being the catalysts of industrial processes. Directed evolution, 
rational design and biodiversity screening and combined approches are the main 
strategies to reengineer enzymes for addressing application demands. Directed 
evolution has emerged as a powerful enabling method for improving enzyme 
properties in iterative cycles of diversity generation and screening (Figure 1).  
 
A main advantage of directed evolution compared to rational design is that it 
does not require structural or mechanistic information for protein optimization. 
Directed protein evolution has been successfully used for altering and improving 
protein properties (solubility, expression, enantioselectivity, stability and activity 
in unusual environment, allosteric interactions, tolerance to pH), as well as for 
regulating other molecules and systems, including RNA, DNA regulatory 
elements, biosynthetic pathways and genetic regulatory circuits (58-60).  
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Figure 1. Procedure of a directed evolution experiment. It involves three key steps: 1) selection a 
good starting sequence and mutating the parent to create a library of variants; 2) identification 
variants with improved function and 3) isolation of gene encoding for improved variant and 
repeating the process until the desired function is achieved. 
 
A parent sequence (or sequences) is chosen based on its perceived proximity to 
the desired function and its evolvability (the ability of a protein to adapt in 
response to mutation and selective pressure). A parent protein for directed 
evolution should exhibit enough of the desired function that small improvements 
can be reliably discerned in a high-throughput screen.  
 
Variants library should be generated with high probability of finding improved 
variants given the screening capacity. With a high-throughput screening method, 
a library can be constructed to generate the large potential improvement. Arnold 
and coworkers(61) showed that very low mutation rates result in many functional 
sequences but only a small number are unique sequences, however very high 
mutation rates produce diverse sequences but few retain function. Schwaneberg 
and coworkers(62) reviewed random mutagenesis methods, focused library 
generation methods and computational tools for high-quality mutant libraries 
generation. Schwaneberg and coworkers (63) also summarized criteria for an 
ideal mutagenesis methods: unbiased mutational spectrum, controllable mutation 
frequency, consecutive nucleotide substitutions or codon-based substitutions, 
enable subset mutagenesis (e.g. introduction mainly positively or negatively 
charged amino acid), independent of gene length, technically simple and 
reproducible, and economical. 
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Screening is used to identify library members improved in the targeted property. 
Identification of improved variants though selection or screening is “analogous” to 
evolutionary pressure in natural evolution (i.e. only the fittest survive). As the 
word “directed” in directed evolution implies, laboratory evolutionary pressure is 
defined and applied by the researcher in screening system. Gradually increasing 
the selection pressure or evolving against a series of intermediate challenges 
often accumulates useful single mutations and yields desired variants (64).  
 
Traditional methods for screening employ microtiter plate formats (96-well, 384-
well, 1,536-well (65) and even 1,000,000-well (66)) or solid phase assay (agar 
plate, filter paper and nitrocellulose membrane), which typically enable the 
screening of no more than 106 variants by using robotic automation (67). 
Sometimes, fast and universal analytic methods like HPLC (68) or GC-MS (69) 
are utilized for performing an efficient screen of a non-natural substrate. However, 
the number of screened mutants is limited to 104-106. In recent years flow 
cytometry systems (67, 70, 71) have become increasingly attractive, especially 
after the development of emulsion technology offering compartmentalization and 
high throughput up to 107/h. In addition, Weitz and coworkers (72) recently 
reported a promising ultrahigh-throughput screening in drop-based microfluidics, 
by which one can screen a library of 108 in about 10 h. Dijkhuizen et al. 
compared in a review (73) six kinds of library screening strategies (Figure 2). 
Selection techniques rely on a direct link between cell growth and improved or 
acquired enzyme function and therefore it is limited to engineering detoxifying 
enzymes (e.g. b-lactamase) or enzymes that synthesize essential nutrients for 
cell growth and survival. The traditional microtiter plate screenings are medium-
throughput and the most simplistic format of screening. It involves the incubation 
of colonies with the substrate of targeted enzyme. The crucial factor with this 
screening technique is that substrate conversion creates a visual signal, such as 
fluorescence or color, to identify colonies expressing an enzyme with desirable 
properties. Microtiter plate based screenings are the most commonly applied 
method in identifying desirable enzyme variants. Microtiter plate based 
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screenings enable the use of various analytical tools and in the mean while they 
offer a great dynamic range. Their screening capacity is usually limited to less 
than 104 variants per day. Screening based on microfluidic device and sorting 
device is a new screening platform for directed evolution, which offers ultra-high-
throughput. It allows the discriminate between wild-type and a less active mutant 
and allows for the addition of substrates and quenchers at desired time thus 
extending the scope of directed evolution screening strategies. Cell as micro-
rector, cell surface display and in vitro compartmentalization technology are also 
FACS (fluorescence-activated cell sorting system) dependent methods for high-
throughput screening and allow 109-1010 screening capacity. 
 
Once improved enzymes are identified, encoding genes are isolated and 
subjected to further iterative cycles of mutation and screening in order to 
accumulate beneficial mutations until the targeted improvement is hopefully 
achieved. The number of iterations required depends on the starting point, the 
protein fold and the selected properties which determine the possible mutational 
load and achievable improvement. 
 
Four accepted requirements for successful directed evolution 
(http://www.che.caltech.edu/groups/fha/) are, 1) the desired function must be 
physically possible; 2) the function must also be biologically, or evolutionarily, 
feasible. In practice, this means that there exists a mutational pathway to get 
from here to there through ever-improving variants (see above). A good 
experiment will maximize the likelihood; 3) Suitable host (E. coli or S. cerevisiae) 
which allows functional expression of more than 106 variants per µg of DNA. 4) A 
rapid screen or selection that reflects the desired function. How rapid the screen 
must be depends on how rare mutations leading to the desired property are and 
how many must be accumulated to achieve the desired result. 
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Figure 2. Overview of screening technologies. (A) Experimental steps from obtaining the gene 
library as PCR product to the actual screen. Note that cloning and transformation efficiency are 
often limiting library size; (B) Explanation of symbols; (C) Cell growth/survival selection and agar 
plate screening; (D) Microtiter plate screening; (E) Cell as micro-reactor; (F) Cell surface display; 
(G) Cell-in-droplet; and (H) In vitro compartmentalization (73).  
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2.2 Directed enzyme evolution for pH tolerance of enzymes 
Application of enzymes in processes at a specified pH necessitates protein 
engineering to change their pH performance. Directed evolution and rational 
design method were applied to improve enzyme specific activity at certain pH or 
shift their pH profiles. Some representative success stories of directed protein 
evolution improving pH performance are summarized in Table 1. 
Table 1. Improvement obtained from directed evolution or rational design for pH performance. 
Enzymes Mutagenesis 
methods 
Screening 
methods 
Improvements References 
Human  
β-glucuronidase 
EpPCR and 
saturation 
mutagenesis 
Flow 
cytometry 
60-fold more active (kcat/Km) at pH 7.0 
and were up to an order of magnitude 
more effective at catalyzing the 
conversion of two structurally 
disparate glucuronide prodrugs to 
anticancer agents 
2008 (74) 
Bacterial xylanase DNA shuffling Agar plate 
assay 
About 5-fold improvement of specific 
activity at pH 9.0 
2008 (75) 
Human pancreatic 
lipase 
EpPCR Agar plate 
and microtiter 
plate assay 
1.5-fold of activity improvement at 
acidic pH 
2010 (76) 
Bacterial arginine 
deiminase 
EpPCR and site 
directed 
mutagenesis  
Microtiter 
plate assay 
pH optimum shifted from pH 6.5 to pH 
7; 4-fold of activity improvement at pH 
7.4 
2010 (3) 
Bacterial α-amylase EpPCR Microtiter 
plate assay 
5-fold higher activity at pH 10 than 
wild type 
2003 (77) 
Eukaryote D-
pantonohydrolase 
EpPCR and 
DNA shuffling 
Agar plate 
assay 
10.5-fold higher specific activity and 
retain 85% of its original activity after 
incubation under low pH 
2006 (78) 
Vanadium 
chloroperoxidase 
EpPCR, site 
saturation 
mutagenesis 
and site directed 
mutagenesis 
Microtiter 
plate assay 
About 100-fold improvement of 
specific activity at pH 8 
2006 (79) 
Bacterial class-A non-
specific acid 
phosphatase (PhoN)   
Site directed 
mutagenesis 
 
1.6-fold of activity improvement over 
broder pH range 
2006 (80) 
Aspergillus niger PhyA 
phytase 
Site directed 
mutagenesis 
 
pH shifted from 5.5 to 3.8 (1.7 unit); 
2.66 -fold improvement of activity at 
pH 3.5 than wild type. 
2006 (81) 
Bacillus cereus β-
amylase 
Site directed 
mutagenesis 
 
pH optimum shifted to pH 4.2-4.8 by 
2 pH units. 
2004 (82) 
Phytase Site directed 
mutagenesis 
 
pH optimum shifted by 0.5-1 pH unit; 
a slight increase in maximum specific 
activity 
2002 (83) 
Alcohol 
dehydrogenase 
Site directed 
mutagenesis 
 
pH optimum shifted from 7.8  to 9.0; 
about 2-fold improvement of 
maximum activity at pH 9.0 than that 
of wild type 
1991 (84) 
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Many examples of rational reengineering of an enzyme pH optimum exist (Table 
1). For shifting the pH optimum, a deep understanding of molecular dynamics is 
essential part of understanding enzyme flexibility. Rational design method 
successfully shifted enzyme pH profile. pH dependence of an enzyme is 
determined by the ionization of the catalytic groups, which is affected by various 
interactions involved in their microenvironments. In order to catalyze certain 
reactions, ionizable residues in active site should act as nucleophile or acid/base 
catalyst and they need to maintain proper ionization state for proper activities of 
proteins. The pKa value of the proton donor and the catalytic nucleophilic residue 
are therefore limiting the pH range at which the enzyme can function, and 
therefore pH-dependent activity can be differed by the pKa of the key residues. 
The pKa value of the residue is governed by intrinsic acidity of the functional 
group and other factors (electrostatic interaction from neighboring and the 
heterogeneous dielectric environment in the protein solution system). The 
electrostatic potential generated by the charged titratable residues affects the 
ground state of the protein, such as stability, binding to ligands and pKa values of 
ionizable groups. The electrostatic potential of proteins can be calculated by 
using computational procedures (Delphi, UHBD, CHARMM) and can be 
increased or decreased through mutations. For shifting the pH optimum of 
enzymes, many researchers have tried to substitute catalytic residue by site-
directed mutagenesis (Table 1).  
 
Yoo and coworkers (85) analyzed the relation between the shift of pH optimum 
and change in electrostatic potential due to mutation using Delphi. They identified 
key residues of xylanase responsible for electrostatic potential of catalytic 
residues but not affecting the catalysis directly. The latter hypothesis was proven 
by site directed mutagenesis in a later report. Wyss and coworkers (83) 
summarized strategies for enzyme pH profile modification, 1) replacement of 
ionizable groups that are directly  involved in substrate or product binding and/or 
catalysis by nonionizable ones or by amino acids with different charge or pKa 
values; 2) replacement of residues that are in direct contact with residues 
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mentioned in 1) by forming hydrogen bonds and/or salt bridges; 3) alteration of 
longer-range (indirect) charge-charge interactions by modification of the surface 
charge of the enzyme. 
 
When there is no structure-function relationship information available for an 
enzyme, directed evolution is the best option to tailor the pH performance of 
enzyme for application demands (Table 1). Directed evolution allows improving 
all properties that can be reflected in a screening system through iterative rounds 
of diversity generation and screening. Small libraries of a few thousand variants 
are often sufficient to find improved muteins even without rational understanding 
of the targeted property (76, 86). Using MTP assay, epPCR mutant libraries with 
a ratio of 50 % active and 50 % inactive clones have often been used 
successfully in directed evolution, improving enzyme properties by gradual 
changes (one or two amino acids changes per round of mutagenesis and 
screening). 
 
2.3 Directed enzyme evolution for medical application 
Directed evolution has been very useful for improving enzymes for industrial 
needs. In recent years, there is also growing number of enzymes applied for 
therapeutic purpose. For the development of protein therapeutics, directed 
evolution started to be used to tailor enzyme properties in medical field, for 
example drug delivery (87, 88) and has proven to be a useful tool for generating 
protein variants with enhanced therapeutic potential (88), for example, improving 
the effectiveness of therapeutic enzymes, antibodies, vaccines and viruses. Here, 
the improvements of therapeutic protein for anti-tumor application by directed 
evolution are discussed in more details. 
 
2.3.1 Prodrug enzymes for tumor chemotherapy    
Prodrug cancer chemotherapy has attracted considerable interest due to the 
possibilities it provids to overcome various barriers to drug formulation and 
delivery (such as poor aqueous solubility, chemical instability, insufficient oral 
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adsorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity 
and local irritation) (89). Examples of such drugs currently in use in cancer 
treatment include 5-fluorocytosine, cyclophosphamide, capecitabine, mitomycin 
C, and AQ4N (90). However, the side effects of prodrug therapy remain a serious 
concern which arises from the fact that noncancerous cells also possess the 
capacity to degrade them. This has triggered the interest to generate more 
effective prodrug-activating enzymes so that prodrugs can kill tumor cells at 
concentrations that generate little or no side effects. Further goals are to design 
more powerful and tumor-specific drugs, and to devise more effective methods 
for delivering them specifically to tumors. 
 
By applying directed evolution through the technique of error-prone PCR, Martin 
and coworkers (90) indentified YieF variant exhibiting >5-fold increased capacity 
to kill HeLa cells. Furthermore, YieF variant was proved to be effectively 
delivered to tumor cells using a strain of Salmonella typhimurium (SL 7838). 
 
Human β-glucuronidase, due to low intrinsic immunogenicity in humans, is an 
attractive enzyme for tumor-specific prodrug activation. However its utility is 
limited by low activity at physiological pH. Roffler and coworkers (74) developed 
a high-throughput screening procedure for enzymatic activity based on the stable 
retention of fluorescent reaction product in mammalian cells expressing properly 
folded glycoproteins on their surface. This procedure was utilized to screen error-
prone PCR and saturation mutagenesis libraries to isolate β-glucuronidase 
tetramers that were up to 60-fold more active (kcat/Km) at pH 7.0 and were up to 
one order of magnitude more effective at catalyzing the conversion of two 
structurally disparate glucuronide prodrugs to anticancer agents. 
 
2.3.2 Oncolytic viruses for tumor chemotherapy  
Viral-mediated oncolysis is a novel cancer therapeutic approach with the 
potential to be more effective and less toxic than current therapies due to the 
agents’ selective growth and amplification in tumor cells. To date, these agents 
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have been regarded as highly safe in patients but have generally fallen short of 
their expected therapeutic value as monotherapies.  
 
Consequently, new approaches to generate highly potent oncolytic viruses are 
required. For the latter purpose, Hermiston and coworkers (91) developed a new 
method and termed it also ‘‘Directed Evolution’’ for creating highly potent 
oncolytic viruses. Viral serotypes representing Ad subgroups B-F were pooled 
and passaged twice on sub-confluent cultures of the target tumor cell lines at a 
particle-per-cell ratio of approximately 200 to invite recombination between 
serotypes (Figure 3). Supernatants from the second round of the high viral 
particle-per-cell infection of sub-confluent cultures were then used in a 10-fold 
dilution series to infect confluent T-75 tissue culture flasks of target tumor cell 
lines PC-3, HT-29, Panc-1 and MDA-231. Using this ‘‘Directed Evolution’’ 
methodology, the novel generated chimeric oncolytic virus ColoAd1 
demonstrated ~ 2 log increase in both potency and selectivity when compared to 
ONYX-015 on colon cancer cells. In vivo and ex vivo studies therefore validated 
the innovative general approach for deriving clinically-relevant and potent anti-
cancer virotherapies. 
 
Figure 3. Hermiston’s “Directed Evolution” process of viruses and derivative viral pools (91). 
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2.3.3 Amino acid depriving enzyme for anti-tumor applications 
Naturally available enzymes are usually not optimally suited for therapeutic 
purposes. This incompatibility often relates to the stability or activity of the 
enzymes under body conditions.  
 
Despite many successful efforts to broaden the understanding of the structural 
basis of protein stability, there is still no universal strategy to stabilize protein by a 
limited number of rationally designed mutations. Well-known and reasonably 
successful types of rational engineering work include substitutions that increase 
rigidity (e.g. substitute amino acid Xxx with Pro or substitute Gly with other amino 
acid Xxx or the introduction of disulfides). These substitutions have effects on the 
entropy of the unfolded state, improvement of molecular packing (e.g. shortening 
of loops, improvement of interactions in the hydrophobic core, for example, by 
the removal of internal cavities), modification of surface charge networks or 
reinforcement of a higher oligomerization state.  
 
Directed evolution provides a powerful approach for improving thermostability 
and does not need understanding of structure-function relationship. Most 
strategies for screening for enzyme stability rely on measuring residual enzyme 
activity before and after exposure to a denaturing challenge (e.g. high 
temperature, organic solvents, extreme pH) (92).  
 
Bacterial L-asparaginases have been used as therapeutic agents in the 
treatment of lymphoblastic leukaemia. The main restrictions to the therapeutic 
use of L-asparaginase include its premature inactivation. As a result frequent 
injections are required to maintain therapeutic levels. Repeated injections and 
high dose can cause several types of side reactions from mild allergies and the 
development of immune responses to dangerous anaphylactic shocks (93). 
Enhancing the stability of L-asparaginase by protein engineering improves its 
body-residence time, and thereby minimizes immunosuppressive effects by 
lowering the therapeutic dose. Labrou and coworkers (94) obtained a 
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reengineered L-asparaginase with enhanced thermal stability. Single mutation on 
the surface of the protein resulted in ~10 degree increased Tm value (half-
inactivation temperature). The thermostable variant has to be tested further on 
animals and ⁄ or humans in order to be advanced to a potent therapeutic drug. 
 
Another example of a reengineered amino acid-deprivating enzyme is PpADI. 
PpADI is a promising anti-tumor enzyme however with a non-physiological 
optimal pH and relative high Km value which hindering its medical application. By 
directed evolution and site saturation mutagenesis, PpADI variants with higher 
activity at physiological pH and at low arginine concentration of were obtained 
with improved properties to become a potent anti-tumor drug (see chapter 3 and 
chapter 4). In vitro and in vivo test of the improved variants are required to 
evaluate the anti-tumor effectiveness.  
 
2.3.4 Affibody molecules for cancer prognosis 
Affibody molecules represent a new class of affinity proteins that are based on 
the Z-domain scaffold derived from staphylococcal protein A (95). Among the 
scaffold proteins, Affibody molecules constitute the smallest non-cysteine-
containing protein scaffold. The small size (~ 7 kDa), robust structure, and 
straightforward production procedures (either by recombinant production in 
bacteria or by chemical synthesis) make Affibody molecules attractive targeting 
agents for in vivo radionuclide imaging (96) as well as for various 
biotechnological applications (97, 98). The small size offers a convenient affinity 
maturation principle. Gene synthesis allows randomizing the whole gene to 
generate diverse mutant library. The potential use of radiolabeled Affibody 
molecules for high-contrast radionuclide imaging of biomarkers has been 
demonstrated in preclinical studies and in pilot clinical studies. Affibody 
molecules are non-immunoglobulin-derived affinity proteins based on a three-
helical bundle protein domain.  
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Several of affinity proteins have been investigated for both in vivo diagnostics 
and therapy of tumor in radionuclide molecular imaging. Affinity proteins in tumor-
targeted therapy can affect tumor progression by altering signal transduction or 
by delivering a payload of toxin, drug or radionuclide. EGFR (epidermal growth 
factor receptor), one of the receptor in ErbB family, has been extensively studied 
as biomarkers in tumor targeting and over expressed in various malignancies, 
associated with poor patient prognosis and are therefore interesting targets for 
solid tumors. High affinity and especially slow dissociation rate are important for 
obtaining high contrast images. Affinity in the low nanomolar range is considered 
as a prerequisite for successful use of peptide-based tracers. 
 
Ståhl and coworkers (99) described the affinity maturation procedure for the 
generation of Affibody molecules binding with high affinity and specificity to 
EGFR. The library for affinity maturation was constructed using a single 
oligonucleotide for the rerandomization of desired positions. The new binders 
were selected with phage display technology and the best second-generation 
binders were characterized in vitro using real-time biospecific interaction analysis 
(BIA) for their binding to recombinant EGFR and with flow cytometry for their 
binding to native EGFR. Second-generation binders achieved an approximately 
30-fold improvement in affinity (Kd = 5-10 nM) for the soluble extracellular domain 
of EGFR in biospecific interaction analysis using Biacore. 
 
2.3.5 Interferon for anti-tumor applicaiton 
Alpha interferons (IFN-as) are members of the diverse helical-bundle superfamily 
of cytokine genes, which have potent antiviral and antiproliferative activities and 
therefore can be used as anticancer and antiviral agents. However, doselimiting 
toxicity, receptor cross-reactivity, and short serum half-lives significantly reduce 
the clinical use of many of these cytokines. 
 
Patten and coworkers (100) performed a family shuffling experiment with over 20 
human interferon-α (Hu-IFN-α) genes. Antiviral assay and proliferation assay 
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were used to indentify clones with improved activity on Hu-IFN-α receptor. One 
clone showed 285,000-fold improved activity relative to Hu-IFN-α2a and 185-fold 
relative to Hu-IFN-α1 (most active native human interferon). 
 
Selective breeding using DNA shuffling has proved to be very effective method to 
rapidly improve pharmaceutical proteins by which initially have low levels of the 
desired “activity” (101, 102). Backcrossing of evolved recommbinants with the 
wild type genes removes functionally neutral changes, which might reduce the 
immunogenicity of evolved proteins (103). 
 
2.4 Conclusion 
Proteins, especially enzymes, have gained a central role in modern chemical, 
biotechnological, and biopharmaceutical industries. Directed evolution has over 
the past proved to be a versatile and successful approach for tailoring protein 
properties to industrial, agricultural and medical demands and for advancing our 
understanding of structure-function relationships in biocatalysts. Appropriate 
library generation and screening methods should be employed concerning the 
target protein and desired property. To set up a sophisticated screening method, 
complex conditions in human body (pH, ion concentration, proteases, hormones 
etc.) should be considered. Subsequent in vivo or in vitro test of improved 
variants should be carried out to further validate the screening assay. 
Development of diversity generation and high-throughput screening method will 
enable evolution to solve problems efficiently. Especially, directed evolution 
provides a powerful strategy to rapidly advance the development of improved 
protein-based drugs (enzymes and antibodies, peptide and ligands). Directed 
evolution promises to play an increasingly important role to generate “desirable” 
drugs. 
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Chapter 3 
Chapter 3. Directed evolution of Arginine 
deiminase for increased activity at physiological 
pH 
 
3. 1 Abstract 
Arginine deiminase (ADI; EC 3.5.3.6) has been studied as a potential anti-tumor 
drug for the treatment of arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCCs) and melanomas. Studies with human lymphatic leukemia cell 
lines confirmed that ADI is a potential anti-angiogenic agent effective in the 
treatment of leukemia. ADI from Pseudomonas plecoglossicida (PpADI) was 
cloned and expressed in E.coli. A main limitation of PpADI lies in its pH-
dependent activity profile with a pH optimum at 6.5. A pH shift from 6.5 to 7.5 
results in ~80 % activity drop (pH of human plasma is 7.35 to 7.45). For shifting 
PpADI pH optimum to netrual pH, a directed evolution protocol based on an 
adapted citrulline screening protocol in microtiter plate (MTP) format was 
developed and validated. Proof of concept for ADI engineering resulted in a pH 
optimum of pH 7.0 and increased activity under physiological conditions: at pH 
7.4, variant M2 (K5T, D44E and H404R) is 4-fold more active than the wild type 
PpADI and retains ~30 % of its activity relative to its pH optimum, compared to 
~10 % in the case of the wild type PpADI. 
 
3.2 Introduction 
Arginine deiminase (ADI) is a potential cancer therapy agent for the treatment of 
arginine-auxotrophic tumors (e.g. hepatocellular carcinomas and melanomas). 
The hepatocellular carcinoma (HCC) accounts annually for approximately 1 
million new cases worldwide. In the US the incidence rate (per 100,000 persons; 
1992-2002) of HCC is 8.6 with a mortality rate of 6.5 due to low responses of 
hepatoma to chemotherapeutic treatments (27). Current research efforts are 
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focused on ADI’s in vivo inhibitory effect towards HCCs, leukemia, melanomas 
and human umbilical vein endothelial cells (HUVEC) (104-106), clinical trials for 
HCC (phase III) and melanoma (phase I/II) (105, 107), and PEG formulation of 
ADI to improve its efficacy as a clinical drug, including serum half-life and 
antigenicity (16, 108). ADI inhibited the growth of cultured leukemia cells at 
concentrations of 5-10 ng/ml, which were about 20-100 times lower than those of 
the L-asparaginase standard resulting in fewer side effects (106, 109). Arginine 
deprivation is speculated to be the molecular reason for ADI’s inhibitory effect on 
human lymphatic leukemia (106). ADIs catalyze the first step of the arginine 
deiminase (ADI) pathway by hydrolyzing arginine to citrulline and ammonium. 
Several ADI genes have been identified, purified, and characterized from 
bacteria, archaea and some eukaryotes excluding mammalian cells and 
summarized in a recent review (27). None of these ADIs is from a kinetic point of 
view ideally suited for in vivo applications in humans under physiological 
conditions.  
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. For the proof of concept, an 
ADI isolated from Pseudomonas plecoglossicida CGMCC2039 (accession 
number: ABS70718) which can be functionally expressed in E. coli has been 
employed. Directed evolution approaches employ mainly E. coli as host due to its 
fast growth and high transformation efficiency which is a prerequisite for 
generating complex mutant libraries. Over the last decades, directed protein 
evolution has become a versatile and successful approach for tailoring protein 
properties for industrial demands (mainly in chemical synthesis) and for 
advancing our understanding of structure-function relationships in enzymes. A 
directed evolution experiment comprises iterative cycles of diversity generation 
and functional selection for improved variants. Only a few manuscripts for 
phytases (83), xylanases (110), amylases (77, 82, 111), and an alcohol 
deyhdrogenase (112) reported a shift of pH optima using directed evolution 
algorithms. None of these directed evolution campaigns targeted a medical 
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application and arginine deiminase has to our best knowledge not been altered in 
its pH activity/resistance by directed evolution.  
 
Comparison of PaADI (Pseudomonas aeruginosa, pH optimum 5.6; His405) and 
MaADI (Mycoplasma arginini ADI, pH optimum 6.5, Arg397) led to the 
speculation that substitution of His by Arg might contribute to MaADI’s increased 
pH optimum (17). A sequence alignment of four ADIs (MaADI, MyADI 
(Mycoplasma arthritidis ADI), PaADI and PpADI) shows that for both 
Pseudomonas ADIs the synonymous amino acid positions (404 & 405), contain a 
His whereas both Mycoplasma ADIs contain at corresponding positions an Arg. 
Interestingly, both Mycoplasma ADIs have an pH optimum approximately one pH 
unit higher than both Pseudomonas ADIs. 
 
In this study we report the first directed ADI evolution protocol in which the pH 
profile of PpADI was shifted to higher pH values representing a conceptional 
proof that ADI properties can be tailored for demands in vivo treatment of 
arginine-auxotrophic tumors. An emphasis is given on detailed description of 
directed evolution conditions (mutagenic and screening).   
 
3.3 Materials and methods 
3.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
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plasmid (MEGAWHOP, 20 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
Pseudomonas plecoglossicida CGMCC2039 was provided by Professor Zhihao 
Sun (Jiangnan University, Wuxi, China). 
 
3.3.2 Methods 
3.3.2.1 Reagents used in assays 
Acid-ferric solution 
To dH2O (600 ml), concentrated H3PO4 (70 ml, 85 %) and concentrated H2SO4 
(160 ml, 90-91 %) were added slowly. After cooling to room temperature, 
FeCl3·6H2O (10 ml, 10 g/L) was added in the above solution, finally the total 
volume was adjusted to 1 liter with dH2O. 
 
Diacetyl monoxime -thiosemicarbazide (DAM-TSC) solution 
DAM solution (10 g/L) and TSC solution (0.3 g/L) were prepared separately. The 
two solutions were mixed (volume ratio = 1:1) just prior to use. 
 
3.3.2.2 Cloning of ADI into pET42b(+) 
The arginine deiminase (ADI) gene was amplified from Pseudomonas 
plecoglossicida CGMCC2039 by colony PCR (94°C for 10 min, 1 cycle; 94°C, 30 
s/ 54°C, 30 s/ 72°C, 165 s, 29 cycles; 72°C for 5 min, 1 cycle) using primer (5’-
CCGCATTCCGCTGAAAAACAGAAGTACGG-3’ and 5’-
CTTCTCGAGTTAGTAGTTGATCGGGTCGCGCACG-3’), 1.5 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix and a colony of Pseudomonas 
plecoglossicida CGMCC2039. Amplification product was purified by gel 
extraction, digested using NdeI (20 U) and XhoI (20 U) and purified using 
QIAquick PCR purification kit (QIAGEN, Hilden, Germany). Cloning vector 
pET42b(+) was digested with NdeI (20 U) and XhoI (20 U), and purified by gel 
extraction kit (QIAGEN, Hilden, Germany). Digested ADI gene and pET42b(+) 
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were ligated using T4 DNA ligase (1 U) to give pET42b(+)-ADI and transformed 
into E. coli BL21-Gold (DE3).  
 
3.3.2.3 Site directed mutagenesis of PpADI gene at position H404 
Site directed mutagenesis of ADI gene was performed according to the published 
method (113) on plasmid pET42b(+)-ADI. The following oligonucleotides were 
used for mutagenesis of H404R: 5’-
GGCCGTGGCGGCGGCCGTTGCATGACCTGCCCG-3’ and 5’-
CGGGCAGGTCATGCAACGGCCGCCGCCACGGCC-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 
cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 
s, 1 cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 
cycle), 2 U of PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, 
Finland), 0.20 mM of dNTP mix, 25 pmol of each primer together with 100 ng of 
template (pET42b(+) harboring ADI gene) were used. Following the PCR, DpnI 
(40 U; New England Biolabs) was added, and incubated overnight at 37°C. The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
3.3.2.4 Site sturation mutagenesis of PpADI gene at nine amino acid 
position  
Site saturation mutagenesis of ADI gene was performed according to the 
published method (113) on plasmid pET42b(+)-ADI. The oligonucleotides were 
used for mutagenesis were listed in table 1 (underlining indicated the substituted 
nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 cycle; 95°C, 30 
s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 s, 1 cycle; 95°C, 
30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 cycle), 2 U of 
PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, Finland), 0.20 mM 
of dNTP mix, 25 pmol of each primer together with 100 ng of template (pET42b(+) 
harboring ADI gene) were used. Following the PCR, DpnI (40 U; New England 
Biolabs) was added, and incubated overnight at 37°C. The PCR products were 
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purified by using a QIAquick PCR Purification Kit (Qiagen) and transformed into 
E. coli BL21-Gold (DE3) for expression. 
 
Table 1. Primer sequences for site saturation mutagenesis. 
Primer name Sequences 
Leu 41 FP AACTGCGACGAGCTGNNNTTCGACGATGTGATC   
Leu 41 RP GATCACATCG TCGAANNNCA GCTCGTCGCAGTT 
Asn 360 FP TGGGATGACGGCAACAACNNNGTGGCGCTGGAG 
Asn 360 RP CTCCAGCGCC ACCACNNNGT TGCCGTCATCCCA 
Arg401 FP GAACTGGGCCGGGGCNNNGGCGGCGGCCACTGC   
Arg401 RP GCAGTGGCCGCCGCCNNNGCCCCGGCCCAGTTC 
Phe163 FP CTGCCCAACACCCAGNNNACCCGCGACACCACC    
Phe163 RP GGTGGTGTCGCGGGTNNNCTGGGTGTTGGGCAG 
Asn160 FP CTGCCGCCGCTGCCCNNNACCCAGTTCACCCGC 
Asn160 RP GCGGGTGAACTGGGTNNNGGGCAGCGGCGGCAG 
Arg185 FP ATGTACTGGCCGGCNNNCGCCAGGAAACCCTG 
Arg185 RP CAGGGTTTCCTGGCGNNNGCCGGCCAGTACAT 
Arg243 FP ATCGGCATGGGTGAGNNNACCTCGCGCCAGGCC 
Arg243 RP GGCCTGGCGCGAGGTNNNCTCACCCATGCCGAT 
His405 FP GGCCGTGGCGGCGGCNNNTGCATGACCTGCCCG 
His405 RP CGGGCAGGTCATGCANNNGCCGCCGCCACGGCC 
Gly403 FP GCCGGGGCCGTGGCNNNGGCCACTGCATGACC 
Gly403 RP GGTCATGCAGTGGCCNNNGCCACGGCCCCGGCC 
 
 
3.3.2.5 Construction of PpADI error-prone library 
The library was generated by the standard error-prone PCR (epPCR) using 
improved variant H404R as template. For the mutagenic PCR (95°C for 2 min, 1 
cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C for 3 min, 1 cycle), 2.5 
U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of template (pET42b(+) 
harboring ADI gene H404R), 0.01-0.1 mM of MnCl2 and 10 pmol of each primer 
(5’-TACATATGTCCGCTGAAAAACAGAAG-3’ and 5’- GTGCTCGAGTTAGTAGT 
TGATCGG-3’) were used. The PCR products were purified by using a QIAquick 
PCR Purification Kit. The purified epPCR products were cloned into expression 
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plasmid pET42b(+) by MEGAWHOP(114). For MEGAWHOP (68°C for 5 min, 1 
cycle; 95°C for 5 min, 1 cycle; 95°C, 1 min/ 55°C, 1 min/ 68°C, 13 min 30 s, 24 
cycles; 68°C for 30 min, 1 cycle), 1 U of Taq DNA polymerase, 0.1 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix together with 200 ng of template (pET42b(+) 
harboring ADI gene H404R) were used. Following the PCR, DpnI (40 U; New 
England Biolabs) was added, and incubated (4 h; 37°C). The MEGAWHOP 
products were transformed into E. coli BL21-Gold (DE3) for expression and 
screening. 
 
3.3.2.6 Expression of PpADI in LB media with IPTG induction 
The strain E. coli BL21-Gold (DE3)/ pET42b-PpADI was cultured at 37°C in 20 ml 
of LB media that contained 50 µg/ml kanamycine to an absorbance of 0.6 at 
578nm. Then, isopropyl β-D-thio-galactopyranoside (IPTG) was added to a final 
concentration 0.2 mM. The cells were harvested after 9 h induction with IPTG at 
37°C. The expressed rADI was analyzed by SDS-PAGE.  
 
3.3.2.7 Expression of PpADI in auto-induction media 
A chemically defined auto-induction medium (115) containing salts and trace 
metals, vitamins including vitamin B12, and glucose, glycerol, and lactose were 
test for PpADI expression. Five kinds of auto-induction media LS-5052, P-5052, 
MD-5052, TYM-5052 and TYP-5052 were tested for the ADI expression, under 
the following conditions: 20 ml LB media in 100 ml flask, 37°C, 250 rpm, 20 h. 
The expressed rADI was analyzed by SDS-PAGE. 
 
3.3.2.8 Cultivation and expression of PpADI in 96-well plates 
Colonies grown on LBkan agar plates were transferred, by using toothpicks, into 
96-well microtiter plates (flat bottom, polystyrene plates; Greiner Bio-One GmbH, 
Frickenhausen, Germany), containing non-inducing medium LSG (150 µL) (115) 
supplemented with kanamycin (50 µg/ml). After 16 h of cultivation in a microtiter 
plate shaker (Multitron II, Infors GmbH, Einsbach, Germany; 37°C, 900 rpm, 70 
% humidity), each well was replicated using a replicator (EnzyScreen BV, Leiden, 
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Netherlands) into a second series of 96-well microtiter plates containing 150 µL 
of auto-induction media LS-5052 (115) supplemented with kanamycin (50 µg/ml). 
The first set of plates was stored at -80°C after addition of glycerol. The clones in 
the second set of plates were cultivated for 12 h (Multitron II, Infors GmbH, 37°C, 
900 rpm) and used for screening.  
 
3.3.2.9 Screening Procedure 
96-well plate format citrulline colorimetric screening assay 
A modified protocol of citrulline detection based on carbamido-diacetyl reaction 
(116) (see Figure 1A for assay mechanism) was used for ADI activity 
measurement. Screening for increased activity was carried out by measuring the 
activity at pH 7.4 and 6.4. 20 µl of cell culture was transferred to 96-well 
microtiter plate. Enzyme reaction was initiated by addition of arginine solution 
(100 µl, 100 mM) supplemented with cetyltrimethylammoniumbromide (CTAB, 4 
mM), and incubated (20 min, 37°C). Subsequently, acid-ferric solution (60 µl) and 
diacetyl monoxime (DAM, 20 µl, 0.5 M) were added. The reaction mixture was 
further incubated (15 min, 55°C). Absorbance was measured at 492 nm using a 
microtiter plate reader (Tecan Sunrise, Tecan Group AG, Zurich, Switzerland).  
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking ADI and in a separate experiment 
containing ADI. Apparent standard deviation was based on the absolute 
absorbance values obtained from the ADI wild type plate. The true standard 
deviation was calculated by subtracting the background absorbance value of the 
microtiter plate lacking ADI from the apparent values. 
 
Cuvette format citrulline colorimetric assay 
ADI activity was routinely measured using a modified protocol of the citrulline 
detection with DAM and TSC (117) (see Figure 1A for assay mechanism) in 
Eppendorf tubes. Enzyme reaction was initiated by addition of arginine solution 
(200 µl, 100 mM) to a 2-ml eppendorf tube containing crude cell lysate (50 µl), 
and incubated (20 min, 37°C). Subsequently, acid-ferric solution (250 µl) was 
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added to stop the enzyme reaction. After appropriate dilution with deionized 
water to ensure the concentration of produced citrulline is within linear detection 
range, the reaction mixture (400 µl) was mixed with acid-ferric solution (600 µl) 
and DAM-TSC solution (100 µl). The reaction mixture was further incubated (30 
min, 70°C), followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a Specord 200 (Analytik Jena AG, 
Jena, Germany). 
 
Normalization of protein expression for wild type ADI and variants  
Agilent Protein 230 Kit (Agilent Protein 230 Kit, Agilent Technologies 
Deutschland GmbH, Böblingen, Germany) and Agilent 2100 Bioanalyzer (Agilent 
2100 Bioanalyzer, Agilent Technologies Deutschland GmbH, Böblingen, 
Germany) were used for normalization of protein expression in crude cell extract. 
The protocol used was according to Agilent protein 230 Kit Guide except BSA 
was used as an internal standard. 
 
3.3.2.10 Expression of ADI in shaking flask and purification 
Shaking flasks (1 liter) containing auto induction media LS-5052 (200 ml) 
supplemented with kanamycin (50 µg/ml) were inoculated with a 1:200 dilution of 
overnight culture (E. coli BL21-Gold(DE3) harboring pET42b-ADI) grown in non-
inducing media LSG. After 12 h of expression, E. coli cells were harvested by 
centrifugation (Eppendorf 5810R 4°C, 3220 g, 30 min) and resuspended in 
phosphate buffer (20 ml, NaxPO4, 20 mM, pH 7.0). E. coli cells were 
subsequently lysed by using a high-pressure homogenizer (1500 bar, 2 cycles; 
Avestin Emulsiflex, Mannheim, Germany). The disrupted cells were centrifuged 
(Eppendorf 5417R, 4°C, 13000 g, 20 min) and the supernatant was further 
cleared by filtration through a low protein-binding filter (0.45 µm; Minisart RC 25 
single use syringe filter; Sartorius, Hamburg, Germany). ADI wild type and 
mutants (H404R and K5T D44E H404R) were subsequently purified by a column 
chromatography procedure: (i) The filtered cell lysates were subjected to a 
Super-Q anion exchange column, which had been pre-equilibrated with 50 mM 
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phosphate buffer (NaxPO4, pH 7.0). 20 ml of cell lysate was loaded. ADI were 
eluted by a NaCl step elution in phosphate buffer (NaxPO4, 50 mM,  pH 7.0) at a 
rate of 3 ml/min. (ii) The obtained ADI protein from ion exchange chromatography 
was subjected to a gel filtration column (Matrix: Toyoperl HW-55S, Bed volume: 
33 ml, Bed height: 40 cm, Column: Omnifit). 
 
Purified ADI was subsequently concentrated using a Amicon ultra-4 centrifugal 
filter device (Millipore Corporation, Billerica, U.S.A.) with a 30-kDa cut-off 
membrane. Total protein concentration was determined by BCATM assay kit 
(Pierce, Born, Germany) and homogeneity of the purified sample was controlled 
by SDS-page electrophoresis using standard molecular biology techniques. 
 
3.3.2.11 Characterization of ADI wild type and mutants 
Determination of kcat and Km of ADI wild type and the mutants 
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath. After 10 min preincubation at 37°C, the enzyme reaction was initiated 
by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the substrate solution (200 
µl, 0.2 mM to 10 mM of arginine, 0.5 M phosphate buffer, pH 7.4) in deep well 
plates. The reaction mixture was incubated (37°C) and every two minutes 
reaction mixture (30 µl) of each well was transferred to acid-ferric solution (30 µl) 
to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. Ferric-acid solution (90 µl) and DAM-TSC 
solution (15 µl) were added to each well. The 96-well PCR plate was then 
incubated (70°C, 30 min) in thermal cycler (Eppendorf Mastercyler gradient) for 
color development, followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a microtiter plate reader 
(SPECTROstar Omega, BMG LABTECH, Offenburg, Germany). The initial 
velocity data obtained were fitted to the equation v = Vmax[S]/([S] + Km) (where v 
is the initial velocity, Vmax the maximum velocity, [S] the substrate concentration, 
and Km the Michaelis constant) using GraphPad Prism software (GraphPad 
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software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax 
and enzyme concentration. 
 
Determination of pH profile 
Enzyme reaction was carried out at 37°C in a water bath using the following 
substrate solution: arginine 0.1 M, pH 5-8 phosphate/acetate buffer (0.5 M 
phosphate, 50 mM acetate). After 10 min preincubation at 37°C, the enzyme 
reaction was initiated by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the 
substrate solution (200 µl) in deep well plates. The reaction mixture was 
incubated (37°C, 10 min) and acid-ferric solution (250 µl) was transferred to each 
well to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. The reaction mixture (60 µl), ferric-acid solution 
(90 µl) and DAM-TSC solution (15 µl) were transferred to a 96-well PCR plate. 
The 96-well PCR plate was then incubated (70°C, 30 min) in thermal cycler 
(Eppendorf Mastercyler gradient) for color development, followed by incubation in 
ice water to stop color development. Absorbance was measured at 530 nm using 
a microtiter plate reader (SPECTROstar Omega, Germany). 
 
3.3.2.12 Molecular Modeling 
Two crystal structures of PaADI (PDB codes: 1RXX, 2A9G) were used to model 
the mutations H405R and D44E. Only one monomeric unit of the tetrameric 
PaADI was used for the modeling study employing Swiss-PDB viewer (118) 
(www.expasy.org/spdbv). PaADI variants (H405R; D44E) were generated using 
the mutate command of Swiss-PDB viewer. The side chain rotamer with the best 
score was used for subsequent energy optimized with parameter of GROMOS96 
force field for in vacuum minimization (119).  
 
3.3.2.13 Stability of PpADI in presence of serum  
Purified PpADI (wild type, M1, M2; 20 µl) was incubated (37°C, 60 min) with AB--
human serum (80 ul, Invitrogen, Karlsruhe, Germany) and PBS buffer (pH7.4, 80 
ul), respectively. Subsequently, the incubated ADI-serum/PBS mix (20 µl) was 
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added to microtiter plate containing arginine solution (100 µl, 10 mM arginine in 
PBS buffer, pH 7.4) and incubated (37°C, 30 min). Acid-ferric solution (120 µl) 
was added to stop the enzyme reaction. The produced citrulline was detected 
using the assay procedure employed in “Determination of kcat and Km of ADI 
wild type and the mutants”. Before measuring absorbance at 530 nm, 
centrifugation (Eppendorf, 5810R 4°C, 3000 g, 10 min) was performed to remove 
the precipitation in the assay solution (likely proteins in serum were precipitated 
in acidic condition during assay procedure). Meanwhile, a serum control was test 
for the original citrulline concentration of serum using the same procedure 
mentioned above except that instead of PpADI, elution buffer of gel filtration 
(NaxPO4, 50 mM, pH 7.4) was used. All the absorbance values at 530 nm of 
ADI-serum sample were subtracted the value of serum control to get the citrulline 
concentration produced by PpADI. The residual activities of PpADI after 
incubation in serum compared to that in PBS buffer were calculated to show the 
stability of PpADI after incubated in human serum. 
 
3.3.2.14 Activity of PpADI (wild type, M1, M2) towards arginine derivative 
dimethylarginine 
Purified PpADI (wild type, M1, M2; 15 µl, ~0.2 mg/ml final concentration; >20-fold 
concentration used for kinetic constant determination) was incubated (37°C, 4 h) 
with (NG, NG)-dimethylarginine solution (20 mM, 100 µl). Acid-ferric solution (120 
µl) was added to stop the enzyme reaction. Activity was recorded by citrulline 
detection using citrulline colorimetric assay (see 3.3.2.11 Characterization of ADI 
wild type and mutants). 
 
3.4 Results 
3.4.1 PpADI cloning 
PpADI was cloned into pET42b(+) and expressed in E.coli BL21-Gold(DE3) 
using auto-induction media LS-5052 (see figure 2). The nucleotide sequence of 
PpADI comprises 1,254 bp nucleotide (figure 1) encoding 417 amino acids which 
have 85% identity to ADI from P. aeruginosa (PaADI). The PpADI cloned into 
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pET42b(+) was confirmed by nucleotide sequencing. As indicated in Figure 1, 
sequence analysis of ADI gene showed that there was one synonymous 
mutation at amino acid position D78 (GAT to GAC) compared to ADI-sequence 
of P. plecoglossicida CGMCC2039 deposited in NCBI (accession number: 
EU030267). The deduced ADI protein sequence has a calculated molecular 
weight of 46.5 kDa and shows 85% identity to ADI from P. aeruginosa. This clone 
was used for subsequent directed evolution experiments.  
 
 
Figure 1. DNA electrophoresis of PpADI. 
 
 
Figure 2. PpADI sequencing results. 
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3.4.2 PpADI expression in LB media with IPTG as inducer 
PpADI was successfully expressed in LB media with IPTG as inducer. Figure 3 
(lane 4) shows the expression band of PpADI observed at ~45 kDa, which is 
similar to the calculated molecular weight of 46 kDa (based on 
http://expasy.org/tools/pi_tool.html). 
 
Figure 3. SDS-PAGE of PpADI expression. Lane 1: P. plecoglossicida; Lane 2: E. coli BL21-Gold 
(DE3)/ pET42b; Lane 3: E. coli BL21-Gold (DE3)/ pET42b-PpADI WT, without IPTG; Lane 4: E. 
coli BL21-Gold (DE3)/ pET42b- PpADI WT. 
 
3.4.3 PpADI expression in auto-induction media 
Expressing recombinant protein in auto-induction media is based upon the 
preferences of bacteria to selectively use different carbon sources during diauxic 
growth and upon the often-observed negative regulation of gene expression by 
catabolite repression. Auto-induction is more convenient than IPTG induction 
because the expression strain is simply inoculated into auto-inducing medium 
and grown to saturation without the need to follow culture growth and add 
inducer at the proper time. For high-throughput applications, the auto-induction 
approach has many advantages over traditional induction methods including 
avoidance of the strong induction and apparent toxicity associated with chemical 
inducers such as IPTG.  
Five kinds of auto-induction media LS-5052, P-5052, MD-5052, TYM-5052 and 
TYP-5052 were tested for the ADI expression. Figure 4(A) and 4(B) show ADI 
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activity and corresponding SDS-PAGE band of the PpADI expression in different 
auto-induction media. The expression in auto-induction media LS-5052 is shows 
the highest activity and therefore LS-5052 was used for the following directed 
evolution experiments. 
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Figure 4(A). Activity of PpADI expressed in auto-induction media. 
 
 
 
Figure 4(B). SDS-PAGE of ADI expressed in auto-induction media 1, LS-5052; 2, P-5052; 3, MD-
5052; 4 TYM-5052; 5, TYP-5052. 
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3.4.4 PpADI assay based on citrulline detection 
 
 
Figure 5. Arginine conversion by ADI and detection of citrulline using DAM/TSC assay. 
 
ADI activity was measured by detecting the production of citrulline from arginine, 
according to carbamido diacetyl reaction (colorimetric reaction). The conditions of 
the carbamido diacetyl reaction is as follows： strong acid solution (H3PO4, 
H2SO4), oxidizing agent (Fe3+), diacetyl monoxime (DAM), thiosemicarbazide 
(TSC), and boiling water bath. Figure 5 shows one postulated reaction 
mechanism for the assay which depicts the reaction between citrulline and DAM. 
By the addition of TSC to the reaction system, Coulombe and Favreau(120) 
obtained linearity of response with a more stable pink color which Amax was 
shifted from 490nm to 530nm. 
 
Figure 6 describes the assay procedure for measuring ADI activity in 2 ml 
eppendorf tube. A calibration curve was prepared using citrulline standard 
solution (Figure 7) for determining the citrulline production during the assay. 
 
Figure 6. Citrulline colorimetric assay in cuvette format using DAM/TSC assay. 
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Figure 7. Calibration curve of cuvette format citrulline colorimetric assay. 
 
3.4.5 PpADI screening system for citrulline production in microtiter plates 
Two key performance parameters for identifying improved variants in microtiter 
plate based screening systems are the true standard variation and the linear 
detection range of the employed assay. Standard deviations have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). A modified version of the DAM-TSC assay for citrulline 
detection (Scheme 1) was selected for directed evolution of PpADI. The 
microtiter plate screening format was optimized for simplified handling by 
lowering the color development temperature (55°C instead of 100°C), increasing 
the diacetylmonoxime concentration (~22-fold) and avoiding the use of the 
sensitizer thiosemicarbazide. Figure 8 shows the procedure of screening assay 
of citrulline detection. 
 
Figure 8. Citrulline colorimetric assay in MTP format using DAM assay. 
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Standard deviations of the modified citrulline detection assay have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). The preferred combination (150 µl LS5052 auto-
induction media and 20 µl cell culture, 20 min conversion time and 15 min color 
develop time) resulted in a true standard deviation of 12.8 % after subtracting the 
background (Figure 10). Screening systems with standard deviations around 10 
% have successfully been used in directed evolution experiments (121, 122). A 
wide linear detection window is important for identifying beneficial mutants in 
directed evolution experiments and screening systems for evolved mutants have 
to be constantly adapted for hitting the linear detection window. A linear detection 
range up to 6 mM citrulline could be detected (Figure 9).  
 
 
 
 
 
 
Figure 9. Calibration curve of 96-well microtiter plate format citrulline colorimetric screening assay.  
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Figure 10. Activity values in descending order of the ADI wild-type conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
 
Figure 11. PpADI model derived from PaADI crystal structure (PDB code 2a9gD) by SWISS 
MODEL WORKSPACE.  
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3.4.6 Focused libraries generated by saturation mutagenesis 
PpADI gene shares 83 % sequence identity  with PaADI of which the crystal 
structure was solved (123). After submitting the ADI sequence to SWISS MODEL 
WORKSPACE, a proposed ADI model based on the PaADI crystal structure 
(PDB code 2a9gD) was obtained (Figure 11). According to this model and 
published literatures, 9 amino acid residues: Leu41, Asn160, Phe163, Arg185, 
Arg243, Asn360, Arg401, His404, Gly 403 (Figure 11) close to the active center 
(catalytic triad: Cys406-His278-Glu224) or known to interact with substrate 
arginine were selected for saturation mutagenesis. 
 
Site saturation mutagenesis at position Leu41, Asn160, Phe163, Arg185, Arg243, 
Asn360, Arg401, His404 and Gly 403 were performed. 300 clones were 
screened for each position. However, no improved variant was identified. 
 
3.4.7 Validation of variant M1 (H404R) citrulline colorimetric assay in 
cuvette format 
Position H404 which was suspected to influence ADI pH profile by substitution to 
R404 (15). Compared to wild type PpADI, variant M1 (H404R) shows higher 
activity (1.8-fold) and improved activity ratio of pH 7.4 to 6.4 (4.7-fold). Therefore, 
M1 (H404R) was selected for directed evolution. 
 
3.4.8 epPCR library generation and screening with citrulline detection 
assay by screening error-prone mutant libraries 
Various concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Figure 12 (A) and 12 (B) 
show the epPCR products and the corresponding MEGAWHOP products. 
Concentration of 0.01 mM MnCl2 which generated 53 % inactive mutant was 
selected for library generation. EpPCR mutant libraries with a ratio of 50 % active 
and 50 % inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). A total of 7 variants (listed in 
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Table 2) were identified from an epPCR library of 2400 mutants and used for 
further characterization. The most active variant was sequenced and two 
additional amino acid substitutions (K5T D44E) were identified. 
 
 
Figure 12 (A). Electrophoresis of epPCR products. Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM 
of MnCl2; Lane 3, 0.05 mM of MnCl2.  
 
 
 
Figure 12 (B). Electrophoresis of MEGAWHOP product with epPCR products as megaprimer. 
Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM of MnCl2; Lane 3, 0.05 mM of MnCl2.  
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Figure 13. Relative activity of ADI variants towards arginine. The relative activity is the ratio of the 
activity at the pH of each variant relative to the activity at pH 7.4 of wild type ADI. White: ADI wild 
type, grey: M1 (H404R), black: M2 (K5T D44E H404R). 
 
Table 2. Activity of ADI variants towards arginine determined using citrulline colorimetric 
assay in cuvette format. Samples were diluted to ensure that detected citrulline 
concentrations are within the linear detection range of the citrulline colorimetric assay. 
Wild type, mutant M1 and the “best variant” M2 are in bold and prominent expression 
mutants (9-B3-1; 21-D5-1) are italized. 
Normalized [ADI][a] 
Citrulline production 
(mM/mg) 
Relative to activity at pH 7.4 
of WT 
ADI variants pH 7.4 pH 6.4 pH 7.4 pH 6.4 
Activity at pH 
7.4/ activity at 
pH 6.4 
WT 
9.83 
(0.74)[b] 
124.92 
(1.98) 1.00 (0.15) 12.69 (0.01) 0.08 (0.01) 
M1 
(H404R) 
17.80 
(0.49) 
45.95 
(0.87) 1.81 (0.06) 4.67 (0.02) 0.39 (0.02) 
M2 
(K5T D44E 
H404R) 
38.99 
(0.79) 39.20 (0.31) 3.96 (0.02) 3.98 (0.02) 0.99 (0.03) 
9-B3-1 
24.89 
(0.45) 54.50 (1.80) 2.53 (0.03) 5.54 (0.03) 0.46 (0.02) 
21-D5-1 
25.68 
(2.68) 50.95 (2.36) 2.61 (0.07) 5.18 (0.02) 0.50 (0.01) 
15-G10-2 
13.11 
(0.53) 47.02 (0.47) 1.33 (0.09) 4.78 (0.02) 0.28 (0.01) 
2-H4-2 
12.50 
(0.07) 21.58 (0.09) 1.27 (0.06) 2.19 (0.04) 0.58 (0.01) 
1-G11-1 
24.91 
(0.20) 29.12 (0.33) 2.53 (0.03) 2.96 (0.03) 0.85 (0.02) 
24-E10-1 
14.62 
(0.62) 32.82 (0.52) 1.49 (0.08) 3.34 (0.03) 0.45 (0.02) 
[a] (Based on quantification employing Agilent 2100 Bioanalyzer (Agilent Protein 230 Kit)) 
[b] (Standard error of triplicate measurements are given in brackets below each absolute 
and normalized value.) 
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Figure 14. Elution profile of wild type PpADI and improved variants from epPCR library, 
generated with Protein 230 Kit using a mircofluidic device (Agilent Bioanalyzer). BSA was added 
as an internal standard. 
 
3.4.9 Characterization of PpADI variants 
3.4.9.1 Determination of kcat and Km of ADI wild type and the mutants 
Variants selected from epPCR were first characterized using the crude cell 
extract to identify the most promising variants (Table 2). Using an activity ratio of 
pH 7.4 to 6.4 proved to be an effective method to eliminate expression mutants. 
Additionally ADI concentration in crude cell extract was determined using the 
Agilent Protein 230 Kit. Microfluidic elution profiles (Figure 14) semi-quantify 
differences in expression between the wild type PpADI and variants. 
Normalization of activities against the corresponding ADI concentrations reveals 
improvements in specific activities of ADI mutants (Table 2). M1, the starting 
variant for the directed evolution campaign, and M2 were selected for detailed 
characterization studies. M2 has as “best identified variants” (Figure 13) a more 
than 2.5-fold higher activity ratio at pH 7.4 to pH 6.4 than M1 and a 12-fold higher 
activity ratio than wild type in crude cell lysates. 
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For kinetic characterization of ADI variants the citrulline production was 
maintained between 0.2-0.8 mM. Calibration curve in Figure 4 shows the linear 
detection range in the employed 96-well PCR plate format citrulline colorimetric 
assay system. Figure 15 summarizes the kcat and Km values of wild type PpADI, 
identified variants M1 (H404) and M2 (K5T D44E H404R) which were expressed 
in shaking flasks cultures and purified using a two step procedure (anion 
exchange followed by gel filtration). Both variants M1 and M2 show an increase 
in kcat and Km for citrulline production at pH 7.4. Variant M2 shows a 4-fold higher 
kcat as also obtained for specific activity in Table 2 using the crude cell extract, 
validating the characterization procedure with crude cell lysate. Furthermore, an 
increased Km from 0.7 mM (wild type PpADI) to 1.2 mM (M1) and 2.5 mM (M2) 
was found. 
 
 
Figure 15. Kinetic parameters of ADI and mutants for conversion of arginine to citrulline. White: 
ADI wild type, grey: M1 (H404R), black: M2 (K5T D44E H404R). Values reported are the average 
of three measurements, and average deviations from the mean values are shown. Embedded 
calibration curve shows linearity of citrulline colorimetric assay in 96-well PCR plate format which 
was used to determine arginine conversions and kinetic constants.  
 
3.4.9.2 Relative pH profile of wild type and mutant 
The relative pH profile (Figure 16) of wild type PpADI and M1 (H404R) shows an 
identical pH optimum at pH 6.5. Compared to wild type PpADI, variant M2 (K5T 
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D44E H404R) shows a pH optimum at pH 7.0 which is shifted remarkably (0.5 
pH units). Both M1 and M2 show decreased specific activities at pH 6.5, and 
increased specific activity at pH 7.5. At pH 7.0, the specific activity of M2 
exceeds that of wild type PaADI (data not shown). 
 
Figure 16. pH profile of wild type ADI, M1(H404R), M2(K5T/D44E/H404R). The relative activity is 
the ratio of the catalytic activity at the pH relative to the maximum activity of each enzyme. (■) WT, 
(▲) M1 (H404R), (●) M2 (K5T/D44E/H404R). 
 
 
3.4.10 Stability of PpADI in the presence of human serum  
Table 3 summarizes the stability of PpADI variants in serum (37°C, 60 min; 
standard deviation of three measurements in brackets). The mutants M1 and M2 
have a similar stability in serum when compared to the wild-type PpADI wild type.  
The substitution D44E and H404R do not destabilize further the PpADI in serum.  
 
Table 3. Stability of PpADI variants in the presence of human serum. 
 PpADI WT M1 M2 
No incubation (A530) 0.08 0.27 0.98 
Incubation with serum (37°C, 
60 min) (A530) 0.05 0.15 0.69 
Residual activity 60 % 55 % 70 % 
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3.4.11 Activity of PpADI (wild type, M1, M2) towards arginine derivative (NG, 
NG)-dimethylarginine  
No detectable conversion of (NG, NG)-dimethylarginine could be detected with 
PpADI variants.  
 
3.5 Discussion 
ADI properties have to date not been engineered through directed evolution 
algorithms despite their often poor performances under physiological conditions 
and their medical importance as potential anti-tumor drug. Chemically modified of 
ADI (e.g. through PEGylation) (27) and fusion protein (e. g. Human serum 
albumin fusion, HSA) (124) have been used for addressing activity and stability 
demands in vivo. Directed evolution offers opportunities to directly improve ADI 
properties for in vivo applications and small libraries of a few thousand variants 
have often been sufficient to find improved muteins in directed evolution 
experiments (55, 125).  
 
Our main intention in this report is to provide a validated protocol for directed ADI 
evolution and improving the activity at the physiological pH 7.4. Pseudomonas 
plecoglossicida CGMCC2039 (PpADI, 7.8 U/mg; pH optimum 6.5) was selected 
for the directed evolution studies due to its functional expression in E. coli, 
coverage of sequence space in patents and “potential” for activity improvement. 
PpADI is a relatively slow ADI when compared to Mycoplasma ADIs like MhADI 
(Mycoplasma hominus ADI, 35 U/mg) which would have been good alternatives 
for directed evolution studies (105). Reported ADI activities range from 0.115 to 
140.3 IU/mg. One unit is commonly defined as the ADI amount that converts 1 
µmol of L-arginine into 1 µmol of L-citrulline per minute (27).  
 
Screening of PpADI variants yielded three amino acid positions 5, 44 and 404. 
Positions 44 and 404 resulted in a 4-fold higher kcat at pH 7.4 and a significant 
shift in the pH optimum (0.5 units) when compared to wild type PpADI (Figure 17 
& 8). Position 5 did not show any effect on PpADI activity.   
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Figure 17. Structural alignment of mutant M1 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The crystal structure of PaADI which was diffracted in 
absence of the substrate arginine (1RXX) was used to investigate the substitution of His405 to 
Arg405. The Arg405 variant shows with respect the Asp280 a different orientation of the 
guanidinium group when compared to side chain of His405 (in orange).  
 
Galkin and coworkers postulated that the histidine in position 404 (corresponding 
position in “their” PaADI is 405) is a key residue in controlling activity at acidic 
and neutral pH. In protonated state of the imidazolium ring a hydrogen bonding 
interaction can be formed with the oxygen of Asp280 (carboxyl group). This 
hydrogen bond favors stabilizing interactions between Asp280 and the substrate 
arginine. His405 in PaADI was reported (17) to share protons with Asp280 and 
Glu13 and to be important for modulating electrostatic environments of closely 
located catalytic groups. The same report postulated that H405 is likely to be 
protonated when the substrate arginine binds to catalytic triad (His278, Glu224, 
Cys406) (2). Based on these reports the His404 in PpADI was subjected to a site 
directed mutagenesis to Arg404 and named M1. The M1 variant (H404R) shows 
40 % residual activity compared to wild type PpADI at pH 6.4 and a 1.8-fold 
increase in activity at pH 7.4 (see Table 1). In the M1 (H404R) mutant (see the 
model in Figure 17; based PaADI 1RXX; residue His404 in PpADI corresponds to 
His405 in PaADI), the conformational effect due to the extended side chain of 
Arg likely weakens the hydrogen bond to Asp280 and thus reduces the stabilizing 
effect on arginine binding. As a result the activity of M1 is reduced, especially at 
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lower pH values at which His405 is protonated. However at elevated pHs, His405 
becomes increasingly deprotonated whereas Arg405 remains protonated and 
can therefore still stabilize Asp280 for arginine binding. The electrostatic effect 
suggested by theoretical and experimental studies have evidenced the 
importance of positively charged residues to modulate the reaction rate of PaADI 
(126). At pH 6.4, histidine in wild type PpADI and arginine in M1 are both 
positively charged. At pH 7.4, histidine is only partially positive charged and 
PpADI’s activity is reduced (>90 %) while arginine in M1 remains positively 
charged preserving M1’s activity (Figure 17).   
 
 
Figure 18. Structural alignment of mutant M2 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The PaADI crystal structure in presence of substrate arginine 
was used (2A9G) to investigate the role of the substitution Asp44 to Glu44. The latter was solved 
for an inactive variant in which Cys406 was replaced by Ala406. The extended side chain of 
Glu44 might improve the hydrogen bond interaction with the Arg399 inducing a conformational 
shift of loop 1. 
 
The PpADI H404R was used as starting variant for directed evolution. The amino 
acid position 44 was identified from a epPCR library (2400 variants screened) 
resulting in a triple mutant M2 (K5T D44E H404R). For investigating the role of 
each position the double mutants (K5T H404R) and (D44E H404R) were 
generated. Only the double mutant (D44E H404R) revealed improvements in kcat 
(4-fold, pH 7.4; Figure 18). The rationale behind the effects of the mutation D44E 
on the PpADI activity is more complex to extrapolate from the available ADI 
crystal structures. Comparative crystallographic studies have shown that the 
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entrance of the active site is decorated by 4 loops that undergo conformational 
transitions upon arginine binding (17). The loops exhibit significant shifts that limit 
the access of water molecules to the active site. The Asp44 is located in loop 1 
(residues 30-46) and upon binding of the substrate, Asp44 comes closer to the 
positively charged Arg399 located on loop 4 (residues 392 to 403). In the D44E 
mutant, the longer side chain reduces the distance with Arg399 favoring the 
formation of hydrogen bond (see model in Figure 18). The reinforced interaction 
between Glu44 and Arg399 might expedite conformational changes in loops, 
probably confining the arginine substrate in the active site and hence promote 
arginine conversion. In the future, we plan to further investigate the influence of 
H404R and D44E using molecular dynamics simulations, further boost the kcat at 
pH 7.4 and reduce the Km value of PpADI.  
 
Overall site directed mutagenesis of position H404R and one round of directed 
evolution (2400 variants screened) resulted in a triple mutant M2 (K5T D44E 
H404R) with 4-fold higher kcat at pH 7.4 (compared to wild type; Figure 4). The 
best mutant isolated, M2, has specific activity of 31.3 U/mg at pH 7.4 which is 
already after one round of evolution close to the specific activity of MhADI (35 
U/mg) (127) at its pH optimum. The stability and specificity of improved PpADI 
variants are furthermore important for cancer treatment in vivo. First experiments 
in AB-human serum (Invitrogen) showed an unaltered stability of M2 compared to 
the wild type PpADI and (NG, NG)-dimethylarginine conversion could not detect 
with the citrulline colorimetic assay.   
 
3.6 Conclusion 
In summary, a directed evolution protocol has been developed for PpADI and 
validated by increasing the kcat of PpADI at physiological pH (7.4). The reported 
screening system is the first one employed in directed ADI evolution and can 
likely be used for other ADIs and other properties such as temperature stability, 
salt/detergent stability or protease resistance. 
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Chapter 4 
Chapter 4. PpADI reengineered for efficient 
operation under physiological conditions 
 
4.1 Abstract 
The proof of concept for ADI engineering by directed evolution resulted in variant 
M2 (K5T/D44E/H404R). M2 has a pH optimum of pH 7.0 and 4-fold higher kcat 
value than the wild type PpADI (pH 7.4, 0.5 M phosphate buffer) and an 
increased Km value for substrate arginine. In this chapter, in order to improve the 
catalytic efficiency of PpADI at low concentration of arginine, variant M5 
(K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated from an epPCR library: 
at pH 7.4 (PBS buffer), the S0.5 value decreased from 2.01 mM (parent M3, 
K5T/D44E/A128T/H404R) to 1.48 mM (M5) and 0.81 mM (M6). The S0.5 value of 
M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat value 
improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 11.64 
s-1 (M6, 64.7-fold). 
 
4.2 Introduction 
ADI-based arginine depletion is a target specific therapy for arginine-auxotrophic 
tumors (e.g. hepatocellular carcinomas and melanomas) and pegylated ADI is 
currently under clinical trials for HCC with promising results (45). HCC is the third 
leading cause of cancer mortality world wide with a less than 10 % 5-year 
survival rate (EU and USA) (128) due to low responses of hepatoma to 
chemotherapeutic treatments. In 1999, US Food and Drug Administration (FDA) 
designated ADI-PEG-20 orphan drug status for the treatment of HCC and 
invasive malignant melanomas, and in 2005 European Agency for the Evaluation 
of Medicinal Products (EMEA) also granted ADI-PEG-20 orphan drug status for 
the treatment of HCC. Phase II trials of ADI-PEG-20 in patients with metastatic 
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hepatocellular carcinomas have shown that the drug is safe, well tolerated, and 
may benefit patients with unresectable HCC. Izzo and coworker suspected that 
combination therapies of arginine deprivation and growth inhibition via kinase 
inhibitors might improve the survival rate further more. Additionally, ADI can 
enhance radio sensitivity of human mammary adenocarcinoma (MCF-7 cells) 
(48), exerts anti-proliferative and anti-angiogenic activities and inhibits the growth 
of viruses such as HIV-1 and hepatitis (49, 50). Current research efforts are 
focused on ADI’s in vivo inhibitory effect towards leukemia, melanoma, prostate 
cancer, renal cell carcinoma, and human umbilical vein endothelial cells (HUVEC) 
(19, 44, 51-53), clinical trials for HCC (phase II) (45) and melanoma (phase I/II) 
(46), and inhibitory mechanisms of ADI to tumors (54).  
 
Arginine deprivation is believed to be a main molecular reason for ADI’s inhibitory 
effects on arginine auxotrophic tumors which do not express argininosuccinate 
synthetase (ASS). ADIs catalyze the first step of the arginine dehydrolase 
pathway by hydrolyzing arginine to citrulline and ammonium. ADI genes have 
been identified, purified, and characterized from bacteria, archaea and some 
eukaryotes excluding mammalian cells (see review (27)). Enzymatic properties of 
several recombinant ADIs have been examined, such as specific activity, 
functional expression level, temperature optimum, pH optimum, substrate affinity 
for arginine, and half-life in human plasma. Only the ADI from Mycoplasma 
hominis has so far been developed as orphan drug by Pheonix Pharmacologics 
Inc. for HCC and melanoma (129). From enzyme kinetic point of view, none of 
the ADIs is ideally suited for in vivo applications under physiological conditions. 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. PpADI (ADI from 
Pseudomonas plecoglossicida) was functionally expressed in E. coli with a 
simple protocol and has been engineered for the first time by directed evolution 
for improved activity at physiological pH (3). The variant M2 (K5T/D44E/H404R), 
by our group reported, showed a 4-fold higher specific activity than the wild type 
PpADI (0.5 M phosphate buffer, pH 7.4), but a increased Km value (3.5-fold). 
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High activity at low arginine concentration is an important prerequisite for ADI’s 
medical application, allowing low ADI dose required per treatment. 
In the present work, we improved the directed evolution protocol and identified a 
PpADI variant with further improved activity and slightly decreased “Km value” 
and PpADI variant with lowered Km value maintaining its high catalytic activity. 
Those variants were characterized in respect to their kinetic constants. 
 
4.3 Materials and methods 
4.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
plasmid (MEGAWHOP, 25 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
4.3.2 Methods 
4.3.2.1 Site saturation mutagenesis of PpADI M2 at position A128 
Site directed mutagenesis of PpADI M2 (K5T/D44E/H404R) at position A128 was 
performed according to the published method (130). The following 
oligonucleotides were used for mutagenesis of A128: 5’-
CTGATCGGCGGCGTGNNNGGCCAGGACCTGCCG-3’ and 5’- 
CGGCAGGTCCTGGCCNNNCACGCCGCCGATCAG-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 98°C for 30 s, 1 
cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 3 cycles. Second stage: 98°C for 30 
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s, 1 cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 15 cycles; 72°C for 3 min, 1 
cycle), 2 U of PhuS DNA polymerase, 0.20 mM of dNTP mix, 25 pmol of each 
primer together with 100 ng of template (pET42b(+) harboring PpADI M2 gene) 
were used. Following the PCR, DpnI (40 U; New England Biolabs) was added, 
and incubated overnight at 37°C. The PCR products were purified by using a 
QIAquick PCR Purification Kit (Qiagen) and transformed into E. coli BL21-Gold 
(DE3) for expression. 
 
4.3.2.2 Construction of PpADI error-prone library 
EpPCR library was generated by the standard error-prone PCR (epPCR) using 
improved variant M3 (K5T/D44E/A128T/H404R) as template. For the mutagenic 
PCR (95°C for 2 min, 1 cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C 
for 3 min, 1 cycle), 2.5 U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of 
template (pET42b(+) harboring PpADI M3 gene), 0.01-0.1 mM of MnCl2 and 10 
pmol of each primer (5’-TACATATGTCCGCTGAAACACAGAAG-3’ and 5’-
GTGCTCGAGTTAGTAGTTGATCGG-3’) were used. The PCR products were 
purified by using a QIAquick PCR Purification Kit. The purified epPCR products 
were cloned into expression plasmid pET42b(+) by MEGAWHOP (114). For 
MEGAWHOP (72°C for 5 min, 1 cycle; 98°C for 1 min 30 s, 1 cycle; 98°C, 45 s/ 
55°C, 45 s/72°C, 4 min, 24 cycles; 72°C for 10 min, 1 cycle), 1.2 U of PfuS DNA 
polymerase, 0.20 mM of dNTP mix, 500 ng of epPCR products together with 50 
ng of template (pET42b(+) harboring PpADI gene of variant M3) were used. 
Following the PCR, DpnI (40 U; New England Biolabs) was added, and incubated 
(overnight; 37°C). The MEGAWHOP products were transformed into E. coli BL21-
Gold (DE3) for expression and screening. 
 
4.3.2.3 Site directed mutagenesis at position D38 of PpADI M4 
Site directed mutagenesis of PpADI variant M4 at position D38 was performed 
according to the published method on plasmid pET42b(+)-ADI-M4 
(K5T/D44E/A128T/E296K/H404R). The following oligonucleotides were used for 
mutagenesis of D38H: 5’-ACCCCGAGCAACTGCCACGAGCTGCTGTTCGAC-3’ 
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and 5’-GTCGAACAGCAGCTCGTGGCAGTTGCTCGGGGT-3’ (underlining 
indicated the substituted nucleotide). Conditions for mutagenic PCR are as 
described in “Site saturation mutagenesis of PpADI M2 at position A128”.The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.4 Site saturation mutagenesis at position D38 and E296 of PpADI M3 
Site saturation mutagenesis library at position D38 and E296 of PpADI variant M3 
(K5T/D44E/A128T/H404R) were generated according to the published method on 
plasmid pET42b(+)-ADI-M3 using the  following oligonucleotides: D38FP (5’-
ACCCCGAGCAACTGCNNNGAGCTGCTGTTCGAC-3’), D38RP (5’-
GTCGAACAGCAGCTCNNNGCAGTTGCTCGGGGT-3’) and E296FP (5’-
GTCACGGTTTTCCCGNNNGTGGTGCGCGAGATC-3’), E296RP (5’-
GATCTCGCGCACCACNNNCGGGAAAACCGTGAC-3’) (underlining indicated 
the substituted nucleotide). Conditions for mutagenic PCR are as described in 
“Site saturation mutagenesis of PpADI M3 gene at position A128”.The PCR 
products were purified by using a QIAquick PCR Purification Kit (Qiagen) and 
transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.5 Cultivation and expression of PpADI in 96-well plates 
Cultivation and expression in 96-well plates (flat bottom, polystyrene plates; 
Greiner Bio-One GmbH, Frickenhausen, Germany) were performed as previously 
described in 3.3.2.8. 
 
4.3.2.6 Improved screening system in 96-well plate to identify PpADI 
variants with high activities at low arginine concentration 
As describe previously, the modified protocol of citrulline detection based on 
carbamido-diacetyl reaction was used for screening for improved ADI affinity to 
arginine at pH 7.4. 15 µl of cell culture was transferred to 96-well microtiter plate. 
Enzyme reaction was initiated by addition of arginine solution (105 µl, 1mM 
arginine in PBS buffer, pH 7.4) supplemented with 
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cetyltrimethylammoniumbromide (CTAB, 4 mM), and incubated (10 min, 37°C). 
The following color development procedure was carried out as described 
previously (3). 
 
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking PpADI and in a separate experiment 
containing PpADI variant M3. Apparent standard deviation was based on the 
absolute absorbance values obtained from the PpADI variant M3 plate. The true 
standard deviation was calculated by subtracting the background absorbance 
value of the microtiter plate lacking ADI from the apparent values. 
 
4.3.2.7 Expression of PpADI in shaking flask and purification  
Expression of PpADI in shaking flasks and purification (by anion exchange 
chromatography and gel filtration) was performed as previously described in 
3.3.2.10.  
 
4.3.2.8 Characterization of PpADI variants 
Preliminary determination of kinetic constants for site saturation mutagenesis 
variants of position 38 and 296  
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in 
incubator (Heraeus Holding GmbH, Hanau, Germany) using cell crude extract.  2 
ml of expression culture was harvested by centrifugation (Eppendorf 5415R 4°C, 
13,000 g, 10 min) and then freezed (-20°C, overnight). Cell lysate was prepared 
by resuspending the cell pellet in lysozyme (91000 U, 50 mM phosphate buffer, 
pH 7.4, 1.3 ml) followed by incubation (37°C, 40 min) and centrifugation (4°C, 
13,000 g, 10 min). 15 µl of diluted (4 times diluted with 50 mM phosphate buffer, 
pH 7.4) cell lysate was transferred to 96-well microtiter plates. Enzyme reaction 
was initiated by addition of arginine solution (105 µl, 0.25-10 mM arginine in PBS 
buffer, pH 7.4) and incubated (7 min, 37°C). Subsequently, ferric-acid solution 
(120 µl) was added to each well to stop enzyme reaction. 60 µl of terminated 
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enzyme reaction mixture was transferred to 96-well PCR plate for color 
development. Ferric-acid solution (90 µl) and DAM-TSC solution (15 µl) were 
added to each well. The 96-well PCR plate was then incubated (70°C, 30 min) in 
thermal cycler (Eppendorf Mastercyler gradient) for color development, followed 
by incubation in ice water to stop color development. Absorbance was measured 
at 530 nm using a microtiter plate reader (Tecan Sunrise TC reader, Tecan Group 
AG, Zurich, Switzerland). The initial velocity data obtained were fitted to the 
equation v = Vmax[S]/([S] + Km) (where v is the initial velocity, Vmax the maximum 
velocity, [S] the substrate concentration, and Km the Michaelis constant) using 
GraphPad Prism software (GraphPad software, San Diego, CA, USA). The kcat 
was calculated from the ratio of Vmax and enzyme concentration. 
 
Determination of kinetic constants of PpADI wild type and variants M3, M4, M5, 
M6 
The kcat and S0.5 values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath as described previously using purified enzyme (50 µl, 0.1-1.8 µM) to 
and substrate solution (200 µl, 0.5 mM to 10 mM of arginine, PBS buffer, pH 7.4) 
in deep well plates.  
 
The initial velocity data obtained were fitted to the sigmoidal model of kinetics 
equation v = Vmaxn/(S0.5n + Kn) (where v is the initial velocity, Vmax is the maximum 
velocity, K is the substrate concentration, and S0.5 is the ligand concentration 
producing half occupation (131)) using GraphPad Prism software (GraphPad 
software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax and 
enzyme concentration. 
 
4.3.2.9 Native polyacrylamide gel electrophoresis of PpADI variants 
10% of polyacrylamide native gels were used for protein electrophoresis to 
analyze the native form of PpADI variants. Purified protein of PpADI variants (7 µl 
of protein and 3 µl of loading dye) were loaded into each lane of native gel. The 
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molecular marker used in the gel is NativeMarkTM Unstained Protein Standard 
(Invitrogen, Darmstadt, Germany). The electrophoresis was performed with 
tris/glycine buffer (pH 8.3) and electrophoresis chamber was incubated in ice-
water bath. Protein bands were stained with Coomassie brilliant blue solution.  
 
4.3.2.10 Homology modeling 
Homology modeling approach was used for the structure prediction of PpADI. 
The model was built by using the automated structure prediction tool, Protein 
homology/analogy recognition engine (Phyre: http://www.sbg.bio.ic.ac.uk/~phyre/) 
(132). The crystal structure of PaADI (PDB ID: 2A9G) was used as template by 
the server and It has 84.9% sequence identity (http://blast.ncbi.nlm.nih.gov/Blast) 
with PpADI. Procheck program suit (http://www.ebi.ac.uk/thornton-
srv/software/PROCHECK/) (133) was used to assess the stereochemical quality 
of the model. Ramachandran plot which represented that 84.7% residues were 
present in the most favoured region and 14.7% in additional allowed region 
(Figure 3).  Dfire was used to access non bonded atomic interaction in the model 
(http://sparks.informatics.iupui.edu/hzhou/dfire.html/) (134), and Qmean 
(http://swissmodel.expasy.org/qmean/cgi/index.cgi) (135) for the estimation of 
global protein quality. Swiss-PdbViewer (118) was used to create the tetramer 
structure by fitting the monomer model on the 4 units of the 2A9G template. The 
variant M6 (D38H, D44E, A128T, E296K, H404R) were created by using the 
“mutate” tool of the Swiss-PdbViewer and by selecting rotamers with the best 
fitness score. All tetramers were energy minimized in vacuum using GROMOS 
43B1 force field (119).  
 
4.4 Results 
4.4.1 Improved screening system in microtiter plates to identify PpADI 
variants with high activities at low arginine concentration 
Screening assay was based on the validated citrulline colorimetric screening 
protocol in microtiter plate, as reported previously (3). In order to screen for 
variants with high activity at low arginine concentration under physiological 
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condition concerning pH and ion concentrations, 1 mM arginine in PBS buffer 
(pH 7.4) as substrate solution was employed in screening assay and enzyme 
reaction time was controlled accordingly (10 min). The coefficient of variation is 
an important performance criterion of a screening system to determine its 
accuracy. Optimized assay condition with 1 mM arginine (PBS buffer, pH 7.4) as 
substrate resulted in true coefficient of variation of 14.9 % (Figure 1). The 
resulting low absolute absorbance value is a main reason for the high true 
coefficient of variation (14.9 %). In the previous screening system, 100 mM 
arginine in 0.5 M sodium phosphate buffer was used and yielded higher activity 
variants but with higher Km value. 
 
 
 
Figure 1. Activity values in descending order of the PpADI variant M3 conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
4.4.2 Genealogic tree of directed PpADI evolution  
Figure 2 shows the two rounds of PpADI evolution, generation of saturation 
mutagenesis libraries and recombination of beneficial positions to finally obtain 
the PpADI variant M6 with 64.7-fold higher kcat and reduced S0.5 (1.3 mM (WT) to 
0.81 mM (M6). Based on structure-function analysis of PaADI[16], M1 was 
generated by substitute His at position 404 with Arg. Position 404 is through 
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interactions with position Asp280 involved in substrate stabilization during 
catalysis. M1 was subject to the first round of epPCR library, from which M2 was 
identified showing a 4-fold improved kcat value and increased Km value (2.5 mM 
in 0.5 mM sodium phosphate buffer, pH 7.4)[15]. M3 was generated by a site 
saturation mutagenesis library at position 128 which increased in another clone 
the expression level (data not shown). In order to improve PpADI towards 
medical application demands (high activity at low arginine concentration), a 
second epPCR mutant library was constructed using M3 as parent. M4 with 
decreased S0.5 value (0.81 mM) and M5 with increased Kcat value (17.56 s-1) 
were identified after screening of ~1400 clones. In M4 the position E296 was 
identified to be important for lowering S0.5 and in M5 position D38 was identified 
to be important for activity increase. M6 was finally constructed by combining the 
substations at position D38 and E296. Saturation mutagenesis of these two 
positions did not yield any further improved S0.5 or activity variant.  
 
 
Figure 2. Genealogic tree of PpADI variants (M1 to M6) with generated amino acid substitutions. 
Novel substitutions are indicated by an asterisk. 
 
4.4.3 EpPCR library construction and screening for variants with high 
activities at low arginine concentration 
Variant M2 was used as a starting template. As described previously, M2 shifts 
the pH optimum from pH 6.5 to pH 7.0 and has a 4-fold faster kcat than PpADI 
wild type. In one sequenced mutant, position A128 was identified to be 
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responsible for higher expression (data not shown). Site saturation mutagenesis 
on M2 therefore was carried out at position A128. The resulting variant M3 
(K5T/D44E/A128T/H404R) showed a ~2-fold improved expression and was 
subsequently used as parent template for epPCR library. 
 
Three concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Instead of 0.02 mM 
MnCl2, 0.05 mM MnCl2 which generated 46 % of inactive mutant was selected for 
library generation. EpPCR mutant libraries with a ratio of ~50 % active and ~50 
% inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). Two variants M4 and M5 
were identified from this epPCR library (~1400 clones) and further characterized. 
Variant M4 and M5 were sequenced and one additional amino acid substitution 
was identified for each variant, E296K and D38H, respectively. 
 
4.4.4 Site saturation mutagenesis of PpADI at position D38 and E296 
To investigate their role in improving of catalytic performance for arginine, site 
saturation mutagenesis library at position D38 and E296 were generated using 
PpADI M3 as template. For each position, ~300 clones were screened at low 
concentration of arginine (1 mM, PBS buffer, pH 7.4), using 96-well plate format 
citrulline colorimetric screening assay.  
 
After the screening of site saturation mutagenesis libraries of position 38 and 296, 
variants with higher activity were chosen for preliminary kinetic investigation using 
crude cell extract. Beneficial mutants were identified and sequenced from both 
sites (Table 1). At position 38, the following beneficial substitutions were found: 
D38R (three times, AGA, CGG, CGT) and D38K (twice, AAG, AAA). In all cases, 
the negatively charged acidic amino Asp had been replaced by positively charged 
amino acids, Arg or His. Substitution by negatively charged Glu resulted in a 
clone showing a parent M3-like kinetic behavior. Hydrophobic amino acid 
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substitution by Pro resulted inactive clone under assay conditions. At position 296, 
the following substitutions were found to be beneficial: E296K (twice, AAA, AAG), 
E296N (once, AAC), E296T (once, ACC), E296G (once, GGA). Among these 
substitutions, variants with substitution to positively charged residue Lys show 
lowest S0.5 value for arginine while substitution by uncharged amino acids (Asn, 
Thr, Gly) shows relatively marginal improvement compared to E296K. 
Hydrophobic amino acid substitution by Pro and Trp resulted in very low activity 
clones. 
Table 1. Nucleotide and amino acid substitutions at position 38 in PpADI M3. 
 PpADI 
variants Substitution at position 38 km (mM) 
M3 (parent) Asp (GAC) 3.74 ± 0.35 
SSM-D38R Arg (AGA, CGG, CGT) 1.16 ± 0.21 
SSM-D38K Lys (AAG, AAA) 1.01 ± 0.28 
SSM-D38E Glu (GAG) 2.95 ± 0.77 
SSM-D38P Pro (CCA) n. d. 
SSM-D38T Thr (ACC) n. d. 
M5 His (CAC) 1.26 ± 0.12 
Kinetic experiments were performed with crude cell extracts. 
 
 
Table 2. Nucleotide and amino acid substitutions at position 296 in PpADI M3. 
 PpADI 
variants Substitution at position 296 km (mM) 
M3 (parent) Glu (GAA) 3.74 ± 0.35 
SSM-E296K Lys (AAA, AAG) 0.20 ± 0.01 
SSM-E296N Asn (AAC) 0.53 ± 0.04 
SSM-E296T Thr (ACC) 0.61 ± 0.04 
SSM-E296Q Gln (CAA) 0.79 ± 0.06 
SSM-E296G Gly (GGA) 1.29 ± 0.12 
SSM-E296W Trp (TGG) n. d. 
SSM-E296P Pro (CCT) n. d. 
M4 Lys (AAA) 0.27 ± 0.02 
Kinetic experiments were performed with crude cell extracts.  
* n. d. activity not detectable under assay conditions. 
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4.4.5 Determination of kinetic constants (kcat and S0.5) of PpADI wild type 
and variants M3, M4, M5 and M6 
 
Table 3. Kinetic constants of wild type PpADI and variants. 
 Wild type M3 (parent) M4 M5 M6 
kcat (s-1) 0.18 ± 0.05 10.13 ± 0.36 5.88 ± 0.09 17.56 ± 1.15 11.64 ± 0.50 
S0.5 (mM) 1.30 ± 0.25 2.01 ± 0.19 0.81 ± 0.03 1.48 ± 0.17 0.81 ± 0.09 
* Kinetic contants of PpADI wild type is different from our previous report because in stead of 
0.5 M phosphate buffer, PBS buffer was used for kinetic measurements. Kcat value of PpADI 
wild type dropped from 5.6 s-1 to 0.18 s-1 and kcat value of M2 is reduced ~2-fold. 
 
M3, the parent of the second round of PpADI epPCR library, M4 with decreased 
S0.5, M5 with increased kcat and best variant M6 with best combination of kcat 
value and S0.5 were selected for detailed characterization studies.  
 
Kinetic characterization of PpADI variants was performed using PBS buffer (pH 
7.4), which is commonly used in biological research. PBS buffer helps to 
maintain a constant pH and its osmolarity and ion concentrations usually match 
those of the human body. Citrulline production of PpADI variants was maintained 
between 0.2-0.8 mM. Table 3 summarizes the kcat and S0.5 values of parent M3 
(K5T/D44E/A128T/H404R), variants M4 (K5T/D44E/A128T/E296K/H404R), M5 
(K5T/D44E/A128T/D38H/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R), which were expressed in shaking 
flasks cultures and purified using a two step procedure (anion exchange follows 
by gel filtration). Compared to parent M3 (S0.5 = 2.01 mM), both variants M4 and 
M5 have a lower S0.5 for arginine conversion at pH 7.4, 0.81 mM and 1.48 mM, 
respectively. Variant M4 shows a decreased kcat value, 58% of parent M3 while 
M5 shows a 1.7-fold higher kcat compared to parent M3. Variant M6 with 
combined mutations (K5T/D38H/D44E/A128T/E296K/H404R) shows decreased 
S0.5 value, 40 % of parent M3 (K5T/D44E/A128T/H404R), 62 % of PpADI wild 
type, and a 64.7-fold faster kcat value than PpADI wild type. M6 is 42.3-fold faster 
than PpADI wild type with 0.4 mM arginine (PBS buffer, pH 7.4) as substrate. 
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After two rounds of epPCR libraries coupled with site directed mutagenesis, a 
variant M6 with 64.7-fold higher kcat and lower S0.5 value (0.81 mM) than PpADI 
wild type (0.31 mM). At low concentration of arginine, activity of M6 enhanced 
dramatically than M3 and wild type. For example, M6 is 42.3-fold faster than 
PpADI wild type in 0.4 mM arginine (PBS buffer, pH 7.4). 
 
4.4.6 Native polyacrylamide gel electrophoresis of PpADI variants 
Multimeric form of PpADI variants were investigated by native polyacrylamide gel 
electrophoresis. As shown in Figure 3, two distinct protein bands representing 
two multimeric forms tetramer and dimer (molecular weight of a subunit is ~ 46 
kDa) were observed, but with different concentration percentage. The major 
multimeric form of M3 is dimer. Compared to M3, M4 with an additional mutation 
E296K shows a very different pattern: tetramer is the main form; while M5 with 
an additional mutation D38H contains more or less equal amount of dimer and 
tetramer. M6, with both mutations E296K and D38H, contains more tetramer than 
dimer. 
 
 
 
Figure 3. Native polyacrylamide gel electrophoresis of PpADI variants (M3 to M6) with different 
dimer/tetramer distribution. Single subunit has a molecular weight of ~46 kDa. 
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4.5 Discussion 
 
Directed evolution allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
Small libraries of a few thousand variants are often sufficient to find improved 
variants [18] even without rational understanding of the targeted property. After 
establishing a first directed ADI evolution protocol yielding mutant M2, we 
adjusted the screening system to better reflect ADI’s application conditions. 
Prerequisite for ADI to become an effective anti-tumor agent is that low 
concentrations of arginine in human plasma can effectively be converted. 
 
Figure 2 shows the genealogic tree of PpADI evolution and before discussing the 
influence of each substitution individually the effect on kinetics are briefly 
summarized. Amino acid substitution D44E (M2) increases kcat and S0.5, 
substitution A128T (M3) increases the expression level, and substitution E296K 
(M4) decreases kcat and S0.5 and is responsible for tetramer formation. 
Substitution D38H (M5) increase largely kcat and reduces slightly S0.5. The 
combination of all mentioned residues in M6 result in a finally 64.7-fold improved 
PpADI activity and reduced S0.5 (1.30 to 0.81 mM).    
 
PpADI M3 was obtained from site saturation mutagenesis library at position A128 
using M2 as template (Figure 2). M3 shows improved functional expression level 
of ADI (data not shown) and was used as parent for generating an epPCR library. 
Screening of epPCR library yielded two improved variants M4 and M5, carrying 
an additional mutation, E296K (M4) and D38H (M5). M4 has a decreased S0.5 
(0.81 mM) and a decreased kcat value (5.88 s-1; see Table 3). M5 has a 
decreased S0.5 (1.48 mM) and an increased kcat value (17.56 s-1) when compared 
to parent M3 (S0.5, 2.01 mM; kcat, 10.03 s-1; see Table 3). M6 which harbors both 
substitutions (E296K and D38H) has a decreased S0.5 value (0.81 mM) 
compared to the parent M3 (1.30 mM) and the wild type (2.01 mM), and a 64.7-
fold higher kcat value than the PpADI wild type.   
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Despite further enhancing the activity of PpADI, it is crucial for an efficient 
conversion of the substrate arginine in human plasma (100-120 µM arginine) to 
reduce PpADI’s “Km” (S0.5) value. Figure 4 shows the kinetics of PpADI WT, 
parent M3, and the variants M4, M5 and M6. M3 has a significantly higher kcat 
value compared to WT, but its activity at low concentration of arginine (<1.0 mM) 
is very low (S0.5 value 2.01 mM). In contrast, the most efficient variant M6 with a 
decreased S0.5 value (0.81 mM) shows a remarkable activity improvement at low 
concentrations of arginine (<0.5 mM; see Figure 4). M6 has additional two amino 
acid substitutions (D38H and E296K) compared to M3 which increases kcat and 
reduces the S0.5 value. The combination of D38H and E296K improves especially 
the activity of M6 at low arginine concentrations (< 0.5 mM; see Figure 4). 
 
Figure 4. Kinetic curve of PpADI wild type, M3, M5 and M6. (▲) PpADI wild type, (▼) M3, (●) M4, 
(♦) M5 and (■) M6. 
 
 
Figure 5 shows the tetrameric model (based on PaADI, PDB code 2A9G) of 
PpADI WT (Figure 5A) and variant M6 (Figure 5B). Monomeric units are 
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indicated with the letters a, b, c and d. The access channel to the active sites of 
each monomer is highlighted in square and faces an internal cavity generated by 
the assembly of four PpADI monomers. The substitutions D38H (in blue) and 
D44E (in green) are localized at the interface of monomer pair a-b and c-d. The 
substitution of Glu by Asp at position 44 provides a longer side chain in close 
proximity of the also negatively charged residue Asp43 (Figure 6A). The 
substitution E296K is localized at the border of the entrance to the internal cavity 
of the PpADI tetramer. E296K promotes the tetramer formation likely by 
introducing stabilizing interactions with other residues, for example with Thr33 
(hydrogen bond). E296K inverts the charge at this position and its increased 
length of the side chain might promote further interactions to a neighboring 
monomer (Figure 6A). The combination of D44E and E296K results in a 
population consisting of mainly tetramers (see Figure 3; mutein M4). Interestingly 
with the formation of a tetramer (M4) the S0.5 value is reduced which indicates 
that the tetramer complex formation promotes interactions with the substrate 
arginine at low concentrations. The substitution D38H together with the E296K in 
the mutein M6 reestablishes an almost equal population of PpADI dimers and 
tetramers. A hypothesis is that Lys of the E296K has an electrostatic stabilizing 
interaction with the Glu38 in the M4 but not to the neutral His38. 
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Figure 5. A). The model of WT tetramer after energy minimization in vacuum (GROMOS 43B1). 
B). The model of M6 tetramer after energy minimization in vacuum (GROMOS 43B1). Active site 
residues are represented in CRK format in a square (Blue). Mutated residues are shown in 
licorice format in different colors like D38H (blue), D44E (green), A128T (magenta), E296K (red) 
and H404R (violet). Substrate arginine is represented in orange color by licorice format.  
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Figure 6. A). Structure model of variant M6. E296K is involved in intermonomer interaction 
(between chain a (orange) and b (green)) with Thr33. D44E is involved in intermonomer 
interaction, between chain A (orange) and B (green), with Asp43 (violet). B). Structure alignment 
of PpADI WT model and M6 model with four loops (loop 1:30-46, loop 2:178-175, loop 3:271-281 
and loop 4: 393-404) surrounding the entrance of the active site. The substitutions in these loops 
and the residues involved in the interaction with those substitutions are representing: D38H 
(orange), D44E (yellow) and H404R (cyan, in M6; gray, in WT), Ser35 (green), Arg 400 (pink), 
substrate arginine (ochre), catalytic triad His278, Asp280 and Cys406 (violet, highlighted in an 
oval) 
 
Figure 6B shows that the active site of the PaADI is surrounded by four loops 
(loop 1: 30-46, loop 2: 178-185, loop 3: 271-281, and loop 4: 393-404). These 
four loops undergo a conformational transition upon arginine binding and tighten 
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the surrounding of the arginine substrate[16]. D38 is located in loop 1 and faces 
towards the substrate access channel. In PpADI model (Figure 6B), the D38H 
mutation promotes the formation of a hydrogen bond interaction with the 
neighboring residues Ser35, contributing to the stability of the entropically 
unfavorable folded conformation of loop1. The rigidified loop 1 might be 
beneficial for arginine conversion. According to PaADI structure analysis, the 
side chain of gating residue Arg401 (Arg400 in PpADI) is located at the active 
site entrance and fills the substrate-binding site. The structure analysis of the 
C406A PaADI-L-arginine complex[16] shows that the Arg401 side chain (Arg400 
in PpADI) is displaced by the substrate arginine to a position near the active site 
entrance that allows its hydrocarbon chain to assist shielding the catalytic site 
from solvent. D38 is involved in an ionic interaction and hydrogen bonding with 
Arg400. The substitution of Asp to His at position 38 results in a loss of ionic 
interactions to Arg400 due to the different lengths of the side chains. His38 can 
form only a hydrogen bond with active site gating residue Arg400. A weakened 
interaction between position 38 and Arg400 might increase the flexibility of the 
side chain of Arg400 which then might block less efficiently the access of 
arginine to the active site. As a result the variant M5 shows an improved kcat 
value (1.7-fold compared to parent M3) due to the substitution D38H.  
 
For elucidating further the individual role of the five identified amino acid 
substitutions and their influence on the active site geometry and tetramer 
formation crystal structures of variant M4 and M6 have to be solved.  
 
4.6 Conclusion 
In summary, with the modified screening protocol, PpADI variants with improved 
kcat and S0.5 were identified. The increased kcat value and decreased S0.5 value 
result in significant activity improvement of PpADI at low arginine concentrations. 
Especially the kinetic constants of PpADI variant M6 demonstrate that PpADI 
properties can be tailored by directed evolution. The generated PpADI variants 
match from their kinetic behavior therapeutic application demands much better 
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than the wild type PpADI. We therefore hope that by directed evolution improved 
PpADIs will further be investigated in vivo for tumor therapy. 
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Summary and outlook 
Arginine depletion based on ADI is an emerging strategy for anti-tumor treatment. 
ADIs have been studied for the therapy of HCCs and melanomas and were 
approved as an orphan drug for both kinds of tumors. ADI is proved to be 
effective in the treatment of leukemia. The effectiveness of ADIs as anti-tumor 
agent depends on their enzymatic properties (such as Km, kcat, optimum pH, 
stability at neutral pH). Directed evolution, without rational understanding of the 
targeted property, allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
 
In order to improve PpADI activity at physiological pH by directed evolution, a 
colorimetric screening assay based on citrulline detection has been developed in 
96-well microtiter plate format. Single mutation H404R was identified according 
to PpADI homology model (based on PaADI crystal structure), introduced to 
PpADI wild type and eventually resulted in 1.4-fold of increase in kcat. M1 (H404R) 
was used as template for the first round of epPCR library generation. M2 
(K5T/D44E/H404R) obtained from the first round of epPCR library showed 4-fold 
improved kcat value when compared to the PpADI wild type. Furthermore, a shift 
of pH optimum from pH 6.5 to pH 7.0 was observed, combined with an increased 
Km value (2.5 mM) under assay conditions (0.5 M sodium phosphate buffer, pH 
7.4), compared to PpADI wild type (0.7 mM). 
 
Arginine concentration in human plasma is however relatively low (100-120 µM). 
Therefore the second round of epPCR library was performed to decrease Km 
value and further improve kcat value. The validated screening assay was modified 
to reflect more close physiological condition (1 mM arginine in PBS buffer, pH 
7.4). Two important variants with one additional mutation, M4 
(K5T/D44E/A128T/E296K/H404R) with decreased S0.5 vaule, and M5 
(K5T/D38H/D44E/A128T/H404R) with improved kcat were obtained. Their two 
mutations were combined and resulted in variants M6 
  96 
(K5T/D38H/D44E/A128T/E296K/H404R). Under physiological pH in PBS buffer, 
the S0.5 value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); 
the kcat value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-
folds) and 11.64 s-1 (M6, 64.7-fold). 
 
A reamaining challenge facing PpADI’s anti-tumor application is to decrease the 
Km (S0.5) value further close to arginine concentration level in human plasma. A 
more sensitive assay for screening has to be developed with the addition of 
sensitizer like thiosemicarbazide (TSC), optimized temperature and incubation 
time. Improved variants should be tested tested in human plasma or with human 
plasma composition. In vitro testing of ADI variants with arginine auxotrophic 
tumor cell lines is the first step towards in vivo in human. 
 
In summary, directed evolution has been very useful algorithim for improving 
ADI’s kcat and Km at physiological pH (pH 7.4) for its medical application. Hope 
that directed evolution will be become a standard method for therapeutic protein 
like its use in industry.                                
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Abstract 
Abstract 
Arginine deiminase (ADI), an arginine-degrading enzyme, is involved in the first 
step of arginine dihydrolase pathway. It catalyzes the hydrolysis of L-arginine to 
form citrulline and ammonia. ADI has been studied as a potential cancer 
therapeutic agent for the arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCC) and melanomas. Furthermore, studies also indicate that ADI 
is a potential anti-angiogenic agent; therefore it could become a novel anti-cancer 
drug targeting the neovascularization-related tumors. Studies show ADI is more 
potent for the treatment of leukemia than L-asparaginase. However, the anti-
tumor application of ADI for therapeutic purpose faces considerable challenges, 
such as, microbial ADI has low activity at physiological pH (7.35~7.45), short 
circulating half-life (~5 h) and high antigenicity. Pegylation of ADI improved its 
efficacy as a clinical drug, including its half-life in serum and antigenicity. The aim 
of the project is to improve ADI catalytic performance at physiological pH by 
directed evolution. 
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. Directed protein evolution has 
over the last decades become a versatile and successful approach for tailoring 
protein properties to industrial demands and for advancing our understanding of 
structure-function relationships in biocatalysts. Unlike rational design relying on 
the gathering of extensive structure-function relationships of enzymes, directed 
evolution is used to reengineer enzyme properties through iterative rounds of 
diversity generation and function selection for improved variants. 
 
In order to improve the ADI activity at physiological pH, we established a directed 
evolution protocol for this purpose. A microtiter plate (MTP) format colorimetric 
screening assay based on citrulline detection with diacetyl monoxime (DAM) was 
developed. Reaction temperature for color development and DAM concentration 
 IV 
were optimized to ensure sufficient sensitivity, appropriate linear range and 
throughput. With the optimized assay and PpADI wild type expressed in E. coli as 
a model protein, true standard deviation 12.8 % was obtained, which is 
appropriate for the library screening. 
 
With the established microtiter plate assay system, for the first time, we 
reengineered ADI for improved activity at physiological pH (pH 7.4) with higher 
potency in medical application. After one site directed mutagenesis and one 
round of epPCR library screening, variant M2 (K5T/D44E/H404R) was obtained. 
M2 shows 4-fold improved kcat value than the PpADI wild type, a shifted pH 
optimum at pH 7.0 (by 0.5 pH unit), and however an increased Km value, 3.6-fold 
under assay conditions (0.5 M sodium phosphate buffer).  
 
Low Km (S0.5) value for ADI is an important factor for efficient consume of arginine 
in plasma because of the low arginine concentration in human plasma (100-120 
µM). Therefore after our proof of concept of reengineering PpADI by directed 
evolution, we aim to decrease the Km value of PpADI towards arginine and 
improve the kcat furthermore thereby improve the efficiency of arginine depletion 
by ADI. The established citrulline colorimetric assay in 96-well microtiter plate is 
improved to reflect application conditions: PBS buffer and 1 mM arginine were 
used in screening system. After the second round of epPCR library and site 
directed mutagenesis, variant M5 (K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated: at pH 7.4 (PBS buffer), 
the S0.5 value decrease from 2.01 mM (parent M3, K5T/D44E/A128T/H404R) to 
1.48 mM (M5) and 0.81 mM (M6). Under physiological pH in PBS buffer, the S0.5 
value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat 
value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 
11.64 s-1 (M6, 64.7-fold). 
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Chapter 1 Arginine deiminase (ADI) 
Arginine deiminase (ADI) 
 
1.1 Arginine deiminase (ADI)  
Arginine deiminase (ADI, EC 3.5.3.6), an arginine-metabolizing hydrolase, 
catalyzes the hydrolysis of L-arginine to form citrulline and ammonia. This 
reaction is the first step in the L-arginine degradation pathway (ADH, scheme 1, 
(1). First, arginine is deiminated by arginine deiminase. The resulting citrulline is 
converted to carbamoyl phosphate and ornithine by ornithine transcarbamylase 
(EC 2.1.3.3), and finally the carbamoyl phosphate is used to phosphorylate ADP 
by carbamate kinase (EC 2.7.2.2), producing one ATP molecule. ADI is absent in 
humans but present in a wide range of bacterial species such as Pseudomonas 
aeruginosa (2), Pseudomonas plecoglossicida (3) and Mycoplasma arginini (4) 
and in parasitic protists such as Giardia intestinalis (5), Trichomonas Vaginalis 
(6), Trichomonas fetus (7), and Hexamita inflate (8). For pathogenic bacteria, ADI 
is required in arginine dehydrolase pathway for virulence and for energy 
production under anaerobic conditions (9, 10).     
 
 
Scheme 1. Arginine dihydrolase pathway. OTC, ornithine transcarbamylase; CK, carbamate 
kinase. 
 
 
 
 2 
The establishment of a high-level production system for ADI is an essential step 
for further research and development of this enzyme. After ADI was discovered 
from Mycoplasma in 1960s (11), various ADI genes have been cloned, 
expressed in E. coli strains, and the enzyme properties were also studied (Table 
1). 
 3 
Table 1. ADI expression, enzymatic properties and medical applications. 
ADIs Origin 
Expression 
host/vector 
Multimeric 
form Km; kcat 
Optimum 
pH  
Specific 
activity 
Medical 
application References 
MhADI 
(SYN1903) 
Mycoplasma 
hominis PG21* 
E.coli BL21 
(DE3)/pET-47b 
Dimer   0.618 U/mg 
(pH 6.5) 
Human 
melanoma 
(G361), 0.036 
U/ml for 50 % 
IC50 
Japan, 
Harasawa, 
2009 (12) 
MhADI Mycoplasma 
hominis (ATCC 
23114) 
- 
 
Dimer   6.0 35.5 U/mg (pH 
6.0) ;  
3.9 U/mg (pH 
7.4)  
Mouse 
melanoma 
(MH134) in 
vitro, 100 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MhADI Mycoplasma 
hominis (ATCC 
14027) 
- Dimer  0.17 mM 
(pH6.6) 
   USA, Fenske, 
1976(14) 
MhADI Mycoplasma 
hominis  
E.coli BL21 
(DE3)/pET25b 
 0.24 mM; 
0.151 s-1 
   China, Luo, 
2007 (15) 
MhADI Mycoplasma 
hominis 
E.coli    20 U/mg ADI 
(37°C). [a] 
ADI-SS 
PEG20000,  
human 
melanoma, 
human HCC 
USA, Pheonix 
Pharmacologi
cs, Inc., Clark, 
2002 (16) 
PaADI 
(PA5171) 
Pseudomonas 
aeruginosa  
(ATCC 47085D) 
E. coli 
BL21(DE3)/pET10
0 
Tetramer 0.14±0.01 
mM (pH 5.6) 
5.6   USA, 
Dunaway-
Mariano, 2005 
(17) 
PaADI Pseudomonas 
aeruginosa  
 
E. coli 
BL21 (DE3)/ 
pET SUMO 
   CARD-like 
domain, no 
catalytic 
activity 
Human cancer 
cell line SKOV-3 
USA, 
Chakrabarty, 
2006 (18) 
PpADI Pseudomonas 
plecoglossicida 
E. coli 
BL21 Gold-(DE3)/ 
pET42b 
 0.7 mM; 5.6 
s-1 (pH 7.4, 
0.5 M sodium 
phosphate 
buffer) 
6.5 31.3 U/mg (pH 
7.4, 0.5 M 
sodium 
phosphate 
buffer) 
 Germany, 
Schwaneberg, 
 2010 (3) 
 4 
MaADI Mycoplasma 
arginini 
(ATCC 23838D) 
E. coli 
DH5α/PTTQ118 
   32.7 U/mg. [a] Human 
umbilical vein 
endothelial 
(HUVE) 
USA, Shen, 
2002 (19) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
E. coli 
JM101/pADTc1 
Dimer     33.6 U/mg 
(37°C, pH 6.5). 
[a] 
Mouse 
hepatoma, 17 
ng/ml for 50 % 
IC50; mouse 
fibrosarcoma, 
15 ng/ml for 50 
% IC50 
Japan, 
Hayashi, 1994 
(20) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
    42 U/mg 
(37°C, pH 6.5); 
29.9 U/mg 
(37°C, pH 7.4) 
Mouse 
melanoma 
(MH134) in 
vitro, 10 ng/ml 
for 50 % IC50 
Japan, 
Takaku, 1995 
(13) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
-     HUVE, 
neuroblastoma, 
retinoblastoma, 
osteosarcoma, 
5~10 ng/ml for 
50 % IC50 
Germany, 
Schweigerer, 
1999 (21) 
MaADI Mycoplasma 
arginini 
(ATCC 23838) 
- Dimer  0.2 mM 6.0-7.5 50 U/mg Mouse tumor 
carcinoma, 
fibrosarcoma 
and melanoma, 
5~20 ng/ml for 
50 % IC50 
Japan, 
Takaku, 1992 
(22) 
LlADI L. lactis (ATCC 
7962) 
E. coli 
BL21Gold(DE3)/p
GEM-T Easy 
Trimer 8.67 mM 7.2 140.27 U/mg  Korea, Lee, 
2007 (23) 
[a] ADI was expressed in inclusion body and denaturation-renaturation had to be employed to get soluble protein. 
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1.2 ADI structure 
In 1970s, Kakimoto et al. (24, 25) diffracted the first ADI crystals from P. putida 
through multiple-step chromatography followed by crystallization. Almost three 
decades later, the X-ray crystal structure of ADI from P. aeruginosa (PaADI, 
Figure 1A) (26) and M. arginini (MaADI, Figure 1B) (4) were solved to assist in 
understanding structure-function relationships. PaADI and MaADI share 27 % 
sequence identity and belong to guanidino group-modifying enzyme superfamily 
(GMSF). The catalytic triad (Cys-His-Glu/Asp) is conserved in members of the 
GMSF. Both crystal structures of PaADI and MaADI show a characteristic 5-fold 
pseudosymmetrical barrel with ββαβ subunits. Table 2 summarizes the crystal 
structures of PaADI and MaADI. 
 
Figure 1. Structural of ADIs from P. aeruginosa and M. arginini. (A) PaADI (PDB ID: 1RXX) and 
stereo view of its catalytic triad (C406-H278-E224). (B) MaADI (PDB ID: 1S9R) and stereo view 
of its catalytic triad (C398-H269-E213) with substrate L-arginine (27). 
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Table 2.  Crystal structures of ADI in protein data bank (PDB). 
PDB 
code 
Ligand in crystal 
structure Description 
Resolution 
(year) 
2A9G Arginine 
Crystal structure of PaADI variant C406A in 
complex with L-arginine  
2.30 Å 
(2005) 
2AAF  
Crystal structure of PaADI variant H278A 
forming a S-alkylthiouronium reaction 
intermediate  
2.30 Å 
(2005) 
2ABR  
Crystal structure of PaADI variant D280A with L-
arginine forming a S-alkylthiouronium reaction 
intermediate  
2.9 Å 
(2005) 
2ACI  Crystal structure of D166A arginine deiminase  
2.50 Å 
(2005) 
1S9R Arginine 
Crystal structure of MaADI covalently linker with 
a reaction in intermediate  
1.60 Å 
(2004) 
1LXY Citrulline 
Crystal Structure of MaADI covalently linked with 
L-citrulline  
2.00 Å 
(2004) 
1RXX  Crystal structure of MaADI  
2.45 Å 
(2004) 
 
MaADI was crystallized as a homodimer and its catalytic triad is formed by 
Cys398-His269-Glu213. MaADI has a catalytic domain and a five-helix bundle 
domain (Figure 3). The buried and compact substrate binding pocket is located 
approximately at the center of the molecule, from which a small solvent channel 
leads to the surface of the enzyme. The opening to the channel is located 
adjacent to the dimer interface region, which is at the opposite side of the 5-fold 
pseudosymmetric moiety of ADI. The shape and size of the channel does not 
permit transport of the substrate (L-arginine and end product (L-citrulline) in and 
out of the pocket. Substantial conformational changes in ADI are required to 
permit entry of the substrate and expulsion of the end product. The occurrence of 
"closed" and "open" form was suspected to be dependent on binding of substrate. 
 
PaADI has a tetrametric structure with 1630 amino acid residues in total, which 
makes it the largest enzyme of its structural superfamily. The catalytic triad of 
PaADI is Cys406-His278-Glu224. Similar to MaADI, the active site of PaADI is 
  7 
located in a narrow crevice formed by a network of charged residues. Ligand 
binding energy is derived from ion pair and hydrogen bonding interactions 
between active site residues and the guanidinium, carboxylate and ammonium 
groups of the substrate. The proposed substrate-binding model shows that the 
catalytic center contains abundant charged residues (e.g. Asp280, His405, Glu13 
and Arg165). The ion pairing interactions between these residues contribute to 
the integrity and activity of ADI. In addition, Asp116, Asp227, Arg185, Arg401, 
His278, Glu118, and Glu224 are part of an extended charged network. The 
proposed catalytic mechanism suggests that the active site of PaADI is blocked 
by Arg401, and therefore a conformational transition is taking place upon the 
substrate binding. Based on the proposed reaction mechanism, Cys406 is as a 
key residue responsible for the nucleophilic attack on the guanidinium carbon 
atom of arginine. PaADI contains only one hydrophobic residue, Phe-163 and a 
Cys-406 with an unknown protonation state. The known functions of important 
residues are shown in Table 3, and the interactions between important residues 
and substrate arginine are shown in Figure 2. 
 
 
Figure 2. A. stereoscopic view of PaADI key active site residues. B. stereoscopic view of a 
modeled arginine substrate (green) docked in the active site of ADI. Atomic colors are red, 
oxygen; blue, nitrogen; yellow, sulfur; and gray, carbon. Ion pair interactions are shown as 
dashed lines (26). 
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Table 3. Residues important for catalytic function of PaADI (28, 29). 
Residues Known/postulated function or comment 
Cys406 Mounts the nucleophilic attack on the carbon atom of the guanidinium 
group of arginine 
His278 Serves as a general base and activate the water molecule 
Glu224 Modulate the ionization state of His278 
Asp280 Interacts with the imidazole group of His405 F via the carboxylate 
group, which in turn interacts with Glu13. Invariant residue in all 
known ADIs 
Asp280, 
Asp166 
Fix the guanidinium group of the arginine substrate tightly by 
interactions with the carboxyl groups 
Arg401, 
Arg185 
Form ionic interaction with The carboxyl group of the arginine 
substrate 
Phe163 Interacts with the hydrophobic part of arginine substrate 
Glu13 Interacts His405 and is invariant in all known ADIs 
His405 Sometimes is replaced by an arginine, as in the case of McADI. This 
may explain the low pH optimum of PaADI (5.6) in contrast to the 
neutral pH optimum of McADI, the enzyme that contains an arginine 
residue instead of His405 
Arg165 Is fixed by electrostatic interactions with the main chain oxygen atoms 
of Thr408 and His405 and with the hydroxyl group of Thr-408 
Arg401 Blocks the ADI active site via the side chain by forming an ion pair 
with the carboxyl group of Asp166 and occupies approximately the 
same position as the guanidinium group of an arginine substrate 
 
The overall fold of MaADI and PaADI consist of five ββαβ modules in cyclical 
arrangement, generating a pseudo 5-fold symmetrical barrel and an additional 
85-residue α-helical domain inserted between the first and the second ββαβ 
modules giving the typical “Clip-on-fan” moiety. The α-helical domain of PaADI 
mediates tetramer formation and the α-helical domain of MaADI was speculated 
to play a role in activating the series of reaction in arginine dehydrolysis pathway 
(4). Structural alignments by Chakrabarty et al. (18) demonstrated the unique 85 
residue 5-α-helical bundle domain exhibiting structural similarity to the 
mammalian CARD (caspase recruitment domains)-containing proteins and this 
CARD-like domain is present only in the PaADI and MaADI but not in the other 
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GMSF members (Figure 3B). Furthermore, PaADI putative CARD-like domain 
induced apoptosis to cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structural characteristics of the PaADI. A. Ribbon drawing of PaADI (1RXX_A) 
highlighting the two domains. B. The presence of the CARD domain in PaADI and MaADI but its 
absence in other members of the GMSF (guanidino-group modifying superfamily) enzymes such 
as DDAH and AGAT, as shown from the structure-based sequence alignments. The CARD 
domain represents that of caspase-9. DDAH, dimethylarginine dimethylaminohydrolase; AGAT, 
arginine: glycine amidinotransferase. The β-strand and α-helices are shown as arrows and strips 
respectively. Roman numericals I to V are the five ββαβ subunits. The clip moiety (α-helical 
module) in Figure 3 is seen only in PaADI and MaADI which bears structural homology to the six-
α-helical modules that form the CARD domain of the caspase-9 protein molecule. N, N-terminal; 
C, C-terminal. C. A schematic diagram showing the overall fold and topology of PaADI, as 
reported (18). 
 
Comparison of substrate free and substrate bound structure of PaADI gives 
interesting insight into structure changes upon substrate binding (17). Pairwise 
superposition of the free wild-type PaADI (PDB code: 1rxx) and the mutant 
enzyme substrate complexes (PDB code: 2a9g) show that the overall fold of the 
structures remains similar, yet with some local changes. In particular, four loops 
(Figure 4) associated with the active site undergo conformational transitions not 
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related to crystal packing: loop 1 (residues 30-46), loop 2 (residues 178-185), 
loop 3 (residues 271-281, part of this loop is disordered in the apoADI structure), 
and loop 4 (residues 393-404). Residues adjacent to the substrate exhibit the 
most significant shifts. For example, the α-carbon atom of Leu41 (loop 1) shifts 
by 2.7Å and that of Arg185 (loop 2) by 1.8 Å; the α-carbon atom of His278 (loop 
3) shifts by 0.9 Å and that of Gly400 (loop 4) by 4.4 Å. These are localized but 
mechanistically important conformational transitions that tighten the surrounding 
of the substrate. Simultaneously, substrate binding is accompanied by 
displacement of the side chain of Arg401 (loop 4) by more than 8 Å to enable 
access to the active site. The superposition of ADI and PAD4 ADI active site is 
shielded from the solvent by a long loop (residues 25-48 in PaADI) and the 
following two turns of α-helix (residues 49-56). 
 
 
 
 
 
Figure 4 (A). Stereoscopic view of ADI in the unbound and bound states. Superposed molecules 
are colored gray where the trace of the polypeptide chain is similar in both structures. For regions 
exhibiting differences, loops of the apoADI structure are highlighted in blue, and loops of the ADI 
structure complexed with arginine are highlighted in red. 4(B). Structural relationship between ADI 
(yellow) and PAD4 (cyan) (17). 
1.3 Catalytic reaction mechanism of ADI 
The overall reaction catalyzed by ADI is the hydrolytic substitution of the ŋNH2 
group from the guanidinium group Cζ of L-arginine, leading to citrulline and 
ammonia (Figure 5). Herzberg (17) and Arnold (4) proposed ADI catalysis 
mechanism for PaADI (Figure 5) and MaADI, respectively.  Basically, both of the 
proposed mechanisms are composed of three main steps: 1) thiol group of 
B A 
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Cys406 mount a nucleophilic attack on the guanidinium group of arginine and a 
proton is transferred first to ŋNH2 group; 2) water molecule is activated by His278 
and followed by attacking the covalent intermediate to replace and release NH3; 
3) the C-S covalent bond between enzyme and the resulting citrulline is cleaved 
and thus end product citrulline is released and free enzyme is generated for next 
catalytic cycle. 
 
 
Figure 5.  Mechanism of PaADI catalysis of arginine to citrulline and ammonia (17). 
1.4 Anti-tumor application of ADI 
Amino acids depletion is one type of targeted therapy for human cancers which 
are auxotrophic for a particular amino acid. Amino acids degrading enzymes, 
such as asparaginase (30), methioninase (31), arginase (32), arginine deiminase 
(27), phenylalanine ammonialyase (33) and tryptophanase (34) have been 
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studied for inhibition of tumor cells in vitro. The most representative anticancer 
enzyme is asparaginase, which is particularly effective in acute lymphoblastic 
leukaemia. PEG asparaginase is commercialized for acute lymphoblastic 
leukaemia treatment (Oncaspar®, pegaspargase) (35). However, asparaginase 
treatment is sometimes accompanied by serous side-effects including 
anaphylactic shock, coagulapathies as well as liver and pancreatic toxicity (36).  
 
Arginine is an important amino acid involved in the synthesis of a wide range of 
peptides and proteins, production of creatine and nitric oxide, and a myriad of 
metabolic pathways and cellular events. It is a precursor of proline, polyamines, 
glutamine, glutamate, and other neurotransmitters, such as g-aminobutyric acid 
and also serves as a substrate for two important enzymes, arginase and nitric 
oxide synthetase (37). Arginine is an indispensable amino acid to children but a 
semi-essential amino acid in adult humans since many adult somatic cells can 
synthesize it from citrulline in two steps via urea cycles (Figure 6). The enzyme 
argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline and 
aspartic acid to argininosuccinate which is then further converted to arginine and 
fumaric acid by argininosuccinate lyase (ASL). Arginine can be degraded to 
ornithine by the urea cycle enzyme arginase. Ornithine is then converted back to 
citrulline by ornithine carbamoyl transferase (OTC) and then recycles back to 
arginine from citrulline by ASS/ASL. Thus, the ability to regenerate arginine from 
citrulline depends on the amount/activity of ASS and ASL, which are tightly 
coupled. The sensitivity of cells to arginine deprivation depends on the ability of 
ASS and ASL to regenerate arginine from the alternative intermediate (ornithine, 
citrulline and argininosuccinate) in the urea cycle. 
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Firgure 6. Urea cycle. Argininosuccinate synthetase (ASS) catalyzes the conversion of citrulline 
and aspartic acid to argininosuccinate which is then further converted to arginine and fumaric acid 
by argininosuccinate lyase (ASL). Arginine can be degraded to ornithine by the urea cycle 
enzyme arginase. Ornithine is then converted back to citrulline by ornithine carbamoyl transferase 
(OTC) and then recycles back to arginine from citrulline by ASS/ASL.  
 
Arginine begins to become limiting at ~10-4 M, whereas other amino acids can 
sustain growth at 10-5-10-6 M. Wheatley et al. showed that most tumour cell lines 
die considerably more quickly during arginine deprivation than in the absence of 
any other single (or group of) essential amino acids (38). Since 1930 for the first 
time arginine known is essential for the growth of some forms of cancer, the 
potential of arginine degrading enzymes as therapeutic agents was recognized, 
investigated and employed for arginine auxotrophic tumor treatments. Enzymes 
capable of depleting arginine in vitro include arginase existing in human liver, 
arginine decarboxylase from bacterial, plant and human, and ADI from 
microorganism. 
 
Arginine decarboxylase converts arginine to agmatine, which is toxic at high 
plasma concentration. Furthermore, arginine decarboxylase has a short half-life 
and it loses virtually all enzymatic activities upon pegylation though pegylation of 
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arginine decarboxylase is inefficient because not enough lysine residues for 
polyethylene glycol to attach (39). 
 
Arginase is limited for anti-tumor application because of its low substrate affinity 
(Km value 2-4 mM; plasma arginine 100-120 µM), short circulatory half-life (10-15 
min) and sub-optimal enzymatic activity at physiological pH (alkaline pH optimum, 
pH 9.3)(40). Despite these disadvantages of arginase, Lam et al. reported  
remission of hepatocellular carcinoma induced by systemic release of 
endogenous hepatic arginase (41) and Leung et al. proved pegylated 
recombinant human arginase (rhArg-peg 5,000mw) can inhibit ASS-positive 
HCCs while ADI can not (42). 
 
In addition, ADI, another arginine-degrading microbial enzyme, has various 
biological activities including anti-proliferation, anti-angiogenesis and inhibition of 
inducible nitric oxide synthase (iNOs). Figure 7 summarizes how ADI affect many 
arginine-related cellular functions. ADIs (Table 1) have been shown to have 
strong in vitro and in vivo inhibition for arginine auxotrophic tumors (e.g. 
hepatocellular carcinomas (HCCs), melanomas, retinoblastoma (43), prostate 
cancer(44)) and ADI from M. hominis (MhADI) is currently under clinical trial for 
HCC (phase II) (45) and melanomas (phase I/II) (46). Studies on human 
lymphatic leukemia cell lines confirmed ADI’s anti-angiogenic activity. Among all 
the ADIs, MhADI and MaADI were studied most intensively (Table 1). 
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Firgure 7. Summary of ADI effects on arginine-related cellular functions. rADI inhibits NO 
production via iNOS, but potentiates NO production via eNOS in the cultured endothelial cell 
model. rADI enhances or inhibits AS activity in different cells. rADI inhibits de novo protein 
synthesis in cells with low AS activity, but not in cells with high AS activity. Polyamine synthesis 
was not significantly affected by rADI, even in cells with low AS activity. Arrow representation: 
solid, potentiates; blocked, inhibits; dotted, no effect (47).  
 
In 1999, US Food and Drug Administration (FDA) designated ADI-PEG-20 
orphan drug status for treating HCC and invasive malignant melanomas. In 2005, 
also the European Agency for the Evaluation of Medicinal Products (EMEA) also 
granted ADI-PEG-20 orphan drug status for HCC. Phase II trials of ADI-PEG-20 
in patients with metastatic hepatocellular carcinomas have shown that the drug is 
safe, well tolerated, and may benefit patients with unresectable HCC. Izzo and 
coworker suspected that combination therapies of arginine deprivation and 
growth inhibition via kinase inhibitors might improve the survival rate further. 
Additionally, ADI enhances radio sensitivity of human mammary adenocarcinoma 
(MCF-7 cells) (48), exerts anti-proliferative as well as anti-angiogenic activities 
and inhibits the growth of viruses such as HIV-1 and hepatitis (49, 50). Current 
research efforts are focused on ADI’s in vivo inhibitory effect towards leukemia, 
melanoma, prostate cancer, renal cell carcinoma, and human umbilical vein 
endothelial cells (HUVEC) (19, 44, 51-53), clinical trials for HCC (phase II) (45) 
and melanoma (phase I/II) (46), and tumor inhibitory mechanisms of ADI (54). 
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The effectiveness of ADIs as anti-tumor agent depends on their enzymatic 
properties (such as Km, kcat, optimum pH, stability at neutral pH), selectivity on 
tumor cells, stability in blood circulation and immunogenicity. Pegylation (35) has 
been effective in reducing their immunogenicity in animal and increase their 
stability to various hydrolytic enzymes in plasma. Directed evolution as powerful 
algorithm to design proteins allows improving all properties that can be reflected 
in a screening system through iterative rounds of diversity generation and 
screening. Small libraries of a few thousand variants are often sufficient to find 
improved variants (55) even without rational understanding of the targeted 
property. The first example of directed ADI evolution by our group (3) provides a 
simple and effective screening system to improve activity of PpADI at 
physiological pH.  
 
1.5 Conclusion 
ADI-based arginine deprivation is a novel and promising targeted approach to the 
treatment arginine auxotrophic tumors, in particular, melanoma, hepatocellular 
carcinoma and leukemia. Certain mesotheliomas and renal cell cancers were 
also proved to be sensitive to ADI therapy. Due to its low incidence of major side 
effects (myelosuppression and gastrointestinal toxicity or other major organ 
toxicity) arginine deprivation treatment should be combined with other anticancer 
treatments to increase the response rate. Reengineering of ADI by protein 
engineering is a promising strayegy to tailor ADI properties for demands in 
medical applications. Solved ADI crystal structure enables to understand 
structure function relationships and to guide protein engineering. 
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Chapter 2 Directed evolution 
Directed evolution 
 
2.1 Introduction to directed evolution 
Enzymes are increasingly being used in the generation of products that are 
traditionally made using chemical synthesis and the field continues to expand its 
horizons, particularly as applied to the synthesis of the fine chemicals and 
pharmaceuticals (56, 57). Naturally occurring enzymes are often not designed for 
the applications of interest, since after all they are evolved in nature for a 
purpose other than being the catalysts of industrial processes. Directed evolution, 
rational design and biodiversity screening and combined approches are the main 
strategies to reengineer enzymes for addressing application demands. Directed 
evolution has emerged as a powerful enabling method for improving enzyme 
properties in iterative cycles of diversity generation and screening (Figure 1).  
 
A main advantage of directed evolution compared to rational design is that it 
does not require structural or mechanistic information for protein optimization. 
Directed protein evolution has been successfully used for altering and improving 
protein properties (solubility, expression, enantioselectivity, stability and activity 
in unusual environment, allosteric interactions, tolerance to pH), as well as for 
regulating other molecules and systems, including RNA, DNA regulatory 
elements, biosynthetic pathways and genetic regulatory circuits (58-60).  
 
 
 
  18 
 
Figure 1. Procedure of a directed evolution experiment. It involves three key steps: 1) selection a 
good starting sequence and mutating the parent to create a library of variants; 2) identification 
variants with improved function and 3) isolation of gene encoding for improved variant and 
repeating the process until the desired function is achieved. 
 
A parent sequence (or sequences) is chosen based on its perceived proximity to 
the desired function and its evolvability (the ability of a protein to adapt in 
response to mutation and selective pressure). A parent protein for directed 
evolution should exhibit enough of the desired function that small improvements 
can be reliably discerned in a high-throughput screen.  
 
Variants library should be generated with high probability of finding improved 
variants given the screening capacity. With a high-throughput screening method, 
a library can be constructed to generate the large potential improvement. Arnold 
and coworkers(61) showed that very low mutation rates result in many functional 
sequences but only a small number are unique sequences, however very high 
mutation rates produce diverse sequences but few retain function. Schwaneberg 
and coworkers(62) reviewed random mutagenesis methods, focused library 
generation methods and computational tools for high-quality mutant libraries 
generation. Schwaneberg and coworkers (63) also summarized criteria for an 
ideal mutagenesis methods: unbiased mutational spectrum, controllable mutation 
frequency, consecutive nucleotide substitutions or codon-based substitutions, 
enable subset mutagenesis (e.g. introduction mainly positively or negatively 
charged amino acid), independent of gene length, technically simple and 
reproducible, and economical. 
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Screening is used to identify library members improved in the targeted property. 
Identification of improved variants though selection or screening is “analogous” to 
evolutionary pressure in natural evolution (i.e. only the fittest survive). As the 
word “directed” in directed evolution implies, laboratory evolutionary pressure is 
defined and applied by the researcher in screening system. Gradually increasing 
the selection pressure or evolving against a series of intermediate challenges 
often accumulates useful single mutations and yields desired variants (64).  
 
Traditional methods for screening employ microtiter plate formats (96-well, 384-
well, 1,536-well (65) and even 1,000,000-well (66)) or solid phase assay (agar 
plate, filter paper and nitrocellulose membrane), which typically enable the 
screening of no more than 106 variants by using robotic automation (67). 
Sometimes, fast and universal analytic methods like HPLC (68) or GC-MS (69) 
are utilized for performing an efficient screen of a non-natural substrate. However, 
the number of screened mutants is limited to 104-106. In recent years flow 
cytometry systems (67, 70, 71) have become increasingly attractive, especially 
after the development of emulsion technology offering compartmentalization and 
high throughput up to 107/h. In addition, Weitz and coworkers (72) recently 
reported a promising ultrahigh-throughput screening in drop-based microfluidics, 
by which one can screen a library of 108 in about 10 h. Dijkhuizen et al. 
compared in a review (73) six kinds of library screening strategies (Figure 2). 
Selection techniques rely on a direct link between cell growth and improved or 
acquired enzyme function and therefore it is limited to engineering detoxifying 
enzymes (e.g. b-lactamase) or enzymes that synthesize essential nutrients for 
cell growth and survival. The traditional microtiter plate screenings are medium-
throughput and the most simplistic format of screening. It involves the incubation 
of colonies with the substrate of targeted enzyme. The crucial factor with this 
screening technique is that substrate conversion creates a visual signal, such as 
fluorescence or color, to identify colonies expressing an enzyme with desirable 
properties. Microtiter plate based screenings are the most commonly applied 
method in identifying desirable enzyme variants. Microtiter plate based 
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screenings enable the use of various analytical tools and in the mean while they 
offer a great dynamic range. Their screening capacity is usually limited to less 
than 104 variants per day. Screening based on microfluidic device and sorting 
device is a new screening platform for directed evolution, which offers ultra-high-
throughput. It allows the discriminate between wild-type and a less active mutant 
and allows for the addition of substrates and quenchers at desired time thus 
extending the scope of directed evolution screening strategies. Cell as micro-
rector, cell surface display and in vitro compartmentalization technology are also 
FACS (fluorescence-activated cell sorting system) dependent methods for high-
throughput screening and allow 109-1010 screening capacity. 
 
Once improved enzymes are identified, encoding genes are isolated and 
subjected to further iterative cycles of mutation and screening in order to 
accumulate beneficial mutations until the targeted improvement is hopefully 
achieved. The number of iterations required depends on the starting point, the 
protein fold and the selected properties which determine the possible mutational 
load and achievable improvement. 
 
Four accepted requirements for successful directed evolution 
(http://www.che.caltech.edu/groups/fha/) are, 1) the desired function must be 
physically possible; 2) the function must also be biologically, or evolutionarily, 
feasible. In practice, this means that there exists a mutational pathway to get 
from here to there through ever-improving variants (see above). A good 
experiment will maximize the likelihood; 3) Suitable host (E. coli or S. cerevisiae) 
which allows functional expression of more than 106 variants per µg of DNA. 4) A 
rapid screen or selection that reflects the desired function. How rapid the screen 
must be depends on how rare mutations leading to the desired property are and 
how many must be accumulated to achieve the desired result. 
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Figure 2. Overview of screening technologies. (A) Experimental steps from obtaining the gene 
library as PCR product to the actual screen. Note that cloning and transformation efficiency are 
often limiting library size; (B) Explanation of symbols; (C) Cell growth/survival selection and agar 
plate screening; (D) Microtiter plate screening; (E) Cell as micro-reactor; (F) Cell surface display; 
(G) Cell-in-droplet; and (H) In vitro compartmentalization (73).  
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2.2 Directed enzyme evolution for pH tolerance of enzymes 
Application of enzymes in processes at a specified pH necessitates protein 
engineering to change their pH performance. Directed evolution and rational 
design method were applied to improve enzyme specific activity at certain pH or 
shift their pH profiles. Some representative success stories of directed protein 
evolution improving pH performance are summarized in Table 1. 
Table 1. Improvement obtained from directed evolution or rational design for pH performance. 
Enzymes Mutagenesis 
methods 
Screening 
methods 
Improvements References 
Human  
β-glucuronidase 
EpPCR and 
saturation 
mutagenesis 
Flow 
cytometry 
60-fold more active (kcat/Km) at pH 7.0 
and were up to an order of magnitude 
more effective at catalyzing the 
conversion of two structurally 
disparate glucuronide prodrugs to 
anticancer agents 
2008 (74) 
Bacterial xylanase DNA shuffling Agar plate 
assay 
About 5-fold improvement of specific 
activity at pH 9.0 
2008 (75) 
Human pancreatic 
lipase 
EpPCR Agar plate 
and microtiter 
plate assay 
1.5-fold of activity improvement at 
acidic pH 
2010 (76) 
Bacterial arginine 
deiminase 
EpPCR and site 
directed 
mutagenesis  
Microtiter 
plate assay 
pH optimum shifted from pH 6.5 to pH 
7; 4-fold of activity improvement at pH 
7.4 
2010 (3) 
Bacterial α-amylase EpPCR Microtiter 
plate assay 
5-fold higher activity at pH 10 than 
wild type 
2003 (77) 
Eukaryote D-
pantonohydrolase 
EpPCR and 
DNA shuffling 
Agar plate 
assay 
10.5-fold higher specific activity and 
retain 85% of its original activity after 
incubation under low pH 
2006 (78) 
Vanadium 
chloroperoxidase 
EpPCR, site 
saturation 
mutagenesis 
and site directed 
mutagenesis 
Microtiter 
plate assay 
About 100-fold improvement of 
specific activity at pH 8 
2006 (79) 
Bacterial class-A non-
specific acid 
phosphatase (PhoN)   
Site directed 
mutagenesis 
 
1.6-fold of activity improvement over 
broder pH range 
2006 (80) 
Aspergillus niger PhyA 
phytase 
Site directed 
mutagenesis 
 
pH shifted from 5.5 to 3.8 (1.7 unit); 
2.66 -fold improvement of activity at 
pH 3.5 than wild type. 
2006 (81) 
Bacillus cereus β-
amylase 
Site directed 
mutagenesis 
 
pH optimum shifted to pH 4.2-4.8 by 
2 pH units. 
2004 (82) 
Phytase Site directed 
mutagenesis 
 
pH optimum shifted by 0.5-1 pH unit; 
a slight increase in maximum specific 
activity 
2002 (83) 
Alcohol 
dehydrogenase 
Site directed 
mutagenesis 
 
pH optimum shifted from 7.8  to 9.0; 
about 2-fold improvement of 
maximum activity at pH 9.0 than that 
of wild type 
1991 (84) 
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Many examples of rational reengineering of an enzyme pH optimum exist (Table 
1). For shifting the pH optimum, a deep understanding of molecular dynamics is 
essential part of understanding enzyme flexibility. Rational design method 
successfully shifted enzyme pH profile. pH dependence of an enzyme is 
determined by the ionization of the catalytic groups, which is affected by various 
interactions involved in their microenvironments. In order to catalyze certain 
reactions, ionizable residues in active site should act as nucleophile or acid/base 
catalyst and they need to maintain proper ionization state for proper activities of 
proteins. The pKa value of the proton donor and the catalytic nucleophilic residue 
are therefore limiting the pH range at which the enzyme can function, and 
therefore pH-dependent activity can be differed by the pKa of the key residues. 
The pKa value of the residue is governed by intrinsic acidity of the functional 
group and other factors (electrostatic interaction from neighboring and the 
heterogeneous dielectric environment in the protein solution system). The 
electrostatic potential generated by the charged titratable residues affects the 
ground state of the protein, such as stability, binding to ligands and pKa values of 
ionizable groups. The electrostatic potential of proteins can be calculated by 
using computational procedures (Delphi, UHBD, CHARMM) and can be 
increased or decreased through mutations. For shifting the pH optimum of 
enzymes, many researchers have tried to substitute catalytic residue by site-
directed mutagenesis (Table 1).  
 
Yoo and coworkers (85) analyzed the relation between the shift of pH optimum 
and change in electrostatic potential due to mutation using Delphi. They identified 
key residues of xylanase responsible for electrostatic potential of catalytic 
residues but not affecting the catalysis directly. The latter hypothesis was proven 
by site directed mutagenesis in a later report. Wyss and coworkers (83) 
summarized strategies for enzyme pH profile modification, 1) replacement of 
ionizable groups that are directly  involved in substrate or product binding and/or 
catalysis by nonionizable ones or by amino acids with different charge or pKa 
values; 2) replacement of residues that are in direct contact with residues 
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mentioned in 1) by forming hydrogen bonds and/or salt bridges; 3) alteration of 
longer-range (indirect) charge-charge interactions by modification of the surface 
charge of the enzyme. 
 
When there is no structure-function relationship information available for an 
enzyme, directed evolution is the best option to tailor the pH performance of 
enzyme for application demands (Table 1). Directed evolution allows improving 
all properties that can be reflected in a screening system through iterative rounds 
of diversity generation and screening. Small libraries of a few thousand variants 
are often sufficient to find improved muteins even without rational understanding 
of the targeted property (76, 86). Using MTP assay, epPCR mutant libraries with 
a ratio of 50 % active and 50 % inactive clones have often been used 
successfully in directed evolution, improving enzyme properties by gradual 
changes (one or two amino acids changes per round of mutagenesis and 
screening). 
 
2.3 Directed enzyme evolution for medical application 
Directed evolution has been very useful for improving enzymes for industrial 
needs. In recent years, there is also growing number of enzymes applied for 
therapeutic purpose. For the development of protein therapeutics, directed 
evolution started to be used to tailor enzyme properties in medical field, for 
example drug delivery (87, 88) and has proven to be a useful tool for generating 
protein variants with enhanced therapeutic potential (88), for example, improving 
the effectiveness of therapeutic enzymes, antibodies, vaccines and viruses. Here, 
the improvements of therapeutic protein for anti-tumor application by directed 
evolution are discussed in more details. 
 
2.3.1 Prodrug enzymes for tumor chemotherapy    
Prodrug cancer chemotherapy has attracted considerable interest due to the 
possibilities it provids to overcome various barriers to drug formulation and 
delivery (such as poor aqueous solubility, chemical instability, insufficient oral 
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adsorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity 
and local irritation) (89). Examples of such drugs currently in use in cancer 
treatment include 5-fluorocytosine, cyclophosphamide, capecitabine, mitomycin 
C, and AQ4N (90). However, the side effects of prodrug therapy remain a serious 
concern which arises from the fact that noncancerous cells also possess the 
capacity to degrade them. This has triggered the interest to generate more 
effective prodrug-activating enzymes so that prodrugs can kill tumor cells at 
concentrations that generate little or no side effects. Further goals are to design 
more powerful and tumor-specific drugs, and to devise more effective methods 
for delivering them specifically to tumors. 
 
By applying directed evolution through the technique of error-prone PCR, Martin 
and coworkers (90) indentified YieF variant exhibiting >5-fold increased capacity 
to kill HeLa cells. Furthermore, YieF variant was proved to be effectively 
delivered to tumor cells using a strain of Salmonella typhimurium (SL 7838). 
 
Human β-glucuronidase, due to low intrinsic immunogenicity in humans, is an 
attractive enzyme for tumor-specific prodrug activation. However its utility is 
limited by low activity at physiological pH. Roffler and coworkers (74) developed 
a high-throughput screening procedure for enzymatic activity based on the stable 
retention of fluorescent reaction product in mammalian cells expressing properly 
folded glycoproteins on their surface. This procedure was utilized to screen error-
prone PCR and saturation mutagenesis libraries to isolate β-glucuronidase 
tetramers that were up to 60-fold more active (kcat/Km) at pH 7.0 and were up to 
one order of magnitude more effective at catalyzing the conversion of two 
structurally disparate glucuronide prodrugs to anticancer agents. 
 
2.3.2 Oncolytic viruses for tumor chemotherapy  
Viral-mediated oncolysis is a novel cancer therapeutic approach with the 
potential to be more effective and less toxic than current therapies due to the 
agents’ selective growth and amplification in tumor cells. To date, these agents 
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have been regarded as highly safe in patients but have generally fallen short of 
their expected therapeutic value as monotherapies.  
 
Consequently, new approaches to generate highly potent oncolytic viruses are 
required. For the latter purpose, Hermiston and coworkers (91) developed a new 
method and termed it also ‘‘Directed Evolution’’ for creating highly potent 
oncolytic viruses. Viral serotypes representing Ad subgroups B-F were pooled 
and passaged twice on sub-confluent cultures of the target tumor cell lines at a 
particle-per-cell ratio of approximately 200 to invite recombination between 
serotypes (Figure 3). Supernatants from the second round of the high viral 
particle-per-cell infection of sub-confluent cultures were then used in a 10-fold 
dilution series to infect confluent T-75 tissue culture flasks of target tumor cell 
lines PC-3, HT-29, Panc-1 and MDA-231. Using this ‘‘Directed Evolution’’ 
methodology, the novel generated chimeric oncolytic virus ColoAd1 
demonstrated ~ 2 log increase in both potency and selectivity when compared to 
ONYX-015 on colon cancer cells. In vivo and ex vivo studies therefore validated 
the innovative general approach for deriving clinically-relevant and potent anti-
cancer virotherapies. 
 
Figure 3. Hermiston’s “Directed Evolution” process of viruses and derivative viral pools (91). 
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2.3.3 Amino acid depriving enzyme for anti-tumor applications 
Naturally available enzymes are usually not optimally suited for therapeutic 
purposes. This incompatibility often relates to the stability or activity of the 
enzymes under body conditions.  
 
Despite many successful efforts to broaden the understanding of the structural 
basis of protein stability, there is still no universal strategy to stabilize protein by a 
limited number of rationally designed mutations. Well-known and reasonably 
successful types of rational engineering work include substitutions that increase 
rigidity (e.g. substitute amino acid Xxx with Pro or substitute Gly with other amino 
acid Xxx or the introduction of disulfides). These substitutions have effects on the 
entropy of the unfolded state, improvement of molecular packing (e.g. shortening 
of loops, improvement of interactions in the hydrophobic core, for example, by 
the removal of internal cavities), modification of surface charge networks or 
reinforcement of a higher oligomerization state.  
 
Directed evolution provides a powerful approach for improving thermostability 
and does not need understanding of structure-function relationship. Most 
strategies for screening for enzyme stability rely on measuring residual enzyme 
activity before and after exposure to a denaturing challenge (e.g. high 
temperature, organic solvents, extreme pH) (92).  
 
Bacterial L-asparaginases have been used as therapeutic agents in the 
treatment of lymphoblastic leukaemia. The main restrictions to the therapeutic 
use of L-asparaginase include its premature inactivation. As a result frequent 
injections are required to maintain therapeutic levels. Repeated injections and 
high dose can cause several types of side reactions from mild allergies and the 
development of immune responses to dangerous anaphylactic shocks (93). 
Enhancing the stability of L-asparaginase by protein engineering improves its 
body-residence time, and thereby minimizes immunosuppressive effects by 
lowering the therapeutic dose. Labrou and coworkers (94) obtained a 
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reengineered L-asparaginase with enhanced thermal stability. Single mutation on 
the surface of the protein resulted in ~10 degree increased Tm value (half-
inactivation temperature). The thermostable variant has to be tested further on 
animals and ⁄ or humans in order to be advanced to a potent therapeutic drug. 
 
Another example of a reengineered amino acid-deprivating enzyme is PpADI. 
PpADI is a promising anti-tumor enzyme however with a non-physiological 
optimal pH and relative high Km value which hindering its medical application. By 
directed evolution and site saturation mutagenesis, PpADI variants with higher 
activity at physiological pH and at low arginine concentration of were obtained 
with improved properties to become a potent anti-tumor drug (see chapter 3 and 
chapter 4). In vitro and in vivo test of the improved variants are required to 
evaluate the anti-tumor effectiveness.  
 
2.3.4 Affibody molecules for cancer prognosis 
Affibody molecules represent a new class of affinity proteins that are based on 
the Z-domain scaffold derived from staphylococcal protein A (95). Among the 
scaffold proteins, Affibody molecules constitute the smallest non-cysteine-
containing protein scaffold. The small size (~ 7 kDa), robust structure, and 
straightforward production procedures (either by recombinant production in 
bacteria or by chemical synthesis) make Affibody molecules attractive targeting 
agents for in vivo radionuclide imaging (96) as well as for various 
biotechnological applications (97, 98). The small size offers a convenient affinity 
maturation principle. Gene synthesis allows randomizing the whole gene to 
generate diverse mutant library. The potential use of radiolabeled Affibody 
molecules for high-contrast radionuclide imaging of biomarkers has been 
demonstrated in preclinical studies and in pilot clinical studies. Affibody 
molecules are non-immunoglobulin-derived affinity proteins based on a three-
helical bundle protein domain.  
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Several of affinity proteins have been investigated for both in vivo diagnostics 
and therapy of tumor in radionuclide molecular imaging. Affinity proteins in tumor-
targeted therapy can affect tumor progression by altering signal transduction or 
by delivering a payload of toxin, drug or radionuclide. EGFR (epidermal growth 
factor receptor), one of the receptor in ErbB family, has been extensively studied 
as biomarkers in tumor targeting and over expressed in various malignancies, 
associated with poor patient prognosis and are therefore interesting targets for 
solid tumors. High affinity and especially slow dissociation rate are important for 
obtaining high contrast images. Affinity in the low nanomolar range is considered 
as a prerequisite for successful use of peptide-based tracers. 
 
Ståhl and coworkers (99) described the affinity maturation procedure for the 
generation of Affibody molecules binding with high affinity and specificity to 
EGFR. The library for affinity maturation was constructed using a single 
oligonucleotide for the rerandomization of desired positions. The new binders 
were selected with phage display technology and the best second-generation 
binders were characterized in vitro using real-time biospecific interaction analysis 
(BIA) for their binding to recombinant EGFR and with flow cytometry for their 
binding to native EGFR. Second-generation binders achieved an approximately 
30-fold improvement in affinity (Kd = 5-10 nM) for the soluble extracellular domain 
of EGFR in biospecific interaction analysis using Biacore. 
 
2.3.5 Interferon for anti-tumor applicaiton 
Alpha interferons (IFN-as) are members of the diverse helical-bundle superfamily 
of cytokine genes, which have potent antiviral and antiproliferative activities and 
therefore can be used as anticancer and antiviral agents. However, doselimiting 
toxicity, receptor cross-reactivity, and short serum half-lives significantly reduce 
the clinical use of many of these cytokines. 
 
Patten and coworkers (100) performed a family shuffling experiment with over 20 
human interferon-α (Hu-IFN-α) genes. Antiviral assay and proliferation assay 
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were used to indentify clones with improved activity on Hu-IFN-α receptor. One 
clone showed 285,000-fold improved activity relative to Hu-IFN-α2a and 185-fold 
relative to Hu-IFN-α1 (most active native human interferon). 
 
Selective breeding using DNA shuffling has proved to be very effective method to 
rapidly improve pharmaceutical proteins by which initially have low levels of the 
desired “activity” (101, 102). Backcrossing of evolved recommbinants with the 
wild type genes removes functionally neutral changes, which might reduce the 
immunogenicity of evolved proteins (103). 
 
2.4 Conclusion 
Proteins, especially enzymes, have gained a central role in modern chemical, 
biotechnological, and biopharmaceutical industries. Directed evolution has over 
the past proved to be a versatile and successful approach for tailoring protein 
properties to industrial, agricultural and medical demands and for advancing our 
understanding of structure-function relationships in biocatalysts. Appropriate 
library generation and screening methods should be employed concerning the 
target protein and desired property. To set up a sophisticated screening method, 
complex conditions in human body (pH, ion concentration, proteases, hormones 
etc.) should be considered. Subsequent in vivo or in vitro test of improved 
variants should be carried out to further validate the screening assay. 
Development of diversity generation and high-throughput screening method will 
enable evolution to solve problems efficiently. Especially, directed evolution 
provides a powerful strategy to rapidly advance the development of improved 
protein-based drugs (enzymes and antibodies, peptide and ligands). Directed 
evolution promises to play an increasingly important role to generate “desirable” 
drugs. 
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Chapter 3 
Chapter 3. Directed evolution of Arginine 
deiminase for increased activity at physiological 
pH 
 
3. 1 Abstract 
Arginine deiminase (ADI; EC 3.5.3.6) has been studied as a potential anti-tumor 
drug for the treatment of arginine-auxotrophic tumors, such as hepatocellular 
carcinomas (HCCs) and melanomas. Studies with human lymphatic leukemia cell 
lines confirmed that ADI is a potential anti-angiogenic agent effective in the 
treatment of leukemia. ADI from Pseudomonas plecoglossicida (PpADI) was 
cloned and expressed in E.coli. A main limitation of PpADI lies in its pH-
dependent activity profile with a pH optimum at 6.5. A pH shift from 6.5 to 7.5 
results in ~80 % activity drop (pH of human plasma is 7.35 to 7.45). For shifting 
PpADI pH optimum to netrual pH, a directed evolution protocol based on an 
adapted citrulline screening protocol in microtiter plate (MTP) format was 
developed and validated. Proof of concept for ADI engineering resulted in a pH 
optimum of pH 7.0 and increased activity under physiological conditions: at pH 
7.4, variant M2 (K5T, D44E and H404R) is 4-fold more active than the wild type 
PpADI and retains ~30 % of its activity relative to its pH optimum, compared to 
~10 % in the case of the wild type PpADI. 
 
3.2 Introduction 
Arginine deiminase (ADI) is a potential cancer therapy agent for the treatment of 
arginine-auxotrophic tumors (e.g. hepatocellular carcinomas and melanomas). 
The hepatocellular carcinoma (HCC) accounts annually for approximately 1 
million new cases worldwide. In the US the incidence rate (per 100,000 persons; 
1992-2002) of HCC is 8.6 with a mortality rate of 6.5 due to low responses of 
hepatoma to chemotherapeutic treatments (27). Current research efforts are 
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focused on ADI’s in vivo inhibitory effect towards HCCs, leukemia, melanomas 
and human umbilical vein endothelial cells (HUVEC) (104-106), clinical trials for 
HCC (phase III) and melanoma (phase I/II) (105, 107), and PEG formulation of 
ADI to improve its efficacy as a clinical drug, including serum half-life and 
antigenicity (16, 108). ADI inhibited the growth of cultured leukemia cells at 
concentrations of 5-10 ng/ml, which were about 20-100 times lower than those of 
the L-asparaginase standard resulting in fewer side effects (106, 109). Arginine 
deprivation is speculated to be the molecular reason for ADI’s inhibitory effect on 
human lymphatic leukemia (106). ADIs catalyze the first step of the arginine 
deiminase (ADI) pathway by hydrolyzing arginine to citrulline and ammonium. 
Several ADI genes have been identified, purified, and characterized from 
bacteria, archaea and some eukaryotes excluding mammalian cells and 
summarized in a recent review (27). None of these ADIs is from a kinetic point of 
view ideally suited for in vivo applications in humans under physiological 
conditions.  
 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. For the proof of concept, an 
ADI isolated from Pseudomonas plecoglossicida CGMCC2039 (accession 
number: ABS70718) which can be functionally expressed in E. coli has been 
employed. Directed evolution approaches employ mainly E. coli as host due to its 
fast growth and high transformation efficiency which is a prerequisite for 
generating complex mutant libraries. Over the last decades, directed protein 
evolution has become a versatile and successful approach for tailoring protein 
properties for industrial demands (mainly in chemical synthesis) and for 
advancing our understanding of structure-function relationships in enzymes. A 
directed evolution experiment comprises iterative cycles of diversity generation 
and functional selection for improved variants. Only a few manuscripts for 
phytases (83), xylanases (110), amylases (77, 82, 111), and an alcohol 
deyhdrogenase (112) reported a shift of pH optima using directed evolution 
algorithms. None of these directed evolution campaigns targeted a medical 
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application and arginine deiminase has to our best knowledge not been altered in 
its pH activity/resistance by directed evolution.  
 
Comparison of PaADI (Pseudomonas aeruginosa, pH optimum 5.6; His405) and 
MaADI (Mycoplasma arginini ADI, pH optimum 6.5, Arg397) led to the 
speculation that substitution of His by Arg might contribute to MaADI’s increased 
pH optimum (17). A sequence alignment of four ADIs (MaADI, MyADI 
(Mycoplasma arthritidis ADI), PaADI and PpADI) shows that for both 
Pseudomonas ADIs the synonymous amino acid positions (404 & 405), contain a 
His whereas both Mycoplasma ADIs contain at corresponding positions an Arg. 
Interestingly, both Mycoplasma ADIs have an pH optimum approximately one pH 
unit higher than both Pseudomonas ADIs. 
 
In this study we report the first directed ADI evolution protocol in which the pH 
profile of PpADI was shifted to higher pH values representing a conceptional 
proof that ADI properties can be tailored for demands in vivo treatment of 
arginine-auxotrophic tumors. An emphasis is given on detailed description of 
directed evolution conditions (mutagenic and screening).   
 
3.3 Materials and methods 
3.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
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plasmid (MEGAWHOP, 20 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
Pseudomonas plecoglossicida CGMCC2039 was provided by Professor Zhihao 
Sun (Jiangnan University, Wuxi, China). 
 
3.3.2 Methods 
3.3.2.1 Reagents used in assays 
Acid-ferric solution 
To dH2O (600 ml), concentrated H3PO4 (70 ml, 85 %) and concentrated H2SO4 
(160 ml, 90-91 %) were added slowly. After cooling to room temperature, 
FeCl3·6H2O (10 ml, 10 g/L) was added in the above solution, finally the total 
volume was adjusted to 1 liter with dH2O. 
 
Diacetyl monoxime -thiosemicarbazide (DAM-TSC) solution 
DAM solution (10 g/L) and TSC solution (0.3 g/L) were prepared separately. The 
two solutions were mixed (volume ratio = 1:1) just prior to use. 
 
3.3.2.2 Cloning of ADI into pET42b(+) 
The arginine deiminase (ADI) gene was amplified from Pseudomonas 
plecoglossicida CGMCC2039 by colony PCR (94°C for 10 min, 1 cycle; 94°C, 30 
s/ 54°C, 30 s/ 72°C, 165 s, 29 cycles; 72°C for 5 min, 1 cycle) using primer (5’-
CCGCATTCCGCTGAAAAACAGAAGTACGG-3’ and 5’-
CTTCTCGAGTTAGTAGTTGATCGGGTCGCGCACG-3’), 1.5 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix and a colony of Pseudomonas 
plecoglossicida CGMCC2039. Amplification product was purified by gel 
extraction, digested using NdeI (20 U) and XhoI (20 U) and purified using 
QIAquick PCR purification kit (QIAGEN, Hilden, Germany). Cloning vector 
pET42b(+) was digested with NdeI (20 U) and XhoI (20 U), and purified by gel 
extraction kit (QIAGEN, Hilden, Germany). Digested ADI gene and pET42b(+) 
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were ligated using T4 DNA ligase (1 U) to give pET42b(+)-ADI and transformed 
into E. coli BL21-Gold (DE3).  
 
3.3.2.3 Site directed mutagenesis of PpADI gene at position H404 
Site directed mutagenesis of ADI gene was performed according to the published 
method (113) on plasmid pET42b(+)-ADI. The following oligonucleotides were 
used for mutagenesis of H404R: 5’-
GGCCGTGGCGGCGGCCGTTGCATGACCTGCCCG-3’ and 5’-
CGGGCAGGTCATGCAACGGCCGCCGCCACGGCC-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 
cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 
s, 1 cycle; 95°C, 30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 
cycle), 2 U of PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, 
Finland), 0.20 mM of dNTP mix, 25 pmol of each primer together with 100 ng of 
template (pET42b(+) harboring ADI gene) were used. Following the PCR, DpnI 
(40 U; New England Biolabs) was added, and incubated overnight at 37°C. The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
3.3.2.4 Site sturation mutagenesis of PpADI gene at nine amino acid 
position  
Site saturation mutagenesis of ADI gene was performed according to the 
published method (113) on plasmid pET42b(+)-ADI. The oligonucleotides were 
used for mutagenesis were listed in table 1 (underlining indicated the substituted 
nucleotide). For the mutagenic PCR (First stage: 95°C for 30 s, 1 cycle; 95°C, 30 
s/ 55°C, 1 min/ 72°C, 130 s, 3 cycles. Second stage: 95°C for 30 s, 1 cycle; 95°C, 
30 s/ 55°C, 1 min/ 72°C, 130 s, 15 cycles; 68°C for 30 min, 1 cycle), 2 U of 
PhusionTM Hot Start DNA polymerase (Finnzymes, Keilaranta, Finland), 0.20 mM 
of dNTP mix, 25 pmol of each primer together with 100 ng of template (pET42b(+) 
harboring ADI gene) were used. Following the PCR, DpnI (40 U; New England 
Biolabs) was added, and incubated overnight at 37°C. The PCR products were 
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purified by using a QIAquick PCR Purification Kit (Qiagen) and transformed into 
E. coli BL21-Gold (DE3) for expression. 
 
Table 1. Primer sequences for site saturation mutagenesis. 
Primer name Sequences 
Leu 41 FP AACTGCGACGAGCTGNNNTTCGACGATGTGATC   
Leu 41 RP GATCACATCG TCGAANNNCA GCTCGTCGCAGTT 
Asn 360 FP TGGGATGACGGCAACAACNNNGTGGCGCTGGAG 
Asn 360 RP CTCCAGCGCC ACCACNNNGT TGCCGTCATCCCA 
Arg401 FP GAACTGGGCCGGGGCNNNGGCGGCGGCCACTGC   
Arg401 RP GCAGTGGCCGCCGCCNNNGCCCCGGCCCAGTTC 
Phe163 FP CTGCCCAACACCCAGNNNACCCGCGACACCACC    
Phe163 RP GGTGGTGTCGCGGGTNNNCTGGGTGTTGGGCAG 
Asn160 FP CTGCCGCCGCTGCCCNNNACCCAGTTCACCCGC 
Asn160 RP GCGGGTGAACTGGGTNNNGGGCAGCGGCGGCAG 
Arg185 FP ATGTACTGGCCGGCNNNCGCCAGGAAACCCTG 
Arg185 RP CAGGGTTTCCTGGCGNNNGCCGGCCAGTACAT 
Arg243 FP ATCGGCATGGGTGAGNNNACCTCGCGCCAGGCC 
Arg243 RP GGCCTGGCGCGAGGTNNNCTCACCCATGCCGAT 
His405 FP GGCCGTGGCGGCGGCNNNTGCATGACCTGCCCG 
His405 RP CGGGCAGGTCATGCANNNGCCGCCGCCACGGCC 
Gly403 FP GCCGGGGCCGTGGCNNNGGCCACTGCATGACC 
Gly403 RP GGTCATGCAGTGGCCNNNGCCACGGCCCCGGCC 
 
 
3.3.2.5 Construction of PpADI error-prone library 
The library was generated by the standard error-prone PCR (epPCR) using 
improved variant H404R as template. For the mutagenic PCR (95°C for 2 min, 1 
cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C for 3 min, 1 cycle), 2.5 
U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of template (pET42b(+) 
harboring ADI gene H404R), 0.01-0.1 mM of MnCl2 and 10 pmol of each primer 
(5’-TACATATGTCCGCTGAAAAACAGAAG-3’ and 5’- GTGCTCGAGTTAGTAGT 
TGATCGG-3’) were used. The PCR products were purified by using a QIAquick 
PCR Purification Kit. The purified epPCR products were cloned into expression 
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plasmid pET42b(+) by MEGAWHOP(114). For MEGAWHOP (68°C for 5 min, 1 
cycle; 95°C for 5 min, 1 cycle; 95°C, 1 min/ 55°C, 1 min/ 68°C, 13 min 30 s, 24 
cycles; 68°C for 30 min, 1 cycle), 1 U of Taq DNA polymerase, 0.1 U of Pfu DNA 
polymerase, 0.20 mM of dNTP mix together with 200 ng of template (pET42b(+) 
harboring ADI gene H404R) were used. Following the PCR, DpnI (40 U; New 
England Biolabs) was added, and incubated (4 h; 37°C). The MEGAWHOP 
products were transformed into E. coli BL21-Gold (DE3) for expression and 
screening. 
 
3.3.2.6 Expression of PpADI in LB media with IPTG induction 
The strain E. coli BL21-Gold (DE3)/ pET42b-PpADI was cultured at 37°C in 20 ml 
of LB media that contained 50 µg/ml kanamycine to an absorbance of 0.6 at 
578nm. Then, isopropyl β-D-thio-galactopyranoside (IPTG) was added to a final 
concentration 0.2 mM. The cells were harvested after 9 h induction with IPTG at 
37°C. The expressed rADI was analyzed by SDS-PAGE.  
 
3.3.2.7 Expression of PpADI in auto-induction media 
A chemically defined auto-induction medium (115) containing salts and trace 
metals, vitamins including vitamin B12, and glucose, glycerol, and lactose were 
test for PpADI expression. Five kinds of auto-induction media LS-5052, P-5052, 
MD-5052, TYM-5052 and TYP-5052 were tested for the ADI expression, under 
the following conditions: 20 ml LB media in 100 ml flask, 37°C, 250 rpm, 20 h. 
The expressed rADI was analyzed by SDS-PAGE. 
 
3.3.2.8 Cultivation and expression of PpADI in 96-well plates 
Colonies grown on LBkan agar plates were transferred, by using toothpicks, into 
96-well microtiter plates (flat bottom, polystyrene plates; Greiner Bio-One GmbH, 
Frickenhausen, Germany), containing non-inducing medium LSG (150 µL) (115) 
supplemented with kanamycin (50 µg/ml). After 16 h of cultivation in a microtiter 
plate shaker (Multitron II, Infors GmbH, Einsbach, Germany; 37°C, 900 rpm, 70 
% humidity), each well was replicated using a replicator (EnzyScreen BV, Leiden, 
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Netherlands) into a second series of 96-well microtiter plates containing 150 µL 
of auto-induction media LS-5052 (115) supplemented with kanamycin (50 µg/ml). 
The first set of plates was stored at -80°C after addition of glycerol. The clones in 
the second set of plates were cultivated for 12 h (Multitron II, Infors GmbH, 37°C, 
900 rpm) and used for screening.  
 
3.3.2.9 Screening Procedure 
96-well plate format citrulline colorimetric screening assay 
A modified protocol of citrulline detection based on carbamido-diacetyl reaction 
(116) (see Figure 1A for assay mechanism) was used for ADI activity 
measurement. Screening for increased activity was carried out by measuring the 
activity at pH 7.4 and 6.4. 20 µl of cell culture was transferred to 96-well 
microtiter plate. Enzyme reaction was initiated by addition of arginine solution 
(100 µl, 100 mM) supplemented with cetyltrimethylammoniumbromide (CTAB, 4 
mM), and incubated (20 min, 37°C). Subsequently, acid-ferric solution (60 µl) and 
diacetyl monoxime (DAM, 20 µl, 0.5 M) were added. The reaction mixture was 
further incubated (15 min, 55°C). Absorbance was measured at 492 nm using a 
microtiter plate reader (Tecan Sunrise, Tecan Group AG, Zurich, Switzerland).  
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking ADI and in a separate experiment 
containing ADI. Apparent standard deviation was based on the absolute 
absorbance values obtained from the ADI wild type plate. The true standard 
deviation was calculated by subtracting the background absorbance value of the 
microtiter plate lacking ADI from the apparent values. 
 
Cuvette format citrulline colorimetric assay 
ADI activity was routinely measured using a modified protocol of the citrulline 
detection with DAM and TSC (117) (see Figure 1A for assay mechanism) in 
Eppendorf tubes. Enzyme reaction was initiated by addition of arginine solution 
(200 µl, 100 mM) to a 2-ml eppendorf tube containing crude cell lysate (50 µl), 
and incubated (20 min, 37°C). Subsequently, acid-ferric solution (250 µl) was 
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added to stop the enzyme reaction. After appropriate dilution with deionized 
water to ensure the concentration of produced citrulline is within linear detection 
range, the reaction mixture (400 µl) was mixed with acid-ferric solution (600 µl) 
and DAM-TSC solution (100 µl). The reaction mixture was further incubated (30 
min, 70°C), followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a Specord 200 (Analytik Jena AG, 
Jena, Germany). 
 
Normalization of protein expression for wild type ADI and variants  
Agilent Protein 230 Kit (Agilent Protein 230 Kit, Agilent Technologies 
Deutschland GmbH, Böblingen, Germany) and Agilent 2100 Bioanalyzer (Agilent 
2100 Bioanalyzer, Agilent Technologies Deutschland GmbH, Böblingen, 
Germany) were used for normalization of protein expression in crude cell extract. 
The protocol used was according to Agilent protein 230 Kit Guide except BSA 
was used as an internal standard. 
 
3.3.2.10 Expression of ADI in shaking flask and purification 
Shaking flasks (1 liter) containing auto induction media LS-5052 (200 ml) 
supplemented with kanamycin (50 µg/ml) were inoculated with a 1:200 dilution of 
overnight culture (E. coli BL21-Gold(DE3) harboring pET42b-ADI) grown in non-
inducing media LSG. After 12 h of expression, E. coli cells were harvested by 
centrifugation (Eppendorf 5810R 4°C, 3220 g, 30 min) and resuspended in 
phosphate buffer (20 ml, NaxPO4, 20 mM, pH 7.0). E. coli cells were 
subsequently lysed by using a high-pressure homogenizer (1500 bar, 2 cycles; 
Avestin Emulsiflex, Mannheim, Germany). The disrupted cells were centrifuged 
(Eppendorf 5417R, 4°C, 13000 g, 20 min) and the supernatant was further 
cleared by filtration through a low protein-binding filter (0.45 µm; Minisart RC 25 
single use syringe filter; Sartorius, Hamburg, Germany). ADI wild type and 
mutants (H404R and K5T D44E H404R) were subsequently purified by a column 
chromatography procedure: (i) The filtered cell lysates were subjected to a 
Super-Q anion exchange column, which had been pre-equilibrated with 50 mM 
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phosphate buffer (NaxPO4, pH 7.0). 20 ml of cell lysate was loaded. ADI were 
eluted by a NaCl step elution in phosphate buffer (NaxPO4, 50 mM,  pH 7.0) at a 
rate of 3 ml/min. (ii) The obtained ADI protein from ion exchange chromatography 
was subjected to a gel filtration column (Matrix: Toyoperl HW-55S, Bed volume: 
33 ml, Bed height: 40 cm, Column: Omnifit). 
 
Purified ADI was subsequently concentrated using a Amicon ultra-4 centrifugal 
filter device (Millipore Corporation, Billerica, U.S.A.) with a 30-kDa cut-off 
membrane. Total protein concentration was determined by BCATM assay kit 
(Pierce, Born, Germany) and homogeneity of the purified sample was controlled 
by SDS-page electrophoresis using standard molecular biology techniques. 
 
3.3.2.11 Characterization of ADI wild type and mutants 
Determination of kcat and Km of ADI wild type and the mutants 
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath. After 10 min preincubation at 37°C, the enzyme reaction was initiated 
by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the substrate solution (200 
µl, 0.2 mM to 10 mM of arginine, 0.5 M phosphate buffer, pH 7.4) in deep well 
plates. The reaction mixture was incubated (37°C) and every two minutes 
reaction mixture (30 µl) of each well was transferred to acid-ferric solution (30 µl) 
to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. Ferric-acid solution (90 µl) and DAM-TSC 
solution (15 µl) were added to each well. The 96-well PCR plate was then 
incubated (70°C, 30 min) in thermal cycler (Eppendorf Mastercyler gradient) for 
color development, followed by incubation in ice water to stop color development. 
Absorbance was measured at 530 nm using a microtiter plate reader 
(SPECTROstar Omega, BMG LABTECH, Offenburg, Germany). The initial 
velocity data obtained were fitted to the equation v = Vmax[S]/([S] + Km) (where v 
is the initial velocity, Vmax the maximum velocity, [S] the substrate concentration, 
and Km the Michaelis constant) using GraphPad Prism software (GraphPad 
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software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax 
and enzyme concentration. 
 
Determination of pH profile 
Enzyme reaction was carried out at 37°C in a water bath using the following 
substrate solution: arginine 0.1 M, pH 5-8 phosphate/acetate buffer (0.5 M 
phosphate, 50 mM acetate). After 10 min preincubation at 37°C, the enzyme 
reaction was initiated by addition of purified enzyme (50 µl, 0.2-0.5 µM) to the 
substrate solution (200 µl) in deep well plates. The reaction mixture was 
incubated (37°C, 10 min) and acid-ferric solution (250 µl) was transferred to each 
well to stop the enzyme reaction. The color development was subsequently 
performed in 96-well PCR plate. The reaction mixture (60 µl), ferric-acid solution 
(90 µl) and DAM-TSC solution (15 µl) were transferred to a 96-well PCR plate. 
The 96-well PCR plate was then incubated (70°C, 30 min) in thermal cycler 
(Eppendorf Mastercyler gradient) for color development, followed by incubation in 
ice water to stop color development. Absorbance was measured at 530 nm using 
a microtiter plate reader (SPECTROstar Omega, Germany). 
 
3.3.2.12 Molecular Modeling 
Two crystal structures of PaADI (PDB codes: 1RXX, 2A9G) were used to model 
the mutations H405R and D44E. Only one monomeric unit of the tetrameric 
PaADI was used for the modeling study employing Swiss-PDB viewer (118) 
(www.expasy.org/spdbv). PaADI variants (H405R; D44E) were generated using 
the mutate command of Swiss-PDB viewer. The side chain rotamer with the best 
score was used for subsequent energy optimized with parameter of GROMOS96 
force field for in vacuum minimization (119).  
 
3.3.2.13 Stability of PpADI in presence of serum  
Purified PpADI (wild type, M1, M2; 20 µl) was incubated (37°C, 60 min) with AB--
human serum (80 ul, Invitrogen, Karlsruhe, Germany) and PBS buffer (pH7.4, 80 
ul), respectively. Subsequently, the incubated ADI-serum/PBS mix (20 µl) was 
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added to microtiter plate containing arginine solution (100 µl, 10 mM arginine in 
PBS buffer, pH 7.4) and incubated (37°C, 30 min). Acid-ferric solution (120 µl) 
was added to stop the enzyme reaction. The produced citrulline was detected 
using the assay procedure employed in “Determination of kcat and Km of ADI 
wild type and the mutants”. Before measuring absorbance at 530 nm, 
centrifugation (Eppendorf, 5810R 4°C, 3000 g, 10 min) was performed to remove 
the precipitation in the assay solution (likely proteins in serum were precipitated 
in acidic condition during assay procedure). Meanwhile, a serum control was test 
for the original citrulline concentration of serum using the same procedure 
mentioned above except that instead of PpADI, elution buffer of gel filtration 
(NaxPO4, 50 mM, pH 7.4) was used. All the absorbance values at 530 nm of 
ADI-serum sample were subtracted the value of serum control to get the citrulline 
concentration produced by PpADI. The residual activities of PpADI after 
incubation in serum compared to that in PBS buffer were calculated to show the 
stability of PpADI after incubated in human serum. 
 
3.3.2.14 Activity of PpADI (wild type, M1, M2) towards arginine derivative 
dimethylarginine 
Purified PpADI (wild type, M1, M2; 15 µl, ~0.2 mg/ml final concentration; >20-fold 
concentration used for kinetic constant determination) was incubated (37°C, 4 h) 
with (NG, NG)-dimethylarginine solution (20 mM, 100 µl). Acid-ferric solution (120 
µl) was added to stop the enzyme reaction. Activity was recorded by citrulline 
detection using citrulline colorimetric assay (see 3.3.2.11 Characterization of ADI 
wild type and mutants). 
 
3.4 Results 
3.4.1 PpADI cloning 
PpADI was cloned into pET42b(+) and expressed in E.coli BL21-Gold(DE3) 
using auto-induction media LS-5052 (see figure 2). The nucleotide sequence of 
PpADI comprises 1,254 bp nucleotide (figure 1) encoding 417 amino acids which 
have 85% identity to ADI from P. aeruginosa (PaADI). The PpADI cloned into 
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pET42b(+) was confirmed by nucleotide sequencing. As indicated in Figure 1, 
sequence analysis of ADI gene showed that there was one synonymous 
mutation at amino acid position D78 (GAT to GAC) compared to ADI-sequence 
of P. plecoglossicida CGMCC2039 deposited in NCBI (accession number: 
EU030267). The deduced ADI protein sequence has a calculated molecular 
weight of 46.5 kDa and shows 85% identity to ADI from P. aeruginosa. This clone 
was used for subsequent directed evolution experiments.  
 
 
Figure 1. DNA electrophoresis of PpADI. 
 
 
Figure 2. PpADI sequencing results. 
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3.4.2 PpADI expression in LB media with IPTG as inducer 
PpADI was successfully expressed in LB media with IPTG as inducer. Figure 3 
(lane 4) shows the expression band of PpADI observed at ~45 kDa, which is 
similar to the calculated molecular weight of 46 kDa (based on 
http://expasy.org/tools/pi_tool.html). 
 
Figure 3. SDS-PAGE of PpADI expression. Lane 1: P. plecoglossicida; Lane 2: E. coli BL21-Gold 
(DE3)/ pET42b; Lane 3: E. coli BL21-Gold (DE3)/ pET42b-PpADI WT, without IPTG; Lane 4: E. 
coli BL21-Gold (DE3)/ pET42b- PpADI WT. 
 
3.4.3 PpADI expression in auto-induction media 
Expressing recombinant protein in auto-induction media is based upon the 
preferences of bacteria to selectively use different carbon sources during diauxic 
growth and upon the often-observed negative regulation of gene expression by 
catabolite repression. Auto-induction is more convenient than IPTG induction 
because the expression strain is simply inoculated into auto-inducing medium 
and grown to saturation without the need to follow culture growth and add 
inducer at the proper time. For high-throughput applications, the auto-induction 
approach has many advantages over traditional induction methods including 
avoidance of the strong induction and apparent toxicity associated with chemical 
inducers such as IPTG.  
Five kinds of auto-induction media LS-5052, P-5052, MD-5052, TYM-5052 and 
TYP-5052 were tested for the ADI expression. Figure 4(A) and 4(B) show ADI 
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activity and corresponding SDS-PAGE band of the PpADI expression in different 
auto-induction media. The expression in auto-induction media LS-5052 is shows 
the highest activity and therefore LS-5052 was used for the following directed 
evolution experiments. 
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Figure 4(A). Activity of PpADI expressed in auto-induction media. 
 
 
 
Figure 4(B). SDS-PAGE of ADI expressed in auto-induction media 1, LS-5052; 2, P-5052; 3, MD-
5052; 4 TYM-5052; 5, TYP-5052. 
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3.4.4 PpADI assay based on citrulline detection 
 
 
Figure 5. Arginine conversion by ADI and detection of citrulline using DAM/TSC assay. 
 
ADI activity was measured by detecting the production of citrulline from arginine, 
according to carbamido diacetyl reaction (colorimetric reaction). The conditions of 
the carbamido diacetyl reaction is as follows： strong acid solution (H3PO4, 
H2SO4), oxidizing agent (Fe3+), diacetyl monoxime (DAM), thiosemicarbazide 
(TSC), and boiling water bath. Figure 5 shows one postulated reaction 
mechanism for the assay which depicts the reaction between citrulline and DAM. 
By the addition of TSC to the reaction system, Coulombe and Favreau(120) 
obtained linearity of response with a more stable pink color which Amax was 
shifted from 490nm to 530nm. 
 
Figure 6 describes the assay procedure for measuring ADI activity in 2 ml 
eppendorf tube. A calibration curve was prepared using citrulline standard 
solution (Figure 7) for determining the citrulline production during the assay. 
 
Figure 6. Citrulline colorimetric assay in cuvette format using DAM/TSC assay. 
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Figure 7. Calibration curve of cuvette format citrulline colorimetric assay. 
 
3.4.5 PpADI screening system for citrulline production in microtiter plates 
Two key performance parameters for identifying improved variants in microtiter 
plate based screening systems are the true standard variation and the linear 
detection range of the employed assay. Standard deviations have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). A modified version of the DAM-TSC assay for citrulline 
detection (Scheme 1) was selected for directed evolution of PpADI. The 
microtiter plate screening format was optimized for simplified handling by 
lowering the color development temperature (55°C instead of 100°C), increasing 
the diacetylmonoxime concentration (~22-fold) and avoiding the use of the 
sensitizer thiosemicarbazide. Figure 8 shows the procedure of screening assay 
of citrulline detection. 
 
Figure 8. Citrulline colorimetric assay in MTP format using DAM assay. 
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Standard deviations of the modified citrulline detection assay have been reduced 
by optimizing expression and screening conditions (various auto-induction media 
and assay conditions such as amount of cell, conversion time and color 
development procedure). The preferred combination (150 µl LS5052 auto-
induction media and 20 µl cell culture, 20 min conversion time and 15 min color 
develop time) resulted in a true standard deviation of 12.8 % after subtracting the 
background (Figure 10). Screening systems with standard deviations around 10 
% have successfully been used in directed evolution experiments (121, 122). A 
wide linear detection window is important for identifying beneficial mutants in 
directed evolution experiments and screening systems for evolved mutants have 
to be constantly adapted for hitting the linear detection window. A linear detection 
range up to 6 mM citrulline could be detected (Figure 9).  
 
 
 
 
 
 
Figure 9. Calibration curve of 96-well microtiter plate format citrulline colorimetric screening assay.  
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Figure 10. Activity values in descending order of the ADI wild-type conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
 
Figure 11. PpADI model derived from PaADI crystal structure (PDB code 2a9gD) by SWISS 
MODEL WORKSPACE.  
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3.4.6 Focused libraries generated by saturation mutagenesis 
PpADI gene shares 83 % sequence identity  with PaADI of which the crystal 
structure was solved (123). After submitting the ADI sequence to SWISS MODEL 
WORKSPACE, a proposed ADI model based on the PaADI crystal structure 
(PDB code 2a9gD) was obtained (Figure 11). According to this model and 
published literatures, 9 amino acid residues: Leu41, Asn160, Phe163, Arg185, 
Arg243, Asn360, Arg401, His404, Gly 403 (Figure 11) close to the active center 
(catalytic triad: Cys406-His278-Glu224) or known to interact with substrate 
arginine were selected for saturation mutagenesis. 
 
Site saturation mutagenesis at position Leu41, Asn160, Phe163, Arg185, Arg243, 
Asn360, Arg401, His404 and Gly 403 were performed. 300 clones were 
screened for each position. However, no improved variant was identified. 
 
3.4.7 Validation of variant M1 (H404R) citrulline colorimetric assay in 
cuvette format 
Position H404 which was suspected to influence ADI pH profile by substitution to 
R404 (15). Compared to wild type PpADI, variant M1 (H404R) shows higher 
activity (1.8-fold) and improved activity ratio of pH 7.4 to 6.4 (4.7-fold). Therefore, 
M1 (H404R) was selected for directed evolution. 
 
3.4.8 epPCR library generation and screening with citrulline detection 
assay by screening error-prone mutant libraries 
Various concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Figure 12 (A) and 12 (B) 
show the epPCR products and the corresponding MEGAWHOP products. 
Concentration of 0.01 mM MnCl2 which generated 53 % inactive mutant was 
selected for library generation. EpPCR mutant libraries with a ratio of 50 % active 
and 50 % inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). A total of 7 variants (listed in 
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Table 2) were identified from an epPCR library of 2400 mutants and used for 
further characterization. The most active variant was sequenced and two 
additional amino acid substitutions (K5T D44E) were identified. 
 
 
Figure 12 (A). Electrophoresis of epPCR products. Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM 
of MnCl2; Lane 3, 0.05 mM of MnCl2.  
 
 
 
Figure 12 (B). Electrophoresis of MEGAWHOP product with epPCR products as megaprimer. 
Lane 1, 0.01 mM of MnCl2; Lane 2, 0.02 mM of MnCl2; Lane 3, 0.05 mM of MnCl2.  
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Figure 13. Relative activity of ADI variants towards arginine. The relative activity is the ratio of the 
activity at the pH of each variant relative to the activity at pH 7.4 of wild type ADI. White: ADI wild 
type, grey: M1 (H404R), black: M2 (K5T D44E H404R). 
 
Table 2. Activity of ADI variants towards arginine determined using citrulline colorimetric 
assay in cuvette format. Samples were diluted to ensure that detected citrulline 
concentrations are within the linear detection range of the citrulline colorimetric assay. 
Wild type, mutant M1 and the “best variant” M2 are in bold and prominent expression 
mutants (9-B3-1; 21-D5-1) are italized. 
Normalized [ADI][a] 
Citrulline production 
(mM/mg) 
Relative to activity at pH 7.4 
of WT 
ADI variants pH 7.4 pH 6.4 pH 7.4 pH 6.4 
Activity at pH 
7.4/ activity at 
pH 6.4 
WT 
9.83 
(0.74)[b] 
124.92 
(1.98) 1.00 (0.15) 12.69 (0.01) 0.08 (0.01) 
M1 
(H404R) 
17.80 
(0.49) 
45.95 
(0.87) 1.81 (0.06) 4.67 (0.02) 0.39 (0.02) 
M2 
(K5T D44E 
H404R) 
38.99 
(0.79) 39.20 (0.31) 3.96 (0.02) 3.98 (0.02) 0.99 (0.03) 
9-B3-1 
24.89 
(0.45) 54.50 (1.80) 2.53 (0.03) 5.54 (0.03) 0.46 (0.02) 
21-D5-1 
25.68 
(2.68) 50.95 (2.36) 2.61 (0.07) 5.18 (0.02) 0.50 (0.01) 
15-G10-2 
13.11 
(0.53) 47.02 (0.47) 1.33 (0.09) 4.78 (0.02) 0.28 (0.01) 
2-H4-2 
12.50 
(0.07) 21.58 (0.09) 1.27 (0.06) 2.19 (0.04) 0.58 (0.01) 
1-G11-1 
24.91 
(0.20) 29.12 (0.33) 2.53 (0.03) 2.96 (0.03) 0.85 (0.02) 
24-E10-1 
14.62 
(0.62) 32.82 (0.52) 1.49 (0.08) 3.34 (0.03) 0.45 (0.02) 
[a] (Based on quantification employing Agilent 2100 Bioanalyzer (Agilent Protein 230 Kit)) 
[b] (Standard error of triplicate measurements are given in brackets below each absolute 
and normalized value.) 
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Figure 14. Elution profile of wild type PpADI and improved variants from epPCR library, 
generated with Protein 230 Kit using a mircofluidic device (Agilent Bioanalyzer). BSA was added 
as an internal standard. 
 
3.4.9 Characterization of PpADI variants 
3.4.9.1 Determination of kcat and Km of ADI wild type and the mutants 
Variants selected from epPCR were first characterized using the crude cell 
extract to identify the most promising variants (Table 2). Using an activity ratio of 
pH 7.4 to 6.4 proved to be an effective method to eliminate expression mutants. 
Additionally ADI concentration in crude cell extract was determined using the 
Agilent Protein 230 Kit. Microfluidic elution profiles (Figure 14) semi-quantify 
differences in expression between the wild type PpADI and variants. 
Normalization of activities against the corresponding ADI concentrations reveals 
improvements in specific activities of ADI mutants (Table 2). M1, the starting 
variant for the directed evolution campaign, and M2 were selected for detailed 
characterization studies. M2 has as “best identified variants” (Figure 13) a more 
than 2.5-fold higher activity ratio at pH 7.4 to pH 6.4 than M1 and a 12-fold higher 
activity ratio than wild type in crude cell lysates. 
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For kinetic characterization of ADI variants the citrulline production was 
maintained between 0.2-0.8 mM. Calibration curve in Figure 4 shows the linear 
detection range in the employed 96-well PCR plate format citrulline colorimetric 
assay system. Figure 15 summarizes the kcat and Km values of wild type PpADI, 
identified variants M1 (H404) and M2 (K5T D44E H404R) which were expressed 
in shaking flasks cultures and purified using a two step procedure (anion 
exchange followed by gel filtration). Both variants M1 and M2 show an increase 
in kcat and Km for citrulline production at pH 7.4. Variant M2 shows a 4-fold higher 
kcat as also obtained for specific activity in Table 2 using the crude cell extract, 
validating the characterization procedure with crude cell lysate. Furthermore, an 
increased Km from 0.7 mM (wild type PpADI) to 1.2 mM (M1) and 2.5 mM (M2) 
was found. 
 
 
Figure 15. Kinetic parameters of ADI and mutants for conversion of arginine to citrulline. White: 
ADI wild type, grey: M1 (H404R), black: M2 (K5T D44E H404R). Values reported are the average 
of three measurements, and average deviations from the mean values are shown. Embedded 
calibration curve shows linearity of citrulline colorimetric assay in 96-well PCR plate format which 
was used to determine arginine conversions and kinetic constants.  
 
3.4.9.2 Relative pH profile of wild type and mutant 
The relative pH profile (Figure 16) of wild type PpADI and M1 (H404R) shows an 
identical pH optimum at pH 6.5. Compared to wild type PpADI, variant M2 (K5T 
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D44E H404R) shows a pH optimum at pH 7.0 which is shifted remarkably (0.5 
pH units). Both M1 and M2 show decreased specific activities at pH 6.5, and 
increased specific activity at pH 7.5. At pH 7.0, the specific activity of M2 
exceeds that of wild type PaADI (data not shown). 
 
Figure 16. pH profile of wild type ADI, M1(H404R), M2(K5T/D44E/H404R). The relative activity is 
the ratio of the catalytic activity at the pH relative to the maximum activity of each enzyme. (■) WT, 
(▲) M1 (H404R), (●) M2 (K5T/D44E/H404R). 
 
 
3.4.10 Stability of PpADI in the presence of human serum  
Table 3 summarizes the stability of PpADI variants in serum (37°C, 60 min; 
standard deviation of three measurements in brackets). The mutants M1 and M2 
have a similar stability in serum when compared to the wild-type PpADI wild type.  
The substitution D44E and H404R do not destabilize further the PpADI in serum.  
 
Table 3. Stability of PpADI variants in the presence of human serum. 
 PpADI WT M1 M2 
No incubation (A530) 0.08 0.27 0.98 
Incubation with serum (37°C, 
60 min) (A530) 0.05 0.15 0.69 
Residual activity 60 % 55 % 70 % 
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3.4.11 Activity of PpADI (wild type, M1, M2) towards arginine derivative (NG, 
NG)-dimethylarginine  
No detectable conversion of (NG, NG)-dimethylarginine could be detected with 
PpADI variants.  
 
3.5 Discussion 
ADI properties have to date not been engineered through directed evolution 
algorithms despite their often poor performances under physiological conditions 
and their medical importance as potential anti-tumor drug. Chemically modified of 
ADI (e.g. through PEGylation) (27) and fusion protein (e. g. Human serum 
albumin fusion, HSA) (124) have been used for addressing activity and stability 
demands in vivo. Directed evolution offers opportunities to directly improve ADI 
properties for in vivo applications and small libraries of a few thousand variants 
have often been sufficient to find improved muteins in directed evolution 
experiments (55, 125).  
 
Our main intention in this report is to provide a validated protocol for directed ADI 
evolution and improving the activity at the physiological pH 7.4. Pseudomonas 
plecoglossicida CGMCC2039 (PpADI, 7.8 U/mg; pH optimum 6.5) was selected 
for the directed evolution studies due to its functional expression in E. coli, 
coverage of sequence space in patents and “potential” for activity improvement. 
PpADI is a relatively slow ADI when compared to Mycoplasma ADIs like MhADI 
(Mycoplasma hominus ADI, 35 U/mg) which would have been good alternatives 
for directed evolution studies (105). Reported ADI activities range from 0.115 to 
140.3 IU/mg. One unit is commonly defined as the ADI amount that converts 1 
µmol of L-arginine into 1 µmol of L-citrulline per minute (27).  
 
Screening of PpADI variants yielded three amino acid positions 5, 44 and 404. 
Positions 44 and 404 resulted in a 4-fold higher kcat at pH 7.4 and a significant 
shift in the pH optimum (0.5 units) when compared to wild type PpADI (Figure 17 
& 8). Position 5 did not show any effect on PpADI activity.   
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Figure 17. Structural alignment of mutant M1 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The crystal structure of PaADI which was diffracted in 
absence of the substrate arginine (1RXX) was used to investigate the substitution of His405 to 
Arg405. The Arg405 variant shows with respect the Asp280 a different orientation of the 
guanidinium group when compared to side chain of His405 (in orange).  
 
Galkin and coworkers postulated that the histidine in position 404 (corresponding 
position in “their” PaADI is 405) is a key residue in controlling activity at acidic 
and neutral pH. In protonated state of the imidazolium ring a hydrogen bonding 
interaction can be formed with the oxygen of Asp280 (carboxyl group). This 
hydrogen bond favors stabilizing interactions between Asp280 and the substrate 
arginine. His405 in PaADI was reported (17) to share protons with Asp280 and 
Glu13 and to be important for modulating electrostatic environments of closely 
located catalytic groups. The same report postulated that H405 is likely to be 
protonated when the substrate arginine binds to catalytic triad (His278, Glu224, 
Cys406) (2). Based on these reports the His404 in PpADI was subjected to a site 
directed mutagenesis to Arg404 and named M1. The M1 variant (H404R) shows 
40 % residual activity compared to wild type PpADI at pH 6.4 and a 1.8-fold 
increase in activity at pH 7.4 (see Table 1). In the M1 (H404R) mutant (see the 
model in Figure 17; based PaADI 1RXX; residue His404 in PpADI corresponds to 
His405 in PaADI), the conformational effect due to the extended side chain of 
Arg likely weakens the hydrogen bond to Asp280 and thus reduces the stabilizing 
effect on arginine binding. As a result the activity of M1 is reduced, especially at 
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lower pH values at which His405 is protonated. However at elevated pHs, His405 
becomes increasingly deprotonated whereas Arg405 remains protonated and 
can therefore still stabilize Asp280 for arginine binding. The electrostatic effect 
suggested by theoretical and experimental studies have evidenced the 
importance of positively charged residues to modulate the reaction rate of PaADI 
(126). At pH 6.4, histidine in wild type PpADI and arginine in M1 are both 
positively charged. At pH 7.4, histidine is only partially positive charged and 
PpADI’s activity is reduced (>90 %) while arginine in M1 remains positively 
charged preserving M1’s activity (Figure 17).   
 
 
Figure 18. Structural alignment of mutant M2 model with corresponding residues of the crystal 
structures of the PaADI (in orange). The PaADI crystal structure in presence of substrate arginine 
was used (2A9G) to investigate the role of the substitution Asp44 to Glu44. The latter was solved 
for an inactive variant in which Cys406 was replaced by Ala406. The extended side chain of 
Glu44 might improve the hydrogen bond interaction with the Arg399 inducing a conformational 
shift of loop 1. 
 
The PpADI H404R was used as starting variant for directed evolution. The amino 
acid position 44 was identified from a epPCR library (2400 variants screened) 
resulting in a triple mutant M2 (K5T D44E H404R). For investigating the role of 
each position the double mutants (K5T H404R) and (D44E H404R) were 
generated. Only the double mutant (D44E H404R) revealed improvements in kcat 
(4-fold, pH 7.4; Figure 18). The rationale behind the effects of the mutation D44E 
on the PpADI activity is more complex to extrapolate from the available ADI 
crystal structures. Comparative crystallographic studies have shown that the 
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entrance of the active site is decorated by 4 loops that undergo conformational 
transitions upon arginine binding (17). The loops exhibit significant shifts that limit 
the access of water molecules to the active site. The Asp44 is located in loop 1 
(residues 30-46) and upon binding of the substrate, Asp44 comes closer to the 
positively charged Arg399 located on loop 4 (residues 392 to 403). In the D44E 
mutant, the longer side chain reduces the distance with Arg399 favoring the 
formation of hydrogen bond (see model in Figure 18). The reinforced interaction 
between Glu44 and Arg399 might expedite conformational changes in loops, 
probably confining the arginine substrate in the active site and hence promote 
arginine conversion. In the future, we plan to further investigate the influence of 
H404R and D44E using molecular dynamics simulations, further boost the kcat at 
pH 7.4 and reduce the Km value of PpADI.  
 
Overall site directed mutagenesis of position H404R and one round of directed 
evolution (2400 variants screened) resulted in a triple mutant M2 (K5T D44E 
H404R) with 4-fold higher kcat at pH 7.4 (compared to wild type; Figure 4). The 
best mutant isolated, M2, has specific activity of 31.3 U/mg at pH 7.4 which is 
already after one round of evolution close to the specific activity of MhADI (35 
U/mg) (127) at its pH optimum. The stability and specificity of improved PpADI 
variants are furthermore important for cancer treatment in vivo. First experiments 
in AB-human serum (Invitrogen) showed an unaltered stability of M2 compared to 
the wild type PpADI and (NG, NG)-dimethylarginine conversion could not detect 
with the citrulline colorimetic assay.   
 
3.6 Conclusion 
In summary, a directed evolution protocol has been developed for PpADI and 
validated by increasing the kcat of PpADI at physiological pH (7.4). The reported 
screening system is the first one employed in directed ADI evolution and can 
likely be used for other ADIs and other properties such as temperature stability, 
salt/detergent stability or protease resistance. 
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Chapter 4 
Chapter 4. PpADI reengineered for efficient 
operation under physiological conditions 
 
4.1 Abstract 
The proof of concept for ADI engineering by directed evolution resulted in variant 
M2 (K5T/D44E/H404R). M2 has a pH optimum of pH 7.0 and 4-fold higher kcat 
value than the wild type PpADI (pH 7.4, 0.5 M phosphate buffer) and an 
increased Km value for substrate arginine. In this chapter, in order to improve the 
catalytic efficiency of PpADI at low concentration of arginine, variant M5 
(K5T/D38H/D44E/A128T/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R) were generated from an epPCR library: 
at pH 7.4 (PBS buffer), the S0.5 value decreased from 2.01 mM (parent M3, 
K5T/D44E/A128T/H404R) to 1.48 mM (M5) and 0.81 mM (M6). The S0.5 value of 
M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); the kcat value 
improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-folds) and 11.64 
s-1 (M6, 64.7-fold). 
 
4.2 Introduction 
ADI-based arginine depletion is a target specific therapy for arginine-auxotrophic 
tumors (e.g. hepatocellular carcinomas and melanomas) and pegylated ADI is 
currently under clinical trials for HCC with promising results (45). HCC is the third 
leading cause of cancer mortality world wide with a less than 10 % 5-year 
survival rate (EU and USA) (128) due to low responses of hepatoma to 
chemotherapeutic treatments. In 1999, US Food and Drug Administration (FDA) 
designated ADI-PEG-20 orphan drug status for the treatment of HCC and 
invasive malignant melanomas, and in 2005 European Agency for the Evaluation 
of Medicinal Products (EMEA) also granted ADI-PEG-20 orphan drug status for 
the treatment of HCC. Phase II trials of ADI-PEG-20 in patients with metastatic 
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hepatocellular carcinomas have shown that the drug is safe, well tolerated, and 
may benefit patients with unresectable HCC. Izzo and coworker suspected that 
combination therapies of arginine deprivation and growth inhibition via kinase 
inhibitors might improve the survival rate further more. Additionally, ADI can 
enhance radio sensitivity of human mammary adenocarcinoma (MCF-7 cells) 
(48), exerts anti-proliferative and anti-angiogenic activities and inhibits the growth 
of viruses such as HIV-1 and hepatitis (49, 50). Current research efforts are 
focused on ADI’s in vivo inhibitory effect towards leukemia, melanoma, prostate 
cancer, renal cell carcinoma, and human umbilical vein endothelial cells (HUVEC) 
(19, 44, 51-53), clinical trials for HCC (phase II) (45) and melanoma (phase I/II) 
(46), and inhibitory mechanisms of ADI to tumors (54).  
 
Arginine deprivation is believed to be a main molecular reason for ADI’s inhibitory 
effects on arginine auxotrophic tumors which do not express argininosuccinate 
synthetase (ASS). ADIs catalyze the first step of the arginine dehydrolase 
pathway by hydrolyzing arginine to citrulline and ammonium. ADI genes have 
been identified, purified, and characterized from bacteria, archaea and some 
eukaryotes excluding mammalian cells (see review (27)). Enzymatic properties of 
several recombinant ADIs have been examined, such as specific activity, 
functional expression level, temperature optimum, pH optimum, substrate affinity 
for arginine, and half-life in human plasma. Only the ADI from Mycoplasma 
hominis has so far been developed as orphan drug by Pheonix Pharmacologics 
Inc. for HCC and melanoma (129). From enzyme kinetic point of view, none of 
the ADIs is ideally suited for in vivo applications under physiological conditions. 
Protein engineering by rational design and directed evolution offers opportunities 
to tailor ADI properties to physiological conditions. PpADI (ADI from 
Pseudomonas plecoglossicida) was functionally expressed in E. coli with a 
simple protocol and has been engineered for the first time by directed evolution 
for improved activity at physiological pH (3). The variant M2 (K5T/D44E/H404R), 
by our group reported, showed a 4-fold higher specific activity than the wild type 
PpADI (0.5 M phosphate buffer, pH 7.4), but a increased Km value (3.5-fold). 
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High activity at low arginine concentration is an important prerequisite for ADI’s 
medical application, allowing low ADI dose required per treatment. 
In the present work, we improved the directed evolution protocol and identified a 
PpADI variant with further improved activity and slightly decreased “Km value” 
and PpADI variant with lowered Km value maintaining its high catalytic activity. 
Those variants were characterized in respect to their kinetic constants. 
 
4.3 Materials and methods 
4.3.1 Materials 
All chemicals were of analytical-reagent grade or higher quality and were 
purchased from Fluka (Neu-Ulm, Germany), Sigma-Aldrich (Steinheim, Germany) 
and Applichem (Darmstadt, Germany), except the resins for purification (TOSOH, 
Stuttgart, Germany). All enzymes were purchased from New England Biolabs 
(Frankfurt, Germany), Fermentas (St. Leon-Rt, Germany), and Sigma-Aldrich 
Chemie (Taufkirchen, Germany), unless stated otherwise. 
Thermal cycler (Mastercyler gradient; Eppendorf, Hamburg, Germany) and thin-
wall PCR tubes (Multi-ultra tubes; 0.2 µl; Carl Roth, Germany) were used in all 
PCRs. The PCR volume was always 50 µl except for Megaprimer PCR of whole 
plasmid (MEGAWHOP, 25 µl); larger volumes were prepared in multiple 50-µl 
PCRs. The amount of DNA in cloning experiments was quantified by using a 
NanoDrop photometer (NanoDrop Technologies, Germany).  
 
4.3.2 Methods 
4.3.2.1 Site saturation mutagenesis of PpADI M2 at position A128 
Site directed mutagenesis of PpADI M2 (K5T/D44E/H404R) at position A128 was 
performed according to the published method (130). The following 
oligonucleotides were used for mutagenesis of A128: 5’-
CTGATCGGCGGCGTGNNNGGCCAGGACCTGCCG-3’ and 5’- 
CGGCAGGTCCTGGCCNNNCACGCCGCCGATCAG-3’ (underlining indicated 
the substituted nucleotide). For the mutagenic PCR (First stage: 98°C for 30 s, 1 
cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 3 cycles. Second stage: 98°C for 30 
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s, 1 cycle; 98°C, 30 s/ 55°C, 1 min/ 72°C, 3 min, 15 cycles; 72°C for 3 min, 1 
cycle), 2 U of PhuS DNA polymerase, 0.20 mM of dNTP mix, 25 pmol of each 
primer together with 100 ng of template (pET42b(+) harboring PpADI M2 gene) 
were used. Following the PCR, DpnI (40 U; New England Biolabs) was added, 
and incubated overnight at 37°C. The PCR products were purified by using a 
QIAquick PCR Purification Kit (Qiagen) and transformed into E. coli BL21-Gold 
(DE3) for expression. 
 
4.3.2.2 Construction of PpADI error-prone library 
EpPCR library was generated by the standard error-prone PCR (epPCR) using 
improved variant M3 (K5T/D44E/A128T/H404R) as template. For the mutagenic 
PCR (95°C for 2 min, 1 cycle; 95°C, 30 s/ 55°C, 30 s/ 72°C, 30 s, 29 cycles; 72°C 
for 3 min, 1 cycle), 2.5 U of Taq DNA polymerase, 0.20 mM of dNTP mix, 50 ng of 
template (pET42b(+) harboring PpADI M3 gene), 0.01-0.1 mM of MnCl2 and 10 
pmol of each primer (5’-TACATATGTCCGCTGAAACACAGAAG-3’ and 5’-
GTGCTCGAGTTAGTAGTTGATCGG-3’) were used. The PCR products were 
purified by using a QIAquick PCR Purification Kit. The purified epPCR products 
were cloned into expression plasmid pET42b(+) by MEGAWHOP (114). For 
MEGAWHOP (72°C for 5 min, 1 cycle; 98°C for 1 min 30 s, 1 cycle; 98°C, 45 s/ 
55°C, 45 s/72°C, 4 min, 24 cycles; 72°C for 10 min, 1 cycle), 1.2 U of PfuS DNA 
polymerase, 0.20 mM of dNTP mix, 500 ng of epPCR products together with 50 
ng of template (pET42b(+) harboring PpADI gene of variant M3) were used. 
Following the PCR, DpnI (40 U; New England Biolabs) was added, and incubated 
(overnight; 37°C). The MEGAWHOP products were transformed into E. coli BL21-
Gold (DE3) for expression and screening. 
 
4.3.2.3 Site directed mutagenesis at position D38 of PpADI M4 
Site directed mutagenesis of PpADI variant M4 at position D38 was performed 
according to the published method on plasmid pET42b(+)-ADI-M4 
(K5T/D44E/A128T/E296K/H404R). The following oligonucleotides were used for 
mutagenesis of D38H: 5’-ACCCCGAGCAACTGCCACGAGCTGCTGTTCGAC-3’ 
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and 5’-GTCGAACAGCAGCTCGTGGCAGTTGCTCGGGGT-3’ (underlining 
indicated the substituted nucleotide). Conditions for mutagenic PCR are as 
described in “Site saturation mutagenesis of PpADI M2 at position A128”.The 
PCR products were purified by using a QIAquick PCR Purification Kit (Qiagen) 
and transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.4 Site saturation mutagenesis at position D38 and E296 of PpADI M3 
Site saturation mutagenesis library at position D38 and E296 of PpADI variant M3 
(K5T/D44E/A128T/H404R) were generated according to the published method on 
plasmid pET42b(+)-ADI-M3 using the  following oligonucleotides: D38FP (5’-
ACCCCGAGCAACTGCNNNGAGCTGCTGTTCGAC-3’), D38RP (5’-
GTCGAACAGCAGCTCNNNGCAGTTGCTCGGGGT-3’) and E296FP (5’-
GTCACGGTTTTCCCGNNNGTGGTGCGCGAGATC-3’), E296RP (5’-
GATCTCGCGCACCACNNNCGGGAAAACCGTGAC-3’) (underlining indicated 
the substituted nucleotide). Conditions for mutagenic PCR are as described in 
“Site saturation mutagenesis of PpADI M3 gene at position A128”.The PCR 
products were purified by using a QIAquick PCR Purification Kit (Qiagen) and 
transformed into E. coli BL21-Gold (DE3) for expression. 
 
4.3.2.5 Cultivation and expression of PpADI in 96-well plates 
Cultivation and expression in 96-well plates (flat bottom, polystyrene plates; 
Greiner Bio-One GmbH, Frickenhausen, Germany) were performed as previously 
described in 3.3.2.8. 
 
4.3.2.6 Improved screening system in 96-well plate to identify PpADI 
variants with high activities at low arginine concentration 
As describe previously, the modified protocol of citrulline detection based on 
carbamido-diacetyl reaction was used for screening for improved ADI affinity to 
arginine at pH 7.4. 15 µl of cell culture was transferred to 96-well microtiter plate. 
Enzyme reaction was initiated by addition of arginine solution (105 µl, 1mM 
arginine in PBS buffer, pH 7.4) supplemented with 
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cetyltrimethylammoniumbromide (CTAB, 4 mM), and incubated (10 min, 37°C). 
The following color development procedure was carried out as described 
previously (3). 
 
Standard deviation measurements were performed in 96-well plate format using 
culture from BL21-Gold (DE3) lacking PpADI and in a separate experiment 
containing PpADI variant M3. Apparent standard deviation was based on the 
absolute absorbance values obtained from the PpADI variant M3 plate. The true 
standard deviation was calculated by subtracting the background absorbance 
value of the microtiter plate lacking ADI from the apparent values. 
 
4.3.2.7 Expression of PpADI in shaking flask and purification  
Expression of PpADI in shaking flasks and purification (by anion exchange 
chromatography and gel filtration) was performed as previously described in 
3.3.2.10.  
 
4.3.2.8 Characterization of PpADI variants 
Preliminary determination of kinetic constants for site saturation mutagenesis 
variants of position 38 and 296  
The kcat and Km values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in 
incubator (Heraeus Holding GmbH, Hanau, Germany) using cell crude extract.  2 
ml of expression culture was harvested by centrifugation (Eppendorf 5415R 4°C, 
13,000 g, 10 min) and then freezed (-20°C, overnight). Cell lysate was prepared 
by resuspending the cell pellet in lysozyme (91000 U, 50 mM phosphate buffer, 
pH 7.4, 1.3 ml) followed by incubation (37°C, 40 min) and centrifugation (4°C, 
13,000 g, 10 min). 15 µl of diluted (4 times diluted with 50 mM phosphate buffer, 
pH 7.4) cell lysate was transferred to 96-well microtiter plates. Enzyme reaction 
was initiated by addition of arginine solution (105 µl, 0.25-10 mM arginine in PBS 
buffer, pH 7.4) and incubated (7 min, 37°C). Subsequently, ferric-acid solution 
(120 µl) was added to each well to stop enzyme reaction. 60 µl of terminated 
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enzyme reaction mixture was transferred to 96-well PCR plate for color 
development. Ferric-acid solution (90 µl) and DAM-TSC solution (15 µl) were 
added to each well. The 96-well PCR plate was then incubated (70°C, 30 min) in 
thermal cycler (Eppendorf Mastercyler gradient) for color development, followed 
by incubation in ice water to stop color development. Absorbance was measured 
at 530 nm using a microtiter plate reader (Tecan Sunrise TC reader, Tecan Group 
AG, Zurich, Switzerland). The initial velocity data obtained were fitted to the 
equation v = Vmax[S]/([S] + Km) (where v is the initial velocity, Vmax the maximum 
velocity, [S] the substrate concentration, and Km the Michaelis constant) using 
GraphPad Prism software (GraphPad software, San Diego, CA, USA). The kcat 
was calculated from the ratio of Vmax and enzyme concentration. 
 
Determination of kinetic constants of PpADI wild type and variants M3, M4, M5, 
M6 
The kcat and S0.5 values were determined from initial velocity data measured as a 
function of substrate concentration. Enzyme reaction was carried out at 37°C in a 
water bath as described previously using purified enzyme (50 µl, 0.1-1.8 µM) to 
and substrate solution (200 µl, 0.5 mM to 10 mM of arginine, PBS buffer, pH 7.4) 
in deep well plates.  
 
The initial velocity data obtained were fitted to the sigmoidal model of kinetics 
equation v = Vmaxn/(S0.5n + Kn) (where v is the initial velocity, Vmax is the maximum 
velocity, K is the substrate concentration, and S0.5 is the ligand concentration 
producing half occupation (131)) using GraphPad Prism software (GraphPad 
software, San Diego, CA, USA). The kcat was calculated from the ratio of Vmax and 
enzyme concentration. 
 
4.3.2.9 Native polyacrylamide gel electrophoresis of PpADI variants 
10% of polyacrylamide native gels were used for protein electrophoresis to 
analyze the native form of PpADI variants. Purified protein of PpADI variants (7 µl 
of protein and 3 µl of loading dye) were loaded into each lane of native gel. The 
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molecular marker used in the gel is NativeMarkTM Unstained Protein Standard 
(Invitrogen, Darmstadt, Germany). The electrophoresis was performed with 
tris/glycine buffer (pH 8.3) and electrophoresis chamber was incubated in ice-
water bath. Protein bands were stained with Coomassie brilliant blue solution.  
 
4.3.2.10 Homology modeling 
Homology modeling approach was used for the structure prediction of PpADI. 
The model was built by using the automated structure prediction tool, Protein 
homology/analogy recognition engine (Phyre: http://www.sbg.bio.ic.ac.uk/~phyre/) 
(132). The crystal structure of PaADI (PDB ID: 2A9G) was used as template by 
the server and It has 84.9% sequence identity (http://blast.ncbi.nlm.nih.gov/Blast) 
with PpADI. Procheck program suit (http://www.ebi.ac.uk/thornton-
srv/software/PROCHECK/) (133) was used to assess the stereochemical quality 
of the model. Ramachandran plot which represented that 84.7% residues were 
present in the most favoured region and 14.7% in additional allowed region 
(Figure 3).  Dfire was used to access non bonded atomic interaction in the model 
(http://sparks.informatics.iupui.edu/hzhou/dfire.html/) (134), and Qmean 
(http://swissmodel.expasy.org/qmean/cgi/index.cgi) (135) for the estimation of 
global protein quality. Swiss-PdbViewer (118) was used to create the tetramer 
structure by fitting the monomer model on the 4 units of the 2A9G template. The 
variant M6 (D38H, D44E, A128T, E296K, H404R) were created by using the 
“mutate” tool of the Swiss-PdbViewer and by selecting rotamers with the best 
fitness score. All tetramers were energy minimized in vacuum using GROMOS 
43B1 force field (119).  
 
4.4 Results 
4.4.1 Improved screening system in microtiter plates to identify PpADI 
variants with high activities at low arginine concentration 
Screening assay was based on the validated citrulline colorimetric screening 
protocol in microtiter plate, as reported previously (3). In order to screen for 
variants with high activity at low arginine concentration under physiological 
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condition concerning pH and ion concentrations, 1 mM arginine in PBS buffer 
(pH 7.4) as substrate solution was employed in screening assay and enzyme 
reaction time was controlled accordingly (10 min). The coefficient of variation is 
an important performance criterion of a screening system to determine its 
accuracy. Optimized assay condition with 1 mM arginine (PBS buffer, pH 7.4) as 
substrate resulted in true coefficient of variation of 14.9 % (Figure 1). The 
resulting low absolute absorbance value is a main reason for the high true 
coefficient of variation (14.9 %). In the previous screening system, 100 mM 
arginine in 0.5 M sodium phosphate buffer was used and yielded higher activity 
variants but with higher Km value. 
 
 
 
Figure 1. Activity values in descending order of the PpADI variant M3 conversion of arginine to 
citrulline in a 96-well microtiter plate using the optimized assay protocol. The apparent 
coefficients of variation were calculated without subtracting the background and the true 
coefficients of variation after background subtraction.  
 
4.4.2 Genealogic tree of directed PpADI evolution  
Figure 2 shows the two rounds of PpADI evolution, generation of saturation 
mutagenesis libraries and recombination of beneficial positions to finally obtain 
the PpADI variant M6 with 64.7-fold higher kcat and reduced S0.5 (1.3 mM (WT) to 
0.81 mM (M6). Based on structure-function analysis of PaADI[16], M1 was 
generated by substitute His at position 404 with Arg. Position 404 is through 
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interactions with position Asp280 involved in substrate stabilization during 
catalysis. M1 was subject to the first round of epPCR library, from which M2 was 
identified showing a 4-fold improved kcat value and increased Km value (2.5 mM 
in 0.5 mM sodium phosphate buffer, pH 7.4)[15]. M3 was generated by a site 
saturation mutagenesis library at position 128 which increased in another clone 
the expression level (data not shown). In order to improve PpADI towards 
medical application demands (high activity at low arginine concentration), a 
second epPCR mutant library was constructed using M3 as parent. M4 with 
decreased S0.5 value (0.81 mM) and M5 with increased Kcat value (17.56 s-1) 
were identified after screening of ~1400 clones. In M4 the position E296 was 
identified to be important for lowering S0.5 and in M5 position D38 was identified 
to be important for activity increase. M6 was finally constructed by combining the 
substations at position D38 and E296. Saturation mutagenesis of these two 
positions did not yield any further improved S0.5 or activity variant.  
 
 
Figure 2. Genealogic tree of PpADI variants (M1 to M6) with generated amino acid substitutions. 
Novel substitutions are indicated by an asterisk. 
 
4.4.3 EpPCR library construction and screening for variants with high 
activities at low arginine concentration 
Variant M2 was used as a starting template. As described previously, M2 shifts 
the pH optimum from pH 6.5 to pH 7.0 and has a 4-fold faster kcat than PpADI 
wild type. In one sequenced mutant, position A128 was identified to be 
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responsible for higher expression (data not shown). Site saturation mutagenesis 
on M2 therefore was carried out at position A128. The resulting variant M3 
(K5T/D44E/A128T/H404R) showed a ~2-fold improved expression and was 
subsequently used as parent template for epPCR library. 
 
Three concentrations of MnCl2 (0.01-0.10 mM) were used in epPCR library 
generation to adjust the ratio of active to inactive clones. Instead of 0.02 mM 
MnCl2, 0.05 mM MnCl2 which generated 46 % of inactive mutant was selected for 
library generation. EpPCR mutant libraries with a ratio of ~50 % active and ~50 
% inactive clones have often been used successfully in directed evolution, 
improving enzyme properties by gradual changes (one or two amino acids 
changes per round of mutagenesis and screening). Two variants M4 and M5 
were identified from this epPCR library (~1400 clones) and further characterized. 
Variant M4 and M5 were sequenced and one additional amino acid substitution 
was identified for each variant, E296K and D38H, respectively. 
 
4.4.4 Site saturation mutagenesis of PpADI at position D38 and E296 
To investigate their role in improving of catalytic performance for arginine, site 
saturation mutagenesis library at position D38 and E296 were generated using 
PpADI M3 as template. For each position, ~300 clones were screened at low 
concentration of arginine (1 mM, PBS buffer, pH 7.4), using 96-well plate format 
citrulline colorimetric screening assay.  
 
After the screening of site saturation mutagenesis libraries of position 38 and 296, 
variants with higher activity were chosen for preliminary kinetic investigation using 
crude cell extract. Beneficial mutants were identified and sequenced from both 
sites (Table 1). At position 38, the following beneficial substitutions were found: 
D38R (three times, AGA, CGG, CGT) and D38K (twice, AAG, AAA). In all cases, 
the negatively charged acidic amino Asp had been replaced by positively charged 
amino acids, Arg or His. Substitution by negatively charged Glu resulted in a 
clone showing a parent M3-like kinetic behavior. Hydrophobic amino acid 
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substitution by Pro resulted inactive clone under assay conditions. At position 296, 
the following substitutions were found to be beneficial: E296K (twice, AAA, AAG), 
E296N (once, AAC), E296T (once, ACC), E296G (once, GGA). Among these 
substitutions, variants with substitution to positively charged residue Lys show 
lowest S0.5 value for arginine while substitution by uncharged amino acids (Asn, 
Thr, Gly) shows relatively marginal improvement compared to E296K. 
Hydrophobic amino acid substitution by Pro and Trp resulted in very low activity 
clones. 
Table 1. Nucleotide and amino acid substitutions at position 38 in PpADI M3. 
 PpADI 
variants Substitution at position 38 km (mM) 
M3 (parent) Asp (GAC) 3.74 ± 0.35 
SSM-D38R Arg (AGA, CGG, CGT) 1.16 ± 0.21 
SSM-D38K Lys (AAG, AAA) 1.01 ± 0.28 
SSM-D38E Glu (GAG) 2.95 ± 0.77 
SSM-D38P Pro (CCA) n. d. 
SSM-D38T Thr (ACC) n. d. 
M5 His (CAC) 1.26 ± 0.12 
Kinetic experiments were performed with crude cell extracts. 
 
 
Table 2. Nucleotide and amino acid substitutions at position 296 in PpADI M3. 
 PpADI 
variants Substitution at position 296 km (mM) 
M3 (parent) Glu (GAA) 3.74 ± 0.35 
SSM-E296K Lys (AAA, AAG) 0.20 ± 0.01 
SSM-E296N Asn (AAC) 0.53 ± 0.04 
SSM-E296T Thr (ACC) 0.61 ± 0.04 
SSM-E296Q Gln (CAA) 0.79 ± 0.06 
SSM-E296G Gly (GGA) 1.29 ± 0.12 
SSM-E296W Trp (TGG) n. d. 
SSM-E296P Pro (CCT) n. d. 
M4 Lys (AAA) 0.27 ± 0.02 
Kinetic experiments were performed with crude cell extracts.  
* n. d. activity not detectable under assay conditions. 
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4.4.5 Determination of kinetic constants (kcat and S0.5) of PpADI wild type 
and variants M3, M4, M5 and M6 
 
Table 3. Kinetic constants of wild type PpADI and variants. 
 Wild type M3 (parent) M4 M5 M6 
kcat (s-1) 0.18 ± 0.05 10.13 ± 0.36 5.88 ± 0.09 17.56 ± 1.15 11.64 ± 0.50 
S0.5 (mM) 1.30 ± 0.25 2.01 ± 0.19 0.81 ± 0.03 1.48 ± 0.17 0.81 ± 0.09 
* Kinetic contants of PpADI wild type is different from our previous report because in stead of 
0.5 M phosphate buffer, PBS buffer was used for kinetic measurements. Kcat value of PpADI 
wild type dropped from 5.6 s-1 to 0.18 s-1 and kcat value of M2 is reduced ~2-fold. 
 
M3, the parent of the second round of PpADI epPCR library, M4 with decreased 
S0.5, M5 with increased kcat and best variant M6 with best combination of kcat 
value and S0.5 were selected for detailed characterization studies.  
 
Kinetic characterization of PpADI variants was performed using PBS buffer (pH 
7.4), which is commonly used in biological research. PBS buffer helps to 
maintain a constant pH and its osmolarity and ion concentrations usually match 
those of the human body. Citrulline production of PpADI variants was maintained 
between 0.2-0.8 mM. Table 3 summarizes the kcat and S0.5 values of parent M3 
(K5T/D44E/A128T/H404R), variants M4 (K5T/D44E/A128T/E296K/H404R), M5 
(K5T/D44E/A128T/D38H/H404R) and M6 
(K5T/D38H/D44E/A128T/E296K/H404R), which were expressed in shaking 
flasks cultures and purified using a two step procedure (anion exchange follows 
by gel filtration). Compared to parent M3 (S0.5 = 2.01 mM), both variants M4 and 
M5 have a lower S0.5 for arginine conversion at pH 7.4, 0.81 mM and 1.48 mM, 
respectively. Variant M4 shows a decreased kcat value, 58% of parent M3 while 
M5 shows a 1.7-fold higher kcat compared to parent M3. Variant M6 with 
combined mutations (K5T/D38H/D44E/A128T/E296K/H404R) shows decreased 
S0.5 value, 40 % of parent M3 (K5T/D44E/A128T/H404R), 62 % of PpADI wild 
type, and a 64.7-fold faster kcat value than PpADI wild type. M6 is 42.3-fold faster 
than PpADI wild type with 0.4 mM arginine (PBS buffer, pH 7.4) as substrate. 
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After two rounds of epPCR libraries coupled with site directed mutagenesis, a 
variant M6 with 64.7-fold higher kcat and lower S0.5 value (0.81 mM) than PpADI 
wild type (0.31 mM). At low concentration of arginine, activity of M6 enhanced 
dramatically than M3 and wild type. For example, M6 is 42.3-fold faster than 
PpADI wild type in 0.4 mM arginine (PBS buffer, pH 7.4). 
 
4.4.6 Native polyacrylamide gel electrophoresis of PpADI variants 
Multimeric form of PpADI variants were investigated by native polyacrylamide gel 
electrophoresis. As shown in Figure 3, two distinct protein bands representing 
two multimeric forms tetramer and dimer (molecular weight of a subunit is ~ 46 
kDa) were observed, but with different concentration percentage. The major 
multimeric form of M3 is dimer. Compared to M3, M4 with an additional mutation 
E296K shows a very different pattern: tetramer is the main form; while M5 with 
an additional mutation D38H contains more or less equal amount of dimer and 
tetramer. M6, with both mutations E296K and D38H, contains more tetramer than 
dimer. 
 
 
 
Figure 3. Native polyacrylamide gel electrophoresis of PpADI variants (M3 to M6) with different 
dimer/tetramer distribution. Single subunit has a molecular weight of ~46 kDa. 
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4.5 Discussion 
 
Directed evolution allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
Small libraries of a few thousand variants are often sufficient to find improved 
variants [18] even without rational understanding of the targeted property. After 
establishing a first directed ADI evolution protocol yielding mutant M2, we 
adjusted the screening system to better reflect ADI’s application conditions. 
Prerequisite for ADI to become an effective anti-tumor agent is that low 
concentrations of arginine in human plasma can effectively be converted. 
 
Figure 2 shows the genealogic tree of PpADI evolution and before discussing the 
influence of each substitution individually the effect on kinetics are briefly 
summarized. Amino acid substitution D44E (M2) increases kcat and S0.5, 
substitution A128T (M3) increases the expression level, and substitution E296K 
(M4) decreases kcat and S0.5 and is responsible for tetramer formation. 
Substitution D38H (M5) increase largely kcat and reduces slightly S0.5. The 
combination of all mentioned residues in M6 result in a finally 64.7-fold improved 
PpADI activity and reduced S0.5 (1.30 to 0.81 mM).    
 
PpADI M3 was obtained from site saturation mutagenesis library at position A128 
using M2 as template (Figure 2). M3 shows improved functional expression level 
of ADI (data not shown) and was used as parent for generating an epPCR library. 
Screening of epPCR library yielded two improved variants M4 and M5, carrying 
an additional mutation, E296K (M4) and D38H (M5). M4 has a decreased S0.5 
(0.81 mM) and a decreased kcat value (5.88 s-1; see Table 3). M5 has a 
decreased S0.5 (1.48 mM) and an increased kcat value (17.56 s-1) when compared 
to parent M3 (S0.5, 2.01 mM; kcat, 10.03 s-1; see Table 3). M6 which harbors both 
substitutions (E296K and D38H) has a decreased S0.5 value (0.81 mM) 
compared to the parent M3 (1.30 mM) and the wild type (2.01 mM), and a 64.7-
fold higher kcat value than the PpADI wild type.   
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Despite further enhancing the activity of PpADI, it is crucial for an efficient 
conversion of the substrate arginine in human plasma (100-120 µM arginine) to 
reduce PpADI’s “Km” (S0.5) value. Figure 4 shows the kinetics of PpADI WT, 
parent M3, and the variants M4, M5 and M6. M3 has a significantly higher kcat 
value compared to WT, but its activity at low concentration of arginine (<1.0 mM) 
is very low (S0.5 value 2.01 mM). In contrast, the most efficient variant M6 with a 
decreased S0.5 value (0.81 mM) shows a remarkable activity improvement at low 
concentrations of arginine (<0.5 mM; see Figure 4). M6 has additional two amino 
acid substitutions (D38H and E296K) compared to M3 which increases kcat and 
reduces the S0.5 value. The combination of D38H and E296K improves especially 
the activity of M6 at low arginine concentrations (< 0.5 mM; see Figure 4). 
 
Figure 4. Kinetic curve of PpADI wild type, M3, M5 and M6. (▲) PpADI wild type, (▼) M3, (●) M4, 
(♦) M5 and (■) M6. 
 
 
Figure 5 shows the tetrameric model (based on PaADI, PDB code 2A9G) of 
PpADI WT (Figure 5A) and variant M6 (Figure 5B). Monomeric units are 
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indicated with the letters a, b, c and d. The access channel to the active sites of 
each monomer is highlighted in square and faces an internal cavity generated by 
the assembly of four PpADI monomers. The substitutions D38H (in blue) and 
D44E (in green) are localized at the interface of monomer pair a-b and c-d. The 
substitution of Glu by Asp at position 44 provides a longer side chain in close 
proximity of the also negatively charged residue Asp43 (Figure 6A). The 
substitution E296K is localized at the border of the entrance to the internal cavity 
of the PpADI tetramer. E296K promotes the tetramer formation likely by 
introducing stabilizing interactions with other residues, for example with Thr33 
(hydrogen bond). E296K inverts the charge at this position and its increased 
length of the side chain might promote further interactions to a neighboring 
monomer (Figure 6A). The combination of D44E and E296K results in a 
population consisting of mainly tetramers (see Figure 3; mutein M4). Interestingly 
with the formation of a tetramer (M4) the S0.5 value is reduced which indicates 
that the tetramer complex formation promotes interactions with the substrate 
arginine at low concentrations. The substitution D38H together with the E296K in 
the mutein M6 reestablishes an almost equal population of PpADI dimers and 
tetramers. A hypothesis is that Lys of the E296K has an electrostatic stabilizing 
interaction with the Glu38 in the M4 but not to the neutral His38. 
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Figure 5. A). The model of WT tetramer after energy minimization in vacuum (GROMOS 43B1). 
B). The model of M6 tetramer after energy minimization in vacuum (GROMOS 43B1). Active site 
residues are represented in CRK format in a square (Blue). Mutated residues are shown in 
licorice format in different colors like D38H (blue), D44E (green), A128T (magenta), E296K (red) 
and H404R (violet). Substrate arginine is represented in orange color by licorice format.  
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Figure 6. A). Structure model of variant M6. E296K is involved in intermonomer interaction 
(between chain a (orange) and b (green)) with Thr33. D44E is involved in intermonomer 
interaction, between chain A (orange) and B (green), with Asp43 (violet). B). Structure alignment 
of PpADI WT model and M6 model with four loops (loop 1:30-46, loop 2:178-175, loop 3:271-281 
and loop 4: 393-404) surrounding the entrance of the active site. The substitutions in these loops 
and the residues involved in the interaction with those substitutions are representing: D38H 
(orange), D44E (yellow) and H404R (cyan, in M6; gray, in WT), Ser35 (green), Arg 400 (pink), 
substrate arginine (ochre), catalytic triad His278, Asp280 and Cys406 (violet, highlighted in an 
oval) 
 
Figure 6B shows that the active site of the PaADI is surrounded by four loops 
(loop 1: 30-46, loop 2: 178-185, loop 3: 271-281, and loop 4: 393-404). These 
four loops undergo a conformational transition upon arginine binding and tighten 
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the surrounding of the arginine substrate[16]. D38 is located in loop 1 and faces 
towards the substrate access channel. In PpADI model (Figure 6B), the D38H 
mutation promotes the formation of a hydrogen bond interaction with the 
neighboring residues Ser35, contributing to the stability of the entropically 
unfavorable folded conformation of loop1. The rigidified loop 1 might be 
beneficial for arginine conversion. According to PaADI structure analysis, the 
side chain of gating residue Arg401 (Arg400 in PpADI) is located at the active 
site entrance and fills the substrate-binding site. The structure analysis of the 
C406A PaADI-L-arginine complex[16] shows that the Arg401 side chain (Arg400 
in PpADI) is displaced by the substrate arginine to a position near the active site 
entrance that allows its hydrocarbon chain to assist shielding the catalytic site 
from solvent. D38 is involved in an ionic interaction and hydrogen bonding with 
Arg400. The substitution of Asp to His at position 38 results in a loss of ionic 
interactions to Arg400 due to the different lengths of the side chains. His38 can 
form only a hydrogen bond with active site gating residue Arg400. A weakened 
interaction between position 38 and Arg400 might increase the flexibility of the 
side chain of Arg400 which then might block less efficiently the access of 
arginine to the active site. As a result the variant M5 shows an improved kcat 
value (1.7-fold compared to parent M3) due to the substitution D38H.  
 
For elucidating further the individual role of the five identified amino acid 
substitutions and their influence on the active site geometry and tetramer 
formation crystal structures of variant M4 and M6 have to be solved.  
 
4.6 Conclusion 
In summary, with the modified screening protocol, PpADI variants with improved 
kcat and S0.5 were identified. The increased kcat value and decreased S0.5 value 
result in significant activity improvement of PpADI at low arginine concentrations. 
Especially the kinetic constants of PpADI variant M6 demonstrate that PpADI 
properties can be tailored by directed evolution. The generated PpADI variants 
match from their kinetic behavior therapeutic application demands much better 
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than the wild type PpADI. We therefore hope that by directed evolution improved 
PpADIs will further be investigated in vivo for tumor therapy. 
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Summary and outlook 
Arginine depletion based on ADI is an emerging strategy for anti-tumor treatment. 
ADIs have been studied for the therapy of HCCs and melanomas and were 
approved as an orphan drug for both kinds of tumors. ADI is proved to be 
effective in the treatment of leukemia. The effectiveness of ADIs as anti-tumor 
agent depends on their enzymatic properties (such as Km, kcat, optimum pH, 
stability at neutral pH). Directed evolution, without rational understanding of the 
targeted property, allows improving all properties that can be reflected in a 
screening system through iterative rounds of diversity generation and screening. 
 
In order to improve PpADI activity at physiological pH by directed evolution, a 
colorimetric screening assay based on citrulline detection has been developed in 
96-well microtiter plate format. Single mutation H404R was identified according 
to PpADI homology model (based on PaADI crystal structure), introduced to 
PpADI wild type and eventually resulted in 1.4-fold of increase in kcat. M1 (H404R) 
was used as template for the first round of epPCR library generation. M2 
(K5T/D44E/H404R) obtained from the first round of epPCR library showed 4-fold 
improved kcat value when compared to the PpADI wild type. Furthermore, a shift 
of pH optimum from pH 6.5 to pH 7.0 was observed, combined with an increased 
Km value (2.5 mM) under assay conditions (0.5 M sodium phosphate buffer, pH 
7.4), compared to PpADI wild type (0.7 mM). 
 
Arginine concentration in human plasma is however relatively low (100-120 µM). 
Therefore the second round of epPCR library was performed to decrease Km 
value and further improve kcat value. The validated screening assay was modified 
to reflect more close physiological condition (1 mM arginine in PBS buffer, pH 
7.4). Two important variants with one additional mutation, M4 
(K5T/D44E/A128T/E296K/H404R) with decreased S0.5 vaule, and M5 
(K5T/D38H/D44E/A128T/H404R) with improved kcat were obtained. Their two 
mutations were combined and resulted in variants M6 
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(K5T/D38H/D44E/A128T/E296K/H404R). Under physiological pH in PBS buffer, 
the S0.5 value of M6 (0.81 mM) is lower than that of PpADI wild type (1.30 mM); 
the kcat value improved from 0.18 s-1 (PpADI wild type) to 17.56 s-1 (M5, 97.6-
folds) and 11.64 s-1 (M6, 64.7-fold). 
 
A reamaining challenge facing PpADI’s anti-tumor application is to decrease the 
Km (S0.5) value further close to arginine concentration level in human plasma. A 
more sensitive assay for screening has to be developed with the addition of 
sensitizer like thiosemicarbazide (TSC), optimized temperature and incubation 
time. Improved variants should be tested tested in human plasma or with human 
plasma composition. In vitro testing of ADI variants with arginine auxotrophic 
tumor cell lines is the first step towards in vivo in human. 
 
In summary, directed evolution has been very useful algorithim for improving 
ADI’s kcat and Km at physiological pH (pH 7.4) for its medical application. Hope 
that directed evolution will be become a standard method for therapeutic protein 
like its use in industry.                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  97 
Publication list 
Publications 
 
1. Leilei Zhu, Kang Lan Tee, Danilo Roccatano,  Burcu Sonmez, Ye Ni, Zhi-Hao 
Sun, and Ulrich Schwaneberg. Directed evolution of an antitumor drug (Arginine 
Deiminase PpADI) for increased activity at physiological pH. ChemBioChem. 
2010, 11, 691-697. 
2. Leilei Zhu, Rajni Verma, Danilo Roccatano, Ye Ni, Zhi-Hao Sun, and Ulrich 
Schwaneberg. A potential anti-tumor drug (arginine deiminase) reengineered for 
efficient operation under physiological conditions. ChemBioChem. In press. 
3. Ye Ni, Zhenwei Li, Zhihao Sun, Pu Zheng, Yongmei Liu and Leilei Zhu, Ulrich 
Schwaneberg. Expression of arginine deiminase from Pseudomonas 
plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity. 
Current Microbiology. 2009, 58(6):593-598. 
 
 
Patent 
1. Directed evolution of arginine deiminase for increased activity at physiological 
pH. Application number: PCT/EP2010/061884. 
 
 
 
 
 
 
 
 
 
 
  98 
 
 
Curriculum vitae 
Personal data 
 
Name: Leilei Zhu 
Gender: Female 
Date of Birth: 27th April, 1982  
Place of Birth: Weifang, China 
Marital Status: Married 
Nationality: Chinese 
 
 
Education 
2009- PhD fellow of biotechnology, RWTH Aachen University, 
Aachen, Germany 
2007-2009 PhD fellow of engineering and science, Jacobs University 
Bremen, Bremen, Germany 
2005-2007        Master of biochemical engineering, Jiangnan University 
(Southern Yantze University), Wuxi, China 
2001-2005        Bachelor of biotechnology, Jiangnan University (Southern 
Yantze University), Wuxi, China 
 
 
2001-1998 The first high school of Hanting, Weifang, China 
1998-1994        The sixth middle school of Hanting, Weifang, China 
1989-1994        Primary school of Liuhe, Weifang, China 
 
 
